Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
chromosomal is a Chromosome, human is a Eukaryote, DCAMKL1 is a Gene, KIAA0369 is a Gene, DCX is a Gene, XLIS is a Gene, Human is a Eukaryote, DCAMKL1 is a Gene, KIAA0369 is a Gene, DCX is a Gene, gene is a Gene, DCAMKL1 is a Gene, gene is a Gene, Ca2+/calmodulin is a ProteinComplex, protein kinases is a Enzyme, human is a Eukaryote, tissues is a Tissue, DCAMKL1 is a Gene, exons is a Exon, exon is a Exon, DCAMKL1 is a Gene, chromosome is a Chromosome, DCAMKL1 is a Gene, human is a Eukaryote, fetal brain is a Tissue, transcript is a Transcript
44_task0
Sentence: Genomic structure, chromosomal mapping, and expression pattern of human DCAMKL1 (KIAA0369), a homologue of DCX (XLIS). Human DCAMKL1, also known as KIAA0369, is a homologue of DCX (Xq22. 3), a gene associated with X-linked lissencephaly and subcortical band heterotopia. This suggests that DCAMKL1 may play a role in neuronal migration. The gene also shows similarity to Ca2+/calmodulin-dependent protein kinases. We have determined its genomic structure, regional mapping, and expression pattern in human tissues. DCAMKL1 consists of at least 18 exons ranging from 58 to 3359 bp in length. We have characterized the exon/intron borders, and primers were designed to amplify each individual exon for mutation analysis. DCAMKL1 was mapped to chromosome 13q13 by fluorescence in situ hybridization. Northern blot analysis showed DCAMKL1 to be predominantly expressed in human fetal brain as a major transcript of about 5.8 kb. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Tissue, ProteinComplex, Enzyme, Chromosome, Exon, Gene, Transcript, Eukaryote
[ "O", "O", "O", "B-Chromosome", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Eukaryote", "B-Gene", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "B-ProteinComplex", "O", "O", "B-Enzyme", "I-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Exon", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Exon", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "B-Chromosome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Transcript", "O", "O", "O", "O", "O", "O" ]
Genomic structure, chromosomal mapping, and expression pattern of human DCAMKL1 (KIAA0369), a homologue of DCX (XLIS). Human DCAMKL1, also known as KIAA0369, is a homologue of DCX (Xq22. 3), a gene associated with X-linked lissencephaly and subcortical band heterotopia. This suggests that DCAMKL1 may play a role in neuronal migration. The gene also shows similarity to Ca2+/calmodulin-dependent protein kinases. We have determined its genomic structure, regional mapping, and expression pattern in human tissues. DCAMKL1 consists of at least 18 exons ranging from 58 to 3359 bp in length. We have characterized the exon/intron borders, and primers were designed to amplify each individual exon for mutation analysis. DCAMKL1 was mapped to chromosome 13q13 by fluorescence in situ hybridization. Northern blot analysis showed DCAMKL1 to be predominantly expressed in human fetal brain as a major transcript of about 5.8 kb.
[ "Genomic", "structure", ",", "chromosomal", "mapping", ",", "and", "expression", "pattern", "of", "human", "DCAMKL1", "(", "KIAA0369", ")", ",", "a", "homologue", "of", "DCX", "(", "XLIS", ")", ".", "Human", "DCAMKL1", ",", "also", "known", "as", "KIAA0369", ",", "is", "a", "homologue", "of", "DCX", "(", "Xq22", ".", "3", ")", ",", "a", "gene", "associated", "with", "X", "-", "linked", "lissencephaly", "and", "subcortical", "band", "heterotopia", ".", "This", "suggests", "that", "DCAMKL1", "may", "play", "a", "role", "in", "neuronal", "migration", ".", "The", "gene", "also", "shows", "similarity", "to", "Ca2+/calmodulin", "-", "dependent", "protein", "kinases", ".", "We", "have", "determined", "its", "genomic", "structure", ",", "regional", "mapping", ",", "and", "expression", "pattern", "in", "human", "tissues", ".", "DCAMKL1", "consists", "of", "at", "least", "18", "exons", "ranging", "from", "58", "to", "3359", "bp", "in", "length", ".", "We", "have", "characterized", "the", "exon", "/", "intron", "borders", ",", "and", "primers", "were", "designed", "to", "amplify", "each", "individual", "exon", "for", "mutation", "analysis", ".", "DCAMKL1", "was", "mapped", "to", "chromosome", "13q13", "by", "fluorescence", "in", "situ", "hybridization", ".", "Northern", "blot", "analysis", "showed", "DCAMKL1", "to", "be", "predominantly", "expressed", "in", "human", "fetal", "brain", "as", "a", "major", "transcript", "of", "about", "5.8", "kb", ".", "\n" ]
[ "ProteinComplex", "Enzyme", "Chromosome", "Tissue", "Transcript", "Gene", "Eukaryote", "Exon" ]
chromosomal is a Chromosome, human is a Eukaryote, DCAMKL1 is a Gene, KIAA0369 is a Gene, DCX is a Gene, XLIS is a Gene, Human is a Eukaryote, DCAMKL1 is a Gene, KIAA0369 is a Gene, DCX is a Gene, gene is a Gene, DCAMKL1 is a Gene, gene is a Gene, Ca2+/calmodulin is a ProteinComplex, protein kinases is a Enzyme, human is a Eukaryote, tissues is a Tissue, DCAMKL1 is a Gene, exons is a Exon, exon is a Exon, DCAMKL1 is a Gene, chromosome is a Chromosome, DCAMKL1 is a Gene, human is a Eukaryote, fetal brain is a Tissue, transcript is a Transcript
44_task1
Sentence: Genomic structure, chromosomal mapping, and expression pattern of human DCAMKL1 (KIAA0369), a homologue of DCX (XLIS). Human DCAMKL1, also known as KIAA0369, is a homologue of DCX (Xq22. 3), a gene associated with X-linked lissencephaly and subcortical band heterotopia. This suggests that DCAMKL1 may play a role in neuronal migration. The gene also shows similarity to Ca2+/calmodulin-dependent protein kinases. We have determined its genomic structure, regional mapping, and expression pattern in human tissues. DCAMKL1 consists of at least 18 exons ranging from 58 to 3359 bp in length. We have characterized the exon/intron borders, and primers were designed to amplify each individual exon for mutation analysis. DCAMKL1 was mapped to chromosome 13q13 by fluorescence in situ hybridization. Northern blot analysis showed DCAMKL1 to be predominantly expressed in human fetal brain as a major transcript of about 5.8 kb. Instructions: please typing these entity words according to sentence: chromosomal, human, DCAMKL1, KIAA0369, DCX, XLIS, Human, DCAMKL1, KIAA0369, DCX, gene, DCAMKL1, gene, Ca2+/calmodulin, protein kinases, human, tissues, DCAMKL1, exons, exon, DCAMKL1, chromosome, DCAMKL1, human, fetal brain, transcript Options: Tissue, ProteinComplex, Enzyme, Chromosome, Exon, Gene, Transcript, Eukaryote
[ "O", "O", "O", "B-Chromosome", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Eukaryote", "B-Gene", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "B-ProteinComplex", "O", "O", "B-Enzyme", "I-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Exon", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Exon", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "B-Chromosome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Transcript", "O", "O", "O", "O", "O", "O" ]
Genomic structure, chromosomal mapping, and expression pattern of human DCAMKL1 (KIAA0369), a homologue of DCX (XLIS). Human DCAMKL1, also known as KIAA0369, is a homologue of DCX (Xq22. 3), a gene associated with X-linked lissencephaly and subcortical band heterotopia. This suggests that DCAMKL1 may play a role in neuronal migration. The gene also shows similarity to Ca2+/calmodulin-dependent protein kinases. We have determined its genomic structure, regional mapping, and expression pattern in human tissues. DCAMKL1 consists of at least 18 exons ranging from 58 to 3359 bp in length. We have characterized the exon/intron borders, and primers were designed to amplify each individual exon for mutation analysis. DCAMKL1 was mapped to chromosome 13q13 by fluorescence in situ hybridization. Northern blot analysis showed DCAMKL1 to be predominantly expressed in human fetal brain as a major transcript of about 5.8 kb.
[ "Genomic", "structure", ",", "chromosomal", "mapping", ",", "and", "expression", "pattern", "of", "human", "DCAMKL1", "(", "KIAA0369", ")", ",", "a", "homologue", "of", "DCX", "(", "XLIS", ")", ".", "Human", "DCAMKL1", ",", "also", "known", "as", "KIAA0369", ",", "is", "a", "homologue", "of", "DCX", "(", "Xq22", ".", "3", ")", ",", "a", "gene", "associated", "with", "X", "-", "linked", "lissencephaly", "and", "subcortical", "band", "heterotopia", ".", "This", "suggests", "that", "DCAMKL1", "may", "play", "a", "role", "in", "neuronal", "migration", ".", "The", "gene", "also", "shows", "similarity", "to", "Ca2+/calmodulin", "-", "dependent", "protein", "kinases", ".", "We", "have", "determined", "its", "genomic", "structure", ",", "regional", "mapping", ",", "and", "expression", "pattern", "in", "human", "tissues", ".", "DCAMKL1", "consists", "of", "at", "least", "18", "exons", "ranging", "from", "58", "to", "3359", "bp", "in", "length", ".", "We", "have", "characterized", "the", "exon", "/", "intron", "borders", ",", "and", "primers", "were", "designed", "to", "amplify", "each", "individual", "exon", "for", "mutation", "analysis", ".", "DCAMKL1", "was", "mapped", "to", "chromosome", "13q13", "by", "fluorescence", "in", "situ", "hybridization", ".", "Northern", "blot", "analysis", "showed", "DCAMKL1", "to", "be", "predominantly", "expressed", "in", "human", "fetal", "brain", "as", "a", "major", "transcript", "of", "about", "5.8", "kb", ".", "\n" ]
[ "ProteinComplex", "Enzyme", "Chromosome", "Tissue", "Transcript", "Gene", "Eukaryote", "Exon" ]
chromosomal, human, DCAMKL1, KIAA0369, DCX, XLIS, Human, DCAMKL1, KIAA0369, DCX, gene, DCAMKL1, gene, Ca2+/calmodulin, protein kinases, human, tissues, DCAMKL1, exons, exon, DCAMKL1, chromosome, DCAMKL1, human, fetal brain, transcript
44_task2
Sentence: Genomic structure, chromosomal mapping, and expression pattern of human DCAMKL1 (KIAA0369), a homologue of DCX (XLIS). Human DCAMKL1, also known as KIAA0369, is a homologue of DCX (Xq22. 3), a gene associated with X-linked lissencephaly and subcortical band heterotopia. This suggests that DCAMKL1 may play a role in neuronal migration. The gene also shows similarity to Ca2+/calmodulin-dependent protein kinases. We have determined its genomic structure, regional mapping, and expression pattern in human tissues. DCAMKL1 consists of at least 18 exons ranging from 58 to 3359 bp in length. We have characterized the exon/intron borders, and primers were designed to amplify each individual exon for mutation analysis. DCAMKL1 was mapped to chromosome 13q13 by fluorescence in situ hybridization. Northern blot analysis showed DCAMKL1 to be predominantly expressed in human fetal brain as a major transcript of about 5.8 kb. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Chromosome", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Gene", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "O", "B-Eukaryote", "B-Gene", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "B-ProteinComplex", "O", "O", "B-Enzyme", "I-Enzyme", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Exon", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Exon", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "B-Chromosome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "I-Tissue", "O", "O", "O", "B-Transcript", "O", "O", "O", "O", "O", "O" ]
Genomic structure, chromosomal mapping, and expression pattern of human DCAMKL1 (KIAA0369), a homologue of DCX (XLIS). Human DCAMKL1, also known as KIAA0369, is a homologue of DCX (Xq22. 3), a gene associated with X-linked lissencephaly and subcortical band heterotopia. This suggests that DCAMKL1 may play a role in neuronal migration. The gene also shows similarity to Ca2+/calmodulin-dependent protein kinases. We have determined its genomic structure, regional mapping, and expression pattern in human tissues. DCAMKL1 consists of at least 18 exons ranging from 58 to 3359 bp in length. We have characterized the exon/intron borders, and primers were designed to amplify each individual exon for mutation analysis. DCAMKL1 was mapped to chromosome 13q13 by fluorescence in situ hybridization. Northern blot analysis showed DCAMKL1 to be predominantly expressed in human fetal brain as a major transcript of about 5.8 kb.
[ "Genomic", "structure", ",", "chromosomal", "mapping", ",", "and", "expression", "pattern", "of", "human", "DCAMKL1", "(", "KIAA0369", ")", ",", "a", "homologue", "of", "DCX", "(", "XLIS", ")", ".", "Human", "DCAMKL1", ",", "also", "known", "as", "KIAA0369", ",", "is", "a", "homologue", "of", "DCX", "(", "Xq22", ".", "3", ")", ",", "a", "gene", "associated", "with", "X", "-", "linked", "lissencephaly", "and", "subcortical", "band", "heterotopia", ".", "This", "suggests", "that", "DCAMKL1", "may", "play", "a", "role", "in", "neuronal", "migration", ".", "The", "gene", "also", "shows", "similarity", "to", "Ca2+/calmodulin", "-", "dependent", "protein", "kinases", ".", "We", "have", "determined", "its", "genomic", "structure", ",", "regional", "mapping", ",", "and", "expression", "pattern", "in", "human", "tissues", ".", "DCAMKL1", "consists", "of", "at", "least", "18", "exons", "ranging", "from", "58", "to", "3359", "bp", "in", "length", ".", "We", "have", "characterized", "the", "exon", "/", "intron", "borders", ",", "and", "primers", "were", "designed", "to", "amplify", "each", "individual", "exon", "for", "mutation", "analysis", ".", "DCAMKL1", "was", "mapped", "to", "chromosome", "13q13", "by", "fluorescence", "in", "situ", "hybridization", ".", "Northern", "blot", "analysis", "showed", "DCAMKL1", "to", "be", "predominantly", "expressed", "in", "human", "fetal", "brain", "as", "a", "major", "transcript", "of", "about", "5.8", "kb", ".", "\n" ]
[ "ProteinComplex", "Enzyme", "Chromosome", "Tissue", "Transcript", "Gene", "Eukaryote", "Exon" ]
Chirurgie is an umlsterm, Behandlung is an umlsterm, Tumormetastasen is an umlsterm, Metastasen is an umlsterm, Trokareinstichstelle is an umlsterm, Kontraindikationen is an umlsterm, Techniken is an umlsterm, Instrumente is an umlsterm, Techniken is an umlsterm, Chirurgie is an umlsterm, Behandlung is an umlsterm, Tumoren is an umlsterm
DerChirurg.70680210.ger.abstr_task0
Sentence: Zusammenfassung . Die Bedeutung der laparoskopischen Chirurgie zur operativen Behandlung benigner gastrointestinaler Erkrankungen nimmt immer mehr zu , wohingegen diese operative Vorgehensweise bei malignen Erkrankungen weiterhin sehr umstritten bleibt . Obwohl die Lokalisation von Tumormetastasen im Bereich von Wundraendern an sich nichts Neues darstellt , so ist doch das moegliche Auftreten von Metastasen im Bereich der Trokareinstichstelle der Haupteinwand gegen das laparoskopische Operieren von Malignomen . In diesem Zusammenhang ist es notwendig Indikationen und Kontraindikationen sowie das standardisierte laparoskopische Procedere , genau zu definieren . Alleinige laparoskopische Techniken oder kombiniert laparoskopisch/offene Verfahren bieten jeweils Vor- und Nachteile , die der Chirurg in seine therapeutische Entscheidung mit einfliessen lassen sollte . Die individuelle Erfahrung des Operationsteams und die Ausdehnung der malignen Erkrankung legt die Grenzen des laparoskopisch Machbaren fest . Nur durch eine Fortfuehrung der Forschungsaktivitaet , der Entwicklung " intelligenter " Instrumente sowie der Etablierung standardisierter Techniken kann die laparoskopische Chirurgie einen klaren Stellenwert bei der Behandlung maligner gastrointestinaler Tumoren erhalten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Die Bedeutung der laparoskopischen Chirurgie zur operativen Behandlung benigner gastrointestinaler Erkrankungen nimmt immer mehr zu , wohingegen diese operative Vorgehensweise bei malignen Erkrankungen weiterhin sehr umstritten bleibt . Obwohl die Lokalisation von Tumormetastasen im Bereich von Wundraendern an sich nichts Neues darstellt , so ist doch das moegliche Auftreten von Metastasen im Bereich der Trokareinstichstelle der Haupteinwand gegen das laparoskopische Operieren von Malignomen . In diesem Zusammenhang ist es notwendig Indikationen und Kontraindikationen sowie das standardisierte laparoskopische Procedere , genau zu definieren . Alleinige laparoskopische Techniken oder kombiniert laparoskopisch/offene Verfahren bieten jeweils Vor- und Nachteile , die der Chirurg in seine therapeutische Entscheidung mit einfliessen lassen sollte . Die individuelle Erfahrung des Operationsteams und die Ausdehnung der malignen Erkrankung legt die Grenzen des laparoskopisch Machbaren fest . Nur durch eine Fortfuehrung der Forschungsaktivitaet , der Entwicklung " intelligenter " Instrumente sowie der Etablierung standardisierter Techniken kann die laparoskopische Chirurgie einen klaren Stellenwert bei der Behandlung maligner gastrointestinaler Tumoren erhalten .
[ "Zusammenfassung", ".", "Die", "Bedeutung", "der", "laparoskopischen", "Chirurgie", "zur", "operativen", "Behandlung", "benigner", "gastrointestinaler", "Erkrankungen", "nimmt", "immer", "mehr", "zu", ",", "wohingegen", "diese", "operative", "Vorgehensweise", "bei", "malignen", "Erkrankungen", "weiterhin", "sehr", "umstritten", "bleibt", ".", "Obwohl", "die", "Lokalisation", "von", "Tumormetastasen", "im", "Bereich", "von", "Wundraendern", "an", "sich", "nichts", "Neues", "darstellt", ",", "so", "ist", "doch", "das", "moegliche", "Auftreten", "von", "Metastasen", "im", "Bereich", "der", "Trokareinstichstelle", "der", "Haupteinwand", "gegen", "das", "laparoskopische", "Operieren", "von", "Malignomen", ".", "In", "diesem", "Zusammenhang", "ist", "es", "notwendig", "Indikationen", "und", "Kontraindikationen", "sowie", "das", "standardisierte", "laparoskopische", "Procedere", ",", "genau", "zu", "definieren", ".", "Alleinige", "laparoskopische", "Techniken", "oder", "kombiniert", "laparoskopisch", "/", "offene", "Verfahren", "bieten", "jeweils", "Vor-", "und", "Nachteile", ",", "die", "der", "Chirurg", "in", "seine", "therapeutische", "Entscheidung", "mit", "einfliessen", "lassen", "sollte", ".", "Die", "individuelle", "Erfahrung", "des", "Operationsteams", "und", "die", "Ausdehnung", "der", "malignen", "Erkrankung", "legt", "die", "Grenzen", "des", "laparoskopisch", "Machbaren", "fest", ".", "Nur", "durch", "eine", "Fortfuehrung", "der", "Forschungsaktivitaet", ",", "der", "Entwicklung", "\"", "intelligenter", "\"", "Instrumente", "sowie", "der", "Etablierung", "standardisierter", "Techniken", "kann", "die", "laparoskopische", "Chirurgie", "einen", "klaren", "Stellenwert", "bei", "der", "Behandlung", "maligner", "gastrointestinaler", "Tumoren", "erhalten", "." ]
[ "umlsterm" ]
Chirurgie is an umlsterm, Behandlung is an umlsterm, Tumormetastasen is an umlsterm, Metastasen is an umlsterm, Trokareinstichstelle is an umlsterm, Kontraindikationen is an umlsterm, Techniken is an umlsterm, Instrumente is an umlsterm, Techniken is an umlsterm, Chirurgie is an umlsterm, Behandlung is an umlsterm, Tumoren is an umlsterm
DerChirurg.70680210.ger.abstr_task1
Sentence: Zusammenfassung . Die Bedeutung der laparoskopischen Chirurgie zur operativen Behandlung benigner gastrointestinaler Erkrankungen nimmt immer mehr zu , wohingegen diese operative Vorgehensweise bei malignen Erkrankungen weiterhin sehr umstritten bleibt . Obwohl die Lokalisation von Tumormetastasen im Bereich von Wundraendern an sich nichts Neues darstellt , so ist doch das moegliche Auftreten von Metastasen im Bereich der Trokareinstichstelle der Haupteinwand gegen das laparoskopische Operieren von Malignomen . In diesem Zusammenhang ist es notwendig Indikationen und Kontraindikationen sowie das standardisierte laparoskopische Procedere , genau zu definieren . Alleinige laparoskopische Techniken oder kombiniert laparoskopisch/offene Verfahren bieten jeweils Vor- und Nachteile , die der Chirurg in seine therapeutische Entscheidung mit einfliessen lassen sollte . Die individuelle Erfahrung des Operationsteams und die Ausdehnung der malignen Erkrankung legt die Grenzen des laparoskopisch Machbaren fest . Nur durch eine Fortfuehrung der Forschungsaktivitaet , der Entwicklung " intelligenter " Instrumente sowie der Etablierung standardisierter Techniken kann die laparoskopische Chirurgie einen klaren Stellenwert bei der Behandlung maligner gastrointestinaler Tumoren erhalten . Instructions: please typing these entity words according to sentence: Chirurgie, Behandlung, Tumormetastasen, Metastasen, Trokareinstichstelle, Kontraindikationen, Techniken, Instrumente, Techniken, Chirurgie, Behandlung, Tumoren Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Die Bedeutung der laparoskopischen Chirurgie zur operativen Behandlung benigner gastrointestinaler Erkrankungen nimmt immer mehr zu , wohingegen diese operative Vorgehensweise bei malignen Erkrankungen weiterhin sehr umstritten bleibt . Obwohl die Lokalisation von Tumormetastasen im Bereich von Wundraendern an sich nichts Neues darstellt , so ist doch das moegliche Auftreten von Metastasen im Bereich der Trokareinstichstelle der Haupteinwand gegen das laparoskopische Operieren von Malignomen . In diesem Zusammenhang ist es notwendig Indikationen und Kontraindikationen sowie das standardisierte laparoskopische Procedere , genau zu definieren . Alleinige laparoskopische Techniken oder kombiniert laparoskopisch/offene Verfahren bieten jeweils Vor- und Nachteile , die der Chirurg in seine therapeutische Entscheidung mit einfliessen lassen sollte . Die individuelle Erfahrung des Operationsteams und die Ausdehnung der malignen Erkrankung legt die Grenzen des laparoskopisch Machbaren fest . Nur durch eine Fortfuehrung der Forschungsaktivitaet , der Entwicklung " intelligenter " Instrumente sowie der Etablierung standardisierter Techniken kann die laparoskopische Chirurgie einen klaren Stellenwert bei der Behandlung maligner gastrointestinaler Tumoren erhalten .
[ "Zusammenfassung", ".", "Die", "Bedeutung", "der", "laparoskopischen", "Chirurgie", "zur", "operativen", "Behandlung", "benigner", "gastrointestinaler", "Erkrankungen", "nimmt", "immer", "mehr", "zu", ",", "wohingegen", "diese", "operative", "Vorgehensweise", "bei", "malignen", "Erkrankungen", "weiterhin", "sehr", "umstritten", "bleibt", ".", "Obwohl", "die", "Lokalisation", "von", "Tumormetastasen", "im", "Bereich", "von", "Wundraendern", "an", "sich", "nichts", "Neues", "darstellt", ",", "so", "ist", "doch", "das", "moegliche", "Auftreten", "von", "Metastasen", "im", "Bereich", "der", "Trokareinstichstelle", "der", "Haupteinwand", "gegen", "das", "laparoskopische", "Operieren", "von", "Malignomen", ".", "In", "diesem", "Zusammenhang", "ist", "es", "notwendig", "Indikationen", "und", "Kontraindikationen", "sowie", "das", "standardisierte", "laparoskopische", "Procedere", ",", "genau", "zu", "definieren", ".", "Alleinige", "laparoskopische", "Techniken", "oder", "kombiniert", "laparoskopisch", "/", "offene", "Verfahren", "bieten", "jeweils", "Vor-", "und", "Nachteile", ",", "die", "der", "Chirurg", "in", "seine", "therapeutische", "Entscheidung", "mit", "einfliessen", "lassen", "sollte", ".", "Die", "individuelle", "Erfahrung", "des", "Operationsteams", "und", "die", "Ausdehnung", "der", "malignen", "Erkrankung", "legt", "die", "Grenzen", "des", "laparoskopisch", "Machbaren", "fest", ".", "Nur", "durch", "eine", "Fortfuehrung", "der", "Forschungsaktivitaet", ",", "der", "Entwicklung", "\"", "intelligenter", "\"", "Instrumente", "sowie", "der", "Etablierung", "standardisierter", "Techniken", "kann", "die", "laparoskopische", "Chirurgie", "einen", "klaren", "Stellenwert", "bei", "der", "Behandlung", "maligner", "gastrointestinaler", "Tumoren", "erhalten", "." ]
[ "umlsterm" ]
Chirurgie, Behandlung, Tumormetastasen, Metastasen, Trokareinstichstelle, Kontraindikationen, Techniken, Instrumente, Techniken, Chirurgie, Behandlung, Tumoren
DerChirurg.70680210.ger.abstr_task2
Sentence: Zusammenfassung . Die Bedeutung der laparoskopischen Chirurgie zur operativen Behandlung benigner gastrointestinaler Erkrankungen nimmt immer mehr zu , wohingegen diese operative Vorgehensweise bei malignen Erkrankungen weiterhin sehr umstritten bleibt . Obwohl die Lokalisation von Tumormetastasen im Bereich von Wundraendern an sich nichts Neues darstellt , so ist doch das moegliche Auftreten von Metastasen im Bereich der Trokareinstichstelle der Haupteinwand gegen das laparoskopische Operieren von Malignomen . In diesem Zusammenhang ist es notwendig Indikationen und Kontraindikationen sowie das standardisierte laparoskopische Procedere , genau zu definieren . Alleinige laparoskopische Techniken oder kombiniert laparoskopisch/offene Verfahren bieten jeweils Vor- und Nachteile , die der Chirurg in seine therapeutische Entscheidung mit einfliessen lassen sollte . Die individuelle Erfahrung des Operationsteams und die Ausdehnung der malignen Erkrankung legt die Grenzen des laparoskopisch Machbaren fest . Nur durch eine Fortfuehrung der Forschungsaktivitaet , der Entwicklung " intelligenter " Instrumente sowie der Etablierung standardisierter Techniken kann die laparoskopische Chirurgie einen klaren Stellenwert bei der Behandlung maligner gastrointestinaler Tumoren erhalten . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O" ]
Zusammenfassung . Die Bedeutung der laparoskopischen Chirurgie zur operativen Behandlung benigner gastrointestinaler Erkrankungen nimmt immer mehr zu , wohingegen diese operative Vorgehensweise bei malignen Erkrankungen weiterhin sehr umstritten bleibt . Obwohl die Lokalisation von Tumormetastasen im Bereich von Wundraendern an sich nichts Neues darstellt , so ist doch das moegliche Auftreten von Metastasen im Bereich der Trokareinstichstelle der Haupteinwand gegen das laparoskopische Operieren von Malignomen . In diesem Zusammenhang ist es notwendig Indikationen und Kontraindikationen sowie das standardisierte laparoskopische Procedere , genau zu definieren . Alleinige laparoskopische Techniken oder kombiniert laparoskopisch/offene Verfahren bieten jeweils Vor- und Nachteile , die der Chirurg in seine therapeutische Entscheidung mit einfliessen lassen sollte . Die individuelle Erfahrung des Operationsteams und die Ausdehnung der malignen Erkrankung legt die Grenzen des laparoskopisch Machbaren fest . Nur durch eine Fortfuehrung der Forschungsaktivitaet , der Entwicklung " intelligenter " Instrumente sowie der Etablierung standardisierter Techniken kann die laparoskopische Chirurgie einen klaren Stellenwert bei der Behandlung maligner gastrointestinaler Tumoren erhalten .
[ "Zusammenfassung", ".", "Die", "Bedeutung", "der", "laparoskopischen", "Chirurgie", "zur", "operativen", "Behandlung", "benigner", "gastrointestinaler", "Erkrankungen", "nimmt", "immer", "mehr", "zu", ",", "wohingegen", "diese", "operative", "Vorgehensweise", "bei", "malignen", "Erkrankungen", "weiterhin", "sehr", "umstritten", "bleibt", ".", "Obwohl", "die", "Lokalisation", "von", "Tumormetastasen", "im", "Bereich", "von", "Wundraendern", "an", "sich", "nichts", "Neues", "darstellt", ",", "so", "ist", "doch", "das", "moegliche", "Auftreten", "von", "Metastasen", "im", "Bereich", "der", "Trokareinstichstelle", "der", "Haupteinwand", "gegen", "das", "laparoskopische", "Operieren", "von", "Malignomen", ".", "In", "diesem", "Zusammenhang", "ist", "es", "notwendig", "Indikationen", "und", "Kontraindikationen", "sowie", "das", "standardisierte", "laparoskopische", "Procedere", ",", "genau", "zu", "definieren", ".", "Alleinige", "laparoskopische", "Techniken", "oder", "kombiniert", "laparoskopisch", "/", "offene", "Verfahren", "bieten", "jeweils", "Vor-", "und", "Nachteile", ",", "die", "der", "Chirurg", "in", "seine", "therapeutische", "Entscheidung", "mit", "einfliessen", "lassen", "sollte", ".", "Die", "individuelle", "Erfahrung", "des", "Operationsteams", "und", "die", "Ausdehnung", "der", "malignen", "Erkrankung", "legt", "die", "Grenzen", "des", "laparoskopisch", "Machbaren", "fest", ".", "Nur", "durch", "eine", "Fortfuehrung", "der", "Forschungsaktivitaet", ",", "der", "Entwicklung", "\"", "intelligenter", "\"", "Instrumente", "sowie", "der", "Etablierung", "standardisierter", "Techniken", "kann", "die", "laparoskopische", "Chirurgie", "einen", "klaren", "Stellenwert", "bei", "der", "Behandlung", "maligner", "gastrointestinaler", "Tumoren", "erhalten", "." ]
[ "umlsterm" ]
Luesinfektion is an umlsterm, Hautveraenderung is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Dunkelfeldmikroskopie is an umlsterm, Biopsiematerial is an umlsterm, Spirochaeten is an umlsterm, Lues is an umlsterm, Mundschleimhauterkrankungen is an umlsterm
DerHautarzt.40450639.ger.abstr_task0
Sentence: Zusammenfassung . Wir berichten ueber eine Luesinfektion im Stadium II , die sich klinisch als symptomarme erosive Hautveraenderung im Bereich der Mundhoehle manifestierte . Die Diagnose wurde bei einem Patienten mit Hilfe der Dunkelfeldmikroskopie , ueber das Vorliegen typischer serologischer Parameter und im Biopsiematerial nachweisbarer Spirochaeten gestellt . In Abhaengigkeit von dem klinischen Bild sollte daher die Lues bei differentialdiagnostischen Ueberlegungen zu Mundschleimhauterkrankungen nicht vergessen werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Zusammenfassung . Wir berichten ueber eine Luesinfektion im Stadium II , die sich klinisch als symptomarme erosive Hautveraenderung im Bereich der Mundhoehle manifestierte . Die Diagnose wurde bei einem Patienten mit Hilfe der Dunkelfeldmikroskopie , ueber das Vorliegen typischer serologischer Parameter und im Biopsiematerial nachweisbarer Spirochaeten gestellt . In Abhaengigkeit von dem klinischen Bild sollte daher die Lues bei differentialdiagnostischen Ueberlegungen zu Mundschleimhauterkrankungen nicht vergessen werden .
[ "Zusammenfassung", ".", "Wir", "berichten", "ueber", "eine", "Luesinfektion", "im", "Stadium", "II", ",", "die", "sich", "klinisch", "als", "symptomarme", "erosive", "Hautveraenderung", "im", "Bereich", "der", "Mundhoehle", "manifestierte", ".", "Die", "Diagnose", "wurde", "bei", "einem", "Patienten", "mit", "Hilfe", "der", "Dunkelfeldmikroskopie", ",", "ueber", "das", "Vorliegen", "typischer", "serologischer", "Parameter", "und", "im", "Biopsiematerial", "nachweisbarer", "Spirochaeten", "gestellt", ".", "In", "Abhaengigkeit", "von", "dem", "klinischen", "Bild", "sollte", "daher", "die", "Lues", "bei", "differentialdiagnostischen", "Ueberlegungen", "zu", "Mundschleimhauterkrankungen", "nicht", "vergessen", "werden", "." ]
[ "umlsterm" ]
Luesinfektion is an umlsterm, Hautveraenderung is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Dunkelfeldmikroskopie is an umlsterm, Biopsiematerial is an umlsterm, Spirochaeten is an umlsterm, Lues is an umlsterm, Mundschleimhauterkrankungen is an umlsterm
DerHautarzt.40450639.ger.abstr_task1
Sentence: Zusammenfassung . Wir berichten ueber eine Luesinfektion im Stadium II , die sich klinisch als symptomarme erosive Hautveraenderung im Bereich der Mundhoehle manifestierte . Die Diagnose wurde bei einem Patienten mit Hilfe der Dunkelfeldmikroskopie , ueber das Vorliegen typischer serologischer Parameter und im Biopsiematerial nachweisbarer Spirochaeten gestellt . In Abhaengigkeit von dem klinischen Bild sollte daher die Lues bei differentialdiagnostischen Ueberlegungen zu Mundschleimhauterkrankungen nicht vergessen werden . Instructions: please typing these entity words according to sentence: Luesinfektion, Hautveraenderung, Diagnose, Patienten, Dunkelfeldmikroskopie, Biopsiematerial, Spirochaeten, Lues, Mundschleimhauterkrankungen Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Zusammenfassung . Wir berichten ueber eine Luesinfektion im Stadium II , die sich klinisch als symptomarme erosive Hautveraenderung im Bereich der Mundhoehle manifestierte . Die Diagnose wurde bei einem Patienten mit Hilfe der Dunkelfeldmikroskopie , ueber das Vorliegen typischer serologischer Parameter und im Biopsiematerial nachweisbarer Spirochaeten gestellt . In Abhaengigkeit von dem klinischen Bild sollte daher die Lues bei differentialdiagnostischen Ueberlegungen zu Mundschleimhauterkrankungen nicht vergessen werden .
[ "Zusammenfassung", ".", "Wir", "berichten", "ueber", "eine", "Luesinfektion", "im", "Stadium", "II", ",", "die", "sich", "klinisch", "als", "symptomarme", "erosive", "Hautveraenderung", "im", "Bereich", "der", "Mundhoehle", "manifestierte", ".", "Die", "Diagnose", "wurde", "bei", "einem", "Patienten", "mit", "Hilfe", "der", "Dunkelfeldmikroskopie", ",", "ueber", "das", "Vorliegen", "typischer", "serologischer", "Parameter", "und", "im", "Biopsiematerial", "nachweisbarer", "Spirochaeten", "gestellt", ".", "In", "Abhaengigkeit", "von", "dem", "klinischen", "Bild", "sollte", "daher", "die", "Lues", "bei", "differentialdiagnostischen", "Ueberlegungen", "zu", "Mundschleimhauterkrankungen", "nicht", "vergessen", "werden", "." ]
[ "umlsterm" ]
Luesinfektion, Hautveraenderung, Diagnose, Patienten, Dunkelfeldmikroskopie, Biopsiematerial, Spirochaeten, Lues, Mundschleimhauterkrankungen
DerHautarzt.40450639.ger.abstr_task2
Sentence: Zusammenfassung . Wir berichten ueber eine Luesinfektion im Stadium II , die sich klinisch als symptomarme erosive Hautveraenderung im Bereich der Mundhoehle manifestierte . Die Diagnose wurde bei einem Patienten mit Hilfe der Dunkelfeldmikroskopie , ueber das Vorliegen typischer serologischer Parameter und im Biopsiematerial nachweisbarer Spirochaeten gestellt . In Abhaengigkeit von dem klinischen Bild sollte daher die Lues bei differentialdiagnostischen Ueberlegungen zu Mundschleimhauterkrankungen nicht vergessen werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Zusammenfassung . Wir berichten ueber eine Luesinfektion im Stadium II , die sich klinisch als symptomarme erosive Hautveraenderung im Bereich der Mundhoehle manifestierte . Die Diagnose wurde bei einem Patienten mit Hilfe der Dunkelfeldmikroskopie , ueber das Vorliegen typischer serologischer Parameter und im Biopsiematerial nachweisbarer Spirochaeten gestellt . In Abhaengigkeit von dem klinischen Bild sollte daher die Lues bei differentialdiagnostischen Ueberlegungen zu Mundschleimhauterkrankungen nicht vergessen werden .
[ "Zusammenfassung", ".", "Wir", "berichten", "ueber", "eine", "Luesinfektion", "im", "Stadium", "II", ",", "die", "sich", "klinisch", "als", "symptomarme", "erosive", "Hautveraenderung", "im", "Bereich", "der", "Mundhoehle", "manifestierte", ".", "Die", "Diagnose", "wurde", "bei", "einem", "Patienten", "mit", "Hilfe", "der", "Dunkelfeldmikroskopie", ",", "ueber", "das", "Vorliegen", "typischer", "serologischer", "Parameter", "und", "im", "Biopsiematerial", "nachweisbarer", "Spirochaeten", "gestellt", ".", "In", "Abhaengigkeit", "von", "dem", "klinischen", "Bild", "sollte", "daher", "die", "Lues", "bei", "differentialdiagnostischen", "Ueberlegungen", "zu", "Mundschleimhauterkrankungen", "nicht", "vergessen", "werden", "." ]
[ "umlsterm" ]
pranlukast is a CHEMICAL, leukotriene receptor is a GENE-N, Leukotriene is a CHEMICAL, Pranlukast is a CHEMICAL, CysLt1 is a GENE-Y, leukotriene receptor is a GENE-N, pranlukast is a CHEMICAL, corticosteroids is a CHEMICAL, pranlukast is a CHEMICAL, Pranlukast is a CHEMICAL, pranlukast is a CHEMICAL, pranlukast is a CHEMICAL, Pranlukast is a CHEMICAL, leukotriene is a CHEMICAL
12171_task0
Sentence: Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. OBJECTIVE: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. METHODOLOGY: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with beta2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. RESULTS: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n = 98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of beta2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 +/- 10.1 L/min at baseline, 394.5 +/- 10.1 at week 2, 396.3 +/- 10.4 at week 4). There were no serious adverse reactions. CONCLUSION: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, GENE-N, CHEMICAL
[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. OBJECTIVE: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. METHODOLOGY: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with beta2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. RESULTS: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n = 98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of beta2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 +/- 10.1 L/min at baseline, 394.5 +/- 10.1 at week 2, 396.3 +/- 10.4 at week 4). There were no serious adverse reactions. CONCLUSION: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.
[ "Clinical", "effects", "of", "pranlukast", ",", "an", "oral", "leukotriene", "receptor", "antagonist", ",", "in", "mild", "-", "to", "-", "moderate", "asthma", ":", "a", "4", "week", "randomized", "multicentre", "controlled", "trial", ".", "\n", "OBJECTIVE", ":", "Leukotriene", "antagonists", "are", "increasingly", "used", "in", "asthma", "management", ".", "Pranlukast", "is", "a", "new", ",", "orally", "active", ",", "selective", "inhibitor", "of", "CysLt1", "leukotriene", "receptor", ".", "The", "present", "clinical", "trial", "was", "performed", "to", "study", "the", "effect", "and", "safety", "of", "pranlukast", "in", "mild", "-", "to", "-", "moderate", "asthma", ".", "METHODOLOGY", ":", "A", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "group", "study", "was", "performed", "in", "eight", "medical", "centres", "in", "Korea", ".", "Mild", "-", "to", "-", "moderate", "asthma", "patients", "who", "had", "been", "treated", "with", "beta2-agonists", "and", "/", "or", "inhaled", "corticosteroids", "were", "studied", ".", "The", "patients", "'", "symptoms", "were", "evaluated", "by", "asthma", "diary", "and", "twice", "-", "daily", "peak", "flow", "monitoring", ".", "RESULTS", ":", "Of", "the", "206", "patients", "enrolled", ",", "197", "were", "eligible", "for", "analysis", ".", "The", "pranlukast", "group", "(", "n", "=", "98", ")", "showed", "statistically", "significant", "improvement", "in", "asthma", "symptoms", ",", "including", "asthma", "attack", "rate", ",", "daily", "living", "score", ",", "and", "morning", "and", "evening", "asthma", "scores", ".", "Pranlukast", "significantly", "reduced", "the", "consumption", "of", "beta2-agonist", ".", "Compared", "with", "the", "placebo", "group", ",", "forced", "vital", "capacity", "(", "FVC", ")", "and", "forced", "expiratory", "volume", "in", "1", "s", "(", "FEV1", ")", "were", "not", "significantly", "higher", "in", "the", "pranlukast", "group", ".", "Morning", "and", "evening", "peak", "expiratory", "flow", "(", "PEF", ")", "were", "significantly", "increased", "after", "pranlukast", "treatment", "at", "weeks", "2", "and", "4", "(", "380.8", "+", "/-", "10.1", "L", "/", "min", "at", "baseline", ",", "394.5", "+", "/-", "10.1", "at", "week", "2", ",", "396.3", "+", "/-", "10.4", "at", "week", "4", ")", ".", "There", "were", "no", "serious", "adverse", "reactions", ".", "CONCLUSION", ":", "Pranlukast", ",", "an", "oral", "leukotriene", "antagonist", ",", "was", "well", "tolerated", "and", "was", "effective", "for", "the", "management", "of", "mild", "-", "to", "-", "moderate", "asthma", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
pranlukast is a CHEMICAL, leukotriene receptor is a GENE-N, Leukotriene is a CHEMICAL, Pranlukast is a CHEMICAL, CysLt1 is a GENE-Y, leukotriene receptor is a GENE-N, pranlukast is a CHEMICAL, corticosteroids is a CHEMICAL, pranlukast is a CHEMICAL, Pranlukast is a CHEMICAL, pranlukast is a CHEMICAL, pranlukast is a CHEMICAL, Pranlukast is a CHEMICAL, leukotriene is a CHEMICAL
12171_task1
Sentence: Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. OBJECTIVE: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. METHODOLOGY: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with beta2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. RESULTS: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n = 98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of beta2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 +/- 10.1 L/min at baseline, 394.5 +/- 10.1 at week 2, 396.3 +/- 10.4 at week 4). There were no serious adverse reactions. CONCLUSION: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma. Instructions: please typing these entity words according to sentence: pranlukast, leukotriene receptor, Leukotriene, Pranlukast, CysLt1, leukotriene receptor, pranlukast, corticosteroids, pranlukast, Pranlukast, pranlukast, pranlukast, Pranlukast, leukotriene Options: GENE-Y, GENE-N, CHEMICAL
[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. OBJECTIVE: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. METHODOLOGY: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with beta2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. RESULTS: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n = 98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of beta2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 +/- 10.1 L/min at baseline, 394.5 +/- 10.1 at week 2, 396.3 +/- 10.4 at week 4). There were no serious adverse reactions. CONCLUSION: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.
[ "Clinical", "effects", "of", "pranlukast", ",", "an", "oral", "leukotriene", "receptor", "antagonist", ",", "in", "mild", "-", "to", "-", "moderate", "asthma", ":", "a", "4", "week", "randomized", "multicentre", "controlled", "trial", ".", "\n", "OBJECTIVE", ":", "Leukotriene", "antagonists", "are", "increasingly", "used", "in", "asthma", "management", ".", "Pranlukast", "is", "a", "new", ",", "orally", "active", ",", "selective", "inhibitor", "of", "CysLt1", "leukotriene", "receptor", ".", "The", "present", "clinical", "trial", "was", "performed", "to", "study", "the", "effect", "and", "safety", "of", "pranlukast", "in", "mild", "-", "to", "-", "moderate", "asthma", ".", "METHODOLOGY", ":", "A", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "group", "study", "was", "performed", "in", "eight", "medical", "centres", "in", "Korea", ".", "Mild", "-", "to", "-", "moderate", "asthma", "patients", "who", "had", "been", "treated", "with", "beta2-agonists", "and", "/", "or", "inhaled", "corticosteroids", "were", "studied", ".", "The", "patients", "'", "symptoms", "were", "evaluated", "by", "asthma", "diary", "and", "twice", "-", "daily", "peak", "flow", "monitoring", ".", "RESULTS", ":", "Of", "the", "206", "patients", "enrolled", ",", "197", "were", "eligible", "for", "analysis", ".", "The", "pranlukast", "group", "(", "n", "=", "98", ")", "showed", "statistically", "significant", "improvement", "in", "asthma", "symptoms", ",", "including", "asthma", "attack", "rate", ",", "daily", "living", "score", ",", "and", "morning", "and", "evening", "asthma", "scores", ".", "Pranlukast", "significantly", "reduced", "the", "consumption", "of", "beta2-agonist", ".", "Compared", "with", "the", "placebo", "group", ",", "forced", "vital", "capacity", "(", "FVC", ")", "and", "forced", "expiratory", "volume", "in", "1", "s", "(", "FEV1", ")", "were", "not", "significantly", "higher", "in", "the", "pranlukast", "group", ".", "Morning", "and", "evening", "peak", "expiratory", "flow", "(", "PEF", ")", "were", "significantly", "increased", "after", "pranlukast", "treatment", "at", "weeks", "2", "and", "4", "(", "380.8", "+", "/-", "10.1", "L", "/", "min", "at", "baseline", ",", "394.5", "+", "/-", "10.1", "at", "week", "2", ",", "396.3", "+", "/-", "10.4", "at", "week", "4", ")", ".", "There", "were", "no", "serious", "adverse", "reactions", ".", "CONCLUSION", ":", "Pranlukast", ",", "an", "oral", "leukotriene", "antagonist", ",", "was", "well", "tolerated", "and", "was", "effective", "for", "the", "management", "of", "mild", "-", "to", "-", "moderate", "asthma", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
pranlukast, leukotriene receptor, Leukotriene, Pranlukast, CysLt1, leukotriene receptor, pranlukast, corticosteroids, pranlukast, Pranlukast, pranlukast, pranlukast, Pranlukast, leukotriene
12171_task2
Sentence: Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. OBJECTIVE: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. METHODOLOGY: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with beta2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. RESULTS: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n = 98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of beta2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 +/- 10.1 L/min at baseline, 394.5 +/- 10.1 at week 2, 396.3 +/- 10.4 at week 4). There were no serious adverse reactions. CONCLUSION: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. OBJECTIVE: Leukotriene antagonists are increasingly used in asthma management. Pranlukast is a new, orally active, selective inhibitor of CysLt1 leukotriene receptor. The present clinical trial was performed to study the effect and safety of pranlukast in mild-to-moderate asthma. METHODOLOGY: A randomized, double-blind, placebo-controlled, parallel group study was performed in eight medical centres in Korea. Mild-to-moderate asthma patients who had been treated with beta2-agonists and/or inhaled corticosteroids were studied. The patients' symptoms were evaluated by asthma diary and twice-daily peak flow monitoring. RESULTS: Of the 206 patients enrolled, 197 were eligible for analysis. The pranlukast group (n = 98) showed statistically significant improvement in asthma symptoms, including asthma attack rate, daily living score, and morning and evening asthma scores. Pranlukast significantly reduced the consumption of beta2-agonist. Compared with the placebo group, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1) were not significantly higher in the pranlukast group. Morning and evening peak expiratory flow (PEF) were significantly increased after pranlukast treatment at weeks 2 and 4 (380.8 +/- 10.1 L/min at baseline, 394.5 +/- 10.1 at week 2, 396.3 +/- 10.4 at week 4). There were no serious adverse reactions. CONCLUSION: Pranlukast, an oral leukotriene antagonist, was well tolerated and was effective for the management of mild-to-moderate asthma.
[ "Clinical", "effects", "of", "pranlukast", ",", "an", "oral", "leukotriene", "receptor", "antagonist", ",", "in", "mild", "-", "to", "-", "moderate", "asthma", ":", "a", "4", "week", "randomized", "multicentre", "controlled", "trial", ".", "\n", "OBJECTIVE", ":", "Leukotriene", "antagonists", "are", "increasingly", "used", "in", "asthma", "management", ".", "Pranlukast", "is", "a", "new", ",", "orally", "active", ",", "selective", "inhibitor", "of", "CysLt1", "leukotriene", "receptor", ".", "The", "present", "clinical", "trial", "was", "performed", "to", "study", "the", "effect", "and", "safety", "of", "pranlukast", "in", "mild", "-", "to", "-", "moderate", "asthma", ".", "METHODOLOGY", ":", "A", "randomized", ",", "double", "-", "blind", ",", "placebo", "-", "controlled", ",", "parallel", "group", "study", "was", "performed", "in", "eight", "medical", "centres", "in", "Korea", ".", "Mild", "-", "to", "-", "moderate", "asthma", "patients", "who", "had", "been", "treated", "with", "beta2-agonists", "and", "/", "or", "inhaled", "corticosteroids", "were", "studied", ".", "The", "patients", "'", "symptoms", "were", "evaluated", "by", "asthma", "diary", "and", "twice", "-", "daily", "peak", "flow", "monitoring", ".", "RESULTS", ":", "Of", "the", "206", "patients", "enrolled", ",", "197", "were", "eligible", "for", "analysis", ".", "The", "pranlukast", "group", "(", "n", "=", "98", ")", "showed", "statistically", "significant", "improvement", "in", "asthma", "symptoms", ",", "including", "asthma", "attack", "rate", ",", "daily", "living", "score", ",", "and", "morning", "and", "evening", "asthma", "scores", ".", "Pranlukast", "significantly", "reduced", "the", "consumption", "of", "beta2-agonist", ".", "Compared", "with", "the", "placebo", "group", ",", "forced", "vital", "capacity", "(", "FVC", ")", "and", "forced", "expiratory", "volume", "in", "1", "s", "(", "FEV1", ")", "were", "not", "significantly", "higher", "in", "the", "pranlukast", "group", ".", "Morning", "and", "evening", "peak", "expiratory", "flow", "(", "PEF", ")", "were", "significantly", "increased", "after", "pranlukast", "treatment", "at", "weeks", "2", "and", "4", "(", "380.8", "+", "/-", "10.1", "L", "/", "min", "at", "baseline", ",", "394.5", "+", "/-", "10.1", "at", "week", "2", ",", "396.3", "+", "/-", "10.4", "at", "week", "4", ")", ".", "There", "were", "no", "serious", "adverse", "reactions", ".", "CONCLUSION", ":", "Pranlukast", ",", "an", "oral", "leukotriene", "antagonist", ",", "was", "well", "tolerated", "and", "was", "effective", "for", "the", "management", "of", "mild", "-", "to", "-", "moderate", "asthma", "." ]
[ "GENE-N", "CHEMICAL", "GENE-Y" ]
patients is an umlsterm, colorectal surgery is an umlsterm, epidural anaesthesia is an umlsterm, light is an umlsterm, general anaesthesia is an umlsterm, propofol is an umlsterm, halothane is an umlsterm, ethics is an umlsterm, All is an umlsterm, patients is an umlsterm, epidural anaesthesia is an umlsterm, bupivacaine is an umlsterm, halothane is an umlsterm, light is an umlsterm, general anaesthesia is an umlsterm, thiopental is an umlsterm, halothane is an umlsterm, propofol is an umlsterm, midazolam is an umlsterm, fentanyl is an umlsterm, maintenance is an umlsterm, All is an umlsterm, patients is an umlsterm, non - depolarising muscle relaxants is an umlsterm, oxide - oxygen is an umlsterm, postoperative is an umlsterm, analgesia is an umlsterm, morphine is an umlsterm, operation is an umlsterm, recovery room is an umlsterm, test is an umlsterm, ability is an umlsterm, test is an umlsterm, test is an umlsterm, Heart rate is an umlsterm, blood pressure is an umlsterm, oxygen is an umlsterm, blood gases is an umlsterm, age is an umlsterm, sex is an umlsterm, ASA is an umlsterm, classification is an umlsterm, operation is an umlsterm, tests is an umlsterm, blood pressure is an umlsterm, heart rate is an umlsterm, blood gas analysis is an umlsterm, oxygen is an umlsterm, postoperative is an umlsterm, values is an umlsterm, patients is an umlsterm, propofol is an umlsterm, hypercapnia is an umlsterm, Patients is an umlsterm, propofol is an umlsterm, postoperative nausea is an umlsterm, vomiting is an umlsterm, halothane is an umlsterm, propofol is an umlsterm, halothane is an umlsterm, postoperative is an umlsterm, techniques is an umlsterm, Propofol is an umlsterm, postoperative nausea is an umlsterm, vomiting is an umlsterm, halothane is an umlsterm
DerAnaesthesist.40430159.eng.abstr_task0
Sentence: Early mental and psychomotor recovery was studied in 67 patients undergoing colorectal surgery under continuous epidural anaesthesia and light general anaesthesia using propofol , halothane , and midazolam/fentanyl . The study was approved by the local ethics commitee . All patients received epidural anaesthesia with 0.25% bupivacaine and were then randomly allocated to one of three groups . In group I ( halothane ) , light general anaesthesia was induced with thiopental 3 - 5 mg/kg and maintained with halothane . The propofol group ( II ) received 2 mg/kg for induction and a mean continuous infusion of 1.7 mg/kg - h . In group III ( Mi/Fe ) , midazolam and fentanyl were used for induction and maintenance . All patients were intubated , received non-depolarising muscle relaxants , and were manually ventilated with nitrous oxide-oxygen ( 2 : 1.2 ) . For postoperative analgesia , 0.05 mg/kg morphine was administrated epidurally 30 min before the end of the operation ; 30 , 60 , 90 , and 120 min after arriving in the recovery room , vigilance was assessed using a modified Steward score , the Trieger test , the ability to recall a column of numbers ( KAI test ) , and symbol counting ( CI test ) . Heart rate , blood pressure , arterial oxygen saturation , and blood gases were recorded . Results . The three groups were comparable with regard to age , sex , ASA classification , and duration of anaesthesia and operation ( Table 3 ) . There was no difference between the groups in performance of the recovery tests ( Figs . 2 - 5 ) , blood pressure , heart rate , arterial blood gas analysis ( Fig . 6 ) , or oxygen saturation . Comparing pre- and postoperative values , we found severe psychomotor and mental impairment in all groups . pCO2 was slightly elevated in all groups , but only 3 patients in the propofol group and 6 in the midazolam/fentanyl group developed hypercapnia above 50 mm Hg. Patients receiving propofol or midazolam/fentanyl had significantly less postoperative nausea and vomiting than those receiving halothane ( Table 5 ) . Conclusion . It is concluded that propofol offers no advantage over halothane or midazolam/fentanyl where early postoperative recovery is concerned . Intraoperatively , all three techniques provided good anaesthesia . Propofol and midazolam/fentanyl caused less postoperative nausea and vomiting than halothane anaesthesia . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]
Early mental and psychomotor recovery was studied in 67 patients undergoing colorectal surgery under continuous epidural anaesthesia and light general anaesthesia using propofol , halothane , and midazolam/fentanyl . The study was approved by the local ethics commitee . All patients received epidural anaesthesia with 0.25% bupivacaine and were then randomly allocated to one of three groups . In group I ( halothane ) , light general anaesthesia was induced with thiopental 3 - 5 mg/kg and maintained with halothane . The propofol group ( II ) received 2 mg/kg for induction and a mean continuous infusion of 1.7 mg/kg - h . In group III ( Mi/Fe ) , midazolam and fentanyl were used for induction and maintenance . All patients were intubated , received non-depolarising muscle relaxants , and were manually ventilated with nitrous oxide-oxygen ( 2 : 1.2 ) . For postoperative analgesia , 0.05 mg/kg morphine was administrated epidurally 30 min before the end of the operation ; 30 , 60 , 90 , and 120 min after arriving in the recovery room , vigilance was assessed using a modified Steward score , the Trieger test , the ability to recall a column of numbers ( KAI test ) , and symbol counting ( CI test ) . Heart rate , blood pressure , arterial oxygen saturation , and blood gases were recorded . Results . The three groups were comparable with regard to age , sex , ASA classification , and duration of anaesthesia and operation ( Table 3 ) . There was no difference between the groups in performance of the recovery tests ( Figs . 2 - 5 ) , blood pressure , heart rate , arterial blood gas analysis ( Fig . 6 ) , or oxygen saturation . Comparing pre- and postoperative values , we found severe psychomotor and mental impairment in all groups . pCO2 was slightly elevated in all groups , but only 3 patients in the propofol group and 6 in the midazolam/fentanyl group developed hypercapnia above 50 mm Hg. Patients receiving propofol or midazolam/fentanyl had significantly less postoperative nausea and vomiting than those receiving halothane ( Table 5 ) . Conclusion . It is concluded that propofol offers no advantage over halothane or midazolam/fentanyl where early postoperative recovery is concerned . Intraoperatively , all three techniques provided good anaesthesia . Propofol and midazolam/fentanyl caused less postoperative nausea and vomiting than halothane anaesthesia .
[ "Early", "mental", "and", "psychomotor", "recovery", "was", "studied", "in", "67", "patients", "undergoing", "colorectal", "surgery", "under", "continuous", "epidural", "anaesthesia", "and", "light", "general", "anaesthesia", "using", "propofol", ",", "halothane", ",", "and", "midazolam", "/", "fentanyl", ".", "The", "study", "was", "approved", "by", "the", "local", "ethics", "commitee", ".", "All", "patients", "received", "epidural", "anaesthesia", "with", "0.25", "%", "bupivacaine", "and", "were", "then", "randomly", "allocated", "to", "one", "of", "three", "groups", ".", "In", "group", "I", "(", "halothane", ")", ",", "light", "general", "anaesthesia", "was", "induced", "with", "thiopental", "3", "-", "5", "mg", "/", "kg", "and", "maintained", "with", "halothane", ".", "The", "propofol", "group", "(", "II", ")", "received", "2", "mg", "/", "kg", "for", "induction", "and", "a", "mean", "continuous", "infusion", "of", "1.7", "mg", "/", "kg", "-", "h", ".", "In", "group", "III", "(", "Mi", "/", "Fe", ")", ",", "midazolam", "and", "fentanyl", "were", "used", "for", "induction", "and", "maintenance", ".", "All", "patients", "were", "intubated", ",", "received", "non", "-", "depolarising", "muscle", "relaxants", ",", "and", "were", "manually", "ventilated", "with", "nitrous", "oxide", "-", "oxygen", "(", "2", ":", "1.2", ")", ".", "For", "postoperative", "analgesia", ",", "0.05", "mg", "/", "kg", "morphine", "was", "administrated", "epidurally", "30", "min", "before", "the", "end", "of", "the", "operation", ";", "30", ",", "60", ",", "90", ",", "and", "120", "min", "after", "arriving", "in", "the", "recovery", "room", ",", "vigilance", "was", "assessed", "using", "a", "modified", "Steward", "score", ",", "the", "Trieger", "test", ",", "the", "ability", "to", "recall", "a", "column", "of", "numbers", "(", "KAI", "test", ")", ",", "and", "symbol", "counting", "(", "CI", "test", ")", ".", "Heart", "rate", ",", "blood", "pressure", ",", "arterial", "oxygen", "saturation", ",", "and", "blood", "gases", "were", "recorded", ".", "Results", ".", "The", "three", "groups", "were", "comparable", "with", "regard", "to", "age", ",", "sex", ",", "ASA", "classification", ",", "and", "duration", "of", "anaesthesia", "and", "operation", "(", "Table", "3", ")", ".", "There", "was", "no", "difference", "between", "the", "groups", "in", "performance", "of", "the", "recovery", "tests", "(", "Figs", ".", "2", "-", "5", ")", ",", "blood", "pressure", ",", "heart", "rate", ",", "arterial", "blood", "gas", "analysis", "(", "Fig", ".", "6", ")", ",", "or", "oxygen", "saturation", ".", "Comparing", "pre-", "and", "postoperative", "values", ",", "we", "found", "severe", "psychomotor", "and", "mental", "impairment", "in", "all", "groups", ".", "pCO2", "was", "slightly", "elevated", "in", "all", "groups", ",", "but", "only", "3", "patients", "in", "the", "propofol", "group", "and", "6", "in", "the", "midazolam", "/", "fentanyl", "group", "developed", "hypercapnia", "above", "50", "mm", "Hg", ".", "Patients", "receiving", "propofol", "or", "midazolam", "/", "fentanyl", "had", "significantly", "less", "postoperative", "nausea", "and", "vomiting", "than", "those", "receiving", "halothane", "(", "Table", "5", ")", ".", "Conclusion", ".", "It", "is", "concluded", "that", "propofol", "offers", "no", "advantage", "over", "halothane", "or", "midazolam", "/", "fentanyl", "where", "early", "postoperative", "recovery", "is", "concerned", ".", "Intraoperatively", ",", "all", "three", "techniques", "provided", "good", "anaesthesia", ".", "Propofol", "and", "midazolam", "/", "fentanyl", "caused", "less", "postoperative", "nausea", "and", "vomiting", "than", "halothane", "anaesthesia", "." ]
[ "umlsterm" ]
patients is an umlsterm, colorectal surgery is an umlsterm, epidural anaesthesia is an umlsterm, light is an umlsterm, general anaesthesia is an umlsterm, propofol is an umlsterm, halothane is an umlsterm, ethics is an umlsterm, All is an umlsterm, patients is an umlsterm, epidural anaesthesia is an umlsterm, bupivacaine is an umlsterm, halothane is an umlsterm, light is an umlsterm, general anaesthesia is an umlsterm, thiopental is an umlsterm, halothane is an umlsterm, propofol is an umlsterm, midazolam is an umlsterm, fentanyl is an umlsterm, maintenance is an umlsterm, All is an umlsterm, patients is an umlsterm, non - depolarising muscle relaxants is an umlsterm, oxide - oxygen is an umlsterm, postoperative is an umlsterm, analgesia is an umlsterm, morphine is an umlsterm, operation is an umlsterm, recovery room is an umlsterm, test is an umlsterm, ability is an umlsterm, test is an umlsterm, test is an umlsterm, Heart rate is an umlsterm, blood pressure is an umlsterm, oxygen is an umlsterm, blood gases is an umlsterm, age is an umlsterm, sex is an umlsterm, ASA is an umlsterm, classification is an umlsterm, operation is an umlsterm, tests is an umlsterm, blood pressure is an umlsterm, heart rate is an umlsterm, blood gas analysis is an umlsterm, oxygen is an umlsterm, postoperative is an umlsterm, values is an umlsterm, patients is an umlsterm, propofol is an umlsterm, hypercapnia is an umlsterm, Patients is an umlsterm, propofol is an umlsterm, postoperative nausea is an umlsterm, vomiting is an umlsterm, halothane is an umlsterm, propofol is an umlsterm, halothane is an umlsterm, postoperative is an umlsterm, techniques is an umlsterm, Propofol is an umlsterm, postoperative nausea is an umlsterm, vomiting is an umlsterm, halothane is an umlsterm
DerAnaesthesist.40430159.eng.abstr_task1
Sentence: Early mental and psychomotor recovery was studied in 67 patients undergoing colorectal surgery under continuous epidural anaesthesia and light general anaesthesia using propofol , halothane , and midazolam/fentanyl . The study was approved by the local ethics commitee . All patients received epidural anaesthesia with 0.25% bupivacaine and were then randomly allocated to one of three groups . In group I ( halothane ) , light general anaesthesia was induced with thiopental 3 - 5 mg/kg and maintained with halothane . The propofol group ( II ) received 2 mg/kg for induction and a mean continuous infusion of 1.7 mg/kg - h . In group III ( Mi/Fe ) , midazolam and fentanyl were used for induction and maintenance . All patients were intubated , received non-depolarising muscle relaxants , and were manually ventilated with nitrous oxide-oxygen ( 2 : 1.2 ) . For postoperative analgesia , 0.05 mg/kg morphine was administrated epidurally 30 min before the end of the operation ; 30 , 60 , 90 , and 120 min after arriving in the recovery room , vigilance was assessed using a modified Steward score , the Trieger test , the ability to recall a column of numbers ( KAI test ) , and symbol counting ( CI test ) . Heart rate , blood pressure , arterial oxygen saturation , and blood gases were recorded . Results . The three groups were comparable with regard to age , sex , ASA classification , and duration of anaesthesia and operation ( Table 3 ) . There was no difference between the groups in performance of the recovery tests ( Figs . 2 - 5 ) , blood pressure , heart rate , arterial blood gas analysis ( Fig . 6 ) , or oxygen saturation . Comparing pre- and postoperative values , we found severe psychomotor and mental impairment in all groups . pCO2 was slightly elevated in all groups , but only 3 patients in the propofol group and 6 in the midazolam/fentanyl group developed hypercapnia above 50 mm Hg. Patients receiving propofol or midazolam/fentanyl had significantly less postoperative nausea and vomiting than those receiving halothane ( Table 5 ) . Conclusion . It is concluded that propofol offers no advantage over halothane or midazolam/fentanyl where early postoperative recovery is concerned . Intraoperatively , all three techniques provided good anaesthesia . Propofol and midazolam/fentanyl caused less postoperative nausea and vomiting than halothane anaesthesia . Instructions: please typing these entity words according to sentence: patients, colorectal surgery, epidural anaesthesia, light, general anaesthesia, propofol, halothane, ethics, All, patients, epidural anaesthesia, bupivacaine, halothane, light, general anaesthesia, thiopental, halothane, propofol, midazolam, fentanyl, maintenance, All, patients, non - depolarising muscle relaxants, oxide - oxygen, postoperative, analgesia, morphine, operation, recovery room, test, ability, test, test, Heart rate, blood pressure, oxygen, blood gases, age, sex, ASA, classification, operation, tests, blood pressure, heart rate, blood gas analysis, oxygen, postoperative, values, patients, propofol, hypercapnia, Patients, propofol, postoperative nausea, vomiting, halothane, propofol, halothane, postoperative, techniques, Propofol, postoperative nausea, vomiting, halothane Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]
Early mental and psychomotor recovery was studied in 67 patients undergoing colorectal surgery under continuous epidural anaesthesia and light general anaesthesia using propofol , halothane , and midazolam/fentanyl . The study was approved by the local ethics commitee . All patients received epidural anaesthesia with 0.25% bupivacaine and were then randomly allocated to one of three groups . In group I ( halothane ) , light general anaesthesia was induced with thiopental 3 - 5 mg/kg and maintained with halothane . The propofol group ( II ) received 2 mg/kg for induction and a mean continuous infusion of 1.7 mg/kg - h . In group III ( Mi/Fe ) , midazolam and fentanyl were used for induction and maintenance . All patients were intubated , received non-depolarising muscle relaxants , and were manually ventilated with nitrous oxide-oxygen ( 2 : 1.2 ) . For postoperative analgesia , 0.05 mg/kg morphine was administrated epidurally 30 min before the end of the operation ; 30 , 60 , 90 , and 120 min after arriving in the recovery room , vigilance was assessed using a modified Steward score , the Trieger test , the ability to recall a column of numbers ( KAI test ) , and symbol counting ( CI test ) . Heart rate , blood pressure , arterial oxygen saturation , and blood gases were recorded . Results . The three groups were comparable with regard to age , sex , ASA classification , and duration of anaesthesia and operation ( Table 3 ) . There was no difference between the groups in performance of the recovery tests ( Figs . 2 - 5 ) , blood pressure , heart rate , arterial blood gas analysis ( Fig . 6 ) , or oxygen saturation . Comparing pre- and postoperative values , we found severe psychomotor and mental impairment in all groups . pCO2 was slightly elevated in all groups , but only 3 patients in the propofol group and 6 in the midazolam/fentanyl group developed hypercapnia above 50 mm Hg. Patients receiving propofol or midazolam/fentanyl had significantly less postoperative nausea and vomiting than those receiving halothane ( Table 5 ) . Conclusion . It is concluded that propofol offers no advantage over halothane or midazolam/fentanyl where early postoperative recovery is concerned . Intraoperatively , all three techniques provided good anaesthesia . Propofol and midazolam/fentanyl caused less postoperative nausea and vomiting than halothane anaesthesia .
[ "Early", "mental", "and", "psychomotor", "recovery", "was", "studied", "in", "67", "patients", "undergoing", "colorectal", "surgery", "under", "continuous", "epidural", "anaesthesia", "and", "light", "general", "anaesthesia", "using", "propofol", ",", "halothane", ",", "and", "midazolam", "/", "fentanyl", ".", "The", "study", "was", "approved", "by", "the", "local", "ethics", "commitee", ".", "All", "patients", "received", "epidural", "anaesthesia", "with", "0.25", "%", "bupivacaine", "and", "were", "then", "randomly", "allocated", "to", "one", "of", "three", "groups", ".", "In", "group", "I", "(", "halothane", ")", ",", "light", "general", "anaesthesia", "was", "induced", "with", "thiopental", "3", "-", "5", "mg", "/", "kg", "and", "maintained", "with", "halothane", ".", "The", "propofol", "group", "(", "II", ")", "received", "2", "mg", "/", "kg", "for", "induction", "and", "a", "mean", "continuous", "infusion", "of", "1.7", "mg", "/", "kg", "-", "h", ".", "In", "group", "III", "(", "Mi", "/", "Fe", ")", ",", "midazolam", "and", "fentanyl", "were", "used", "for", "induction", "and", "maintenance", ".", "All", "patients", "were", "intubated", ",", "received", "non", "-", "depolarising", "muscle", "relaxants", ",", "and", "were", "manually", "ventilated", "with", "nitrous", "oxide", "-", "oxygen", "(", "2", ":", "1.2", ")", ".", "For", "postoperative", "analgesia", ",", "0.05", "mg", "/", "kg", "morphine", "was", "administrated", "epidurally", "30", "min", "before", "the", "end", "of", "the", "operation", ";", "30", ",", "60", ",", "90", ",", "and", "120", "min", "after", "arriving", "in", "the", "recovery", "room", ",", "vigilance", "was", "assessed", "using", "a", "modified", "Steward", "score", ",", "the", "Trieger", "test", ",", "the", "ability", "to", "recall", "a", "column", "of", "numbers", "(", "KAI", "test", ")", ",", "and", "symbol", "counting", "(", "CI", "test", ")", ".", "Heart", "rate", ",", "blood", "pressure", ",", "arterial", "oxygen", "saturation", ",", "and", "blood", "gases", "were", "recorded", ".", "Results", ".", "The", "three", "groups", "were", "comparable", "with", "regard", "to", "age", ",", "sex", ",", "ASA", "classification", ",", "and", "duration", "of", "anaesthesia", "and", "operation", "(", "Table", "3", ")", ".", "There", "was", "no", "difference", "between", "the", "groups", "in", "performance", "of", "the", "recovery", "tests", "(", "Figs", ".", "2", "-", "5", ")", ",", "blood", "pressure", ",", "heart", "rate", ",", "arterial", "blood", "gas", "analysis", "(", "Fig", ".", "6", ")", ",", "or", "oxygen", "saturation", ".", "Comparing", "pre-", "and", "postoperative", "values", ",", "we", "found", "severe", "psychomotor", "and", "mental", "impairment", "in", "all", "groups", ".", "pCO2", "was", "slightly", "elevated", "in", "all", "groups", ",", "but", "only", "3", "patients", "in", "the", "propofol", "group", "and", "6", "in", "the", "midazolam", "/", "fentanyl", "group", "developed", "hypercapnia", "above", "50", "mm", "Hg", ".", "Patients", "receiving", "propofol", "or", "midazolam", "/", "fentanyl", "had", "significantly", "less", "postoperative", "nausea", "and", "vomiting", "than", "those", "receiving", "halothane", "(", "Table", "5", ")", ".", "Conclusion", ".", "It", "is", "concluded", "that", "propofol", "offers", "no", "advantage", "over", "halothane", "or", "midazolam", "/", "fentanyl", "where", "early", "postoperative", "recovery", "is", "concerned", ".", "Intraoperatively", ",", "all", "three", "techniques", "provided", "good", "anaesthesia", ".", "Propofol", "and", "midazolam", "/", "fentanyl", "caused", "less", "postoperative", "nausea", "and", "vomiting", "than", "halothane", "anaesthesia", "." ]
[ "umlsterm" ]
patients, colorectal surgery, epidural anaesthesia, light, general anaesthesia, propofol, halothane, ethics, All, patients, epidural anaesthesia, bupivacaine, halothane, light, general anaesthesia, thiopental, halothane, propofol, midazolam, fentanyl, maintenance, All, patients, non - depolarising muscle relaxants, oxide - oxygen, postoperative, analgesia, morphine, operation, recovery room, test, ability, test, test, Heart rate, blood pressure, oxygen, blood gases, age, sex, ASA, classification, operation, tests, blood pressure, heart rate, blood gas analysis, oxygen, postoperative, values, patients, propofol, hypercapnia, Patients, propofol, postoperative nausea, vomiting, halothane, propofol, halothane, postoperative, techniques, Propofol, postoperative nausea, vomiting, halothane
DerAnaesthesist.40430159.eng.abstr_task2
Sentence: Early mental and psychomotor recovery was studied in 67 patients undergoing colorectal surgery under continuous epidural anaesthesia and light general anaesthesia using propofol , halothane , and midazolam/fentanyl . The study was approved by the local ethics commitee . All patients received epidural anaesthesia with 0.25% bupivacaine and were then randomly allocated to one of three groups . In group I ( halothane ) , light general anaesthesia was induced with thiopental 3 - 5 mg/kg and maintained with halothane . The propofol group ( II ) received 2 mg/kg for induction and a mean continuous infusion of 1.7 mg/kg - h . In group III ( Mi/Fe ) , midazolam and fentanyl were used for induction and maintenance . All patients were intubated , received non-depolarising muscle relaxants , and were manually ventilated with nitrous oxide-oxygen ( 2 : 1.2 ) . For postoperative analgesia , 0.05 mg/kg morphine was administrated epidurally 30 min before the end of the operation ; 30 , 60 , 90 , and 120 min after arriving in the recovery room , vigilance was assessed using a modified Steward score , the Trieger test , the ability to recall a column of numbers ( KAI test ) , and symbol counting ( CI test ) . Heart rate , blood pressure , arterial oxygen saturation , and blood gases were recorded . Results . The three groups were comparable with regard to age , sex , ASA classification , and duration of anaesthesia and operation ( Table 3 ) . There was no difference between the groups in performance of the recovery tests ( Figs . 2 - 5 ) , blood pressure , heart rate , arterial blood gas analysis ( Fig . 6 ) , or oxygen saturation . Comparing pre- and postoperative values , we found severe psychomotor and mental impairment in all groups . pCO2 was slightly elevated in all groups , but only 3 patients in the propofol group and 6 in the midazolam/fentanyl group developed hypercapnia above 50 mm Hg. Patients receiving propofol or midazolam/fentanyl had significantly less postoperative nausea and vomiting than those receiving halothane ( Table 5 ) . Conclusion . It is concluded that propofol offers no advantage over halothane or midazolam/fentanyl where early postoperative recovery is concerned . Intraoperatively , all three techniques provided good anaesthesia . Propofol and midazolam/fentanyl caused less postoperative nausea and vomiting than halothane anaesthesia . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]
Early mental and psychomotor recovery was studied in 67 patients undergoing colorectal surgery under continuous epidural anaesthesia and light general anaesthesia using propofol , halothane , and midazolam/fentanyl . The study was approved by the local ethics commitee . All patients received epidural anaesthesia with 0.25% bupivacaine and were then randomly allocated to one of three groups . In group I ( halothane ) , light general anaesthesia was induced with thiopental 3 - 5 mg/kg and maintained with halothane . The propofol group ( II ) received 2 mg/kg for induction and a mean continuous infusion of 1.7 mg/kg - h . In group III ( Mi/Fe ) , midazolam and fentanyl were used for induction and maintenance . All patients were intubated , received non-depolarising muscle relaxants , and were manually ventilated with nitrous oxide-oxygen ( 2 : 1.2 ) . For postoperative analgesia , 0.05 mg/kg morphine was administrated epidurally 30 min before the end of the operation ; 30 , 60 , 90 , and 120 min after arriving in the recovery room , vigilance was assessed using a modified Steward score , the Trieger test , the ability to recall a column of numbers ( KAI test ) , and symbol counting ( CI test ) . Heart rate , blood pressure , arterial oxygen saturation , and blood gases were recorded . Results . The three groups were comparable with regard to age , sex , ASA classification , and duration of anaesthesia and operation ( Table 3 ) . There was no difference between the groups in performance of the recovery tests ( Figs . 2 - 5 ) , blood pressure , heart rate , arterial blood gas analysis ( Fig . 6 ) , or oxygen saturation . Comparing pre- and postoperative values , we found severe psychomotor and mental impairment in all groups . pCO2 was slightly elevated in all groups , but only 3 patients in the propofol group and 6 in the midazolam/fentanyl group developed hypercapnia above 50 mm Hg. Patients receiving propofol or midazolam/fentanyl had significantly less postoperative nausea and vomiting than those receiving halothane ( Table 5 ) . Conclusion . It is concluded that propofol offers no advantage over halothane or midazolam/fentanyl where early postoperative recovery is concerned . Intraoperatively , all three techniques provided good anaesthesia . Propofol and midazolam/fentanyl caused less postoperative nausea and vomiting than halothane anaesthesia .
[ "Early", "mental", "and", "psychomotor", "recovery", "was", "studied", "in", "67", "patients", "undergoing", "colorectal", "surgery", "under", "continuous", "epidural", "anaesthesia", "and", "light", "general", "anaesthesia", "using", "propofol", ",", "halothane", ",", "and", "midazolam", "/", "fentanyl", ".", "The", "study", "was", "approved", "by", "the", "local", "ethics", "commitee", ".", "All", "patients", "received", "epidural", "anaesthesia", "with", "0.25", "%", "bupivacaine", "and", "were", "then", "randomly", "allocated", "to", "one", "of", "three", "groups", ".", "In", "group", "I", "(", "halothane", ")", ",", "light", "general", "anaesthesia", "was", "induced", "with", "thiopental", "3", "-", "5", "mg", "/", "kg", "and", "maintained", "with", "halothane", ".", "The", "propofol", "group", "(", "II", ")", "received", "2", "mg", "/", "kg", "for", "induction", "and", "a", "mean", "continuous", "infusion", "of", "1.7", "mg", "/", "kg", "-", "h", ".", "In", "group", "III", "(", "Mi", "/", "Fe", ")", ",", "midazolam", "and", "fentanyl", "were", "used", "for", "induction", "and", "maintenance", ".", "All", "patients", "were", "intubated", ",", "received", "non", "-", "depolarising", "muscle", "relaxants", ",", "and", "were", "manually", "ventilated", "with", "nitrous", "oxide", "-", "oxygen", "(", "2", ":", "1.2", ")", ".", "For", "postoperative", "analgesia", ",", "0.05", "mg", "/", "kg", "morphine", "was", "administrated", "epidurally", "30", "min", "before", "the", "end", "of", "the", "operation", ";", "30", ",", "60", ",", "90", ",", "and", "120", "min", "after", "arriving", "in", "the", "recovery", "room", ",", "vigilance", "was", "assessed", "using", "a", "modified", "Steward", "score", ",", "the", "Trieger", "test", ",", "the", "ability", "to", "recall", "a", "column", "of", "numbers", "(", "KAI", "test", ")", ",", "and", "symbol", "counting", "(", "CI", "test", ")", ".", "Heart", "rate", ",", "blood", "pressure", ",", "arterial", "oxygen", "saturation", ",", "and", "blood", "gases", "were", "recorded", ".", "Results", ".", "The", "three", "groups", "were", "comparable", "with", "regard", "to", "age", ",", "sex", ",", "ASA", "classification", ",", "and", "duration", "of", "anaesthesia", "and", "operation", "(", "Table", "3", ")", ".", "There", "was", "no", "difference", "between", "the", "groups", "in", "performance", "of", "the", "recovery", "tests", "(", "Figs", ".", "2", "-", "5", ")", ",", "blood", "pressure", ",", "heart", "rate", ",", "arterial", "blood", "gas", "analysis", "(", "Fig", ".", "6", ")", ",", "or", "oxygen", "saturation", ".", "Comparing", "pre-", "and", "postoperative", "values", ",", "we", "found", "severe", "psychomotor", "and", "mental", "impairment", "in", "all", "groups", ".", "pCO2", "was", "slightly", "elevated", "in", "all", "groups", ",", "but", "only", "3", "patients", "in", "the", "propofol", "group", "and", "6", "in", "the", "midazolam", "/", "fentanyl", "group", "developed", "hypercapnia", "above", "50", "mm", "Hg", ".", "Patients", "receiving", "propofol", "or", "midazolam", "/", "fentanyl", "had", "significantly", "less", "postoperative", "nausea", "and", "vomiting", "than", "those", "receiving", "halothane", "(", "Table", "5", ")", ".", "Conclusion", ".", "It", "is", "concluded", "that", "propofol", "offers", "no", "advantage", "over", "halothane", "or", "midazolam", "/", "fentanyl", "where", "early", "postoperative", "recovery", "is", "concerned", ".", "Intraoperatively", ",", "all", "three", "techniques", "provided", "good", "anaesthesia", ".", "Propofol", "and", "midazolam", "/", "fentanyl", "caused", "less", "postoperative", "nausea", "and", "vomiting", "than", "halothane", "anaesthesia", "." ]
[ "umlsterm" ]
19 years is a Value, old is a Person, liver transplant is a Procedure, last six months and within last three years is a Temporal, Tacrolimus is a Drug, twice a day is a Multiplier, at least two weeks is a Temporal, normal is a Qualifier, liver function is a Condition, renal function is a Condition, without is a Negation, complication is a Condition, acute rejection is a Condition
NCT02882113_inc_task0
Sentence: 19 years old and above. Patients who previously have received a liver transplant over the last six months and within last three years. Patients who are on Tacrolimus immunosuppressive therapy twice a day for at least two weeks. Patients who have normal liver function and renal function. Patients who have been monitored without complication such as acute rejection. Patients willing to sign his/her consent. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Person, Multiplier, Procedure, Negation, Drug
[ "B-Value", "I-Value", "B-Person", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "B-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
19 years old and above. Patients who previously have received a liver transplant over the last six months and within last three years. Patients who are on Tacrolimus immunosuppressive therapy twice a day for at least two weeks. Patients who have normal liver function and renal function. Patients who have been monitored without complication such as acute rejection. Patients willing to sign his/her consent.
[ "19", "years", "old", "and", "above", ".", "\n", "Patients", "who", "previously", "have", "received", "a", "liver", "transplant", "over", "the", "last", "six", "months", "and", "within", "last", "three", "years", ".", "\n", "Patients", "who", "are", "on", "Tacrolimus", "immunosuppressive", "therapy", "twice", "a", "day", "for", "at", "least", "two", "weeks", ".", "\n", "Patients", "who", "have", "normal", "liver", "function", "and", "renal", "function", ".", "\n", "Patients", "who", "have", "been", "monitored", "without", "complication", "such", "as", "acute", "rejection", ".", "\n", "Patients", "willing", "to", "sign", "his", "/", "her", "consent", ".", "\n" ]
[ "Temporal", "Procedure", "Condition", "Multiplier", "Drug", "Value", "Negation", "Qualifier", "Person" ]
19 years is a Value, old is a Person, liver transplant is a Procedure, last six months and within last three years is a Temporal, Tacrolimus is a Drug, twice a day is a Multiplier, at least two weeks is a Temporal, normal is a Qualifier, liver function is a Condition, renal function is a Condition, without is a Negation, complication is a Condition, acute rejection is a Condition
NCT02882113_inc_task1
Sentence: 19 years old and above. Patients who previously have received a liver transplant over the last six months and within last three years. Patients who are on Tacrolimus immunosuppressive therapy twice a day for at least two weeks. Patients who have normal liver function and renal function. Patients who have been monitored without complication such as acute rejection. Patients willing to sign his/her consent. Instructions: please typing these entity words according to sentence: 19 years, old, liver transplant, last six months and within last three years, Tacrolimus, twice a day, at least two weeks, normal, liver function, renal function, without, complication, acute rejection Options: Temporal, Condition, Qualifier, Value, Person, Multiplier, Procedure, Negation, Drug
[ "B-Value", "I-Value", "B-Person", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "B-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
19 years old and above. Patients who previously have received a liver transplant over the last six months and within last three years. Patients who are on Tacrolimus immunosuppressive therapy twice a day for at least two weeks. Patients who have normal liver function and renal function. Patients who have been monitored without complication such as acute rejection. Patients willing to sign his/her consent.
[ "19", "years", "old", "and", "above", ".", "\n", "Patients", "who", "previously", "have", "received", "a", "liver", "transplant", "over", "the", "last", "six", "months", "and", "within", "last", "three", "years", ".", "\n", "Patients", "who", "are", "on", "Tacrolimus", "immunosuppressive", "therapy", "twice", "a", "day", "for", "at", "least", "two", "weeks", ".", "\n", "Patients", "who", "have", "normal", "liver", "function", "and", "renal", "function", ".", "\n", "Patients", "who", "have", "been", "monitored", "without", "complication", "such", "as", "acute", "rejection", ".", "\n", "Patients", "willing", "to", "sign", "his", "/", "her", "consent", ".", "\n" ]
[ "Temporal", "Procedure", "Condition", "Multiplier", "Drug", "Value", "Negation", "Qualifier", "Person" ]
19 years, old, liver transplant, last six months and within last three years, Tacrolimus, twice a day, at least two weeks, normal, liver function, renal function, without, complication, acute rejection
NCT02882113_inc_task2
Sentence: 19 years old and above. Patients who previously have received a liver transplant over the last six months and within last three years. Patients who are on Tacrolimus immunosuppressive therapy twice a day for at least two weeks. Patients who have normal liver function and renal function. Patients who have been monitored without complication such as acute rejection. Patients willing to sign his/her consent. Instructions: please extract entity words from the input sentence
[ "B-Value", "I-Value", "B-Person", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "O", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Negation", "B-Condition", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
19 years old and above. Patients who previously have received a liver transplant over the last six months and within last three years. Patients who are on Tacrolimus immunosuppressive therapy twice a day for at least two weeks. Patients who have normal liver function and renal function. Patients who have been monitored without complication such as acute rejection. Patients willing to sign his/her consent.
[ "19", "years", "old", "and", "above", ".", "\n", "Patients", "who", "previously", "have", "received", "a", "liver", "transplant", "over", "the", "last", "six", "months", "and", "within", "last", "three", "years", ".", "\n", "Patients", "who", "are", "on", "Tacrolimus", "immunosuppressive", "therapy", "twice", "a", "day", "for", "at", "least", "two", "weeks", ".", "\n", "Patients", "who", "have", "normal", "liver", "function", "and", "renal", "function", ".", "\n", "Patients", "who", "have", "been", "monitored", "without", "complication", "such", "as", "acute", "rejection", ".", "\n", "Patients", "willing", "to", "sign", "his", "/", "her", "consent", ".", "\n" ]
[ "Temporal", "Procedure", "Condition", "Multiplier", "Drug", "Value", "Negation", "Qualifier", "Person" ]
Hanen ' s ' More Than Words ' is a Intervention_Educational, toddlers with early autism symptoms . is a Participant_Condition, Hanen ' s ' More than Words ' ( HMTW ) , a parent - implemented intervention is a Intervention_Educational, ' business as usual ' control is a Intervention_Control, HMTW intervention is a Intervention_Educational, Children ' s communication and parental responsivity is a Outcome_Mental, Children ' s object interest , a putative moderator is a Outcome_Mental, children ' s communication is a Outcome_Mental
49601_task0
Sentence: A randomized controlled trial of Hanen 's 'More Than Words ' in toddlers with early autism symptoms . BACKGROUND This randomized controlled trial compared Hanen 's 'More than Words ' ( HMTW ) , a parent-implemented intervention , to a 'business as usual ' control group . METHODS Sixty-two children ( 51 boys and 11 girls ; M age = 20 months ; SD = 2.6 ) who met criteria for autism spectrum disorders ( ASD ) and their parents participated in the study . The HMTW intervention was provided over 3.5 months . There were three measurement periods : prior to randomization ( Time 1 ) and at 5 and 9 months post enrollment ( Times 2 and 3 ) . Children 's communication and parental responsivity were measured at each time point . Children 's object interest , a putative moderator , was measured at Time 1 . RESULTS There were no main effects of the HMTW intervention on either parental responsivity or children 's communication . However , the effects on residualized gains in parental responsivity from Time 1 to both Times 2 and 3 yielded noteworthy effect sizes ( Glass 's Δ = .71 , .50 respectively ) . In contrast , there were treatment effects on child communication gains to Time 3 that were moderated by children 's Time 1 object interest . Children with lower levels of Time 1 object interest exhibited facilitated growth in communication ; children with higher levels of object interest exhibited growth attenuation . CONCLUSIONS The HMTW intervention showed differential effects on child communication depending on a baseline child factor . HMTW facilitated communication in children with lower levels of Time 1 object interest . Parents of children who evidence higher object interest may require greater support to implement the HMTW strategies , or may require different strategies than those provided by the HMTW curriculum . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Educational, Intervention_Control, Participant_Condition, Outcome_Mental
[ "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A randomized controlled trial of Hanen 's 'More Than Words ' in toddlers with early autism symptoms . BACKGROUND This randomized controlled trial compared Hanen 's 'More than Words ' ( HMTW ) , a parent-implemented intervention , to a 'business as usual ' control group . METHODS Sixty-two children ( 51 boys and 11 girls ; M age = 20 months ; SD = 2.6 ) who met criteria for autism spectrum disorders ( ASD ) and their parents participated in the study . The HMTW intervention was provided over 3.5 months . There were three measurement periods : prior to randomization ( Time 1 ) and at 5 and 9 months post enrollment ( Times 2 and 3 ) . Children 's communication and parental responsivity were measured at each time point . Children 's object interest , a putative moderator , was measured at Time 1 . RESULTS There were no main effects of the HMTW intervention on either parental responsivity or children 's communication . However , the effects on residualized gains in parental responsivity from Time 1 to both Times 2 and 3 yielded noteworthy effect sizes ( Glass 's Δ = .71 , .50 respectively ) . In contrast , there were treatment effects on child communication gains to Time 3 that were moderated by children 's Time 1 object interest . Children with lower levels of Time 1 object interest exhibited facilitated growth in communication ; children with higher levels of object interest exhibited growth attenuation . CONCLUSIONS The HMTW intervention showed differential effects on child communication depending on a baseline child factor . HMTW facilitated communication in children with lower levels of Time 1 object interest . Parents of children who evidence higher object interest may require greater support to implement the HMTW strategies , or may require different strategies than those provided by the HMTW curriculum .
[ "A", "randomized", "controlled", "trial", "of", "Hanen", "'", "s", "'", "More", "Than", "Words", "'", "in", "toddlers", "with", "early", "autism", "symptoms", ".", "BACKGROUND", "This", "randomized", "controlled", "trial", "compared", "Hanen", "'", "s", "'", "More", "than", "Words", "'", "(", "HMTW", ")", ",", "a", "parent", "-", "implemented", "intervention", ",", "to", "a", "'", "business", "as", "usual", "'", "control", "group", ".", "METHODS", "Sixty", "-", "two", "children", "(", "51", "boys", "and", "11", "girls", ";", "M", "age", "=", "20", "months", ";", "SD", "=", "2.6", ")", "who", "met", "criteria", "for", "autism", "spectrum", "disorders", "(", "ASD", ")", "and", "their", "parents", "participated", "in", "the", "study", ".", "The", "HMTW", "intervention", "was", "provided", "over", "3.5", "months", ".", "There", "were", "three", "measurement", "periods", ":", "prior", "to", "randomization", "(", "Time", "1", ")", "and", "at", "5", "and", "9", "months", "post", "enrollment", "(", "Times", "2", "and", "3", ")", ".", "Children", "'", "s", "communication", "and", "parental", "responsivity", "were", "measured", "at", "each", "time", "point", ".", "Children", "'", "s", "object", "interest", ",", "a", "putative", "moderator", ",", "was", "measured", "at", "Time", "1", ".", "RESULTS", "There", "were", "no", "main", "effects", "of", "the", "HMTW", "intervention", "on", "either", "parental", "responsivity", "or", "children", "'", "s", "communication", ".", "However", ",", "the", "effects", "on", "residualized", "gains", "in", "parental", "responsivity", "from", "Time", "1", "to", "both", "Times", "2", "and", "3", "yielded", "noteworthy", "effect", "sizes", "(", "Glass", "'", "s", "Δ", "=", ".71", ",", ".50", "respectively", ")", ".", "In", "contrast", ",", "there", "were", "treatment", "effects", "on", "child", "communication", "gains", "to", "Time", "3", "that", "were", "moderated", "by", "children", "'", "s", "Time", "1", "object", "interest", ".", "Children", "with", "lower", "levels", "of", "Time", "1", "object", "interest", "exhibited", "facilitated", "growth", "in", "communication", ";", "children", "with", "higher", "levels", "of", "object", "interest", "exhibited", "growth", "attenuation", ".", "CONCLUSIONS", "The", "HMTW", "intervention", "showed", "differential", "effects", "on", "child", "communication", "depending", "on", "a", "baseline", "child", "factor", ".", "HMTW", "facilitated", "communication", "in", "children", "with", "lower", "levels", "of", "Time", "1", "object", "interest", ".", "Parents", "of", "children", "who", "evidence", "higher", "object", "interest", "may", "require", "greater", "support", "to", "implement", "the", "HMTW", "strategies", ",", "or", "may", "require", "different", "strategies", "than", "those", "provided", "by", "the", "HMTW", "curriculum", "." ]
[ "Intervention_Educational", "Outcome_Mental", "Participant_Condition", "Intervention_Control" ]
Hanen ' s ' More Than Words ' is a Intervention_Educational, toddlers with early autism symptoms . is a Participant_Condition, Hanen ' s ' More than Words ' ( HMTW ) , a parent - implemented intervention is a Intervention_Educational, ' business as usual ' control is a Intervention_Control, HMTW intervention is a Intervention_Educational, Children ' s communication and parental responsivity is a Outcome_Mental, Children ' s object interest , a putative moderator is a Outcome_Mental, children ' s communication is a Outcome_Mental
49601_task1
Sentence: A randomized controlled trial of Hanen 's 'More Than Words ' in toddlers with early autism symptoms . BACKGROUND This randomized controlled trial compared Hanen 's 'More than Words ' ( HMTW ) , a parent-implemented intervention , to a 'business as usual ' control group . METHODS Sixty-two children ( 51 boys and 11 girls ; M age = 20 months ; SD = 2.6 ) who met criteria for autism spectrum disorders ( ASD ) and their parents participated in the study . The HMTW intervention was provided over 3.5 months . There were three measurement periods : prior to randomization ( Time 1 ) and at 5 and 9 months post enrollment ( Times 2 and 3 ) . Children 's communication and parental responsivity were measured at each time point . Children 's object interest , a putative moderator , was measured at Time 1 . RESULTS There were no main effects of the HMTW intervention on either parental responsivity or children 's communication . However , the effects on residualized gains in parental responsivity from Time 1 to both Times 2 and 3 yielded noteworthy effect sizes ( Glass 's Δ = .71 , .50 respectively ) . In contrast , there were treatment effects on child communication gains to Time 3 that were moderated by children 's Time 1 object interest . Children with lower levels of Time 1 object interest exhibited facilitated growth in communication ; children with higher levels of object interest exhibited growth attenuation . CONCLUSIONS The HMTW intervention showed differential effects on child communication depending on a baseline child factor . HMTW facilitated communication in children with lower levels of Time 1 object interest . Parents of children who evidence higher object interest may require greater support to implement the HMTW strategies , or may require different strategies than those provided by the HMTW curriculum . Instructions: please typing these entity words according to sentence: Hanen ' s ' More Than Words ', toddlers with early autism symptoms ., Hanen ' s ' More than Words ' ( HMTW ) , a parent - implemented intervention, ' business as usual ' control, HMTW intervention, Children ' s communication and parental responsivity, Children ' s object interest , a putative moderator, children ' s communication Options: Intervention_Educational, Intervention_Control, Participant_Condition, Outcome_Mental
[ "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A randomized controlled trial of Hanen 's 'More Than Words ' in toddlers with early autism symptoms . BACKGROUND This randomized controlled trial compared Hanen 's 'More than Words ' ( HMTW ) , a parent-implemented intervention , to a 'business as usual ' control group . METHODS Sixty-two children ( 51 boys and 11 girls ; M age = 20 months ; SD = 2.6 ) who met criteria for autism spectrum disorders ( ASD ) and their parents participated in the study . The HMTW intervention was provided over 3.5 months . There were three measurement periods : prior to randomization ( Time 1 ) and at 5 and 9 months post enrollment ( Times 2 and 3 ) . Children 's communication and parental responsivity were measured at each time point . Children 's object interest , a putative moderator , was measured at Time 1 . RESULTS There were no main effects of the HMTW intervention on either parental responsivity or children 's communication . However , the effects on residualized gains in parental responsivity from Time 1 to both Times 2 and 3 yielded noteworthy effect sizes ( Glass 's Δ = .71 , .50 respectively ) . In contrast , there were treatment effects on child communication gains to Time 3 that were moderated by children 's Time 1 object interest . Children with lower levels of Time 1 object interest exhibited facilitated growth in communication ; children with higher levels of object interest exhibited growth attenuation . CONCLUSIONS The HMTW intervention showed differential effects on child communication depending on a baseline child factor . HMTW facilitated communication in children with lower levels of Time 1 object interest . Parents of children who evidence higher object interest may require greater support to implement the HMTW strategies , or may require different strategies than those provided by the HMTW curriculum .
[ "A", "randomized", "controlled", "trial", "of", "Hanen", "'", "s", "'", "More", "Than", "Words", "'", "in", "toddlers", "with", "early", "autism", "symptoms", ".", "BACKGROUND", "This", "randomized", "controlled", "trial", "compared", "Hanen", "'", "s", "'", "More", "than", "Words", "'", "(", "HMTW", ")", ",", "a", "parent", "-", "implemented", "intervention", ",", "to", "a", "'", "business", "as", "usual", "'", "control", "group", ".", "METHODS", "Sixty", "-", "two", "children", "(", "51", "boys", "and", "11", "girls", ";", "M", "age", "=", "20", "months", ";", "SD", "=", "2.6", ")", "who", "met", "criteria", "for", "autism", "spectrum", "disorders", "(", "ASD", ")", "and", "their", "parents", "participated", "in", "the", "study", ".", "The", "HMTW", "intervention", "was", "provided", "over", "3.5", "months", ".", "There", "were", "three", "measurement", "periods", ":", "prior", "to", "randomization", "(", "Time", "1", ")", "and", "at", "5", "and", "9", "months", "post", "enrollment", "(", "Times", "2", "and", "3", ")", ".", "Children", "'", "s", "communication", "and", "parental", "responsivity", "were", "measured", "at", "each", "time", "point", ".", "Children", "'", "s", "object", "interest", ",", "a", "putative", "moderator", ",", "was", "measured", "at", "Time", "1", ".", "RESULTS", "There", "were", "no", "main", "effects", "of", "the", "HMTW", "intervention", "on", "either", "parental", "responsivity", "or", "children", "'", "s", "communication", ".", "However", ",", "the", "effects", "on", "residualized", "gains", "in", "parental", "responsivity", "from", "Time", "1", "to", "both", "Times", "2", "and", "3", "yielded", "noteworthy", "effect", "sizes", "(", "Glass", "'", "s", "Δ", "=", ".71", ",", ".50", "respectively", ")", ".", "In", "contrast", ",", "there", "were", "treatment", "effects", "on", "child", "communication", "gains", "to", "Time", "3", "that", "were", "moderated", "by", "children", "'", "s", "Time", "1", "object", "interest", ".", "Children", "with", "lower", "levels", "of", "Time", "1", "object", "interest", "exhibited", "facilitated", "growth", "in", "communication", ";", "children", "with", "higher", "levels", "of", "object", "interest", "exhibited", "growth", "attenuation", ".", "CONCLUSIONS", "The", "HMTW", "intervention", "showed", "differential", "effects", "on", "child", "communication", "depending", "on", "a", "baseline", "child", "factor", ".", "HMTW", "facilitated", "communication", "in", "children", "with", "lower", "levels", "of", "Time", "1", "object", "interest", ".", "Parents", "of", "children", "who", "evidence", "higher", "object", "interest", "may", "require", "greater", "support", "to", "implement", "the", "HMTW", "strategies", ",", "or", "may", "require", "different", "strategies", "than", "those", "provided", "by", "the", "HMTW", "curriculum", "." ]
[ "Intervention_Educational", "Outcome_Mental", "Participant_Condition", "Intervention_Control" ]
Hanen ' s ' More Than Words ', toddlers with early autism symptoms ., Hanen ' s ' More than Words ' ( HMTW ) , a parent - implemented intervention, ' business as usual ' control, HMTW intervention, Children ' s communication and parental responsivity, Children ' s object interest , a putative moderator, children ' s communication
49601_task2
Sentence: A randomized controlled trial of Hanen 's 'More Than Words ' in toddlers with early autism symptoms . BACKGROUND This randomized controlled trial compared Hanen 's 'More than Words ' ( HMTW ) , a parent-implemented intervention , to a 'business as usual ' control group . METHODS Sixty-two children ( 51 boys and 11 girls ; M age = 20 months ; SD = 2.6 ) who met criteria for autism spectrum disorders ( ASD ) and their parents participated in the study . The HMTW intervention was provided over 3.5 months . There were three measurement periods : prior to randomization ( Time 1 ) and at 5 and 9 months post enrollment ( Times 2 and 3 ) . Children 's communication and parental responsivity were measured at each time point . Children 's object interest , a putative moderator , was measured at Time 1 . RESULTS There were no main effects of the HMTW intervention on either parental responsivity or children 's communication . However , the effects on residualized gains in parental responsivity from Time 1 to both Times 2 and 3 yielded noteworthy effect sizes ( Glass 's Δ = .71 , .50 respectively ) . In contrast , there were treatment effects on child communication gains to Time 3 that were moderated by children 's Time 1 object interest . Children with lower levels of Time 1 object interest exhibited facilitated growth in communication ; children with higher levels of object interest exhibited growth attenuation . CONCLUSIONS The HMTW intervention showed differential effects on child communication depending on a baseline child factor . HMTW facilitated communication in children with lower levels of Time 1 object interest . Parents of children who evidence higher object interest may require greater support to implement the HMTW strategies , or may require different strategies than those provided by the HMTW curriculum . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Educational", "I-Intervention_Educational", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A randomized controlled trial of Hanen 's 'More Than Words ' in toddlers with early autism symptoms . BACKGROUND This randomized controlled trial compared Hanen 's 'More than Words ' ( HMTW ) , a parent-implemented intervention , to a 'business as usual ' control group . METHODS Sixty-two children ( 51 boys and 11 girls ; M age = 20 months ; SD = 2.6 ) who met criteria for autism spectrum disorders ( ASD ) and their parents participated in the study . The HMTW intervention was provided over 3.5 months . There were three measurement periods : prior to randomization ( Time 1 ) and at 5 and 9 months post enrollment ( Times 2 and 3 ) . Children 's communication and parental responsivity were measured at each time point . Children 's object interest , a putative moderator , was measured at Time 1 . RESULTS There were no main effects of the HMTW intervention on either parental responsivity or children 's communication . However , the effects on residualized gains in parental responsivity from Time 1 to both Times 2 and 3 yielded noteworthy effect sizes ( Glass 's Δ = .71 , .50 respectively ) . In contrast , there were treatment effects on child communication gains to Time 3 that were moderated by children 's Time 1 object interest . Children with lower levels of Time 1 object interest exhibited facilitated growth in communication ; children with higher levels of object interest exhibited growth attenuation . CONCLUSIONS The HMTW intervention showed differential effects on child communication depending on a baseline child factor . HMTW facilitated communication in children with lower levels of Time 1 object interest . Parents of children who evidence higher object interest may require greater support to implement the HMTW strategies , or may require different strategies than those provided by the HMTW curriculum .
[ "A", "randomized", "controlled", "trial", "of", "Hanen", "'", "s", "'", "More", "Than", "Words", "'", "in", "toddlers", "with", "early", "autism", "symptoms", ".", "BACKGROUND", "This", "randomized", "controlled", "trial", "compared", "Hanen", "'", "s", "'", "More", "than", "Words", "'", "(", "HMTW", ")", ",", "a", "parent", "-", "implemented", "intervention", ",", "to", "a", "'", "business", "as", "usual", "'", "control", "group", ".", "METHODS", "Sixty", "-", "two", "children", "(", "51", "boys", "and", "11", "girls", ";", "M", "age", "=", "20", "months", ";", "SD", "=", "2.6", ")", "who", "met", "criteria", "for", "autism", "spectrum", "disorders", "(", "ASD", ")", "and", "their", "parents", "participated", "in", "the", "study", ".", "The", "HMTW", "intervention", "was", "provided", "over", "3.5", "months", ".", "There", "were", "three", "measurement", "periods", ":", "prior", "to", "randomization", "(", "Time", "1", ")", "and", "at", "5", "and", "9", "months", "post", "enrollment", "(", "Times", "2", "and", "3", ")", ".", "Children", "'", "s", "communication", "and", "parental", "responsivity", "were", "measured", "at", "each", "time", "point", ".", "Children", "'", "s", "object", "interest", ",", "a", "putative", "moderator", ",", "was", "measured", "at", "Time", "1", ".", "RESULTS", "There", "were", "no", "main", "effects", "of", "the", "HMTW", "intervention", "on", "either", "parental", "responsivity", "or", "children", "'", "s", "communication", ".", "However", ",", "the", "effects", "on", "residualized", "gains", "in", "parental", "responsivity", "from", "Time", "1", "to", "both", "Times", "2", "and", "3", "yielded", "noteworthy", "effect", "sizes", "(", "Glass", "'", "s", "Δ", "=", ".71", ",", ".50", "respectively", ")", ".", "In", "contrast", ",", "there", "were", "treatment", "effects", "on", "child", "communication", "gains", "to", "Time", "3", "that", "were", "moderated", "by", "children", "'", "s", "Time", "1", "object", "interest", ".", "Children", "with", "lower", "levels", "of", "Time", "1", "object", "interest", "exhibited", "facilitated", "growth", "in", "communication", ";", "children", "with", "higher", "levels", "of", "object", "interest", "exhibited", "growth", "attenuation", ".", "CONCLUSIONS", "The", "HMTW", "intervention", "showed", "differential", "effects", "on", "child", "communication", "depending", "on", "a", "baseline", "child", "factor", ".", "HMTW", "facilitated", "communication", "in", "children", "with", "lower", "levels", "of", "Time", "1", "object", "interest", ".", "Parents", "of", "children", "who", "evidence", "higher", "object", "interest", "may", "require", "greater", "support", "to", "implement", "the", "HMTW", "strategies", ",", "or", "may", "require", "different", "strategies", "than", "those", "provided", "by", "the", "HMTW", "curriculum", "." ]
[ "Intervention_Educational", "Outcome_Mental", "Participant_Condition", "Intervention_Control" ]
tacrolimus is a NORMALIZABLES, Interferón - á is a PROTEINAS, transaminasas is a PROTEINAS
7_task0
Sentence: Mujer de 42 años en el momento de someterse a trasplante hepático. Entre sus antecedentes personales previos al trasplante destacan apendicectomía en el año 1978, cirrosis hepática de probable origen alcohólico diagnosticada en 1989, HDA secundaria a varices esofágicas grado II en 1996 junto a hipertensión portal y ascitis. En Febrero de 1998 fue diagnosticada de hepatocarcinoma. La paciente recibió trasplante hepático en octubre de 1998 que cursó sin incidencias y fue dada de alta en tratamiento con tacrolimus. A los 18 meses del trasplante la paciente refirió por vez primera debilidad de miembros inferiores y pérdida de sensibilidad de los mismos evolucionando en el plazo de 2 meses a una paraplejia completa que afecta a vejiga urinaria. A la exploración física se observaba paraparesia con amioatrofia por desuso de EEII, hipoestesia subjetiva mayor en EID con nivel D8-D10, afectación de la sensibilidad profunda más intensa en EID sobretodo a nivel vibratoria. ROT presentes, vivos los rotulianos e hipoactivos los aquíleos. RCP extensor bilateral. En este caso también se realizron las siguientes pruebas diagnósticas: RMN cerebral: afectación de cordón medular desde C2 a D10, presentando también lesiones hiperintensa lagunares supratentoriales fundamentalmente a nivel subcortical de lóbulo frontal izquierdo y también lóbulo frontal, parietal y occipital derechos. PEES: patológicos a nivel de tibiales posteriores LCR: determinación sexológica para HTLV-I positiva, resto normal. Determinación sanguínea de anticuerpos (ELISA) y de existencia del virus (HTLV-I), positiva. La paciente fue diagnosticada de paraparesia espástica tropical y tratada con Interferón-á presentando inicialmente discreta mejoría sobretodo a nivel distal de las EEII a pesar de que en últimos días hubo de disminuirse la pauta por aumento de los valores de transaminasas. A pesar de la buena respuesta inicial, la sintomatología ha empeorado progresivamente y en estos momentos es dependiente para la vida diaria y porta sonda vesical permanente tras resultar fallido el intento de reeducación vesical mediante sondaje intermitente. El trasplante hepático, en el momento actual es funcionante. En los tres casos no se indicó la trasplantectomía dada la propagación del virus a sistemas sanguíneo y nervioso e imposibilidad por tanto, dadas las medidas de las que disponemos, de erradicarlo y por la buena función de los órganos trasplantados. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mujer de 42 años en el momento de someterse a trasplante hepático. Entre sus antecedentes personales previos al trasplante destacan apendicectomía en el año 1978, cirrosis hepática de probable origen alcohólico diagnosticada en 1989, HDA secundaria a varices esofágicas grado II en 1996 junto a hipertensión portal y ascitis. En Febrero de 1998 fue diagnosticada de hepatocarcinoma. La paciente recibió trasplante hepático en octubre de 1998 que cursó sin incidencias y fue dada de alta en tratamiento con tacrolimus. A los 18 meses del trasplante la paciente refirió por vez primera debilidad de miembros inferiores y pérdida de sensibilidad de los mismos evolucionando en el plazo de 2 meses a una paraplejia completa que afecta a vejiga urinaria. A la exploración física se observaba paraparesia con amioatrofia por desuso de EEII, hipoestesia subjetiva mayor en EID con nivel D8-D10, afectación de la sensibilidad profunda más intensa en EID sobretodo a nivel vibratoria. ROT presentes, vivos los rotulianos e hipoactivos los aquíleos. RCP extensor bilateral. En este caso también se realizron las siguientes pruebas diagnósticas: RMN cerebral: afectación de cordón medular desde C2 a D10, presentando también lesiones hiperintensa lagunares supratentoriales fundamentalmente a nivel subcortical de lóbulo frontal izquierdo y también lóbulo frontal, parietal y occipital derechos. PEES: patológicos a nivel de tibiales posteriores LCR: determinación sexológica para HTLV-I positiva, resto normal. Determinación sanguínea de anticuerpos (ELISA) y de existencia del virus (HTLV-I), positiva. La paciente fue diagnosticada de paraparesia espástica tropical y tratada con Interferón-á presentando inicialmente discreta mejoría sobretodo a nivel distal de las EEII a pesar de que en últimos días hubo de disminuirse la pauta por aumento de los valores de transaminasas. A pesar de la buena respuesta inicial, la sintomatología ha empeorado progresivamente y en estos momentos es dependiente para la vida diaria y porta sonda vesical permanente tras resultar fallido el intento de reeducación vesical mediante sondaje intermitente. El trasplante hepático, en el momento actual es funcionante. En los tres casos no se indicó la trasplantectomía dada la propagación del virus a sistemas sanguíneo y nervioso e imposibilidad por tanto, dadas las medidas de las que disponemos, de erradicarlo y por la buena función de los órganos trasplantados.
[ "Mujer", "de", "42", "años", "en", "el", "momento", "de", "someterse", "a", "trasplante", "hepático", ".", "\n", "Entre", "sus", "antecedentes", "personales", "previos", "al", "trasplante", "destacan", "apendicectomía", "en", "el", "año", "1978", ",", "cirrosis", "hepática", "de", "probable", "origen", "alcohólico", "diagnosticada", "en", "1989", ",", "HDA", "secundaria", "a", "varices", "esofágicas", "grado", "II", "en", "1996", "junto", "a", "hipertensión", "portal", "y", "ascitis", ".", "En", "Febrero", "de", "1998", "fue", "diagnosticada", "de", "hepatocarcinoma", ".", "\n", "La", "paciente", "recibió", "trasplante", "hepático", "en", "octubre", "de", "1998", "que", "cursó", "sin", "incidencias", "y", "fue", "dada", "de", "alta", "en", "tratamiento", "con", "tacrolimus", ".", "\n", "A", "los", "18", "meses", "del", "trasplante", "la", "paciente", "refirió", "por", "vez", "primera", "debilidad", "de", "miembros", "inferiores", "y", "pérdida", "de", "sensibilidad", "de", "los", "mismos", "evolucionando", "en", "el", "plazo", "de", "2", "meses", "a", "una", "paraplejia", "completa", "que", "afecta", "a", "vejiga", "urinaria", ".", "\n", "A", "la", "exploración", "física", "se", "observaba", "paraparesia", "con", "amioatrofia", "por", "desuso", "de", "EEII", ",", "hipoestesia", "subjetiva", "mayor", "en", "EID", "con", "nivel", "D8-D10", ",", "afectación", "de", "la", "sensibilidad", "profunda", "más", "intensa", "en", "EID", "sobretodo", "a", "nivel", "vibratoria", ".", "ROT", "presentes", ",", "vivos", "los", "rotulianos", "e", "hipoactivos", "los", "aquíleos", ".", "RCP", "extensor", "bilateral", ".", "\n", "En", "este", "caso", "también", "se", "realizron", "las", "siguientes", "pruebas", "diagnósticas", ":", "\n", "RMN", "cerebral", ":", "afectación", "de", "cordón", "medular", "desde", "C2", "a", "D10", ",", "presentando", "también", "lesiones", "hiperintensa", "lagunares", "supratentoriales", "fundamentalmente", "a", "nivel", "subcortical", "de", "lóbulo", "frontal", "izquierdo", "y", "también", "lóbulo", "frontal", ",", "parietal", "y", "occipital", "derechos", ".", "\n", "PEES", ":", "patológicos", "a", "nivel", "de", "tibiales", "posteriores", "LCR", ":", "determinación", "sexológica", "para", "HTLV", "-", "I", "positiva", ",", "resto", "normal", ".", "\n", "Determinación", "sanguínea", "de", "anticuerpos", "(", "ELISA", ")", "y", "de", "existencia", "del", "virus", "(", "HTLV", "-", "I", ")", ",", "positiva", ".", "\n", "La", "paciente", "fue", "diagnosticada", "de", "paraparesia", "espástica", "tropical", "y", "tratada", "con", "Interferón", "-", "á", "presentando", "inicialmente", "discreta", "mejoría", "sobretodo", "a", "nivel", "distal", "de", "las", "EEII", "a", "pesar", "de", "que", "en", "últimos", "días", "hubo", "de", "disminuirse", "la", "pauta", "por", "aumento", "de", "los", "valores", "de", "transaminasas", ".", "A", "pesar", "de", "la", "buena", "respuesta", "inicial", ",", "la", "sintomatología", "ha", "empeorado", "progresivamente", "y", "en", "estos", "momentos", "es", "dependiente", "para", "la", "vida", "diaria", "y", "porta", "sonda", "vesical", "permanente", "tras", "resultar", "fallido", "el", "intento", "de", "reeducación", "vesical", "mediante", "sondaje", "intermitente", ".", "El", "trasplante", "hepático", ",", "en", "el", "momento", "actual", "es", "funcionante", ".", "\n", "En", "los", "tres", "casos", "no", "se", "indicó", "la", "trasplantectomía", "dada", "la", "propagación", "del", "virus", "a", "sistemas", "sanguíneo", "y", "nervioso", "e", "imposibilidad", "por", "tanto", ",", "dadas", "las", "medidas", "de", "las", "que", "disponemos", ",", "de", "erradicarlo", "y", "por", "la", "buena", "función", "de", "los", "órganos", "trasplantados", ".", "\n" ]
[ "PROTEINAS", "NORMALIZABLES" ]
tacrolimus is a NORMALIZABLES, Interferón - á is a PROTEINAS, transaminasas is a PROTEINAS
7_task1
Sentence: Mujer de 42 años en el momento de someterse a trasplante hepático. Entre sus antecedentes personales previos al trasplante destacan apendicectomía en el año 1978, cirrosis hepática de probable origen alcohólico diagnosticada en 1989, HDA secundaria a varices esofágicas grado II en 1996 junto a hipertensión portal y ascitis. En Febrero de 1998 fue diagnosticada de hepatocarcinoma. La paciente recibió trasplante hepático en octubre de 1998 que cursó sin incidencias y fue dada de alta en tratamiento con tacrolimus. A los 18 meses del trasplante la paciente refirió por vez primera debilidad de miembros inferiores y pérdida de sensibilidad de los mismos evolucionando en el plazo de 2 meses a una paraplejia completa que afecta a vejiga urinaria. A la exploración física se observaba paraparesia con amioatrofia por desuso de EEII, hipoestesia subjetiva mayor en EID con nivel D8-D10, afectación de la sensibilidad profunda más intensa en EID sobretodo a nivel vibratoria. ROT presentes, vivos los rotulianos e hipoactivos los aquíleos. RCP extensor bilateral. En este caso también se realizron las siguientes pruebas diagnósticas: RMN cerebral: afectación de cordón medular desde C2 a D10, presentando también lesiones hiperintensa lagunares supratentoriales fundamentalmente a nivel subcortical de lóbulo frontal izquierdo y también lóbulo frontal, parietal y occipital derechos. PEES: patológicos a nivel de tibiales posteriores LCR: determinación sexológica para HTLV-I positiva, resto normal. Determinación sanguínea de anticuerpos (ELISA) y de existencia del virus (HTLV-I), positiva. La paciente fue diagnosticada de paraparesia espástica tropical y tratada con Interferón-á presentando inicialmente discreta mejoría sobretodo a nivel distal de las EEII a pesar de que en últimos días hubo de disminuirse la pauta por aumento de los valores de transaminasas. A pesar de la buena respuesta inicial, la sintomatología ha empeorado progresivamente y en estos momentos es dependiente para la vida diaria y porta sonda vesical permanente tras resultar fallido el intento de reeducación vesical mediante sondaje intermitente. El trasplante hepático, en el momento actual es funcionante. En los tres casos no se indicó la trasplantectomía dada la propagación del virus a sistemas sanguíneo y nervioso e imposibilidad por tanto, dadas las medidas de las que disponemos, de erradicarlo y por la buena función de los órganos trasplantados. Instructions: please typing these entity words according to sentence: tacrolimus, Interferón - á, transaminasas Options: NORMALIZABLES, PROTEINAS
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mujer de 42 años en el momento de someterse a trasplante hepático. Entre sus antecedentes personales previos al trasplante destacan apendicectomía en el año 1978, cirrosis hepática de probable origen alcohólico diagnosticada en 1989, HDA secundaria a varices esofágicas grado II en 1996 junto a hipertensión portal y ascitis. En Febrero de 1998 fue diagnosticada de hepatocarcinoma. La paciente recibió trasplante hepático en octubre de 1998 que cursó sin incidencias y fue dada de alta en tratamiento con tacrolimus. A los 18 meses del trasplante la paciente refirió por vez primera debilidad de miembros inferiores y pérdida de sensibilidad de los mismos evolucionando en el plazo de 2 meses a una paraplejia completa que afecta a vejiga urinaria. A la exploración física se observaba paraparesia con amioatrofia por desuso de EEII, hipoestesia subjetiva mayor en EID con nivel D8-D10, afectación de la sensibilidad profunda más intensa en EID sobretodo a nivel vibratoria. ROT presentes, vivos los rotulianos e hipoactivos los aquíleos. RCP extensor bilateral. En este caso también se realizron las siguientes pruebas diagnósticas: RMN cerebral: afectación de cordón medular desde C2 a D10, presentando también lesiones hiperintensa lagunares supratentoriales fundamentalmente a nivel subcortical de lóbulo frontal izquierdo y también lóbulo frontal, parietal y occipital derechos. PEES: patológicos a nivel de tibiales posteriores LCR: determinación sexológica para HTLV-I positiva, resto normal. Determinación sanguínea de anticuerpos (ELISA) y de existencia del virus (HTLV-I), positiva. La paciente fue diagnosticada de paraparesia espástica tropical y tratada con Interferón-á presentando inicialmente discreta mejoría sobretodo a nivel distal de las EEII a pesar de que en últimos días hubo de disminuirse la pauta por aumento de los valores de transaminasas. A pesar de la buena respuesta inicial, la sintomatología ha empeorado progresivamente y en estos momentos es dependiente para la vida diaria y porta sonda vesical permanente tras resultar fallido el intento de reeducación vesical mediante sondaje intermitente. El trasplante hepático, en el momento actual es funcionante. En los tres casos no se indicó la trasplantectomía dada la propagación del virus a sistemas sanguíneo y nervioso e imposibilidad por tanto, dadas las medidas de las que disponemos, de erradicarlo y por la buena función de los órganos trasplantados.
[ "Mujer", "de", "42", "años", "en", "el", "momento", "de", "someterse", "a", "trasplante", "hepático", ".", "\n", "Entre", "sus", "antecedentes", "personales", "previos", "al", "trasplante", "destacan", "apendicectomía", "en", "el", "año", "1978", ",", "cirrosis", "hepática", "de", "probable", "origen", "alcohólico", "diagnosticada", "en", "1989", ",", "HDA", "secundaria", "a", "varices", "esofágicas", "grado", "II", "en", "1996", "junto", "a", "hipertensión", "portal", "y", "ascitis", ".", "En", "Febrero", "de", "1998", "fue", "diagnosticada", "de", "hepatocarcinoma", ".", "\n", "La", "paciente", "recibió", "trasplante", "hepático", "en", "octubre", "de", "1998", "que", "cursó", "sin", "incidencias", "y", "fue", "dada", "de", "alta", "en", "tratamiento", "con", "tacrolimus", ".", "\n", "A", "los", "18", "meses", "del", "trasplante", "la", "paciente", "refirió", "por", "vez", "primera", "debilidad", "de", "miembros", "inferiores", "y", "pérdida", "de", "sensibilidad", "de", "los", "mismos", "evolucionando", "en", "el", "plazo", "de", "2", "meses", "a", "una", "paraplejia", "completa", "que", "afecta", "a", "vejiga", "urinaria", ".", "\n", "A", "la", "exploración", "física", "se", "observaba", "paraparesia", "con", "amioatrofia", "por", "desuso", "de", "EEII", ",", "hipoestesia", "subjetiva", "mayor", "en", "EID", "con", "nivel", "D8-D10", ",", "afectación", "de", "la", "sensibilidad", "profunda", "más", "intensa", "en", "EID", "sobretodo", "a", "nivel", "vibratoria", ".", "ROT", "presentes", ",", "vivos", "los", "rotulianos", "e", "hipoactivos", "los", "aquíleos", ".", "RCP", "extensor", "bilateral", ".", "\n", "En", "este", "caso", "también", "se", "realizron", "las", "siguientes", "pruebas", "diagnósticas", ":", "\n", "RMN", "cerebral", ":", "afectación", "de", "cordón", "medular", "desde", "C2", "a", "D10", ",", "presentando", "también", "lesiones", "hiperintensa", "lagunares", "supratentoriales", "fundamentalmente", "a", "nivel", "subcortical", "de", "lóbulo", "frontal", "izquierdo", "y", "también", "lóbulo", "frontal", ",", "parietal", "y", "occipital", "derechos", ".", "\n", "PEES", ":", "patológicos", "a", "nivel", "de", "tibiales", "posteriores", "LCR", ":", "determinación", "sexológica", "para", "HTLV", "-", "I", "positiva", ",", "resto", "normal", ".", "\n", "Determinación", "sanguínea", "de", "anticuerpos", "(", "ELISA", ")", "y", "de", "existencia", "del", "virus", "(", "HTLV", "-", "I", ")", ",", "positiva", ".", "\n", "La", "paciente", "fue", "diagnosticada", "de", "paraparesia", "espástica", "tropical", "y", "tratada", "con", "Interferón", "-", "á", "presentando", "inicialmente", "discreta", "mejoría", "sobretodo", "a", "nivel", "distal", "de", "las", "EEII", "a", "pesar", "de", "que", "en", "últimos", "días", "hubo", "de", "disminuirse", "la", "pauta", "por", "aumento", "de", "los", "valores", "de", "transaminasas", ".", "A", "pesar", "de", "la", "buena", "respuesta", "inicial", ",", "la", "sintomatología", "ha", "empeorado", "progresivamente", "y", "en", "estos", "momentos", "es", "dependiente", "para", "la", "vida", "diaria", "y", "porta", "sonda", "vesical", "permanente", "tras", "resultar", "fallido", "el", "intento", "de", "reeducación", "vesical", "mediante", "sondaje", "intermitente", ".", "El", "trasplante", "hepático", ",", "en", "el", "momento", "actual", "es", "funcionante", ".", "\n", "En", "los", "tres", "casos", "no", "se", "indicó", "la", "trasplantectomía", "dada", "la", "propagación", "del", "virus", "a", "sistemas", "sanguíneo", "y", "nervioso", "e", "imposibilidad", "por", "tanto", ",", "dadas", "las", "medidas", "de", "las", "que", "disponemos", ",", "de", "erradicarlo", "y", "por", "la", "buena", "función", "de", "los", "órganos", "trasplantados", ".", "\n" ]
[ "PROTEINAS", "NORMALIZABLES" ]
tacrolimus, Interferón - á, transaminasas
7_task2
Sentence: Mujer de 42 años en el momento de someterse a trasplante hepático. Entre sus antecedentes personales previos al trasplante destacan apendicectomía en el año 1978, cirrosis hepática de probable origen alcohólico diagnosticada en 1989, HDA secundaria a varices esofágicas grado II en 1996 junto a hipertensión portal y ascitis. En Febrero de 1998 fue diagnosticada de hepatocarcinoma. La paciente recibió trasplante hepático en octubre de 1998 que cursó sin incidencias y fue dada de alta en tratamiento con tacrolimus. A los 18 meses del trasplante la paciente refirió por vez primera debilidad de miembros inferiores y pérdida de sensibilidad de los mismos evolucionando en el plazo de 2 meses a una paraplejia completa que afecta a vejiga urinaria. A la exploración física se observaba paraparesia con amioatrofia por desuso de EEII, hipoestesia subjetiva mayor en EID con nivel D8-D10, afectación de la sensibilidad profunda más intensa en EID sobretodo a nivel vibratoria. ROT presentes, vivos los rotulianos e hipoactivos los aquíleos. RCP extensor bilateral. En este caso también se realizron las siguientes pruebas diagnósticas: RMN cerebral: afectación de cordón medular desde C2 a D10, presentando también lesiones hiperintensa lagunares supratentoriales fundamentalmente a nivel subcortical de lóbulo frontal izquierdo y también lóbulo frontal, parietal y occipital derechos. PEES: patológicos a nivel de tibiales posteriores LCR: determinación sexológica para HTLV-I positiva, resto normal. Determinación sanguínea de anticuerpos (ELISA) y de existencia del virus (HTLV-I), positiva. La paciente fue diagnosticada de paraparesia espástica tropical y tratada con Interferón-á presentando inicialmente discreta mejoría sobretodo a nivel distal de las EEII a pesar de que en últimos días hubo de disminuirse la pauta por aumento de los valores de transaminasas. A pesar de la buena respuesta inicial, la sintomatología ha empeorado progresivamente y en estos momentos es dependiente para la vida diaria y porta sonda vesical permanente tras resultar fallido el intento de reeducación vesical mediante sondaje intermitente. El trasplante hepático, en el momento actual es funcionante. En los tres casos no se indicó la trasplantectomía dada la propagación del virus a sistemas sanguíneo y nervioso e imposibilidad por tanto, dadas las medidas de las que disponemos, de erradicarlo y por la buena función de los órganos trasplantados. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "I-PROTEINAS", "I-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Mujer de 42 años en el momento de someterse a trasplante hepático. Entre sus antecedentes personales previos al trasplante destacan apendicectomía en el año 1978, cirrosis hepática de probable origen alcohólico diagnosticada en 1989, HDA secundaria a varices esofágicas grado II en 1996 junto a hipertensión portal y ascitis. En Febrero de 1998 fue diagnosticada de hepatocarcinoma. La paciente recibió trasplante hepático en octubre de 1998 que cursó sin incidencias y fue dada de alta en tratamiento con tacrolimus. A los 18 meses del trasplante la paciente refirió por vez primera debilidad de miembros inferiores y pérdida de sensibilidad de los mismos evolucionando en el plazo de 2 meses a una paraplejia completa que afecta a vejiga urinaria. A la exploración física se observaba paraparesia con amioatrofia por desuso de EEII, hipoestesia subjetiva mayor en EID con nivel D8-D10, afectación de la sensibilidad profunda más intensa en EID sobretodo a nivel vibratoria. ROT presentes, vivos los rotulianos e hipoactivos los aquíleos. RCP extensor bilateral. En este caso también se realizron las siguientes pruebas diagnósticas: RMN cerebral: afectación de cordón medular desde C2 a D10, presentando también lesiones hiperintensa lagunares supratentoriales fundamentalmente a nivel subcortical de lóbulo frontal izquierdo y también lóbulo frontal, parietal y occipital derechos. PEES: patológicos a nivel de tibiales posteriores LCR: determinación sexológica para HTLV-I positiva, resto normal. Determinación sanguínea de anticuerpos (ELISA) y de existencia del virus (HTLV-I), positiva. La paciente fue diagnosticada de paraparesia espástica tropical y tratada con Interferón-á presentando inicialmente discreta mejoría sobretodo a nivel distal de las EEII a pesar de que en últimos días hubo de disminuirse la pauta por aumento de los valores de transaminasas. A pesar de la buena respuesta inicial, la sintomatología ha empeorado progresivamente y en estos momentos es dependiente para la vida diaria y porta sonda vesical permanente tras resultar fallido el intento de reeducación vesical mediante sondaje intermitente. El trasplante hepático, en el momento actual es funcionante. En los tres casos no se indicó la trasplantectomía dada la propagación del virus a sistemas sanguíneo y nervioso e imposibilidad por tanto, dadas las medidas de las que disponemos, de erradicarlo y por la buena función de los órganos trasplantados.
[ "Mujer", "de", "42", "años", "en", "el", "momento", "de", "someterse", "a", "trasplante", "hepático", ".", "\n", "Entre", "sus", "antecedentes", "personales", "previos", "al", "trasplante", "destacan", "apendicectomía", "en", "el", "año", "1978", ",", "cirrosis", "hepática", "de", "probable", "origen", "alcohólico", "diagnosticada", "en", "1989", ",", "HDA", "secundaria", "a", "varices", "esofágicas", "grado", "II", "en", "1996", "junto", "a", "hipertensión", "portal", "y", "ascitis", ".", "En", "Febrero", "de", "1998", "fue", "diagnosticada", "de", "hepatocarcinoma", ".", "\n", "La", "paciente", "recibió", "trasplante", "hepático", "en", "octubre", "de", "1998", "que", "cursó", "sin", "incidencias", "y", "fue", "dada", "de", "alta", "en", "tratamiento", "con", "tacrolimus", ".", "\n", "A", "los", "18", "meses", "del", "trasplante", "la", "paciente", "refirió", "por", "vez", "primera", "debilidad", "de", "miembros", "inferiores", "y", "pérdida", "de", "sensibilidad", "de", "los", "mismos", "evolucionando", "en", "el", "plazo", "de", "2", "meses", "a", "una", "paraplejia", "completa", "que", "afecta", "a", "vejiga", "urinaria", ".", "\n", "A", "la", "exploración", "física", "se", "observaba", "paraparesia", "con", "amioatrofia", "por", "desuso", "de", "EEII", ",", "hipoestesia", "subjetiva", "mayor", "en", "EID", "con", "nivel", "D8-D10", ",", "afectación", "de", "la", "sensibilidad", "profunda", "más", "intensa", "en", "EID", "sobretodo", "a", "nivel", "vibratoria", ".", "ROT", "presentes", ",", "vivos", "los", "rotulianos", "e", "hipoactivos", "los", "aquíleos", ".", "RCP", "extensor", "bilateral", ".", "\n", "En", "este", "caso", "también", "se", "realizron", "las", "siguientes", "pruebas", "diagnósticas", ":", "\n", "RMN", "cerebral", ":", "afectación", "de", "cordón", "medular", "desde", "C2", "a", "D10", ",", "presentando", "también", "lesiones", "hiperintensa", "lagunares", "supratentoriales", "fundamentalmente", "a", "nivel", "subcortical", "de", "lóbulo", "frontal", "izquierdo", "y", "también", "lóbulo", "frontal", ",", "parietal", "y", "occipital", "derechos", ".", "\n", "PEES", ":", "patológicos", "a", "nivel", "de", "tibiales", "posteriores", "LCR", ":", "determinación", "sexológica", "para", "HTLV", "-", "I", "positiva", ",", "resto", "normal", ".", "\n", "Determinación", "sanguínea", "de", "anticuerpos", "(", "ELISA", ")", "y", "de", "existencia", "del", "virus", "(", "HTLV", "-", "I", ")", ",", "positiva", ".", "\n", "La", "paciente", "fue", "diagnosticada", "de", "paraparesia", "espástica", "tropical", "y", "tratada", "con", "Interferón", "-", "á", "presentando", "inicialmente", "discreta", "mejoría", "sobretodo", "a", "nivel", "distal", "de", "las", "EEII", "a", "pesar", "de", "que", "en", "últimos", "días", "hubo", "de", "disminuirse", "la", "pauta", "por", "aumento", "de", "los", "valores", "de", "transaminasas", ".", "A", "pesar", "de", "la", "buena", "respuesta", "inicial", ",", "la", "sintomatología", "ha", "empeorado", "progresivamente", "y", "en", "estos", "momentos", "es", "dependiente", "para", "la", "vida", "diaria", "y", "porta", "sonda", "vesical", "permanente", "tras", "resultar", "fallido", "el", "intento", "de", "reeducación", "vesical", "mediante", "sondaje", "intermitente", ".", "El", "trasplante", "hepático", ",", "en", "el", "momento", "actual", "es", "funcionante", ".", "\n", "En", "los", "tres", "casos", "no", "se", "indicó", "la", "trasplantectomía", "dada", "la", "propagación", "del", "virus", "a", "sistemas", "sanguíneo", "y", "nervioso", "e", "imposibilidad", "por", "tanto", ",", "dadas", "las", "medidas", "de", "las", "que", "disponemos", ",", "de", "erradicarlo", "y", "por", "la", "buena", "función", "de", "los", "órganos", "trasplantados", ".", "\n" ]
[ "PROTEINAS", "NORMALIZABLES" ]
over - expression is a Relation_Trigger, human is a Species, SNCA is a Genes/Proteins, human is a Species, reduce levels is a Relation_Trigger, SNCA is a Genes/Proteins, PD is a Diseases
7815_task0
Sentence: Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Genes/Proteins, Relation_Trigger, Species, Diseases
[ "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "B-Species", "B-Genes/Proteins", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Species", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "B-Genes/Proteins", "O", "O", "O", "O", "O", "O", "O", "B-Diseases", "O" ]
Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.
[ "Since", "over", "-", "expression", "of", "human", "SNCA", "(", "hSNCA", ")", "leads", "to", "death", "of", "dopaminergic", "(", "DA", ")", "neurons", "in", "human", ",", "rodent", "and", "fly", "brain", ",", "hSNCA", "gene", "silencing", "may", "reduce", "levels", "of", "toxic", "forms", "of", "SNCA", "and", "ameliorate", "degeneration", "of", "DA", "neurons", "in", "PD", "." ]
[ "Genes/Proteins", "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species", "Specific_miRNAs" ]
over - expression is a Relation_Trigger, human is a Species, SNCA is a Genes/Proteins, human is a Species, reduce levels is a Relation_Trigger, SNCA is a Genes/Proteins, PD is a Diseases
7815_task1
Sentence: Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD. Instructions: please typing these entity words according to sentence: over - expression, human, SNCA, human, reduce levels, SNCA, PD Options: Genes/Proteins, Relation_Trigger, Species, Diseases
[ "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "B-Species", "B-Genes/Proteins", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Species", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "B-Genes/Proteins", "O", "O", "O", "O", "O", "O", "O", "B-Diseases", "O" ]
Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.
[ "Since", "over", "-", "expression", "of", "human", "SNCA", "(", "hSNCA", ")", "leads", "to", "death", "of", "dopaminergic", "(", "DA", ")", "neurons", "in", "human", ",", "rodent", "and", "fly", "brain", ",", "hSNCA", "gene", "silencing", "may", "reduce", "levels", "of", "toxic", "forms", "of", "SNCA", "and", "ameliorate", "degeneration", "of", "DA", "neurons", "in", "PD", "." ]
[ "Genes/Proteins", "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species", "Specific_miRNAs" ]
over - expression, human, SNCA, human, reduce levels, SNCA, PD
7815_task2
Sentence: Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD. Instructions: please extract entity words from the input sentence
[ "O", "B-Relation_Trigger", "I-Relation_Trigger", "I-Relation_Trigger", "O", "B-Species", "B-Genes/Proteins", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Species", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Relation_Trigger", "I-Relation_Trigger", "O", "O", "O", "O", "B-Genes/Proteins", "O", "O", "O", "O", "O", "O", "O", "B-Diseases", "O" ]
Since over-expression of human SNCA (hSNCA) leads to death of dopaminergic (DA) neurons in human, rodent and fly brain, hSNCA gene silencing may reduce levels of toxic forms of SNCA and ameliorate degeneration of DA neurons in PD.
[ "Since", "over", "-", "expression", "of", "human", "SNCA", "(", "hSNCA", ")", "leads", "to", "death", "of", "dopaminergic", "(", "DA", ")", "neurons", "in", "human", ",", "rodent", "and", "fly", "brain", ",", "hSNCA", "gene", "silencing", "may", "reduce", "levels", "of", "toxic", "forms", "of", "SNCA", "and", "ameliorate", "degeneration", "of", "DA", "neurons", "in", "PD", "." ]
[ "Genes/Proteins", "Relation_Trigger", "Diseases", "Non-Specific_miRNAs", "Species", "Specific_miRNAs" ]
Xeroderma pigmentosum is an umlsterm, Patienten is an umlsterm, Inzidenz is an umlsterm, Haut- is an umlsterm, Schleimhauttumoren is an umlsterm, maligne Melanome is an umlsterm, Lymphknotenmetastase is an umlsterm, malignen Melanoms is an umlsterm, Diagnose is an umlsterm, Xeroderma pigmentosum is an umlsterm
DerHautarzt.40450554.ger.abstr_task0
Sentence: Zusammenfassung . Xeroderma pigmentosum umfasst eine heterogene Gruppe seltener autosomal-rezessiv vererbter Erkrankungen mit unterschiedlichen klinischen Charakteristika und fehlerhaften DNA-Reparaturmechanismen . Die Patienten zeigen eine erhoehte Inzidenz von Haut- und Schleimhauttumoren , v. a. Spinaliomen und Basaliomen . Wir berichten ueber eine 65jaehrige Patientin , die 15 maligne Melanome , ein Spinaliom und eine Lymphknotenmetastase eines malignen Melanoms entwickelte . Die klinische Diagnose eines Xeroderma pigmentosum wurde durch die Komplementationsanalyse bestaetigt , die eine Zuordnung in die Komplementationsgruppe D ergab . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Xeroderma pigmentosum umfasst eine heterogene Gruppe seltener autosomal-rezessiv vererbter Erkrankungen mit unterschiedlichen klinischen Charakteristika und fehlerhaften DNA-Reparaturmechanismen . Die Patienten zeigen eine erhoehte Inzidenz von Haut- und Schleimhauttumoren , v. a. Spinaliomen und Basaliomen . Wir berichten ueber eine 65jaehrige Patientin , die 15 maligne Melanome , ein Spinaliom und eine Lymphknotenmetastase eines malignen Melanoms entwickelte . Die klinische Diagnose eines Xeroderma pigmentosum wurde durch die Komplementationsanalyse bestaetigt , die eine Zuordnung in die Komplementationsgruppe D ergab .
[ "Zusammenfassung", ".", "Xeroderma", "pigmentosum", "umfasst", "eine", "heterogene", "Gruppe", "seltener", "autosomal", "-", "rezessiv", "vererbter", "Erkrankungen", "mit", "unterschiedlichen", "klinischen", "Charakteristika", "und", "fehlerhaften", "DNA", "-", "Reparaturmechanismen", ".", "Die", "Patienten", "zeigen", "eine", "erhoehte", "Inzidenz", "von", "Haut-", "und", "Schleimhauttumoren", ",", "v.", "a.", "Spinaliomen", "und", "Basaliomen", ".", "Wir", "berichten", "ueber", "eine", "65jaehrige", "Patientin", ",", "die", "15", "maligne", "Melanome", ",", "ein", "Spinaliom", "und", "eine", "Lymphknotenmetastase", "eines", "malignen", "Melanoms", "entwickelte", ".", "Die", "klinische", "Diagnose", "eines", "Xeroderma", "pigmentosum", "wurde", "durch", "die", "Komplementationsanalyse", "bestaetigt", ",", "die", "eine", "Zuordnung", "in", "die", "Komplementationsgruppe", "D", "ergab", "." ]
[ "umlsterm" ]
Xeroderma pigmentosum is an umlsterm, Patienten is an umlsterm, Inzidenz is an umlsterm, Haut- is an umlsterm, Schleimhauttumoren is an umlsterm, maligne Melanome is an umlsterm, Lymphknotenmetastase is an umlsterm, malignen Melanoms is an umlsterm, Diagnose is an umlsterm, Xeroderma pigmentosum is an umlsterm
DerHautarzt.40450554.ger.abstr_task1
Sentence: Zusammenfassung . Xeroderma pigmentosum umfasst eine heterogene Gruppe seltener autosomal-rezessiv vererbter Erkrankungen mit unterschiedlichen klinischen Charakteristika und fehlerhaften DNA-Reparaturmechanismen . Die Patienten zeigen eine erhoehte Inzidenz von Haut- und Schleimhauttumoren , v. a. Spinaliomen und Basaliomen . Wir berichten ueber eine 65jaehrige Patientin , die 15 maligne Melanome , ein Spinaliom und eine Lymphknotenmetastase eines malignen Melanoms entwickelte . Die klinische Diagnose eines Xeroderma pigmentosum wurde durch die Komplementationsanalyse bestaetigt , die eine Zuordnung in die Komplementationsgruppe D ergab . Instructions: please typing these entity words according to sentence: Xeroderma pigmentosum, Patienten, Inzidenz, Haut-, Schleimhauttumoren, maligne Melanome, Lymphknotenmetastase, malignen Melanoms, Diagnose, Xeroderma pigmentosum Options: umlsterm
[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Xeroderma pigmentosum umfasst eine heterogene Gruppe seltener autosomal-rezessiv vererbter Erkrankungen mit unterschiedlichen klinischen Charakteristika und fehlerhaften DNA-Reparaturmechanismen . Die Patienten zeigen eine erhoehte Inzidenz von Haut- und Schleimhauttumoren , v. a. Spinaliomen und Basaliomen . Wir berichten ueber eine 65jaehrige Patientin , die 15 maligne Melanome , ein Spinaliom und eine Lymphknotenmetastase eines malignen Melanoms entwickelte . Die klinische Diagnose eines Xeroderma pigmentosum wurde durch die Komplementationsanalyse bestaetigt , die eine Zuordnung in die Komplementationsgruppe D ergab .
[ "Zusammenfassung", ".", "Xeroderma", "pigmentosum", "umfasst", "eine", "heterogene", "Gruppe", "seltener", "autosomal", "-", "rezessiv", "vererbter", "Erkrankungen", "mit", "unterschiedlichen", "klinischen", "Charakteristika", "und", "fehlerhaften", "DNA", "-", "Reparaturmechanismen", ".", "Die", "Patienten", "zeigen", "eine", "erhoehte", "Inzidenz", "von", "Haut-", "und", "Schleimhauttumoren", ",", "v.", "a.", "Spinaliomen", "und", "Basaliomen", ".", "Wir", "berichten", "ueber", "eine", "65jaehrige", "Patientin", ",", "die", "15", "maligne", "Melanome", ",", "ein", "Spinaliom", "und", "eine", "Lymphknotenmetastase", "eines", "malignen", "Melanoms", "entwickelte", ".", "Die", "klinische", "Diagnose", "eines", "Xeroderma", "pigmentosum", "wurde", "durch", "die", "Komplementationsanalyse", "bestaetigt", ",", "die", "eine", "Zuordnung", "in", "die", "Komplementationsgruppe", "D", "ergab", "." ]
[ "umlsterm" ]
Xeroderma pigmentosum, Patienten, Inzidenz, Haut-, Schleimhauttumoren, maligne Melanome, Lymphknotenmetastase, malignen Melanoms, Diagnose, Xeroderma pigmentosum
DerHautarzt.40450554.ger.abstr_task2
Sentence: Zusammenfassung . Xeroderma pigmentosum umfasst eine heterogene Gruppe seltener autosomal-rezessiv vererbter Erkrankungen mit unterschiedlichen klinischen Charakteristika und fehlerhaften DNA-Reparaturmechanismen . Die Patienten zeigen eine erhoehte Inzidenz von Haut- und Schleimhauttumoren , v. a. Spinaliomen und Basaliomen . Wir berichten ueber eine 65jaehrige Patientin , die 15 maligne Melanome , ein Spinaliom und eine Lymphknotenmetastase eines malignen Melanoms entwickelte . Die klinische Diagnose eines Xeroderma pigmentosum wurde durch die Komplementationsanalyse bestaetigt , die eine Zuordnung in die Komplementationsgruppe D ergab . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Xeroderma pigmentosum umfasst eine heterogene Gruppe seltener autosomal-rezessiv vererbter Erkrankungen mit unterschiedlichen klinischen Charakteristika und fehlerhaften DNA-Reparaturmechanismen . Die Patienten zeigen eine erhoehte Inzidenz von Haut- und Schleimhauttumoren , v. a. Spinaliomen und Basaliomen . Wir berichten ueber eine 65jaehrige Patientin , die 15 maligne Melanome , ein Spinaliom und eine Lymphknotenmetastase eines malignen Melanoms entwickelte . Die klinische Diagnose eines Xeroderma pigmentosum wurde durch die Komplementationsanalyse bestaetigt , die eine Zuordnung in die Komplementationsgruppe D ergab .
[ "Zusammenfassung", ".", "Xeroderma", "pigmentosum", "umfasst", "eine", "heterogene", "Gruppe", "seltener", "autosomal", "-", "rezessiv", "vererbter", "Erkrankungen", "mit", "unterschiedlichen", "klinischen", "Charakteristika", "und", "fehlerhaften", "DNA", "-", "Reparaturmechanismen", ".", "Die", "Patienten", "zeigen", "eine", "erhoehte", "Inzidenz", "von", "Haut-", "und", "Schleimhauttumoren", ",", "v.", "a.", "Spinaliomen", "und", "Basaliomen", ".", "Wir", "berichten", "ueber", "eine", "65jaehrige", "Patientin", ",", "die", "15", "maligne", "Melanome", ",", "ein", "Spinaliom", "und", "eine", "Lymphknotenmetastase", "eines", "malignen", "Melanoms", "entwickelte", ".", "Die", "klinische", "Diagnose", "eines", "Xeroderma", "pigmentosum", "wurde", "durch", "die", "Komplementationsanalyse", "bestaetigt", ",", "die", "eine", "Zuordnung", "in", "die", "Komplementationsgruppe", "D", "ergab", "." ]
[ "umlsterm" ]
schizophrenia is a Condition, schizoaffective disorder is a Condition, inpatient is a Visit, hospitalization is a Visit, recent is a Temporal, Currently is a Temporal, treatment is a Procedure, atypical antipsychotic is a Drug, continuation on the medication is a Procedure, recommended is a Mood, living in a stable environment is a Observation
NCT00455663_inc_task0
Sentence: Diagnosis of schizophrenia or schizoaffective disorder If entering the study as an inpatient, hospitalization was recent Currently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended Assumes primary responsibility for taking medication Currently living in a stable environment Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Observation, Procedure, Mood, Visit, Drug
[ "O", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Visit", "O", "B-Visit", "O", "B-Temporal", "O", "B-Temporal", "O", "B-Procedure", "O", "O", "B-Drug", "I-Drug", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Mood", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O" ]
Diagnosis of schizophrenia or schizoaffective disorder If entering the study as an inpatient, hospitalization was recent Currently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended Assumes primary responsibility for taking medication Currently living in a stable environment
[ "Diagnosis", "of", "schizophrenia", "or", "schizoaffective", "disorder", "\n", "If", "entering", "the", "study", "as", "an", "inpatient", ",", "hospitalization", "was", "recent", "\n", "Currently", "receiving", "treatment", "with", "an", "atypical", "antipsychotic", "and", "continuation", "on", "the", "medication", "has", "been", "recommended", "\n", "Assumes", "primary", "responsibility", "for", "taking", "medication", "\n", "Currently", "living", "in", "a", "stable", "environment", "\n" ]
[ "Observation", "Procedure", "Condition", "Drug", "Visit", "Mood", "Temporal" ]
schizophrenia is a Condition, schizoaffective disorder is a Condition, inpatient is a Visit, hospitalization is a Visit, recent is a Temporal, Currently is a Temporal, treatment is a Procedure, atypical antipsychotic is a Drug, continuation on the medication is a Procedure, recommended is a Mood, living in a stable environment is a Observation
NCT00455663_inc_task1
Sentence: Diagnosis of schizophrenia or schizoaffective disorder If entering the study as an inpatient, hospitalization was recent Currently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended Assumes primary responsibility for taking medication Currently living in a stable environment Instructions: please typing these entity words according to sentence: schizophrenia, schizoaffective disorder, inpatient, hospitalization, recent, Currently, treatment, atypical antipsychotic, continuation on the medication, recommended, living in a stable environment Options: Temporal, Condition, Observation, Procedure, Mood, Visit, Drug
[ "O", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Visit", "O", "B-Visit", "O", "B-Temporal", "O", "B-Temporal", "O", "B-Procedure", "O", "O", "B-Drug", "I-Drug", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Mood", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O" ]
Diagnosis of schizophrenia or schizoaffective disorder If entering the study as an inpatient, hospitalization was recent Currently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended Assumes primary responsibility for taking medication Currently living in a stable environment
[ "Diagnosis", "of", "schizophrenia", "or", "schizoaffective", "disorder", "\n", "If", "entering", "the", "study", "as", "an", "inpatient", ",", "hospitalization", "was", "recent", "\n", "Currently", "receiving", "treatment", "with", "an", "atypical", "antipsychotic", "and", "continuation", "on", "the", "medication", "has", "been", "recommended", "\n", "Assumes", "primary", "responsibility", "for", "taking", "medication", "\n", "Currently", "living", "in", "a", "stable", "environment", "\n" ]
[ "Observation", "Procedure", "Condition", "Drug", "Visit", "Mood", "Temporal" ]
schizophrenia, schizoaffective disorder, inpatient, hospitalization, recent, Currently, treatment, atypical antipsychotic, continuation on the medication, recommended, living in a stable environment
NCT00455663_inc_task2
Sentence: Diagnosis of schizophrenia or schizoaffective disorder If entering the study as an inpatient, hospitalization was recent Currently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended Assumes primary responsibility for taking medication Currently living in a stable environment Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "B-Visit", "O", "B-Visit", "O", "B-Temporal", "O", "B-Temporal", "O", "B-Procedure", "O", "O", "B-Drug", "I-Drug", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Mood", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "I-Observation", "O" ]
Diagnosis of schizophrenia or schizoaffective disorder If entering the study as an inpatient, hospitalization was recent Currently receiving treatment with an atypical antipsychotic and continuation on the medication has been recommended Assumes primary responsibility for taking medication Currently living in a stable environment
[ "Diagnosis", "of", "schizophrenia", "or", "schizoaffective", "disorder", "\n", "If", "entering", "the", "study", "as", "an", "inpatient", ",", "hospitalization", "was", "recent", "\n", "Currently", "receiving", "treatment", "with", "an", "atypical", "antipsychotic", "and", "continuation", "on", "the", "medication", "has", "been", "recommended", "\n", "Assumes", "primary", "responsibility", "for", "taking", "medication", "\n", "Currently", "living", "in", "a", "stable", "environment", "\n" ]
[ "Observation", "Procedure", "Condition", "Drug", "Visit", "Mood", "Temporal" ]
EBV nuclear antigen ( EBNA ) 1 is a Protein, EBNA2 is a Protein, EBNA2 is a Protein, Latent membrane protein ( LMP ) 2A is a Protein, LMP1 is a Protein, LMP2B is a Protein, BZLF1 is a Protein
618_task0
Sentence: Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Although case-oriented evidence for an association of Epstein-Barr virus (EBV) with gastric carcinoma has been accumulating recently, the interaction(s) between EBV and gastric epithelial cells is/are largely unknown. In this study, we examined seven EBV-positive gastric carcinoma tissues for viral gene expression at the mRNA level, from which studies on the EBV oncogenicity in human epithelial cells will benefit. Reverse transcription-PCR analysis showed that all seven EBV-positive tumour tissues constitutively expressed EBV nuclear antigen (EBNA) 1 mRNA, but not EBNA2 mRNA. The EBNA transcription was initiated from one of three EBNA promoters, Qp: by contrast, both Cp and Wp were silent, thus resulting in the lack of EBNA2 mRNA. Latent membrane protein (LMP) 2A mRNA was detected in three of seven cases; however, neither LMP1 nor LMP2B mRNA was detected in any of the tumours tested. Transcripts from the BamHI-A region of the viral genome were detectable in all cases. BZLF1 mRNA and the product, an immediate-early gene for EBV replication, was not expressed in any of them, thereby suggesting that the tumour cells carried EBV genomes in a tightly latent form. These findings further extended our previous data regarding EBV latency in gastric carcinoma cells at the protein level, and have affirmed that the programme of viral gene expression in the tumour more closely resembles 'latency I' represented by Burkitt's lymphoma than 'latency II' represented by the majority of nasopharyngeal carcinomas. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Although case-oriented evidence for an association of Epstein-Barr virus (EBV) with gastric carcinoma has been accumulating recently, the interaction(s) between EBV and gastric epithelial cells is/are largely unknown. In this study, we examined seven EBV-positive gastric carcinoma tissues for viral gene expression at the mRNA level, from which studies on the EBV oncogenicity in human epithelial cells will benefit. Reverse transcription-PCR analysis showed that all seven EBV-positive tumour tissues constitutively expressed EBV nuclear antigen (EBNA) 1 mRNA, but not EBNA2 mRNA. The EBNA transcription was initiated from one of three EBNA promoters, Qp: by contrast, both Cp and Wp were silent, thus resulting in the lack of EBNA2 mRNA. Latent membrane protein (LMP) 2A mRNA was detected in three of seven cases; however, neither LMP1 nor LMP2B mRNA was detected in any of the tumours tested. Transcripts from the BamHI-A region of the viral genome were detectable in all cases. BZLF1 mRNA and the product, an immediate-early gene for EBV replication, was not expressed in any of them, thereby suggesting that the tumour cells carried EBV genomes in a tightly latent form. These findings further extended our previous data regarding EBV latency in gastric carcinoma cells at the protein level, and have affirmed that the programme of viral gene expression in the tumour more closely resembles 'latency I' represented by Burkitt's lymphoma than 'latency II' represented by the majority of nasopharyngeal carcinomas.
[ "Transcriptional", "analysis", "of", "Epstein", "-", "Barr", "virus", "gene", "expression", "in", "EBV", "-", "positive", "gastric", "carcinoma", ":", "unique", "viral", "latency", "in", "the", "tumour", "cells", ".", "\n", "Although", "case", "-", "oriented", "evidence", "for", "an", "association", "of", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "with", "gastric", "carcinoma", "has", "been", "accumulating", "recently", ",", "the", "interaction(s", ")", "between", "EBV", "and", "gastric", "epithelial", "cells", "is", "/", "are", "largely", "unknown", ".", "In", "this", "study", ",", "we", "examined", "seven", "EBV", "-", "positive", "gastric", "carcinoma", "tissues", "for", "viral", "gene", "expression", "at", "the", "mRNA", "level", ",", "from", "which", "studies", "on", "the", "EBV", "oncogenicity", "in", "human", "epithelial", "cells", "will", "benefit", ".", "Reverse", "transcription", "-", "PCR", "analysis", "showed", "that", "all", "seven", "EBV", "-", "positive", "tumour", "tissues", "constitutively", "expressed", "EBV", "nuclear", "antigen", "(", "EBNA", ")", "1", "mRNA", ",", "but", "not", "EBNA2", "mRNA", ".", "The", "EBNA", "transcription", "was", "initiated", "from", "one", "of", "three", "EBNA", "promoters", ",", "Qp", ":", "by", "contrast", ",", "both", "Cp", "and", "Wp", "were", "silent", ",", "thus", "resulting", "in", "the", "lack", "of", "EBNA2", "mRNA", ".", "Latent", "membrane", "protein", "(", "LMP", ")", "2A", "mRNA", "was", "detected", "in", "three", "of", "seven", "cases", ";", "however", ",", "neither", "LMP1", "nor", "LMP2B", "mRNA", "was", "detected", "in", "any", "of", "the", "tumours", "tested", ".", "Transcripts", "from", "the", "BamHI", "-", "A", "region", "of", "the", "viral", "genome", "were", "detectable", "in", "all", "cases", ".", "BZLF1", "mRNA", "and", "the", "product", ",", "an", "immediate", "-", "early", "gene", "for", "EBV", "replication", ",", "was", "not", "expressed", "in", "any", "of", "them", ",", "thereby", "suggesting", "that", "the", "tumour", "cells", "carried", "EBV", "genomes", "in", "a", "tightly", "latent", "form", ".", "These", "findings", "further", "extended", "our", "previous", "data", "regarding", "EBV", "latency", "in", "gastric", "carcinoma", "cells", "at", "the", "protein", "level", ",", "and", "have", "affirmed", "that", "the", "programme", "of", "viral", "gene", "expression", "in", "the", "tumour", "more", "closely", "resembles", "'", "latency", "I", "'", "represented", "by", "Burkitt", "'s", "lymphoma", "than", "'", "latency", "II", "'", "represented", "by", "the", "majority", "of", "nasopharyngeal", "carcinomas", "." ]
[ "Protein" ]
EBV nuclear antigen ( EBNA ) 1 is a Protein, EBNA2 is a Protein, EBNA2 is a Protein, Latent membrane protein ( LMP ) 2A is a Protein, LMP1 is a Protein, LMP2B is a Protein, BZLF1 is a Protein
618_task1
Sentence: Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Although case-oriented evidence for an association of Epstein-Barr virus (EBV) with gastric carcinoma has been accumulating recently, the interaction(s) between EBV and gastric epithelial cells is/are largely unknown. In this study, we examined seven EBV-positive gastric carcinoma tissues for viral gene expression at the mRNA level, from which studies on the EBV oncogenicity in human epithelial cells will benefit. Reverse transcription-PCR analysis showed that all seven EBV-positive tumour tissues constitutively expressed EBV nuclear antigen (EBNA) 1 mRNA, but not EBNA2 mRNA. The EBNA transcription was initiated from one of three EBNA promoters, Qp: by contrast, both Cp and Wp were silent, thus resulting in the lack of EBNA2 mRNA. Latent membrane protein (LMP) 2A mRNA was detected in three of seven cases; however, neither LMP1 nor LMP2B mRNA was detected in any of the tumours tested. Transcripts from the BamHI-A region of the viral genome were detectable in all cases. BZLF1 mRNA and the product, an immediate-early gene for EBV replication, was not expressed in any of them, thereby suggesting that the tumour cells carried EBV genomes in a tightly latent form. These findings further extended our previous data regarding EBV latency in gastric carcinoma cells at the protein level, and have affirmed that the programme of viral gene expression in the tumour more closely resembles 'latency I' represented by Burkitt's lymphoma than 'latency II' represented by the majority of nasopharyngeal carcinomas. Instructions: please typing these entity words according to sentence: EBV nuclear antigen ( EBNA ) 1, EBNA2, EBNA2, Latent membrane protein ( LMP ) 2A, LMP1, LMP2B, BZLF1 Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Although case-oriented evidence for an association of Epstein-Barr virus (EBV) with gastric carcinoma has been accumulating recently, the interaction(s) between EBV and gastric epithelial cells is/are largely unknown. In this study, we examined seven EBV-positive gastric carcinoma tissues for viral gene expression at the mRNA level, from which studies on the EBV oncogenicity in human epithelial cells will benefit. Reverse transcription-PCR analysis showed that all seven EBV-positive tumour tissues constitutively expressed EBV nuclear antigen (EBNA) 1 mRNA, but not EBNA2 mRNA. The EBNA transcription was initiated from one of three EBNA promoters, Qp: by contrast, both Cp and Wp were silent, thus resulting in the lack of EBNA2 mRNA. Latent membrane protein (LMP) 2A mRNA was detected in three of seven cases; however, neither LMP1 nor LMP2B mRNA was detected in any of the tumours tested. Transcripts from the BamHI-A region of the viral genome were detectable in all cases. BZLF1 mRNA and the product, an immediate-early gene for EBV replication, was not expressed in any of them, thereby suggesting that the tumour cells carried EBV genomes in a tightly latent form. These findings further extended our previous data regarding EBV latency in gastric carcinoma cells at the protein level, and have affirmed that the programme of viral gene expression in the tumour more closely resembles 'latency I' represented by Burkitt's lymphoma than 'latency II' represented by the majority of nasopharyngeal carcinomas.
[ "Transcriptional", "analysis", "of", "Epstein", "-", "Barr", "virus", "gene", "expression", "in", "EBV", "-", "positive", "gastric", "carcinoma", ":", "unique", "viral", "latency", "in", "the", "tumour", "cells", ".", "\n", "Although", "case", "-", "oriented", "evidence", "for", "an", "association", "of", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "with", "gastric", "carcinoma", "has", "been", "accumulating", "recently", ",", "the", "interaction(s", ")", "between", "EBV", "and", "gastric", "epithelial", "cells", "is", "/", "are", "largely", "unknown", ".", "In", "this", "study", ",", "we", "examined", "seven", "EBV", "-", "positive", "gastric", "carcinoma", "tissues", "for", "viral", "gene", "expression", "at", "the", "mRNA", "level", ",", "from", "which", "studies", "on", "the", "EBV", "oncogenicity", "in", "human", "epithelial", "cells", "will", "benefit", ".", "Reverse", "transcription", "-", "PCR", "analysis", "showed", "that", "all", "seven", "EBV", "-", "positive", "tumour", "tissues", "constitutively", "expressed", "EBV", "nuclear", "antigen", "(", "EBNA", ")", "1", "mRNA", ",", "but", "not", "EBNA2", "mRNA", ".", "The", "EBNA", "transcription", "was", "initiated", "from", "one", "of", "three", "EBNA", "promoters", ",", "Qp", ":", "by", "contrast", ",", "both", "Cp", "and", "Wp", "were", "silent", ",", "thus", "resulting", "in", "the", "lack", "of", "EBNA2", "mRNA", ".", "Latent", "membrane", "protein", "(", "LMP", ")", "2A", "mRNA", "was", "detected", "in", "three", "of", "seven", "cases", ";", "however", ",", "neither", "LMP1", "nor", "LMP2B", "mRNA", "was", "detected", "in", "any", "of", "the", "tumours", "tested", ".", "Transcripts", "from", "the", "BamHI", "-", "A", "region", "of", "the", "viral", "genome", "were", "detectable", "in", "all", "cases", ".", "BZLF1", "mRNA", "and", "the", "product", ",", "an", "immediate", "-", "early", "gene", "for", "EBV", "replication", ",", "was", "not", "expressed", "in", "any", "of", "them", ",", "thereby", "suggesting", "that", "the", "tumour", "cells", "carried", "EBV", "genomes", "in", "a", "tightly", "latent", "form", ".", "These", "findings", "further", "extended", "our", "previous", "data", "regarding", "EBV", "latency", "in", "gastric", "carcinoma", "cells", "at", "the", "protein", "level", ",", "and", "have", "affirmed", "that", "the", "programme", "of", "viral", "gene", "expression", "in", "the", "tumour", "more", "closely", "resembles", "'", "latency", "I", "'", "represented", "by", "Burkitt", "'s", "lymphoma", "than", "'", "latency", "II", "'", "represented", "by", "the", "majority", "of", "nasopharyngeal", "carcinomas", "." ]
[ "Protein" ]
EBV nuclear antigen ( EBNA ) 1, EBNA2, EBNA2, Latent membrane protein ( LMP ) 2A, LMP1, LMP2B, BZLF1
618_task2
Sentence: Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Although case-oriented evidence for an association of Epstein-Barr virus (EBV) with gastric carcinoma has been accumulating recently, the interaction(s) between EBV and gastric epithelial cells is/are largely unknown. In this study, we examined seven EBV-positive gastric carcinoma tissues for viral gene expression at the mRNA level, from which studies on the EBV oncogenicity in human epithelial cells will benefit. Reverse transcription-PCR analysis showed that all seven EBV-positive tumour tissues constitutively expressed EBV nuclear antigen (EBNA) 1 mRNA, but not EBNA2 mRNA. The EBNA transcription was initiated from one of three EBNA promoters, Qp: by contrast, both Cp and Wp were silent, thus resulting in the lack of EBNA2 mRNA. Latent membrane protein (LMP) 2A mRNA was detected in three of seven cases; however, neither LMP1 nor LMP2B mRNA was detected in any of the tumours tested. Transcripts from the BamHI-A region of the viral genome were detectable in all cases. BZLF1 mRNA and the product, an immediate-early gene for EBV replication, was not expressed in any of them, thereby suggesting that the tumour cells carried EBV genomes in a tightly latent form. These findings further extended our previous data regarding EBV latency in gastric carcinoma cells at the protein level, and have affirmed that the programme of viral gene expression in the tumour more closely resembles 'latency I' represented by Burkitt's lymphoma than 'latency II' represented by the majority of nasopharyngeal carcinomas. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: unique viral latency in the tumour cells. Although case-oriented evidence for an association of Epstein-Barr virus (EBV) with gastric carcinoma has been accumulating recently, the interaction(s) between EBV and gastric epithelial cells is/are largely unknown. In this study, we examined seven EBV-positive gastric carcinoma tissues for viral gene expression at the mRNA level, from which studies on the EBV oncogenicity in human epithelial cells will benefit. Reverse transcription-PCR analysis showed that all seven EBV-positive tumour tissues constitutively expressed EBV nuclear antigen (EBNA) 1 mRNA, but not EBNA2 mRNA. The EBNA transcription was initiated from one of three EBNA promoters, Qp: by contrast, both Cp and Wp were silent, thus resulting in the lack of EBNA2 mRNA. Latent membrane protein (LMP) 2A mRNA was detected in three of seven cases; however, neither LMP1 nor LMP2B mRNA was detected in any of the tumours tested. Transcripts from the BamHI-A region of the viral genome were detectable in all cases. BZLF1 mRNA and the product, an immediate-early gene for EBV replication, was not expressed in any of them, thereby suggesting that the tumour cells carried EBV genomes in a tightly latent form. These findings further extended our previous data regarding EBV latency in gastric carcinoma cells at the protein level, and have affirmed that the programme of viral gene expression in the tumour more closely resembles 'latency I' represented by Burkitt's lymphoma than 'latency II' represented by the majority of nasopharyngeal carcinomas.
[ "Transcriptional", "analysis", "of", "Epstein", "-", "Barr", "virus", "gene", "expression", "in", "EBV", "-", "positive", "gastric", "carcinoma", ":", "unique", "viral", "latency", "in", "the", "tumour", "cells", ".", "\n", "Although", "case", "-", "oriented", "evidence", "for", "an", "association", "of", "Epstein", "-", "Barr", "virus", "(", "EBV", ")", "with", "gastric", "carcinoma", "has", "been", "accumulating", "recently", ",", "the", "interaction(s", ")", "between", "EBV", "and", "gastric", "epithelial", "cells", "is", "/", "are", "largely", "unknown", ".", "In", "this", "study", ",", "we", "examined", "seven", "EBV", "-", "positive", "gastric", "carcinoma", "tissues", "for", "viral", "gene", "expression", "at", "the", "mRNA", "level", ",", "from", "which", "studies", "on", "the", "EBV", "oncogenicity", "in", "human", "epithelial", "cells", "will", "benefit", ".", "Reverse", "transcription", "-", "PCR", "analysis", "showed", "that", "all", "seven", "EBV", "-", "positive", "tumour", "tissues", "constitutively", "expressed", "EBV", "nuclear", "antigen", "(", "EBNA", ")", "1", "mRNA", ",", "but", "not", "EBNA2", "mRNA", ".", "The", "EBNA", "transcription", "was", "initiated", "from", "one", "of", "three", "EBNA", "promoters", ",", "Qp", ":", "by", "contrast", ",", "both", "Cp", "and", "Wp", "were", "silent", ",", "thus", "resulting", "in", "the", "lack", "of", "EBNA2", "mRNA", ".", "Latent", "membrane", "protein", "(", "LMP", ")", "2A", "mRNA", "was", "detected", "in", "three", "of", "seven", "cases", ";", "however", ",", "neither", "LMP1", "nor", "LMP2B", "mRNA", "was", "detected", "in", "any", "of", "the", "tumours", "tested", ".", "Transcripts", "from", "the", "BamHI", "-", "A", "region", "of", "the", "viral", "genome", "were", "detectable", "in", "all", "cases", ".", "BZLF1", "mRNA", "and", "the", "product", ",", "an", "immediate", "-", "early", "gene", "for", "EBV", "replication", ",", "was", "not", "expressed", "in", "any", "of", "them", ",", "thereby", "suggesting", "that", "the", "tumour", "cells", "carried", "EBV", "genomes", "in", "a", "tightly", "latent", "form", ".", "These", "findings", "further", "extended", "our", "previous", "data", "regarding", "EBV", "latency", "in", "gastric", "carcinoma", "cells", "at", "the", "protein", "level", ",", "and", "have", "affirmed", "that", "the", "programme", "of", "viral", "gene", "expression", "in", "the", "tumour", "more", "closely", "resembles", "'", "latency", "I", "'", "represented", "by", "Burkitt", "'s", "lymphoma", "than", "'", "latency", "II", "'", "represented", "by", "the", "majority", "of", "nasopharyngeal", "carcinomas", "." ]
[ "Protein" ]
Stat3 is a Protein, signal transducers and activators of transcription 3 is a Protein, Bcl - xL is a Protein, CyclinD1 is a Protein, survivin is a Protein, caspase 9 is a Protein, Stat3 is a Protein, Stat3 is a Protein, Bcl - xL is a Protein, Cyclin D1 is a Protein, survivin is a Protein, caspase 9 is a Protein, Stat3 is a Protein
283_task0
Sentence: Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. The present study investigated the effect of YC-1, a novel anti-cancer agent, on the chemo-sensitivity of hepatocellular carcinoma (HCC). YC-1 was administered with chemo-cytotoxic drug, cisplatin, both in vitro and in vivo. YC-1 alone downregulated the expression of phosphorylated form of signal transducers and activators of transcription 3 (P-Stat3[705]), a key mediator in chemo-resistance. When combined with cisplatin, YC-1 further promoted tumor cell apoptosis, decreased the expression of P-Stat3(705), Bcl-xL, CyclinD1 and survivin, and induced the cleavage of caspase 9 and PARP. Overexpression of Stat3 reversed YC-1 induced cell death. YC-1 inhibited Stat3 activity by enhancing the polyubiquitination of P-Stat3(705) induced by cisplatin. In the in vivo setting, YC-1 combined with cisplatin remarkably suppressed tumor growth in a HCC xenograft model, and this effect was also accompanied by YC-1 mediated downregulation of P-Stat3(705), Bcl-xL, Cyclin D1 and survivin, and induction of cleaved caspase 9 and PARP in the tumor tissues. In conclusion, the present study demonstrated a novel anti-cancer effect of YC-1 in enhancing chemo-sensitivity of HCC cells to cisplatin through a Stat3 dependent manner. This finding provides insight into design of a new therapeutic strategy to improve efficacy of chemotherapy in HCC patients. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. The present study investigated the effect of YC-1, a novel anti-cancer agent, on the chemo-sensitivity of hepatocellular carcinoma (HCC). YC-1 was administered with chemo-cytotoxic drug, cisplatin, both in vitro and in vivo. YC-1 alone downregulated the expression of phosphorylated form of signal transducers and activators of transcription 3 (P-Stat3[705]), a key mediator in chemo-resistance. When combined with cisplatin, YC-1 further promoted tumor cell apoptosis, decreased the expression of P-Stat3(705), Bcl-xL, CyclinD1 and survivin, and induced the cleavage of caspase 9 and PARP. Overexpression of Stat3 reversed YC-1 induced cell death. YC-1 inhibited Stat3 activity by enhancing the polyubiquitination of P-Stat3(705) induced by cisplatin. In the in vivo setting, YC-1 combined with cisplatin remarkably suppressed tumor growth in a HCC xenograft model, and this effect was also accompanied by YC-1 mediated downregulation of P-Stat3(705), Bcl-xL, Cyclin D1 and survivin, and induction of cleaved caspase 9 and PARP in the tumor tissues. In conclusion, the present study demonstrated a novel anti-cancer effect of YC-1 in enhancing chemo-sensitivity of HCC cells to cisplatin through a Stat3 dependent manner. This finding provides insight into design of a new therapeutic strategy to improve efficacy of chemotherapy in HCC patients.
[ "Inhibition", "of", "Stat3", "activity", "by", "YC-1", "enhances", "chemo", "-", "sensitivity", "in", "hepatocellular", "carcinoma", ".", "\n", "The", "present", "study", "investigated", "the", "effect", "of", "YC-1", ",", "a", "novel", "anti", "-", "cancer", "agent", ",", "on", "the", "chemo", "-", "sensitivity", "of", "hepatocellular", "carcinoma", "(", "HCC", ")", ".", "YC-1", "was", "administered", "with", "chemo", "-", "cytotoxic", "drug", ",", "cisplatin", ",", "both", "in", "vitro", "and", "in", "vivo", ".", "YC-1", "alone", "downregulated", "the", "expression", "of", "phosphorylated", "form", "of", "signal", "transducers", "and", "activators", "of", "transcription", "3", "(", "P", "-", "Stat3[705", "]", ")", ",", "a", "key", "mediator", "in", "chemo", "-", "resistance", ".", "When", "combined", "with", "cisplatin", ",", "YC-1", "further", "promoted", "tumor", "cell", "apoptosis", ",", "decreased", "the", "expression", "of", "P", "-", "Stat3(705", ")", ",", "Bcl", "-", "xL", ",", "CyclinD1", "and", "survivin", ",", "and", "induced", "the", "cleavage", "of", "caspase", "9", "and", "PARP", ".", "Overexpression", "of", "Stat3", "reversed", "YC-1", "induced", "cell", "death", ".", "YC-1", "inhibited", "Stat3", "activity", "by", "enhancing", "the", "polyubiquitination", "of", "P", "-", "Stat3(705", ")", "induced", "by", "cisplatin", ".", "In", "the", "in", "vivo", "setting", ",", "YC-1", "combined", "with", "cisplatin", "remarkably", "suppressed", "tumor", "growth", "in", "a", "HCC", "xenograft", "model", ",", "and", "this", "effect", "was", "also", "accompanied", "by", "YC-1", "mediated", "downregulation", "of", "P", "-", "Stat3(705", ")", ",", "Bcl", "-", "xL", ",", "Cyclin", "D1", "and", "survivin", ",", "and", "induction", "of", "cleaved", "caspase", "9", "and", "PARP", "in", "the", "tumor", "tissues", ".", "In", "conclusion", ",", "the", "present", "study", "demonstrated", "a", "novel", "anti", "-", "cancer", "effect", "of", "YC-1", "in", "enhancing", "chemo", "-", "sensitivity", "of", "HCC", "cells", "to", "cisplatin", "through", "a", "Stat3", "dependent", "manner", ".", "This", "finding", "provides", "insight", "into", "design", "of", "a", "new", "therapeutic", "strategy", "to", "improve", "efficacy", "of", "chemotherapy", "in", "HCC", "patients", ".", "\n" ]
[ "Protein", "Entity" ]
Stat3 is a Protein, signal transducers and activators of transcription 3 is a Protein, Bcl - xL is a Protein, CyclinD1 is a Protein, survivin is a Protein, caspase 9 is a Protein, Stat3 is a Protein, Stat3 is a Protein, Bcl - xL is a Protein, Cyclin D1 is a Protein, survivin is a Protein, caspase 9 is a Protein, Stat3 is a Protein
283_task1
Sentence: Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. The present study investigated the effect of YC-1, a novel anti-cancer agent, on the chemo-sensitivity of hepatocellular carcinoma (HCC). YC-1 was administered with chemo-cytotoxic drug, cisplatin, both in vitro and in vivo. YC-1 alone downregulated the expression of phosphorylated form of signal transducers and activators of transcription 3 (P-Stat3[705]), a key mediator in chemo-resistance. When combined with cisplatin, YC-1 further promoted tumor cell apoptosis, decreased the expression of P-Stat3(705), Bcl-xL, CyclinD1 and survivin, and induced the cleavage of caspase 9 and PARP. Overexpression of Stat3 reversed YC-1 induced cell death. YC-1 inhibited Stat3 activity by enhancing the polyubiquitination of P-Stat3(705) induced by cisplatin. In the in vivo setting, YC-1 combined with cisplatin remarkably suppressed tumor growth in a HCC xenograft model, and this effect was also accompanied by YC-1 mediated downregulation of P-Stat3(705), Bcl-xL, Cyclin D1 and survivin, and induction of cleaved caspase 9 and PARP in the tumor tissues. In conclusion, the present study demonstrated a novel anti-cancer effect of YC-1 in enhancing chemo-sensitivity of HCC cells to cisplatin through a Stat3 dependent manner. This finding provides insight into design of a new therapeutic strategy to improve efficacy of chemotherapy in HCC patients. Instructions: please typing these entity words according to sentence: Stat3, signal transducers and activators of transcription 3, Bcl - xL, CyclinD1, survivin, caspase 9, Stat3, Stat3, Bcl - xL, Cyclin D1, survivin, caspase 9, Stat3 Options: Protein
[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. The present study investigated the effect of YC-1, a novel anti-cancer agent, on the chemo-sensitivity of hepatocellular carcinoma (HCC). YC-1 was administered with chemo-cytotoxic drug, cisplatin, both in vitro and in vivo. YC-1 alone downregulated the expression of phosphorylated form of signal transducers and activators of transcription 3 (P-Stat3[705]), a key mediator in chemo-resistance. When combined with cisplatin, YC-1 further promoted tumor cell apoptosis, decreased the expression of P-Stat3(705), Bcl-xL, CyclinD1 and survivin, and induced the cleavage of caspase 9 and PARP. Overexpression of Stat3 reversed YC-1 induced cell death. YC-1 inhibited Stat3 activity by enhancing the polyubiquitination of P-Stat3(705) induced by cisplatin. In the in vivo setting, YC-1 combined with cisplatin remarkably suppressed tumor growth in a HCC xenograft model, and this effect was also accompanied by YC-1 mediated downregulation of P-Stat3(705), Bcl-xL, Cyclin D1 and survivin, and induction of cleaved caspase 9 and PARP in the tumor tissues. In conclusion, the present study demonstrated a novel anti-cancer effect of YC-1 in enhancing chemo-sensitivity of HCC cells to cisplatin through a Stat3 dependent manner. This finding provides insight into design of a new therapeutic strategy to improve efficacy of chemotherapy in HCC patients.
[ "Inhibition", "of", "Stat3", "activity", "by", "YC-1", "enhances", "chemo", "-", "sensitivity", "in", "hepatocellular", "carcinoma", ".", "\n", "The", "present", "study", "investigated", "the", "effect", "of", "YC-1", ",", "a", "novel", "anti", "-", "cancer", "agent", ",", "on", "the", "chemo", "-", "sensitivity", "of", "hepatocellular", "carcinoma", "(", "HCC", ")", ".", "YC-1", "was", "administered", "with", "chemo", "-", "cytotoxic", "drug", ",", "cisplatin", ",", "both", "in", "vitro", "and", "in", "vivo", ".", "YC-1", "alone", "downregulated", "the", "expression", "of", "phosphorylated", "form", "of", "signal", "transducers", "and", "activators", "of", "transcription", "3", "(", "P", "-", "Stat3[705", "]", ")", ",", "a", "key", "mediator", "in", "chemo", "-", "resistance", ".", "When", "combined", "with", "cisplatin", ",", "YC-1", "further", "promoted", "tumor", "cell", "apoptosis", ",", "decreased", "the", "expression", "of", "P", "-", "Stat3(705", ")", ",", "Bcl", "-", "xL", ",", "CyclinD1", "and", "survivin", ",", "and", "induced", "the", "cleavage", "of", "caspase", "9", "and", "PARP", ".", "Overexpression", "of", "Stat3", "reversed", "YC-1", "induced", "cell", "death", ".", "YC-1", "inhibited", "Stat3", "activity", "by", "enhancing", "the", "polyubiquitination", "of", "P", "-", "Stat3(705", ")", "induced", "by", "cisplatin", ".", "In", "the", "in", "vivo", "setting", ",", "YC-1", "combined", "with", "cisplatin", "remarkably", "suppressed", "tumor", "growth", "in", "a", "HCC", "xenograft", "model", ",", "and", "this", "effect", "was", "also", "accompanied", "by", "YC-1", "mediated", "downregulation", "of", "P", "-", "Stat3(705", ")", ",", "Bcl", "-", "xL", ",", "Cyclin", "D1", "and", "survivin", ",", "and", "induction", "of", "cleaved", "caspase", "9", "and", "PARP", "in", "the", "tumor", "tissues", ".", "In", "conclusion", ",", "the", "present", "study", "demonstrated", "a", "novel", "anti", "-", "cancer", "effect", "of", "YC-1", "in", "enhancing", "chemo", "-", "sensitivity", "of", "HCC", "cells", "to", "cisplatin", "through", "a", "Stat3", "dependent", "manner", ".", "This", "finding", "provides", "insight", "into", "design", "of", "a", "new", "therapeutic", "strategy", "to", "improve", "efficacy", "of", "chemotherapy", "in", "HCC", "patients", ".", "\n" ]
[ "Protein", "Entity" ]
Stat3, signal transducers and activators of transcription 3, Bcl - xL, CyclinD1, survivin, caspase 9, Stat3, Stat3, Bcl - xL, Cyclin D1, survivin, caspase 9, Stat3
283_task2
Sentence: Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. The present study investigated the effect of YC-1, a novel anti-cancer agent, on the chemo-sensitivity of hepatocellular carcinoma (HCC). YC-1 was administered with chemo-cytotoxic drug, cisplatin, both in vitro and in vivo. YC-1 alone downregulated the expression of phosphorylated form of signal transducers and activators of transcription 3 (P-Stat3[705]), a key mediator in chemo-resistance. When combined with cisplatin, YC-1 further promoted tumor cell apoptosis, decreased the expression of P-Stat3(705), Bcl-xL, CyclinD1 and survivin, and induced the cleavage of caspase 9 and PARP. Overexpression of Stat3 reversed YC-1 induced cell death. YC-1 inhibited Stat3 activity by enhancing the polyubiquitination of P-Stat3(705) induced by cisplatin. In the in vivo setting, YC-1 combined with cisplatin remarkably suppressed tumor growth in a HCC xenograft model, and this effect was also accompanied by YC-1 mediated downregulation of P-Stat3(705), Bcl-xL, Cyclin D1 and survivin, and induction of cleaved caspase 9 and PARP in the tumor tissues. In conclusion, the present study demonstrated a novel anti-cancer effect of YC-1 in enhancing chemo-sensitivity of HCC cells to cisplatin through a Stat3 dependent manner. This finding provides insight into design of a new therapeutic strategy to improve efficacy of chemotherapy in HCC patients. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Inhibition of Stat3 activity by YC-1 enhances chemo-sensitivity in hepatocellular carcinoma. The present study investigated the effect of YC-1, a novel anti-cancer agent, on the chemo-sensitivity of hepatocellular carcinoma (HCC). YC-1 was administered with chemo-cytotoxic drug, cisplatin, both in vitro and in vivo. YC-1 alone downregulated the expression of phosphorylated form of signal transducers and activators of transcription 3 (P-Stat3[705]), a key mediator in chemo-resistance. When combined with cisplatin, YC-1 further promoted tumor cell apoptosis, decreased the expression of P-Stat3(705), Bcl-xL, CyclinD1 and survivin, and induced the cleavage of caspase 9 and PARP. Overexpression of Stat3 reversed YC-1 induced cell death. YC-1 inhibited Stat3 activity by enhancing the polyubiquitination of P-Stat3(705) induced by cisplatin. In the in vivo setting, YC-1 combined with cisplatin remarkably suppressed tumor growth in a HCC xenograft model, and this effect was also accompanied by YC-1 mediated downregulation of P-Stat3(705), Bcl-xL, Cyclin D1 and survivin, and induction of cleaved caspase 9 and PARP in the tumor tissues. In conclusion, the present study demonstrated a novel anti-cancer effect of YC-1 in enhancing chemo-sensitivity of HCC cells to cisplatin through a Stat3 dependent manner. This finding provides insight into design of a new therapeutic strategy to improve efficacy of chemotherapy in HCC patients.
[ "Inhibition", "of", "Stat3", "activity", "by", "YC-1", "enhances", "chemo", "-", "sensitivity", "in", "hepatocellular", "carcinoma", ".", "\n", "The", "present", "study", "investigated", "the", "effect", "of", "YC-1", ",", "a", "novel", "anti", "-", "cancer", "agent", ",", "on", "the", "chemo", "-", "sensitivity", "of", "hepatocellular", "carcinoma", "(", "HCC", ")", ".", "YC-1", "was", "administered", "with", "chemo", "-", "cytotoxic", "drug", ",", "cisplatin", ",", "both", "in", "vitro", "and", "in", "vivo", ".", "YC-1", "alone", "downregulated", "the", "expression", "of", "phosphorylated", "form", "of", "signal", "transducers", "and", "activators", "of", "transcription", "3", "(", "P", "-", "Stat3[705", "]", ")", ",", "a", "key", "mediator", "in", "chemo", "-", "resistance", ".", "When", "combined", "with", "cisplatin", ",", "YC-1", "further", "promoted", "tumor", "cell", "apoptosis", ",", "decreased", "the", "expression", "of", "P", "-", "Stat3(705", ")", ",", "Bcl", "-", "xL", ",", "CyclinD1", "and", "survivin", ",", "and", "induced", "the", "cleavage", "of", "caspase", "9", "and", "PARP", ".", "Overexpression", "of", "Stat3", "reversed", "YC-1", "induced", "cell", "death", ".", "YC-1", "inhibited", "Stat3", "activity", "by", "enhancing", "the", "polyubiquitination", "of", "P", "-", "Stat3(705", ")", "induced", "by", "cisplatin", ".", "In", "the", "in", "vivo", "setting", ",", "YC-1", "combined", "with", "cisplatin", "remarkably", "suppressed", "tumor", "growth", "in", "a", "HCC", "xenograft", "model", ",", "and", "this", "effect", "was", "also", "accompanied", "by", "YC-1", "mediated", "downregulation", "of", "P", "-", "Stat3(705", ")", ",", "Bcl", "-", "xL", ",", "Cyclin", "D1", "and", "survivin", ",", "and", "induction", "of", "cleaved", "caspase", "9", "and", "PARP", "in", "the", "tumor", "tissues", ".", "In", "conclusion", ",", "the", "present", "study", "demonstrated", "a", "novel", "anti", "-", "cancer", "effect", "of", "YC-1", "in", "enhancing", "chemo", "-", "sensitivity", "of", "HCC", "cells", "to", "cisplatin", "through", "a", "Stat3", "dependent", "manner", ".", "This", "finding", "provides", "insight", "into", "design", "of", "a", "new", "therapeutic", "strategy", "to", "improve", "efficacy", "of", "chemotherapy", "in", "HCC", "patients", ".", "\n" ]
[ "Protein", "Entity" ]
social phobia is a Intervention_Other, : is a Intervention_Physical, anxiety visibility is a Outcome_Mental, social evaluation is a Outcome_Mental, social phobics is a Intervention_Psychological, controls is a Intervention_Control, 32 is a Participant_Sample-size, participants heard their heart sounds first via headphones is a Intervention_Psychological, Social phobics is a Intervention_Psychological, habituation in heart rate is a Outcome_Physical, higher heart rate is a Outcome_Physical, heart rates is a Outcome_Physical, actual heart rate differences is a Outcome_Physical, bodily anxiety symptom is a Outcome_Physical, anxiety levels is a Outcome_Mental
17729_task0
Sentence: Public and private heart rate feedback in social phobia : a manipulation of anxiety visibility . According to cognitive behavioural models of social phobia , bodily symptoms are the main source of information concerning social evaluation for social phobics . Experience and perception of bodily symptoms therefore play an important role in social anxiety . In this study we evaluated the effects of anxiety visibility on patients and controls using feedback of veridical heart sounds . A total of 32 social phobics and 32 controls were asked twice to sit in a chair and appear relaxed while being evaluated . Half of the participants heard their heart sounds first via headphones and then via loudspeakers which were also audible to observers . The presentation order of the heart sound was reversed for the other half of the subjects . Social phobics reported substantially more anxiety than controls . Both groups showed habituation in heart rate from the first to the second presentation , and both groups reported perception of a higher heart rate , but only social phobics reported significantly more anxiety and were more worried about their heart rates in the public than in the private condition . These effects were in excess of actual heart rate differences . In conclusion , social phobics worried about the broadcast of a bodily anxiety symptom , whereas controls did not . Information about arousal made public has a strong potential to increase anxiety levels in social phobics . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Psychological, Intervention_Physical, Intervention_Control, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "B-Intervention_Physical", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O" ]
Public and private heart rate feedback in social phobia : a manipulation of anxiety visibility . According to cognitive behavioural models of social phobia , bodily symptoms are the main source of information concerning social evaluation for social phobics . Experience and perception of bodily symptoms therefore play an important role in social anxiety . In this study we evaluated the effects of anxiety visibility on patients and controls using feedback of veridical heart sounds . A total of 32 social phobics and 32 controls were asked twice to sit in a chair and appear relaxed while being evaluated . Half of the participants heard their heart sounds first via headphones and then via loudspeakers which were also audible to observers . The presentation order of the heart sound was reversed for the other half of the subjects . Social phobics reported substantially more anxiety than controls . Both groups showed habituation in heart rate from the first to the second presentation , and both groups reported perception of a higher heart rate , but only social phobics reported significantly more anxiety and were more worried about their heart rates in the public than in the private condition . These effects were in excess of actual heart rate differences . In conclusion , social phobics worried about the broadcast of a bodily anxiety symptom , whereas controls did not . Information about arousal made public has a strong potential to increase anxiety levels in social phobics .
[ "Public", "and", "private", "heart", "rate", "feedback", "in", "social", "phobia", ":", "a", "manipulation", "of", "anxiety", "visibility", ".", "According", "to", "cognitive", "behavioural", "models", "of", "social", "phobia", ",", "bodily", "symptoms", "are", "the", "main", "source", "of", "information", "concerning", "social", "evaluation", "for", "social", "phobics", ".", "Experience", "and", "perception", "of", "bodily", "symptoms", "therefore", "play", "an", "important", "role", "in", "social", "anxiety", ".", "In", "this", "study", "we", "evaluated", "the", "effects", "of", "anxiety", "visibility", "on", "patients", "and", "controls", "using", "feedback", "of", "veridical", "heart", "sounds", ".", "A", "total", "of", "32", "social", "phobics", "and", "32", "controls", "were", "asked", "twice", "to", "sit", "in", "a", "chair", "and", "appear", "relaxed", "while", "being", "evaluated", ".", "Half", "of", "the", "participants", "heard", "their", "heart", "sounds", "first", "via", "headphones", "and", "then", "via", "loudspeakers", "which", "were", "also", "audible", "to", "observers", ".", "The", "presentation", "order", "of", "the", "heart", "sound", "was", "reversed", "for", "the", "other", "half", "of", "the", "subjects", ".", "Social", "phobics", "reported", "substantially", "more", "anxiety", "than", "controls", ".", "Both", "groups", "showed", "habituation", "in", "heart", "rate", "from", "the", "first", "to", "the", "second", "presentation", ",", "and", "both", "groups", "reported", "perception", "of", "a", "higher", "heart", "rate", ",", "but", "only", "social", "phobics", "reported", "significantly", "more", "anxiety", "and", "were", "more", "worried", "about", "their", "heart", "rates", "in", "the", "public", "than", "in", "the", "private", "condition", ".", "These", "effects", "were", "in", "excess", "of", "actual", "heart", "rate", "differences", ".", "In", "conclusion", ",", "social", "phobics", "worried", "about", "the", "broadcast", "of", "a", "bodily", "anxiety", "symptom", ",", "whereas", "controls", "did", "not", ".", "Information", "about", "arousal", "made", "public", "has", "a", "strong", "potential", "to", "increase", "anxiety", "levels", "in", "social", "phobics", "." ]
[ "Intervention_Psychological", "Outcome_Physical", "Outcome_Mental", "Intervention_Other", "Intervention_Educational", "Participant_Condition", "Intervention_Control", "Participant_Sample-size", "Intervention_Physical" ]
social phobia is a Intervention_Other, : is a Intervention_Physical, anxiety visibility is a Outcome_Mental, social evaluation is a Outcome_Mental, social phobics is a Intervention_Psychological, controls is a Intervention_Control, 32 is a Participant_Sample-size, participants heard their heart sounds first via headphones is a Intervention_Psychological, Social phobics is a Intervention_Psychological, habituation in heart rate is a Outcome_Physical, higher heart rate is a Outcome_Physical, heart rates is a Outcome_Physical, actual heart rate differences is a Outcome_Physical, bodily anxiety symptom is a Outcome_Physical, anxiety levels is a Outcome_Mental
17729_task1
Sentence: Public and private heart rate feedback in social phobia : a manipulation of anxiety visibility . According to cognitive behavioural models of social phobia , bodily symptoms are the main source of information concerning social evaluation for social phobics . Experience and perception of bodily symptoms therefore play an important role in social anxiety . In this study we evaluated the effects of anxiety visibility on patients and controls using feedback of veridical heart sounds . A total of 32 social phobics and 32 controls were asked twice to sit in a chair and appear relaxed while being evaluated . Half of the participants heard their heart sounds first via headphones and then via loudspeakers which were also audible to observers . The presentation order of the heart sound was reversed for the other half of the subjects . Social phobics reported substantially more anxiety than controls . Both groups showed habituation in heart rate from the first to the second presentation , and both groups reported perception of a higher heart rate , but only social phobics reported significantly more anxiety and were more worried about their heart rates in the public than in the private condition . These effects were in excess of actual heart rate differences . In conclusion , social phobics worried about the broadcast of a bodily anxiety symptom , whereas controls did not . Information about arousal made public has a strong potential to increase anxiety levels in social phobics . Instructions: please typing these entity words according to sentence: social phobia, :, anxiety visibility, social evaluation, social phobics, controls, 32, participants heard their heart sounds first via headphones, Social phobics, habituation in heart rate, higher heart rate, heart rates, actual heart rate differences, bodily anxiety symptom, anxiety levels Options: Intervention_Psychological, Intervention_Physical, Intervention_Control, Intervention_Other, Outcome_Physical, Participant_Sample-size, Outcome_Mental
[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "B-Intervention_Physical", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O" ]
Public and private heart rate feedback in social phobia : a manipulation of anxiety visibility . According to cognitive behavioural models of social phobia , bodily symptoms are the main source of information concerning social evaluation for social phobics . Experience and perception of bodily symptoms therefore play an important role in social anxiety . In this study we evaluated the effects of anxiety visibility on patients and controls using feedback of veridical heart sounds . A total of 32 social phobics and 32 controls were asked twice to sit in a chair and appear relaxed while being evaluated . Half of the participants heard their heart sounds first via headphones and then via loudspeakers which were also audible to observers . The presentation order of the heart sound was reversed for the other half of the subjects . Social phobics reported substantially more anxiety than controls . Both groups showed habituation in heart rate from the first to the second presentation , and both groups reported perception of a higher heart rate , but only social phobics reported significantly more anxiety and were more worried about their heart rates in the public than in the private condition . These effects were in excess of actual heart rate differences . In conclusion , social phobics worried about the broadcast of a bodily anxiety symptom , whereas controls did not . Information about arousal made public has a strong potential to increase anxiety levels in social phobics .
[ "Public", "and", "private", "heart", "rate", "feedback", "in", "social", "phobia", ":", "a", "manipulation", "of", "anxiety", "visibility", ".", "According", "to", "cognitive", "behavioural", "models", "of", "social", "phobia", ",", "bodily", "symptoms", "are", "the", "main", "source", "of", "information", "concerning", "social", "evaluation", "for", "social", "phobics", ".", "Experience", "and", "perception", "of", "bodily", "symptoms", "therefore", "play", "an", "important", "role", "in", "social", "anxiety", ".", "In", "this", "study", "we", "evaluated", "the", "effects", "of", "anxiety", "visibility", "on", "patients", "and", "controls", "using", "feedback", "of", "veridical", "heart", "sounds", ".", "A", "total", "of", "32", "social", "phobics", "and", "32", "controls", "were", "asked", "twice", "to", "sit", "in", "a", "chair", "and", "appear", "relaxed", "while", "being", "evaluated", ".", "Half", "of", "the", "participants", "heard", "their", "heart", "sounds", "first", "via", "headphones", "and", "then", "via", "loudspeakers", "which", "were", "also", "audible", "to", "observers", ".", "The", "presentation", "order", "of", "the", "heart", "sound", "was", "reversed", "for", "the", "other", "half", "of", "the", "subjects", ".", "Social", "phobics", "reported", "substantially", "more", "anxiety", "than", "controls", ".", "Both", "groups", "showed", "habituation", "in", "heart", "rate", "from", "the", "first", "to", "the", "second", "presentation", ",", "and", "both", "groups", "reported", "perception", "of", "a", "higher", "heart", "rate", ",", "but", "only", "social", "phobics", "reported", "significantly", "more", "anxiety", "and", "were", "more", "worried", "about", "their", "heart", "rates", "in", "the", "public", "than", "in", "the", "private", "condition", ".", "These", "effects", "were", "in", "excess", "of", "actual", "heart", "rate", "differences", ".", "In", "conclusion", ",", "social", "phobics", "worried", "about", "the", "broadcast", "of", "a", "bodily", "anxiety", "symptom", ",", "whereas", "controls", "did", "not", ".", "Information", "about", "arousal", "made", "public", "has", "a", "strong", "potential", "to", "increase", "anxiety", "levels", "in", "social", "phobics", "." ]
[ "Intervention_Psychological", "Outcome_Physical", "Outcome_Mental", "Intervention_Other", "Intervention_Educational", "Participant_Condition", "Intervention_Control", "Participant_Sample-size", "Intervention_Physical" ]
social phobia, :, anxiety visibility, social evaluation, social phobics, controls, 32, participants heard their heart sounds first via headphones, Social phobics, habituation in heart rate, higher heart rate, heart rates, actual heart rate differences, bodily anxiety symptom, anxiety levels
17729_task2
Sentence: Public and private heart rate feedback in social phobia : a manipulation of anxiety visibility . According to cognitive behavioural models of social phobia , bodily symptoms are the main source of information concerning social evaluation for social phobics . Experience and perception of bodily symptoms therefore play an important role in social anxiety . In this study we evaluated the effects of anxiety visibility on patients and controls using feedback of veridical heart sounds . A total of 32 social phobics and 32 controls were asked twice to sit in a chair and appear relaxed while being evaluated . Half of the participants heard their heart sounds first via headphones and then via loudspeakers which were also audible to observers . The presentation order of the heart sound was reversed for the other half of the subjects . Social phobics reported substantially more anxiety than controls . Both groups showed habituation in heart rate from the first to the second presentation , and both groups reported perception of a higher heart rate , but only social phobics reported significantly more anxiety and were more worried about their heart rates in the public than in the private condition . These effects were in excess of actual heart rate differences . In conclusion , social phobics worried about the broadcast of a bodily anxiety symptom , whereas controls did not . Information about arousal made public has a strong potential to increase anxiety levels in social phobics . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Other", "I-Intervention_Other", "B-Intervention_Physical", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Psychological", "I-Intervention_Psychological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O" ]
Public and private heart rate feedback in social phobia : a manipulation of anxiety visibility . According to cognitive behavioural models of social phobia , bodily symptoms are the main source of information concerning social evaluation for social phobics . Experience and perception of bodily symptoms therefore play an important role in social anxiety . In this study we evaluated the effects of anxiety visibility on patients and controls using feedback of veridical heart sounds . A total of 32 social phobics and 32 controls were asked twice to sit in a chair and appear relaxed while being evaluated . Half of the participants heard their heart sounds first via headphones and then via loudspeakers which were also audible to observers . The presentation order of the heart sound was reversed for the other half of the subjects . Social phobics reported substantially more anxiety than controls . Both groups showed habituation in heart rate from the first to the second presentation , and both groups reported perception of a higher heart rate , but only social phobics reported significantly more anxiety and were more worried about their heart rates in the public than in the private condition . These effects were in excess of actual heart rate differences . In conclusion , social phobics worried about the broadcast of a bodily anxiety symptom , whereas controls did not . Information about arousal made public has a strong potential to increase anxiety levels in social phobics .
[ "Public", "and", "private", "heart", "rate", "feedback", "in", "social", "phobia", ":", "a", "manipulation", "of", "anxiety", "visibility", ".", "According", "to", "cognitive", "behavioural", "models", "of", "social", "phobia", ",", "bodily", "symptoms", "are", "the", "main", "source", "of", "information", "concerning", "social", "evaluation", "for", "social", "phobics", ".", "Experience", "and", "perception", "of", "bodily", "symptoms", "therefore", "play", "an", "important", "role", "in", "social", "anxiety", ".", "In", "this", "study", "we", "evaluated", "the", "effects", "of", "anxiety", "visibility", "on", "patients", "and", "controls", "using", "feedback", "of", "veridical", "heart", "sounds", ".", "A", "total", "of", "32", "social", "phobics", "and", "32", "controls", "were", "asked", "twice", "to", "sit", "in", "a", "chair", "and", "appear", "relaxed", "while", "being", "evaluated", ".", "Half", "of", "the", "participants", "heard", "their", "heart", "sounds", "first", "via", "headphones", "and", "then", "via", "loudspeakers", "which", "were", "also", "audible", "to", "observers", ".", "The", "presentation", "order", "of", "the", "heart", "sound", "was", "reversed", "for", "the", "other", "half", "of", "the", "subjects", ".", "Social", "phobics", "reported", "substantially", "more", "anxiety", "than", "controls", ".", "Both", "groups", "showed", "habituation", "in", "heart", "rate", "from", "the", "first", "to", "the", "second", "presentation", ",", "and", "both", "groups", "reported", "perception", "of", "a", "higher", "heart", "rate", ",", "but", "only", "social", "phobics", "reported", "significantly", "more", "anxiety", "and", "were", "more", "worried", "about", "their", "heart", "rates", "in", "the", "public", "than", "in", "the", "private", "condition", ".", "These", "effects", "were", "in", "excess", "of", "actual", "heart", "rate", "differences", ".", "In", "conclusion", ",", "social", "phobics", "worried", "about", "the", "broadcast", "of", "a", "bodily", "anxiety", "symptom", ",", "whereas", "controls", "did", "not", ".", "Information", "about", "arousal", "made", "public", "has", "a", "strong", "potential", "to", "increase", "anxiety", "levels", "in", "social", "phobics", "." ]
[ "Intervention_Psychological", "Outcome_Physical", "Outcome_Mental", "Intervention_Other", "Intervention_Educational", "Participant_Condition", "Intervention_Control", "Participant_Sample-size", "Intervention_Physical" ]
tsf mutant coat protein is a protein, GroEL is a protein-family, GroEL / S is a protein-complex
1.0alpha7.train.418_task0
Sentence: The percent tsf mutant coat protein bound to GroEL, however, does show a dependence upon GroEL/S concentration. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein, protein-complex
[ "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-complex", "I-protein-complex", "I-protein-complex", "O", "O", "O" ]
The percent tsf mutant coat protein bound to GroEL, however, does show a dependence upon GroEL/S concentration.
[ " ", "The", "percent", " ", "tsf", "mutant", "coat", "protein", "bound", "to", " ", "GroEL", ",", "however", ",", "does", "show", "a", "dependence", "upon", "GroEL", "/", "S", "concentration", ".", " " ]
[ "protein", "protein-family", "protein-complex" ]
tsf mutant coat protein is a protein, GroEL is a protein-family, GroEL / S is a protein-complex
1.0alpha7.train.418_task1
Sentence: The percent tsf mutant coat protein bound to GroEL, however, does show a dependence upon GroEL/S concentration. Instructions: please typing these entity words according to sentence: tsf mutant coat protein, GroEL, GroEL / S Options: protein-family, protein, protein-complex
[ "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-complex", "I-protein-complex", "I-protein-complex", "O", "O", "O" ]
The percent tsf mutant coat protein bound to GroEL, however, does show a dependence upon GroEL/S concentration.
[ " ", "The", "percent", " ", "tsf", "mutant", "coat", "protein", "bound", "to", " ", "GroEL", ",", "however", ",", "does", "show", "a", "dependence", "upon", "GroEL", "/", "S", "concentration", ".", " " ]
[ "protein", "protein-family", "protein-complex" ]
tsf mutant coat protein, GroEL, GroEL / S
1.0alpha7.train.418_task2
Sentence: The percent tsf mutant coat protein bound to GroEL, however, does show a dependence upon GroEL/S concentration. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "B-protein-family", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-complex", "I-protein-complex", "I-protein-complex", "O", "O", "O" ]
The percent tsf mutant coat protein bound to GroEL, however, does show a dependence upon GroEL/S concentration.
[ " ", "The", "percent", " ", "tsf", "mutant", "coat", "protein", "bound", "to", " ", "GroEL", ",", "however", ",", "does", "show", "a", "dependence", "upon", "GroEL", "/", "S", "concentration", ".", " " ]
[ "protein", "protein-family", "protein-complex" ]
eradication is a Outcome_Other, duodenal ulcer recurrence is a Outcome_Physical, duodenal ulcer ( Du ) is a Participant_Condition, DU recurrence is a Outcome_Physical, 190 is a Participant_Sample-size, Gram stained mucosal smear is a Outcome_Other, , is a Outcome_Physical, specific culture is a Outcome_Other, biopsy urease test is a Outcome_Other, histology of H & E staining - were is a Outcome_Other, H. pylori is a Participant_Condition, eradication of H. pylori is a Outcome_Physical, ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ) is a Intervention_Pharmacological, gastroscopy is a Outcome_Other, eradication rate is a Outcome_Other, cimetidine is a Intervention_Pharmacological, Seventy three is a Participant_Sample-size, recurrence rate is a Outcome_Physical, 31 is a Participant_Sample-size, 42 is a Participant_Sample-size, recurrence of DU is a Outcome_Physical
82700_task0
Sentence: The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence -- a 24 month follow-up study . OBJECTIVES To evaluate the effect of eradication of Helicobacter pylori ( H.pylori ) in the patients with duodenal ulcer ( Du ) upon the DU recurrence . METHODS This study was performed for 190 patients with DU . Four different methods-microscopy of Gram stained mucosal smear , specific culture , biopsy urease test , histology of H & E staining-were taken for identifying colonization of H. pylori before treatment , and for finding the eradication of H. pylori 4 weeks after completion of therapy in each treatment group ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ) . To detect DU recurrence , the gastroscopy was performed at 6 , 12 , 18 , and 24 months after therapy . RESULTS The eradication rate of the cimetidine group the omeprazole group , and the CBS group were 0 % , 7.7 % , 0 % , respectively , and that of the double therapy group and the triple therapy group were 44.4 % and 89.3 % , respectively . Seventy three patients who were followed up for 2 years were categorized into two groups according to the eradication of H. pylori . The recurrence rate was 3.2 % both in 1 year and 2 years later in the former group-one consisting of 31 patients with H. pylori eradicated , while the recurrence rate was 57.1 % in 1 year and 78.6 % in 2 years later , in the latter group-the other of 42 patients with H. pylori not eradicated . CONCLUSION The eradication of H. pylori in patients with DU reduces the recurrence of DU . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O" ]
The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence -- a 24 month follow-up study . OBJECTIVES To evaluate the effect of eradication of Helicobacter pylori ( H.pylori ) in the patients with duodenal ulcer ( Du ) upon the DU recurrence . METHODS This study was performed for 190 patients with DU . Four different methods-microscopy of Gram stained mucosal smear , specific culture , biopsy urease test , histology of H & E staining-were taken for identifying colonization of H. pylori before treatment , and for finding the eradication of H. pylori 4 weeks after completion of therapy in each treatment group ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ) . To detect DU recurrence , the gastroscopy was performed at 6 , 12 , 18 , and 24 months after therapy . RESULTS The eradication rate of the cimetidine group the omeprazole group , and the CBS group were 0 % , 7.7 % , 0 % , respectively , and that of the double therapy group and the triple therapy group were 44.4 % and 89.3 % , respectively . Seventy three patients who were followed up for 2 years were categorized into two groups according to the eradication of H. pylori . The recurrence rate was 3.2 % both in 1 year and 2 years later in the former group-one consisting of 31 patients with H. pylori eradicated , while the recurrence rate was 57.1 % in 1 year and 78.6 % in 2 years later , in the latter group-the other of 42 patients with H. pylori not eradicated . CONCLUSION The eradication of H. pylori in patients with DU reduces the recurrence of DU .
[ "The", "effect", "of", "eradication", "of", "Helicobacter", "pylori", "upon", "the", "duodenal", "ulcer", "recurrence", "--", "a", "24", "month", "follow", "-", "up", "study", ".", "OBJECTIVES", "To", "evaluate", "the", "effect", "of", "eradication", "of", "Helicobacter", "pylori", "(", "H.pylori", ")", "in", "the", "patients", "with", "duodenal", "ulcer", "(", "Du", ")", "upon", "the", "DU", "recurrence", ".", "METHODS", "This", "study", "was", "performed", "for", "190", "patients", "with", "DU", ".", "Four", "different", "methods", "-", "microscopy", "of", "Gram", "stained", "mucosal", "smear", ",", "specific", "culture", ",", "biopsy", "urease", "test", ",", "histology", "of", "H", "&", "E", "staining", "-", "were", "taken", "for", "identifying", "colonization", "of", "H.", "pylori", "before", "treatment", ",", "and", "for", "finding", "the", "eradication", "of", "H.", "pylori", "4", "weeks", "after", "completion", "of", "therapy", "in", "each", "treatment", "group", "(", "cometidine", ",", "omeprazole", ",", "colloidal", "bismuth", "subcitrate", "(", "CBS", ")", ",", "CBS", "and", "metronidazole", "double", "therapy", ",", "CBS", ",", "metronidazole", "and", "amoxicillin", "triple", "therapy", ")", ".", "To", "detect", "DU", "recurrence", ",", "the", "gastroscopy", "was", "performed", "at", "6", ",", "12", ",", "18", ",", "and", "24", "months", "after", "therapy", ".", "RESULTS", "The", "eradication", "rate", "of", "the", "cimetidine", "group", "the", "omeprazole", "group", ",", "and", "the", "CBS", "group", "were", "0", "%", ",", "7.7", "%", ",", "0", "%", ",", "respectively", ",", "and", "that", "of", "the", "double", "therapy", "group", "and", "the", "triple", "therapy", "group", "were", "44.4", "%", "and", "89.3", "%", ",", "respectively", ".", "Seventy", "three", "patients", "who", "were", "followed", "up", "for", "2", "years", "were", "categorized", "into", "two", "groups", "according", "to", "the", "eradication", "of", "H.", "pylori", ".", "The", "recurrence", "rate", "was", "3.2", "%", "both", "in", "1", "year", "and", "2", "years", "later", "in", "the", "former", "group", "-", "one", "consisting", "of", "31", "patients", "with", "H.", "pylori", "eradicated", ",", "while", "the", "recurrence", "rate", "was", "57.1", "%", "in", "1", "year", "and", "78.6", "%", "in", "2", "years", "later", ",", "in", "the", "latter", "group", "-", "the", "other", "of", "42", "patients", "with", "H.", "pylori", "not", "eradicated", ".", "CONCLUSION", "The", "eradication", "of", "H.", "pylori", "in", "patients", "with", "DU", "reduces", "the", "recurrence", "of", "DU", "." ]
[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Participant_Sample-size" ]
eradication is a Outcome_Other, duodenal ulcer recurrence is a Outcome_Physical, duodenal ulcer ( Du ) is a Participant_Condition, DU recurrence is a Outcome_Physical, 190 is a Participant_Sample-size, Gram stained mucosal smear is a Outcome_Other, , is a Outcome_Physical, specific culture is a Outcome_Other, biopsy urease test is a Outcome_Other, histology of H & E staining - were is a Outcome_Other, H. pylori is a Participant_Condition, eradication of H. pylori is a Outcome_Physical, ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ) is a Intervention_Pharmacological, gastroscopy is a Outcome_Other, eradication rate is a Outcome_Other, cimetidine is a Intervention_Pharmacological, Seventy three is a Participant_Sample-size, recurrence rate is a Outcome_Physical, 31 is a Participant_Sample-size, 42 is a Participant_Sample-size, recurrence of DU is a Outcome_Physical
82700_task1
Sentence: The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence -- a 24 month follow-up study . OBJECTIVES To evaluate the effect of eradication of Helicobacter pylori ( H.pylori ) in the patients with duodenal ulcer ( Du ) upon the DU recurrence . METHODS This study was performed for 190 patients with DU . Four different methods-microscopy of Gram stained mucosal smear , specific culture , biopsy urease test , histology of H & E staining-were taken for identifying colonization of H. pylori before treatment , and for finding the eradication of H. pylori 4 weeks after completion of therapy in each treatment group ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ) . To detect DU recurrence , the gastroscopy was performed at 6 , 12 , 18 , and 24 months after therapy . RESULTS The eradication rate of the cimetidine group the omeprazole group , and the CBS group were 0 % , 7.7 % , 0 % , respectively , and that of the double therapy group and the triple therapy group were 44.4 % and 89.3 % , respectively . Seventy three patients who were followed up for 2 years were categorized into two groups according to the eradication of H. pylori . The recurrence rate was 3.2 % both in 1 year and 2 years later in the former group-one consisting of 31 patients with H. pylori eradicated , while the recurrence rate was 57.1 % in 1 year and 78.6 % in 2 years later , in the latter group-the other of 42 patients with H. pylori not eradicated . CONCLUSION The eradication of H. pylori in patients with DU reduces the recurrence of DU . Instructions: please typing these entity words according to sentence: eradication, duodenal ulcer recurrence, duodenal ulcer ( Du ), DU recurrence, 190, Gram stained mucosal smear, ,, specific culture, biopsy urease test, histology of H & E staining - were, H. pylori, eradication of H. pylori, ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ), gastroscopy, eradication rate, cimetidine, Seventy three, recurrence rate, 31, 42, recurrence of DU Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O" ]
The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence -- a 24 month follow-up study . OBJECTIVES To evaluate the effect of eradication of Helicobacter pylori ( H.pylori ) in the patients with duodenal ulcer ( Du ) upon the DU recurrence . METHODS This study was performed for 190 patients with DU . Four different methods-microscopy of Gram stained mucosal smear , specific culture , biopsy urease test , histology of H & E staining-were taken for identifying colonization of H. pylori before treatment , and for finding the eradication of H. pylori 4 weeks after completion of therapy in each treatment group ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ) . To detect DU recurrence , the gastroscopy was performed at 6 , 12 , 18 , and 24 months after therapy . RESULTS The eradication rate of the cimetidine group the omeprazole group , and the CBS group were 0 % , 7.7 % , 0 % , respectively , and that of the double therapy group and the triple therapy group were 44.4 % and 89.3 % , respectively . Seventy three patients who were followed up for 2 years were categorized into two groups according to the eradication of H. pylori . The recurrence rate was 3.2 % both in 1 year and 2 years later in the former group-one consisting of 31 patients with H. pylori eradicated , while the recurrence rate was 57.1 % in 1 year and 78.6 % in 2 years later , in the latter group-the other of 42 patients with H. pylori not eradicated . CONCLUSION The eradication of H. pylori in patients with DU reduces the recurrence of DU .
[ "The", "effect", "of", "eradication", "of", "Helicobacter", "pylori", "upon", "the", "duodenal", "ulcer", "recurrence", "--", "a", "24", "month", "follow", "-", "up", "study", ".", "OBJECTIVES", "To", "evaluate", "the", "effect", "of", "eradication", "of", "Helicobacter", "pylori", "(", "H.pylori", ")", "in", "the", "patients", "with", "duodenal", "ulcer", "(", "Du", ")", "upon", "the", "DU", "recurrence", ".", "METHODS", "This", "study", "was", "performed", "for", "190", "patients", "with", "DU", ".", "Four", "different", "methods", "-", "microscopy", "of", "Gram", "stained", "mucosal", "smear", ",", "specific", "culture", ",", "biopsy", "urease", "test", ",", "histology", "of", "H", "&", "E", "staining", "-", "were", "taken", "for", "identifying", "colonization", "of", "H.", "pylori", "before", "treatment", ",", "and", "for", "finding", "the", "eradication", "of", "H.", "pylori", "4", "weeks", "after", "completion", "of", "therapy", "in", "each", "treatment", "group", "(", "cometidine", ",", "omeprazole", ",", "colloidal", "bismuth", "subcitrate", "(", "CBS", ")", ",", "CBS", "and", "metronidazole", "double", "therapy", ",", "CBS", ",", "metronidazole", "and", "amoxicillin", "triple", "therapy", ")", ".", "To", "detect", "DU", "recurrence", ",", "the", "gastroscopy", "was", "performed", "at", "6", ",", "12", ",", "18", ",", "and", "24", "months", "after", "therapy", ".", "RESULTS", "The", "eradication", "rate", "of", "the", "cimetidine", "group", "the", "omeprazole", "group", ",", "and", "the", "CBS", "group", "were", "0", "%", ",", "7.7", "%", ",", "0", "%", ",", "respectively", ",", "and", "that", "of", "the", "double", "therapy", "group", "and", "the", "triple", "therapy", "group", "were", "44.4", "%", "and", "89.3", "%", ",", "respectively", ".", "Seventy", "three", "patients", "who", "were", "followed", "up", "for", "2", "years", "were", "categorized", "into", "two", "groups", "according", "to", "the", "eradication", "of", "H.", "pylori", ".", "The", "recurrence", "rate", "was", "3.2", "%", "both", "in", "1", "year", "and", "2", "years", "later", "in", "the", "former", "group", "-", "one", "consisting", "of", "31", "patients", "with", "H.", "pylori", "eradicated", ",", "while", "the", "recurrence", "rate", "was", "57.1", "%", "in", "1", "year", "and", "78.6", "%", "in", "2", "years", "later", ",", "in", "the", "latter", "group", "-", "the", "other", "of", "42", "patients", "with", "H.", "pylori", "not", "eradicated", ".", "CONCLUSION", "The", "eradication", "of", "H.", "pylori", "in", "patients", "with", "DU", "reduces", "the", "recurrence", "of", "DU", "." ]
[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Participant_Sample-size" ]
eradication, duodenal ulcer recurrence, duodenal ulcer ( Du ), DU recurrence, 190, Gram stained mucosal smear, ,, specific culture, biopsy urease test, histology of H & E staining - were, H. pylori, eradication of H. pylori, ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ), gastroscopy, eradication rate, cimetidine, Seventy three, recurrence rate, 31, 42, recurrence of DU
82700_task2
Sentence: The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence -- a 24 month follow-up study . OBJECTIVES To evaluate the effect of eradication of Helicobacter pylori ( H.pylori ) in the patients with duodenal ulcer ( Du ) upon the DU recurrence . METHODS This study was performed for 190 patients with DU . Four different methods-microscopy of Gram stained mucosal smear , specific culture , biopsy urease test , histology of H & E staining-were taken for identifying colonization of H. pylori before treatment , and for finding the eradication of H. pylori 4 weeks after completion of therapy in each treatment group ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ) . To detect DU recurrence , the gastroscopy was performed at 6 , 12 , 18 , and 24 months after therapy . RESULTS The eradication rate of the cimetidine group the omeprazole group , and the CBS group were 0 % , 7.7 % , 0 % , respectively , and that of the double therapy group and the triple therapy group were 44.4 % and 89.3 % , respectively . Seventy three patients who were followed up for 2 years were categorized into two groups according to the eradication of H. pylori . The recurrence rate was 3.2 % both in 1 year and 2 years later in the former group-one consisting of 31 patients with H. pylori eradicated , while the recurrence rate was 57.1 % in 1 year and 78.6 % in 2 years later , in the latter group-the other of 42 patients with H. pylori not eradicated . CONCLUSION The eradication of H. pylori in patients with DU reduces the recurrence of DU . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "B-Outcome_Physical", "B-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O" ]
The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence -- a 24 month follow-up study . OBJECTIVES To evaluate the effect of eradication of Helicobacter pylori ( H.pylori ) in the patients with duodenal ulcer ( Du ) upon the DU recurrence . METHODS This study was performed for 190 patients with DU . Four different methods-microscopy of Gram stained mucosal smear , specific culture , biopsy urease test , histology of H & E staining-were taken for identifying colonization of H. pylori before treatment , and for finding the eradication of H. pylori 4 weeks after completion of therapy in each treatment group ( cometidine , omeprazole , colloidal bismuth subcitrate ( CBS ) , CBS and metronidazole double therapy , CBS , metronidazole and amoxicillin triple therapy ) . To detect DU recurrence , the gastroscopy was performed at 6 , 12 , 18 , and 24 months after therapy . RESULTS The eradication rate of the cimetidine group the omeprazole group , and the CBS group were 0 % , 7.7 % , 0 % , respectively , and that of the double therapy group and the triple therapy group were 44.4 % and 89.3 % , respectively . Seventy three patients who were followed up for 2 years were categorized into two groups according to the eradication of H. pylori . The recurrence rate was 3.2 % both in 1 year and 2 years later in the former group-one consisting of 31 patients with H. pylori eradicated , while the recurrence rate was 57.1 % in 1 year and 78.6 % in 2 years later , in the latter group-the other of 42 patients with H. pylori not eradicated . CONCLUSION The eradication of H. pylori in patients with DU reduces the recurrence of DU .
[ "The", "effect", "of", "eradication", "of", "Helicobacter", "pylori", "upon", "the", "duodenal", "ulcer", "recurrence", "--", "a", "24", "month", "follow", "-", "up", "study", ".", "OBJECTIVES", "To", "evaluate", "the", "effect", "of", "eradication", "of", "Helicobacter", "pylori", "(", "H.pylori", ")", "in", "the", "patients", "with", "duodenal", "ulcer", "(", "Du", ")", "upon", "the", "DU", "recurrence", ".", "METHODS", "This", "study", "was", "performed", "for", "190", "patients", "with", "DU", ".", "Four", "different", "methods", "-", "microscopy", "of", "Gram", "stained", "mucosal", "smear", ",", "specific", "culture", ",", "biopsy", "urease", "test", ",", "histology", "of", "H", "&", "E", "staining", "-", "were", "taken", "for", "identifying", "colonization", "of", "H.", "pylori", "before", "treatment", ",", "and", "for", "finding", "the", "eradication", "of", "H.", "pylori", "4", "weeks", "after", "completion", "of", "therapy", "in", "each", "treatment", "group", "(", "cometidine", ",", "omeprazole", ",", "colloidal", "bismuth", "subcitrate", "(", "CBS", ")", ",", "CBS", "and", "metronidazole", "double", "therapy", ",", "CBS", ",", "metronidazole", "and", "amoxicillin", "triple", "therapy", ")", ".", "To", "detect", "DU", "recurrence", ",", "the", "gastroscopy", "was", "performed", "at", "6", ",", "12", ",", "18", ",", "and", "24", "months", "after", "therapy", ".", "RESULTS", "The", "eradication", "rate", "of", "the", "cimetidine", "group", "the", "omeprazole", "group", ",", "and", "the", "CBS", "group", "were", "0", "%", ",", "7.7", "%", ",", "0", "%", ",", "respectively", ",", "and", "that", "of", "the", "double", "therapy", "group", "and", "the", "triple", "therapy", "group", "were", "44.4", "%", "and", "89.3", "%", ",", "respectively", ".", "Seventy", "three", "patients", "who", "were", "followed", "up", "for", "2", "years", "were", "categorized", "into", "two", "groups", "according", "to", "the", "eradication", "of", "H.", "pylori", ".", "The", "recurrence", "rate", "was", "3.2", "%", "both", "in", "1", "year", "and", "2", "years", "later", "in", "the", "former", "group", "-", "one", "consisting", "of", "31", "patients", "with", "H.", "pylori", "eradicated", ",", "while", "the", "recurrence", "rate", "was", "57.1", "%", "in", "1", "year", "and", "78.6", "%", "in", "2", "years", "later", ",", "in", "the", "latter", "group", "-", "the", "other", "of", "42", "patients", "with", "H.", "pylori", "not", "eradicated", ".", "CONCLUSION", "The", "eradication", "of", "H.", "pylori", "in", "patients", "with", "DU", "reduces", "the", "recurrence", "of", "DU", "." ]
[ "Intervention_Pharmacological", "Outcome_Other", "Outcome_Physical", "Participant_Condition", "Participant_Sample-size" ]
olive is a Plant, cardiovascular disease is a Disease, olive is a Plant, cardiovascular disease is a Disease, olive is a Plant, olive is a Plant, olive is a Plant, olive is a Plant, olive is a Plant, olive is a Plant, coronary heart disease is a Disease
19858733_task0
Sentence: The Mediterranean diet, in which olive oil is the primary source of fat, is associated with a low mortality for cardiovascular disease. Data concerning olive oil consumption and primary end points for cardiovascular disease are scarce. However, a large body of knowledge exists providing evidence of the benefits of olive oil consumption on secondary end points for the disease. Besides the classical benefits on the lipid profile provided by olive oil consumption compared with that of saturated fat, a broad spectrum of benefits on cardiovascular risk factors is now emerging associated with olive oil consumption. We review the state of the art concerning the knowledge of the most important biological and clinical effects related to olive oil and its minor components. The recent advances in human nutrigenomics associated with olive oil consumption will also be assessed. The wide range of benefits associated with olive oil consumption could contribute to explaining the low rate of cardiovascular mortality found in southern European-Mediterranean countries, in comparison with other westernized countries, despite a high prevalence of coronary heart disease risk factors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Disease, Plant
[ "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "I-Disease", "O", "O", "O" ]
The Mediterranean diet, in which olive oil is the primary source of fat, is associated with a low mortality for cardiovascular disease. Data concerning olive oil consumption and primary end points for cardiovascular disease are scarce. However, a large body of knowledge exists providing evidence of the benefits of olive oil consumption on secondary end points for the disease. Besides the classical benefits on the lipid profile provided by olive oil consumption compared with that of saturated fat, a broad spectrum of benefits on cardiovascular risk factors is now emerging associated with olive oil consumption. We review the state of the art concerning the knowledge of the most important biological and clinical effects related to olive oil and its minor components. The recent advances in human nutrigenomics associated with olive oil consumption will also be assessed. The wide range of benefits associated with olive oil consumption could contribute to explaining the low rate of cardiovascular mortality found in southern European-Mediterranean countries, in comparison with other westernized countries, despite a high prevalence of coronary heart disease risk factors.
[ "The", "Mediterranean", "diet", ",", "in", "which", "olive", "oil", "is", "the", "primary", "source", "of", "fat", ",", "is", "associated", "with", "a", "low", "mortality", "for", "cardiovascular", "disease", ".", "Data", "concerning", "olive", "oil", "consumption", "and", "primary", "end", "points", "for", "cardiovascular", "disease", "are", "scarce", ".", "However", ",", "a", "large", "body", "of", "knowledge", "exists", "providing", "evidence", "of", "the", "benefits", "of", "olive", "oil", "consumption", "on", "secondary", "end", "points", "for", "the", "disease", ".", "Besides", "the", "classical", "benefits", "on", "the", "lipid", "profile", "provided", "by", "olive", "oil", "consumption", "compared", "with", "that", "of", "saturated", "fat", ",", "a", "broad", "spectrum", "of", "benefits", "on", "cardiovascular", "risk", "factors", "is", "now", "emerging", "associated", "with", "olive", "oil", "consumption", ".", "We", "review", "the", "state", "of", "the", "art", "concerning", "the", "knowledge", "of", "the", "most", "important", "biological", "and", "clinical", "effects", "related", "to", "olive", "oil", "and", "its", "minor", "components", ".", "The", "recent", "advances", "in", "human", "nutrigenomics", "associated", "with", "olive", "oil", "consumption", "will", "also", "be", "assessed", ".", "The", "wide", "range", "of", "benefits", "associated", "with", "olive", "oil", "consumption", "could", "contribute", "to", "explaining", "the", "low", "rate", "of", "cardiovascular", "mortality", "found", "in", "southern", "European", "-", "Mediterranean", "countries", ",", "in", "comparison", "with", "other", "westernized", "countries", ",", "despite", "a", "high", "prevalence", "of", "coronary", "heart", "disease", "risk", "factors", "." ]
[ "Disease", "Plant" ]
olive is a Plant, cardiovascular disease is a Disease, olive is a Plant, cardiovascular disease is a Disease, olive is a Plant, olive is a Plant, olive is a Plant, olive is a Plant, olive is a Plant, olive is a Plant, coronary heart disease is a Disease
19858733_task1
Sentence: The Mediterranean diet, in which olive oil is the primary source of fat, is associated with a low mortality for cardiovascular disease. Data concerning olive oil consumption and primary end points for cardiovascular disease are scarce. However, a large body of knowledge exists providing evidence of the benefits of olive oil consumption on secondary end points for the disease. Besides the classical benefits on the lipid profile provided by olive oil consumption compared with that of saturated fat, a broad spectrum of benefits on cardiovascular risk factors is now emerging associated with olive oil consumption. We review the state of the art concerning the knowledge of the most important biological and clinical effects related to olive oil and its minor components. The recent advances in human nutrigenomics associated with olive oil consumption will also be assessed. The wide range of benefits associated with olive oil consumption could contribute to explaining the low rate of cardiovascular mortality found in southern European-Mediterranean countries, in comparison with other westernized countries, despite a high prevalence of coronary heart disease risk factors. Instructions: please typing these entity words according to sentence: olive, cardiovascular disease, olive, cardiovascular disease, olive, olive, olive, olive, olive, olive, coronary heart disease Options: Disease, Plant
[ "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "I-Disease", "O", "O", "O" ]
The Mediterranean diet, in which olive oil is the primary source of fat, is associated with a low mortality for cardiovascular disease. Data concerning olive oil consumption and primary end points for cardiovascular disease are scarce. However, a large body of knowledge exists providing evidence of the benefits of olive oil consumption on secondary end points for the disease. Besides the classical benefits on the lipid profile provided by olive oil consumption compared with that of saturated fat, a broad spectrum of benefits on cardiovascular risk factors is now emerging associated with olive oil consumption. We review the state of the art concerning the knowledge of the most important biological and clinical effects related to olive oil and its minor components. The recent advances in human nutrigenomics associated with olive oil consumption will also be assessed. The wide range of benefits associated with olive oil consumption could contribute to explaining the low rate of cardiovascular mortality found in southern European-Mediterranean countries, in comparison with other westernized countries, despite a high prevalence of coronary heart disease risk factors.
[ "The", "Mediterranean", "diet", ",", "in", "which", "olive", "oil", "is", "the", "primary", "source", "of", "fat", ",", "is", "associated", "with", "a", "low", "mortality", "for", "cardiovascular", "disease", ".", "Data", "concerning", "olive", "oil", "consumption", "and", "primary", "end", "points", "for", "cardiovascular", "disease", "are", "scarce", ".", "However", ",", "a", "large", "body", "of", "knowledge", "exists", "providing", "evidence", "of", "the", "benefits", "of", "olive", "oil", "consumption", "on", "secondary", "end", "points", "for", "the", "disease", ".", "Besides", "the", "classical", "benefits", "on", "the", "lipid", "profile", "provided", "by", "olive", "oil", "consumption", "compared", "with", "that", "of", "saturated", "fat", ",", "a", "broad", "spectrum", "of", "benefits", "on", "cardiovascular", "risk", "factors", "is", "now", "emerging", "associated", "with", "olive", "oil", "consumption", ".", "We", "review", "the", "state", "of", "the", "art", "concerning", "the", "knowledge", "of", "the", "most", "important", "biological", "and", "clinical", "effects", "related", "to", "olive", "oil", "and", "its", "minor", "components", ".", "The", "recent", "advances", "in", "human", "nutrigenomics", "associated", "with", "olive", "oil", "consumption", "will", "also", "be", "assessed", ".", "The", "wide", "range", "of", "benefits", "associated", "with", "olive", "oil", "consumption", "could", "contribute", "to", "explaining", "the", "low", "rate", "of", "cardiovascular", "mortality", "found", "in", "southern", "European", "-", "Mediterranean", "countries", ",", "in", "comparison", "with", "other", "westernized", "countries", ",", "despite", "a", "high", "prevalence", "of", "coronary", "heart", "disease", "risk", "factors", "." ]
[ "Disease", "Plant" ]
olive, cardiovascular disease, olive, cardiovascular disease, olive, olive, olive, olive, olive, olive, coronary heart disease
19858733_task2
Sentence: The Mediterranean diet, in which olive oil is the primary source of fat, is associated with a low mortality for cardiovascular disease. Data concerning olive oil consumption and primary end points for cardiovascular disease are scarce. However, a large body of knowledge exists providing evidence of the benefits of olive oil consumption on secondary end points for the disease. Besides the classical benefits on the lipid profile provided by olive oil consumption compared with that of saturated fat, a broad spectrum of benefits on cardiovascular risk factors is now emerging associated with olive oil consumption. We review the state of the art concerning the knowledge of the most important biological and clinical effects related to olive oil and its minor components. The recent advances in human nutrigenomics associated with olive oil consumption will also be assessed. The wide range of benefits associated with olive oil consumption could contribute to explaining the low rate of cardiovascular mortality found in southern European-Mediterranean countries, in comparison with other westernized countries, despite a high prevalence of coronary heart disease risk factors. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "I-Disease", "O", "O", "O" ]
The Mediterranean diet, in which olive oil is the primary source of fat, is associated with a low mortality for cardiovascular disease. Data concerning olive oil consumption and primary end points for cardiovascular disease are scarce. However, a large body of knowledge exists providing evidence of the benefits of olive oil consumption on secondary end points for the disease. Besides the classical benefits on the lipid profile provided by olive oil consumption compared with that of saturated fat, a broad spectrum of benefits on cardiovascular risk factors is now emerging associated with olive oil consumption. We review the state of the art concerning the knowledge of the most important biological and clinical effects related to olive oil and its minor components. The recent advances in human nutrigenomics associated with olive oil consumption will also be assessed. The wide range of benefits associated with olive oil consumption could contribute to explaining the low rate of cardiovascular mortality found in southern European-Mediterranean countries, in comparison with other westernized countries, despite a high prevalence of coronary heart disease risk factors.
[ "The", "Mediterranean", "diet", ",", "in", "which", "olive", "oil", "is", "the", "primary", "source", "of", "fat", ",", "is", "associated", "with", "a", "low", "mortality", "for", "cardiovascular", "disease", ".", "Data", "concerning", "olive", "oil", "consumption", "and", "primary", "end", "points", "for", "cardiovascular", "disease", "are", "scarce", ".", "However", ",", "a", "large", "body", "of", "knowledge", "exists", "providing", "evidence", "of", "the", "benefits", "of", "olive", "oil", "consumption", "on", "secondary", "end", "points", "for", "the", "disease", ".", "Besides", "the", "classical", "benefits", "on", "the", "lipid", "profile", "provided", "by", "olive", "oil", "consumption", "compared", "with", "that", "of", "saturated", "fat", ",", "a", "broad", "spectrum", "of", "benefits", "on", "cardiovascular", "risk", "factors", "is", "now", "emerging", "associated", "with", "olive", "oil", "consumption", ".", "We", "review", "the", "state", "of", "the", "art", "concerning", "the", "knowledge", "of", "the", "most", "important", "biological", "and", "clinical", "effects", "related", "to", "olive", "oil", "and", "its", "minor", "components", ".", "The", "recent", "advances", "in", "human", "nutrigenomics", "associated", "with", "olive", "oil", "consumption", "will", "also", "be", "assessed", ".", "The", "wide", "range", "of", "benefits", "associated", "with", "olive", "oil", "consumption", "could", "contribute", "to", "explaining", "the", "low", "rate", "of", "cardiovascular", "mortality", "found", "in", "southern", "European", "-", "Mediterranean", "countries", ",", "in", "comparison", "with", "other", "westernized", "countries", ",", "despite", "a", "high", "prevalence", "of", "coronary", "heart", "disease", "risk", "factors", "." ]
[ "Disease", "Plant" ]
Fisteln is an umlsterm, Diagnostik is an umlsterm, Becken is an umlsterm, Tumor is an umlsterm, Fisteln is an umlsterm, Boden is an umlsterm, rezidivfrei is an umlsterm, Embryonalentwicklung is an umlsterm, Schwanzdarms is an umlsterm, Fisteln is an umlsterm, Rectum is an umlsterm, Os sacrum is an umlsterm
DerChirurg.00710712.ger.abstr_task0
Sentence: Zusammenfassung . Bei einer 58 jaehrigen Patientin wurde 1983 auswaerts erstmals eine praesacrale Raumforderung diagnostiziert , die als Abscess behandelt wurde . Im Anschluss daran kam es zu rezidivierenden perianalen Fisteln . Die weitere Diagnostik zeigte einen im kleinen Becken liegenden cystischen Tumor , der als Epidermoidcyste angesehen und entfernt wurde . Histologisch fand sich cystisches Narbengewebe mit einem 4 cm messenden , hoch differenzierten Adenocarcinom . Im weiteren Verlauf kam es erneut zu perianalen Fisteln , ausgehend von einer erneuten praesacralen Raumforderung . Es erfolgte die abdominoperineale Rectumexstirpation und Sacrumteilresektion mit Anlage einer Descendostomie . Histologisch fand sich jetzt Adenocarcinomgewebe auf dem Boden einer Tail-gut-Cyste . Die Patientin ist ein Jahr nach der Operation beschwerde- und rezidivfrei . Die Tail-gut-Cyste ist eine sehr seltene Entitaet , die aus der ungenuegenden Rueckbildung des in der Embryonalentwicklung vorhandenen Schwanzdarms entsteht . Eine maligne Transformation wird bei 10 % beschrieben . Rezidivierende perianale Fisteln und cystische Raumforderungen zwischen Rectum und Os sacrum bzw. Os coccygis sollten an eine Tail-gut-Cyste denken lassen , deren vollstaendige Entfernung anzustreben ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Bei einer 58 jaehrigen Patientin wurde 1983 auswaerts erstmals eine praesacrale Raumforderung diagnostiziert , die als Abscess behandelt wurde . Im Anschluss daran kam es zu rezidivierenden perianalen Fisteln . Die weitere Diagnostik zeigte einen im kleinen Becken liegenden cystischen Tumor , der als Epidermoidcyste angesehen und entfernt wurde . Histologisch fand sich cystisches Narbengewebe mit einem 4 cm messenden , hoch differenzierten Adenocarcinom . Im weiteren Verlauf kam es erneut zu perianalen Fisteln , ausgehend von einer erneuten praesacralen Raumforderung . Es erfolgte die abdominoperineale Rectumexstirpation und Sacrumteilresektion mit Anlage einer Descendostomie . Histologisch fand sich jetzt Adenocarcinomgewebe auf dem Boden einer Tail-gut-Cyste . Die Patientin ist ein Jahr nach der Operation beschwerde- und rezidivfrei . Die Tail-gut-Cyste ist eine sehr seltene Entitaet , die aus der ungenuegenden Rueckbildung des in der Embryonalentwicklung vorhandenen Schwanzdarms entsteht . Eine maligne Transformation wird bei 10 % beschrieben . Rezidivierende perianale Fisteln und cystische Raumforderungen zwischen Rectum und Os sacrum bzw. Os coccygis sollten an eine Tail-gut-Cyste denken lassen , deren vollstaendige Entfernung anzustreben ist .
[ "Zusammenfassung", ".", "Bei", "einer", "58", "jaehrigen", "Patientin", "wurde", "1983", "auswaerts", "erstmals", "eine", "praesacrale", "Raumforderung", "diagnostiziert", ",", "die", "als", "Abscess", "behandelt", "wurde", ".", "Im", "Anschluss", "daran", "kam", "es", "zu", "rezidivierenden", "perianalen", "Fisteln", ".", "Die", "weitere", "Diagnostik", "zeigte", "einen", "im", "kleinen", "Becken", "liegenden", "cystischen", "Tumor", ",", "der", "als", "Epidermoidcyste", "angesehen", "und", "entfernt", "wurde", ".", "Histologisch", "fand", "sich", "cystisches", "Narbengewebe", "mit", "einem", "4", "cm", "messenden", ",", "hoch", "differenzierten", "Adenocarcinom", ".", "Im", "weiteren", "Verlauf", "kam", "es", "erneut", "zu", "perianalen", "Fisteln", ",", "ausgehend", "von", "einer", "erneuten", "praesacralen", "Raumforderung", ".", "Es", "erfolgte", "die", "abdominoperineale", "Rectumexstirpation", "und", "Sacrumteilresektion", "mit", "Anlage", "einer", "Descendostomie", ".", "Histologisch", "fand", "sich", "jetzt", "Adenocarcinomgewebe", "auf", "dem", "Boden", "einer", "Tail", "-", "gut", "-", "Cyste", ".", "Die", "Patientin", "ist", "ein", "Jahr", "nach", "der", "Operation", "beschwerde-", "und", "rezidivfrei", ".", "Die", "Tail", "-", "gut", "-", "Cyste", "ist", "eine", "sehr", "seltene", "Entitaet", ",", "die", "aus", "der", "ungenuegenden", "Rueckbildung", "des", "in", "der", "Embryonalentwicklung", "vorhandenen", "Schwanzdarms", "entsteht", ".", "Eine", "maligne", "Transformation", "wird", "bei", "10", "%", "beschrieben", ".", "Rezidivierende", "perianale", "Fisteln", "und", "cystische", "Raumforderungen", "zwischen", "Rectum", "und", "Os", "sacrum", "bzw", ".", "Os", "coccygis", "sollten", "an", "eine", "Tail", "-", "gut", "-", "Cyste", "denken", "lassen", ",", "deren", "vollstaendige", "Entfernung", "anzustreben", "ist", "." ]
[ "umlsterm" ]
Fisteln is an umlsterm, Diagnostik is an umlsterm, Becken is an umlsterm, Tumor is an umlsterm, Fisteln is an umlsterm, Boden is an umlsterm, rezidivfrei is an umlsterm, Embryonalentwicklung is an umlsterm, Schwanzdarms is an umlsterm, Fisteln is an umlsterm, Rectum is an umlsterm, Os sacrum is an umlsterm
DerChirurg.00710712.ger.abstr_task1
Sentence: Zusammenfassung . Bei einer 58 jaehrigen Patientin wurde 1983 auswaerts erstmals eine praesacrale Raumforderung diagnostiziert , die als Abscess behandelt wurde . Im Anschluss daran kam es zu rezidivierenden perianalen Fisteln . Die weitere Diagnostik zeigte einen im kleinen Becken liegenden cystischen Tumor , der als Epidermoidcyste angesehen und entfernt wurde . Histologisch fand sich cystisches Narbengewebe mit einem 4 cm messenden , hoch differenzierten Adenocarcinom . Im weiteren Verlauf kam es erneut zu perianalen Fisteln , ausgehend von einer erneuten praesacralen Raumforderung . Es erfolgte die abdominoperineale Rectumexstirpation und Sacrumteilresektion mit Anlage einer Descendostomie . Histologisch fand sich jetzt Adenocarcinomgewebe auf dem Boden einer Tail-gut-Cyste . Die Patientin ist ein Jahr nach der Operation beschwerde- und rezidivfrei . Die Tail-gut-Cyste ist eine sehr seltene Entitaet , die aus der ungenuegenden Rueckbildung des in der Embryonalentwicklung vorhandenen Schwanzdarms entsteht . Eine maligne Transformation wird bei 10 % beschrieben . Rezidivierende perianale Fisteln und cystische Raumforderungen zwischen Rectum und Os sacrum bzw. Os coccygis sollten an eine Tail-gut-Cyste denken lassen , deren vollstaendige Entfernung anzustreben ist . Instructions: please typing these entity words according to sentence: Fisteln, Diagnostik, Becken, Tumor, Fisteln, Boden, rezidivfrei, Embryonalentwicklung, Schwanzdarms, Fisteln, Rectum, Os sacrum Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Bei einer 58 jaehrigen Patientin wurde 1983 auswaerts erstmals eine praesacrale Raumforderung diagnostiziert , die als Abscess behandelt wurde . Im Anschluss daran kam es zu rezidivierenden perianalen Fisteln . Die weitere Diagnostik zeigte einen im kleinen Becken liegenden cystischen Tumor , der als Epidermoidcyste angesehen und entfernt wurde . Histologisch fand sich cystisches Narbengewebe mit einem 4 cm messenden , hoch differenzierten Adenocarcinom . Im weiteren Verlauf kam es erneut zu perianalen Fisteln , ausgehend von einer erneuten praesacralen Raumforderung . Es erfolgte die abdominoperineale Rectumexstirpation und Sacrumteilresektion mit Anlage einer Descendostomie . Histologisch fand sich jetzt Adenocarcinomgewebe auf dem Boden einer Tail-gut-Cyste . Die Patientin ist ein Jahr nach der Operation beschwerde- und rezidivfrei . Die Tail-gut-Cyste ist eine sehr seltene Entitaet , die aus der ungenuegenden Rueckbildung des in der Embryonalentwicklung vorhandenen Schwanzdarms entsteht . Eine maligne Transformation wird bei 10 % beschrieben . Rezidivierende perianale Fisteln und cystische Raumforderungen zwischen Rectum und Os sacrum bzw. Os coccygis sollten an eine Tail-gut-Cyste denken lassen , deren vollstaendige Entfernung anzustreben ist .
[ "Zusammenfassung", ".", "Bei", "einer", "58", "jaehrigen", "Patientin", "wurde", "1983", "auswaerts", "erstmals", "eine", "praesacrale", "Raumforderung", "diagnostiziert", ",", "die", "als", "Abscess", "behandelt", "wurde", ".", "Im", "Anschluss", "daran", "kam", "es", "zu", "rezidivierenden", "perianalen", "Fisteln", ".", "Die", "weitere", "Diagnostik", "zeigte", "einen", "im", "kleinen", "Becken", "liegenden", "cystischen", "Tumor", ",", "der", "als", "Epidermoidcyste", "angesehen", "und", "entfernt", "wurde", ".", "Histologisch", "fand", "sich", "cystisches", "Narbengewebe", "mit", "einem", "4", "cm", "messenden", ",", "hoch", "differenzierten", "Adenocarcinom", ".", "Im", "weiteren", "Verlauf", "kam", "es", "erneut", "zu", "perianalen", "Fisteln", ",", "ausgehend", "von", "einer", "erneuten", "praesacralen", "Raumforderung", ".", "Es", "erfolgte", "die", "abdominoperineale", "Rectumexstirpation", "und", "Sacrumteilresektion", "mit", "Anlage", "einer", "Descendostomie", ".", "Histologisch", "fand", "sich", "jetzt", "Adenocarcinomgewebe", "auf", "dem", "Boden", "einer", "Tail", "-", "gut", "-", "Cyste", ".", "Die", "Patientin", "ist", "ein", "Jahr", "nach", "der", "Operation", "beschwerde-", "und", "rezidivfrei", ".", "Die", "Tail", "-", "gut", "-", "Cyste", "ist", "eine", "sehr", "seltene", "Entitaet", ",", "die", "aus", "der", "ungenuegenden", "Rueckbildung", "des", "in", "der", "Embryonalentwicklung", "vorhandenen", "Schwanzdarms", "entsteht", ".", "Eine", "maligne", "Transformation", "wird", "bei", "10", "%", "beschrieben", ".", "Rezidivierende", "perianale", "Fisteln", "und", "cystische", "Raumforderungen", "zwischen", "Rectum", "und", "Os", "sacrum", "bzw", ".", "Os", "coccygis", "sollten", "an", "eine", "Tail", "-", "gut", "-", "Cyste", "denken", "lassen", ",", "deren", "vollstaendige", "Entfernung", "anzustreben", "ist", "." ]
[ "umlsterm" ]
Fisteln, Diagnostik, Becken, Tumor, Fisteln, Boden, rezidivfrei, Embryonalentwicklung, Schwanzdarms, Fisteln, Rectum, Os sacrum
DerChirurg.00710712.ger.abstr_task2
Sentence: Zusammenfassung . Bei einer 58 jaehrigen Patientin wurde 1983 auswaerts erstmals eine praesacrale Raumforderung diagnostiziert , die als Abscess behandelt wurde . Im Anschluss daran kam es zu rezidivierenden perianalen Fisteln . Die weitere Diagnostik zeigte einen im kleinen Becken liegenden cystischen Tumor , der als Epidermoidcyste angesehen und entfernt wurde . Histologisch fand sich cystisches Narbengewebe mit einem 4 cm messenden , hoch differenzierten Adenocarcinom . Im weiteren Verlauf kam es erneut zu perianalen Fisteln , ausgehend von einer erneuten praesacralen Raumforderung . Es erfolgte die abdominoperineale Rectumexstirpation und Sacrumteilresektion mit Anlage einer Descendostomie . Histologisch fand sich jetzt Adenocarcinomgewebe auf dem Boden einer Tail-gut-Cyste . Die Patientin ist ein Jahr nach der Operation beschwerde- und rezidivfrei . Die Tail-gut-Cyste ist eine sehr seltene Entitaet , die aus der ungenuegenden Rueckbildung des in der Embryonalentwicklung vorhandenen Schwanzdarms entsteht . Eine maligne Transformation wird bei 10 % beschrieben . Rezidivierende perianale Fisteln und cystische Raumforderungen zwischen Rectum und Os sacrum bzw. Os coccygis sollten an eine Tail-gut-Cyste denken lassen , deren vollstaendige Entfernung anzustreben ist . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Bei einer 58 jaehrigen Patientin wurde 1983 auswaerts erstmals eine praesacrale Raumforderung diagnostiziert , die als Abscess behandelt wurde . Im Anschluss daran kam es zu rezidivierenden perianalen Fisteln . Die weitere Diagnostik zeigte einen im kleinen Becken liegenden cystischen Tumor , der als Epidermoidcyste angesehen und entfernt wurde . Histologisch fand sich cystisches Narbengewebe mit einem 4 cm messenden , hoch differenzierten Adenocarcinom . Im weiteren Verlauf kam es erneut zu perianalen Fisteln , ausgehend von einer erneuten praesacralen Raumforderung . Es erfolgte die abdominoperineale Rectumexstirpation und Sacrumteilresektion mit Anlage einer Descendostomie . Histologisch fand sich jetzt Adenocarcinomgewebe auf dem Boden einer Tail-gut-Cyste . Die Patientin ist ein Jahr nach der Operation beschwerde- und rezidivfrei . Die Tail-gut-Cyste ist eine sehr seltene Entitaet , die aus der ungenuegenden Rueckbildung des in der Embryonalentwicklung vorhandenen Schwanzdarms entsteht . Eine maligne Transformation wird bei 10 % beschrieben . Rezidivierende perianale Fisteln und cystische Raumforderungen zwischen Rectum und Os sacrum bzw. Os coccygis sollten an eine Tail-gut-Cyste denken lassen , deren vollstaendige Entfernung anzustreben ist .
[ "Zusammenfassung", ".", "Bei", "einer", "58", "jaehrigen", "Patientin", "wurde", "1983", "auswaerts", "erstmals", "eine", "praesacrale", "Raumforderung", "diagnostiziert", ",", "die", "als", "Abscess", "behandelt", "wurde", ".", "Im", "Anschluss", "daran", "kam", "es", "zu", "rezidivierenden", "perianalen", "Fisteln", ".", "Die", "weitere", "Diagnostik", "zeigte", "einen", "im", "kleinen", "Becken", "liegenden", "cystischen", "Tumor", ",", "der", "als", "Epidermoidcyste", "angesehen", "und", "entfernt", "wurde", ".", "Histologisch", "fand", "sich", "cystisches", "Narbengewebe", "mit", "einem", "4", "cm", "messenden", ",", "hoch", "differenzierten", "Adenocarcinom", ".", "Im", "weiteren", "Verlauf", "kam", "es", "erneut", "zu", "perianalen", "Fisteln", ",", "ausgehend", "von", "einer", "erneuten", "praesacralen", "Raumforderung", ".", "Es", "erfolgte", "die", "abdominoperineale", "Rectumexstirpation", "und", "Sacrumteilresektion", "mit", "Anlage", "einer", "Descendostomie", ".", "Histologisch", "fand", "sich", "jetzt", "Adenocarcinomgewebe", "auf", "dem", "Boden", "einer", "Tail", "-", "gut", "-", "Cyste", ".", "Die", "Patientin", "ist", "ein", "Jahr", "nach", "der", "Operation", "beschwerde-", "und", "rezidivfrei", ".", "Die", "Tail", "-", "gut", "-", "Cyste", "ist", "eine", "sehr", "seltene", "Entitaet", ",", "die", "aus", "der", "ungenuegenden", "Rueckbildung", "des", "in", "der", "Embryonalentwicklung", "vorhandenen", "Schwanzdarms", "entsteht", ".", "Eine", "maligne", "Transformation", "wird", "bei", "10", "%", "beschrieben", ".", "Rezidivierende", "perianale", "Fisteln", "und", "cystische", "Raumforderungen", "zwischen", "Rectum", "und", "Os", "sacrum", "bzw", ".", "Os", "coccygis", "sollten", "an", "eine", "Tail", "-", "gut", "-", "Cyste", "denken", "lassen", ",", "deren", "vollstaendige", "Entfernung", "anzustreben", "ist", "." ]
[ "umlsterm" ]
mutants of cyclin E is a protein, CDK2 is a protein, CDK2 is a protein, S phase is a process
1.0alpha7.train.1186_task0
Sentence: Hence, mutants of cyclin E that cannot bind to CDK2 are biologically inert (Kelly et al. 1998 ), and ectopic overexpression of a catalytically inactive mutant of CDK2 prevents a cell from entering S phase (Heuvel and Harlow 1993 ). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: process, protein
[ "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O" ]
Hence, mutants of cyclin E that cannot bind to CDK2 are biologically inert (Kelly et al. 1998 ), and ectopic overexpression of a catalytically inactive mutant of CDK2 prevents a cell from entering S phase (Heuvel and Harlow 1993 ).
[ "Hence", ",", "mutants", "of", " ", "cyclin", "E", "that", "cannot", "bind", "to", " ", "CDK2", "are", "biologically", "inert", "(", "Kelly", "et", "al", ".", "1998", " ", ")", ",", "and", " ", "ectopic", "overexpression", "of", "a", "catalytically", "inactive", "mutant", "of", " ", "CDK2", "prevents", "a", "cell", "from", "entering", " ", "S", "phase", "(", "Heuvel", "and", "Harlow", "1993", " ", ")", "." ]
[ "protein", "protein-family", "process" ]
mutants of cyclin E is a protein, CDK2 is a protein, CDK2 is a protein, S phase is a process
1.0alpha7.train.1186_task1
Sentence: Hence, mutants of cyclin E that cannot bind to CDK2 are biologically inert (Kelly et al. 1998 ), and ectopic overexpression of a catalytically inactive mutant of CDK2 prevents a cell from entering S phase (Heuvel and Harlow 1993 ). Instructions: please typing these entity words according to sentence: mutants of cyclin E, CDK2, CDK2, S phase Options: process, protein
[ "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O" ]
Hence, mutants of cyclin E that cannot bind to CDK2 are biologically inert (Kelly et al. 1998 ), and ectopic overexpression of a catalytically inactive mutant of CDK2 prevents a cell from entering S phase (Heuvel and Harlow 1993 ).
[ "Hence", ",", "mutants", "of", " ", "cyclin", "E", "that", "cannot", "bind", "to", " ", "CDK2", "are", "biologically", "inert", "(", "Kelly", "et", "al", ".", "1998", " ", ")", ",", "and", " ", "ectopic", "overexpression", "of", "a", "catalytically", "inactive", "mutant", "of", " ", "CDK2", "prevents", "a", "cell", "from", "entering", " ", "S", "phase", "(", "Heuvel", "and", "Harlow", "1993", " ", ")", "." ]
[ "protein", "protein-family", "process" ]
mutants of cyclin E, CDK2, CDK2, S phase
1.0alpha7.train.1186_task2
Sentence: Hence, mutants of cyclin E that cannot bind to CDK2 are biologically inert (Kelly et al. 1998 ), and ectopic overexpression of a catalytically inactive mutant of CDK2 prevents a cell from entering S phase (Heuvel and Harlow 1993 ). Instructions: please extract entity words from the input sentence
[ "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "B-process", "I-process", "O", "O", "O", "O", "O", "O", "O", "O" ]
Hence, mutants of cyclin E that cannot bind to CDK2 are biologically inert (Kelly et al. 1998 ), and ectopic overexpression of a catalytically inactive mutant of CDK2 prevents a cell from entering S phase (Heuvel and Harlow 1993 ).
[ "Hence", ",", "mutants", "of", " ", "cyclin", "E", "that", "cannot", "bind", "to", " ", "CDK2", "are", "biologically", "inert", "(", "Kelly", "et", "al", ".", "1998", " ", ")", ",", "and", " ", "ectopic", "overexpression", "of", "a", "catalytically", "inactive", "mutant", "of", " ", "CDK2", "prevents", "a", "cell", "from", "entering", " ", "S", "phase", "(", "Heuvel", "and", "Harlow", "1993", " ", ")", "." ]
[ "protein", "protein-family", "process" ]
pregnant is a Condition, 30 min or more is a Multiplier, moderate to vigorous activity is a Observation, more than 3 times per week is a Multiplier, cardiovascular disease is a Condition, physical limitations is a Condition, moderate is a Qualifier, planning to move is a Observation, in next 12 - 24 months is a Temporal, diabetic is a Condition
NCT02488057_exc_task0
Sentence: pregnant 30 min or more of moderate to vigorous activity more than 3 times per week cardiovascular disease physical limitations that might be aggravated by moderate physical activity planning to move in next 12-24 months diabetic Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Observation, Multiplier
[ "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Qualifier", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O" ]
pregnant 30 min or more of moderate to vigorous activity more than 3 times per week cardiovascular disease physical limitations that might be aggravated by moderate physical activity planning to move in next 12-24 months diabetic
[ "pregnant", "\n", "30", "min", "or", "more", "of", "moderate", "to", "vigorous", "activity", "more", "than", "3", "times", "per", "week", "\n", "cardiovascular", "disease", "\n", "physical", "limitations", "that", "might", "be", "aggravated", "by", "moderate", "physical", "activity", "\n", "planning", "to", "move", "in", "next", "12", "-", "24", "months", "\n", "diabetic", "\n" ]
[ "Observation", "Multiplier", "Condition", "Temporal", "Qualifier" ]
pregnant is a Condition, 30 min or more is a Multiplier, moderate to vigorous activity is a Observation, more than 3 times per week is a Multiplier, cardiovascular disease is a Condition, physical limitations is a Condition, moderate is a Qualifier, planning to move is a Observation, in next 12 - 24 months is a Temporal, diabetic is a Condition
NCT02488057_exc_task1
Sentence: pregnant 30 min or more of moderate to vigorous activity more than 3 times per week cardiovascular disease physical limitations that might be aggravated by moderate physical activity planning to move in next 12-24 months diabetic Instructions: please typing these entity words according to sentence: pregnant, 30 min or more, moderate to vigorous activity, more than 3 times per week, cardiovascular disease, physical limitations, moderate, planning to move, in next 12 - 24 months, diabetic Options: Temporal, Condition, Qualifier, Observation, Multiplier
[ "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Qualifier", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O" ]
pregnant 30 min or more of moderate to vigorous activity more than 3 times per week cardiovascular disease physical limitations that might be aggravated by moderate physical activity planning to move in next 12-24 months diabetic
[ "pregnant", "\n", "30", "min", "or", "more", "of", "moderate", "to", "vigorous", "activity", "more", "than", "3", "times", "per", "week", "\n", "cardiovascular", "disease", "\n", "physical", "limitations", "that", "might", "be", "aggravated", "by", "moderate", "physical", "activity", "\n", "planning", "to", "move", "in", "next", "12", "-", "24", "months", "\n", "diabetic", "\n" ]
[ "Observation", "Multiplier", "Condition", "Temporal", "Qualifier" ]
pregnant, 30 min or more, moderate to vigorous activity, more than 3 times per week, cardiovascular disease, physical limitations, moderate, planning to move, in next 12 - 24 months, diabetic
NCT02488057_exc_task2
Sentence: pregnant 30 min or more of moderate to vigorous activity more than 3 times per week cardiovascular disease physical limitations that might be aggravated by moderate physical activity planning to move in next 12-24 months diabetic Instructions: please extract entity words from the input sentence
[ "B-Condition", "O", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "B-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "I-Multiplier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "B-Qualifier", "O", "O", "O", "B-Observation", "I-Observation", "I-Observation", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "O" ]
pregnant 30 min or more of moderate to vigorous activity more than 3 times per week cardiovascular disease physical limitations that might be aggravated by moderate physical activity planning to move in next 12-24 months diabetic
[ "pregnant", "\n", "30", "min", "or", "more", "of", "moderate", "to", "vigorous", "activity", "more", "than", "3", "times", "per", "week", "\n", "cardiovascular", "disease", "\n", "physical", "limitations", "that", "might", "be", "aggravated", "by", "moderate", "physical", "activity", "\n", "planning", "to", "move", "in", "next", "12", "-", "24", "months", "\n", "diabetic", "\n" ]
[ "Observation", "Multiplier", "Condition", "Temporal", "Qualifier" ]
Hypogonadismus is an umlsterm, Mann is an umlsterm, Haut is an umlsterm, androgenabhaengig is an umlsterm, Hautoberflaeche is an umlsterm, Maenner is an umlsterm, Hypogonadismus is an umlsterm, Akne is an umlsterm, Talgdruesen is an umlsterm, Pubertaet is an umlsterm, Pigmentierung is an umlsterm, Analhaut is an umlsterm, Hautkolorit is an umlsterm, Brust is an umlsterm, Gesicht is an umlsterm, Hautarealen is an umlsterm, maennlichen is an umlsterm, Glatzenbildung is an umlsterm, Behandlung is an umlsterm, Hypogonadismus is an umlsterm, Medikamente is an umlsterm, Androgene is an umlsterm, Gonadotropine is an umlsterm, Hautveraenderungen is an umlsterm, Therapiesystemen is an umlsterm, Testosteron is an umlsterm, Praevalenz is an umlsterm, Syndrome is an umlsterm, Hypogonadismus is an umlsterm
DerHautarzt.00510223.ger.abstr_task0
Sentence: Hypogonadismus beim Mann kann zu dermatologisch relevanten Veraenderungen fuehren , da die Haut und ihre Anhangsgebilde androgenabhaengig sind . Die Hautoberflaeche hypogonadaler Maenner ist duenn und weist vermehrt Faeltelung auf . Bei praepubertaer bestehendem Hypogonadismus bleibt staerkere Akne aus . Es besteht Sebostase durch verminderte Stimulation der Talgdruesen . Die normalerweise waehrend der Pubertaet zunehmende Pigmentierung der Genital- und Analhaut fehlt ; das Hautkolorit des uebrigen Integuments ist fahl . Die Behaarung von Brust , Pubes , Axillen , Gesicht und uebrigen Hautarealen ist rarefiziert ; es kommt nicht zur Entwicklung der typischen maennlichen Glatzenbildung . Von klinischer Bedeutung sind aber auch durch die Behandlung des Hypogonadismus verursachte Erkrankungen oder Reaktionen auf Medikamente . Waehrend Reaktionen auf oral oder intramuskulaer applizierte Androgene oder Gonadotropine selten sind , treten irritative oder allergische Hautveraenderungen insbesondere bei nicht-skrotalen transkutanen Therapiesystemen mit Testosteron haeufiger auf . Eine grosse , bezueglich ihrer Praevalenz aber weniger bedeutsame Gruppe bilden Syndrome mit gleichzeitigem Auftreten von dermatologischen Symptomen und Hypogonadismus . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Hypogonadismus beim Mann kann zu dermatologisch relevanten Veraenderungen fuehren , da die Haut und ihre Anhangsgebilde androgenabhaengig sind . Die Hautoberflaeche hypogonadaler Maenner ist duenn und weist vermehrt Faeltelung auf . Bei praepubertaer bestehendem Hypogonadismus bleibt staerkere Akne aus . Es besteht Sebostase durch verminderte Stimulation der Talgdruesen . Die normalerweise waehrend der Pubertaet zunehmende Pigmentierung der Genital- und Analhaut fehlt ; das Hautkolorit des uebrigen Integuments ist fahl . Die Behaarung von Brust , Pubes , Axillen , Gesicht und uebrigen Hautarealen ist rarefiziert ; es kommt nicht zur Entwicklung der typischen maennlichen Glatzenbildung . Von klinischer Bedeutung sind aber auch durch die Behandlung des Hypogonadismus verursachte Erkrankungen oder Reaktionen auf Medikamente . Waehrend Reaktionen auf oral oder intramuskulaer applizierte Androgene oder Gonadotropine selten sind , treten irritative oder allergische Hautveraenderungen insbesondere bei nicht-skrotalen transkutanen Therapiesystemen mit Testosteron haeufiger auf . Eine grosse , bezueglich ihrer Praevalenz aber weniger bedeutsame Gruppe bilden Syndrome mit gleichzeitigem Auftreten von dermatologischen Symptomen und Hypogonadismus .
[ "Hypogonadismus", "beim", "Mann", "kann", "zu", "dermatologisch", "relevanten", "Veraenderungen", "fuehren", ",", "da", "die", "Haut", "und", "ihre", "Anhangsgebilde", "androgenabhaengig", "sind", ".", "Die", "Hautoberflaeche", "hypogonadaler", "Maenner", "ist", "duenn", "und", "weist", "vermehrt", "Faeltelung", "auf", ".", "Bei", "praepubertaer", "bestehendem", "Hypogonadismus", "bleibt", "staerkere", "Akne", "aus", ".", "Es", "besteht", "Sebostase", "durch", "verminderte", "Stimulation", "der", "Talgdruesen", ".", "Die", "normalerweise", "waehrend", "der", "Pubertaet", "zunehmende", "Pigmentierung", "der", "Genital-", "und", "Analhaut", "fehlt", ";", "das", "Hautkolorit", "des", "uebrigen", "Integuments", "ist", "fahl", ".", "Die", "Behaarung", "von", "Brust", ",", "Pubes", ",", "Axillen", ",", "Gesicht", "und", "uebrigen", "Hautarealen", "ist", "rarefiziert", ";", "es", "kommt", "nicht", "zur", "Entwicklung", "der", "typischen", "maennlichen", "Glatzenbildung", ".", "Von", "klinischer", "Bedeutung", "sind", "aber", "auch", "durch", "die", "Behandlung", "des", "Hypogonadismus", "verursachte", "Erkrankungen", "oder", "Reaktionen", "auf", "Medikamente", ".", "Waehrend", "Reaktionen", "auf", "oral", "oder", "intramuskulaer", "applizierte", "Androgene", "oder", "Gonadotropine", "selten", "sind", ",", "treten", "irritative", "oder", "allergische", "Hautveraenderungen", "insbesondere", "bei", "nicht", "-", "skrotalen", "transkutanen", "Therapiesystemen", "mit", "Testosteron", "haeufiger", "auf", ".", "Eine", "grosse", ",", "bezueglich", "ihrer", "Praevalenz", "aber", "weniger", "bedeutsame", "Gruppe", "bilden", "Syndrome", "mit", "gleichzeitigem", "Auftreten", "von", "dermatologischen", "Symptomen", "und", "Hypogonadismus", "." ]
[ "umlsterm" ]
Hypogonadismus is an umlsterm, Mann is an umlsterm, Haut is an umlsterm, androgenabhaengig is an umlsterm, Hautoberflaeche is an umlsterm, Maenner is an umlsterm, Hypogonadismus is an umlsterm, Akne is an umlsterm, Talgdruesen is an umlsterm, Pubertaet is an umlsterm, Pigmentierung is an umlsterm, Analhaut is an umlsterm, Hautkolorit is an umlsterm, Brust is an umlsterm, Gesicht is an umlsterm, Hautarealen is an umlsterm, maennlichen is an umlsterm, Glatzenbildung is an umlsterm, Behandlung is an umlsterm, Hypogonadismus is an umlsterm, Medikamente is an umlsterm, Androgene is an umlsterm, Gonadotropine is an umlsterm, Hautveraenderungen is an umlsterm, Therapiesystemen is an umlsterm, Testosteron is an umlsterm, Praevalenz is an umlsterm, Syndrome is an umlsterm, Hypogonadismus is an umlsterm
DerHautarzt.00510223.ger.abstr_task1
Sentence: Hypogonadismus beim Mann kann zu dermatologisch relevanten Veraenderungen fuehren , da die Haut und ihre Anhangsgebilde androgenabhaengig sind . Die Hautoberflaeche hypogonadaler Maenner ist duenn und weist vermehrt Faeltelung auf . Bei praepubertaer bestehendem Hypogonadismus bleibt staerkere Akne aus . Es besteht Sebostase durch verminderte Stimulation der Talgdruesen . Die normalerweise waehrend der Pubertaet zunehmende Pigmentierung der Genital- und Analhaut fehlt ; das Hautkolorit des uebrigen Integuments ist fahl . Die Behaarung von Brust , Pubes , Axillen , Gesicht und uebrigen Hautarealen ist rarefiziert ; es kommt nicht zur Entwicklung der typischen maennlichen Glatzenbildung . Von klinischer Bedeutung sind aber auch durch die Behandlung des Hypogonadismus verursachte Erkrankungen oder Reaktionen auf Medikamente . Waehrend Reaktionen auf oral oder intramuskulaer applizierte Androgene oder Gonadotropine selten sind , treten irritative oder allergische Hautveraenderungen insbesondere bei nicht-skrotalen transkutanen Therapiesystemen mit Testosteron haeufiger auf . Eine grosse , bezueglich ihrer Praevalenz aber weniger bedeutsame Gruppe bilden Syndrome mit gleichzeitigem Auftreten von dermatologischen Symptomen und Hypogonadismus . Instructions: please typing these entity words according to sentence: Hypogonadismus, Mann, Haut, androgenabhaengig, Hautoberflaeche, Maenner, Hypogonadismus, Akne, Talgdruesen, Pubertaet, Pigmentierung, Analhaut, Hautkolorit, Brust, Gesicht, Hautarealen, maennlichen, Glatzenbildung, Behandlung, Hypogonadismus, Medikamente, Androgene, Gonadotropine, Hautveraenderungen, Therapiesystemen, Testosteron, Praevalenz, Syndrome, Hypogonadismus Options: umlsterm
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Hypogonadismus beim Mann kann zu dermatologisch relevanten Veraenderungen fuehren , da die Haut und ihre Anhangsgebilde androgenabhaengig sind . Die Hautoberflaeche hypogonadaler Maenner ist duenn und weist vermehrt Faeltelung auf . Bei praepubertaer bestehendem Hypogonadismus bleibt staerkere Akne aus . Es besteht Sebostase durch verminderte Stimulation der Talgdruesen . Die normalerweise waehrend der Pubertaet zunehmende Pigmentierung der Genital- und Analhaut fehlt ; das Hautkolorit des uebrigen Integuments ist fahl . Die Behaarung von Brust , Pubes , Axillen , Gesicht und uebrigen Hautarealen ist rarefiziert ; es kommt nicht zur Entwicklung der typischen maennlichen Glatzenbildung . Von klinischer Bedeutung sind aber auch durch die Behandlung des Hypogonadismus verursachte Erkrankungen oder Reaktionen auf Medikamente . Waehrend Reaktionen auf oral oder intramuskulaer applizierte Androgene oder Gonadotropine selten sind , treten irritative oder allergische Hautveraenderungen insbesondere bei nicht-skrotalen transkutanen Therapiesystemen mit Testosteron haeufiger auf . Eine grosse , bezueglich ihrer Praevalenz aber weniger bedeutsame Gruppe bilden Syndrome mit gleichzeitigem Auftreten von dermatologischen Symptomen und Hypogonadismus .
[ "Hypogonadismus", "beim", "Mann", "kann", "zu", "dermatologisch", "relevanten", "Veraenderungen", "fuehren", ",", "da", "die", "Haut", "und", "ihre", "Anhangsgebilde", "androgenabhaengig", "sind", ".", "Die", "Hautoberflaeche", "hypogonadaler", "Maenner", "ist", "duenn", "und", "weist", "vermehrt", "Faeltelung", "auf", ".", "Bei", "praepubertaer", "bestehendem", "Hypogonadismus", "bleibt", "staerkere", "Akne", "aus", ".", "Es", "besteht", "Sebostase", "durch", "verminderte", "Stimulation", "der", "Talgdruesen", ".", "Die", "normalerweise", "waehrend", "der", "Pubertaet", "zunehmende", "Pigmentierung", "der", "Genital-", "und", "Analhaut", "fehlt", ";", "das", "Hautkolorit", "des", "uebrigen", "Integuments", "ist", "fahl", ".", "Die", "Behaarung", "von", "Brust", ",", "Pubes", ",", "Axillen", ",", "Gesicht", "und", "uebrigen", "Hautarealen", "ist", "rarefiziert", ";", "es", "kommt", "nicht", "zur", "Entwicklung", "der", "typischen", "maennlichen", "Glatzenbildung", ".", "Von", "klinischer", "Bedeutung", "sind", "aber", "auch", "durch", "die", "Behandlung", "des", "Hypogonadismus", "verursachte", "Erkrankungen", "oder", "Reaktionen", "auf", "Medikamente", ".", "Waehrend", "Reaktionen", "auf", "oral", "oder", "intramuskulaer", "applizierte", "Androgene", "oder", "Gonadotropine", "selten", "sind", ",", "treten", "irritative", "oder", "allergische", "Hautveraenderungen", "insbesondere", "bei", "nicht", "-", "skrotalen", "transkutanen", "Therapiesystemen", "mit", "Testosteron", "haeufiger", "auf", ".", "Eine", "grosse", ",", "bezueglich", "ihrer", "Praevalenz", "aber", "weniger", "bedeutsame", "Gruppe", "bilden", "Syndrome", "mit", "gleichzeitigem", "Auftreten", "von", "dermatologischen", "Symptomen", "und", "Hypogonadismus", "." ]
[ "umlsterm" ]
Hypogonadismus, Mann, Haut, androgenabhaengig, Hautoberflaeche, Maenner, Hypogonadismus, Akne, Talgdruesen, Pubertaet, Pigmentierung, Analhaut, Hautkolorit, Brust, Gesicht, Hautarealen, maennlichen, Glatzenbildung, Behandlung, Hypogonadismus, Medikamente, Androgene, Gonadotropine, Hautveraenderungen, Therapiesystemen, Testosteron, Praevalenz, Syndrome, Hypogonadismus
DerHautarzt.00510223.ger.abstr_task2
Sentence: Hypogonadismus beim Mann kann zu dermatologisch relevanten Veraenderungen fuehren , da die Haut und ihre Anhangsgebilde androgenabhaengig sind . Die Hautoberflaeche hypogonadaler Maenner ist duenn und weist vermehrt Faeltelung auf . Bei praepubertaer bestehendem Hypogonadismus bleibt staerkere Akne aus . Es besteht Sebostase durch verminderte Stimulation der Talgdruesen . Die normalerweise waehrend der Pubertaet zunehmende Pigmentierung der Genital- und Analhaut fehlt ; das Hautkolorit des uebrigen Integuments ist fahl . Die Behaarung von Brust , Pubes , Axillen , Gesicht und uebrigen Hautarealen ist rarefiziert ; es kommt nicht zur Entwicklung der typischen maennlichen Glatzenbildung . Von klinischer Bedeutung sind aber auch durch die Behandlung des Hypogonadismus verursachte Erkrankungen oder Reaktionen auf Medikamente . Waehrend Reaktionen auf oral oder intramuskulaer applizierte Androgene oder Gonadotropine selten sind , treten irritative oder allergische Hautveraenderungen insbesondere bei nicht-skrotalen transkutanen Therapiesystemen mit Testosteron haeufiger auf . Eine grosse , bezueglich ihrer Praevalenz aber weniger bedeutsame Gruppe bilden Syndrome mit gleichzeitigem Auftreten von dermatologischen Symptomen und Hypogonadismus . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Hypogonadismus beim Mann kann zu dermatologisch relevanten Veraenderungen fuehren , da die Haut und ihre Anhangsgebilde androgenabhaengig sind . Die Hautoberflaeche hypogonadaler Maenner ist duenn und weist vermehrt Faeltelung auf . Bei praepubertaer bestehendem Hypogonadismus bleibt staerkere Akne aus . Es besteht Sebostase durch verminderte Stimulation der Talgdruesen . Die normalerweise waehrend der Pubertaet zunehmende Pigmentierung der Genital- und Analhaut fehlt ; das Hautkolorit des uebrigen Integuments ist fahl . Die Behaarung von Brust , Pubes , Axillen , Gesicht und uebrigen Hautarealen ist rarefiziert ; es kommt nicht zur Entwicklung der typischen maennlichen Glatzenbildung . Von klinischer Bedeutung sind aber auch durch die Behandlung des Hypogonadismus verursachte Erkrankungen oder Reaktionen auf Medikamente . Waehrend Reaktionen auf oral oder intramuskulaer applizierte Androgene oder Gonadotropine selten sind , treten irritative oder allergische Hautveraenderungen insbesondere bei nicht-skrotalen transkutanen Therapiesystemen mit Testosteron haeufiger auf . Eine grosse , bezueglich ihrer Praevalenz aber weniger bedeutsame Gruppe bilden Syndrome mit gleichzeitigem Auftreten von dermatologischen Symptomen und Hypogonadismus .
[ "Hypogonadismus", "beim", "Mann", "kann", "zu", "dermatologisch", "relevanten", "Veraenderungen", "fuehren", ",", "da", "die", "Haut", "und", "ihre", "Anhangsgebilde", "androgenabhaengig", "sind", ".", "Die", "Hautoberflaeche", "hypogonadaler", "Maenner", "ist", "duenn", "und", "weist", "vermehrt", "Faeltelung", "auf", ".", "Bei", "praepubertaer", "bestehendem", "Hypogonadismus", "bleibt", "staerkere", "Akne", "aus", ".", "Es", "besteht", "Sebostase", "durch", "verminderte", "Stimulation", "der", "Talgdruesen", ".", "Die", "normalerweise", "waehrend", "der", "Pubertaet", "zunehmende", "Pigmentierung", "der", "Genital-", "und", "Analhaut", "fehlt", ";", "das", "Hautkolorit", "des", "uebrigen", "Integuments", "ist", "fahl", ".", "Die", "Behaarung", "von", "Brust", ",", "Pubes", ",", "Axillen", ",", "Gesicht", "und", "uebrigen", "Hautarealen", "ist", "rarefiziert", ";", "es", "kommt", "nicht", "zur", "Entwicklung", "der", "typischen", "maennlichen", "Glatzenbildung", ".", "Von", "klinischer", "Bedeutung", "sind", "aber", "auch", "durch", "die", "Behandlung", "des", "Hypogonadismus", "verursachte", "Erkrankungen", "oder", "Reaktionen", "auf", "Medikamente", ".", "Waehrend", "Reaktionen", "auf", "oral", "oder", "intramuskulaer", "applizierte", "Androgene", "oder", "Gonadotropine", "selten", "sind", ",", "treten", "irritative", "oder", "allergische", "Hautveraenderungen", "insbesondere", "bei", "nicht", "-", "skrotalen", "transkutanen", "Therapiesystemen", "mit", "Testosteron", "haeufiger", "auf", ".", "Eine", "grosse", ",", "bezueglich", "ihrer", "Praevalenz", "aber", "weniger", "bedeutsame", "Gruppe", "bilden", "Syndrome", "mit", "gleichzeitigem", "Auftreten", "von", "dermatologischen", "Symptomen", "und", "Hypogonadismus", "." ]
[ "umlsterm" ]
PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, cerebral cavernous malformations is a Pathological_formation, Cerebral cavernous malformations is a Pathological_formation, CCMs is a Pathological_formation, cerebral vascular lesions is a Pathological_formation, Phosphatase and tension homolog deleted on chromosome 10 is a Gene_or_gene_product, PTEN is a Gene_or_gene_product, tumor is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, tumors is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, endothelial is a Cell, PTEN is a Gene_or_gene_product, proliferating cell nuclear antigen is a Gene_or_gene_product, phosphor - Akt is a Gene_or_gene_product, phosphor - Erk1,2 is a Gene_or_gene_product, CCM is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, PTEN is a Gene_or_gene_product, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, proliferating cell nuclear antigen is a Gene_or_gene_product, Akt is a Gene_or_gene_product, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, CCMs is a Pathological_formation, CCMs is a Pathological_formation, lesions is a Pathological_formation
53_task0
Sentence: Involvement of PTEN promoter methylation in cerebral cavernous malformations. BACKGROUND AND PURPOSE: Cerebral cavernous malformations (CCMs) are prevalent cerebral vascular lesions involving aberrant angiogenesis. However, the underlying mechanism is poorly understood. Phosphatase and tension homolog deleted on chromosome 10 (PTEN), a tumor suppressor, is frequently deficient in various pathologies due to mutation or epigenetic alterations. PTEN promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors. The present study aimed to investigate whether PTEN promoter methylation was involved in CCMs. METHODS: PTEN promoter methylation was detected in surgical specimens of CCMs (n=69) by methylation-specific polymerase chain reaction. The methylation status was correlated to the clinical manifestations and to PTEN expression, which was analyzed by both Western blot and immunohistochemistry. To investigate the endothelial proliferation and the potential signaling pathways affected by PTEN methylation, proliferating cell nuclear antigen as well as phosphor-Akt and phosphor-Erk1,2 were detected by immunofluorescence and Western blot, respectively, in CCM specimens. RESULTS: Methylation-specific polymerase chain reaction revealed PTEN promoter methylation in 15.9% CCMs. Strikingly, 5 of 6 familial CCMs showed PTEN promoter methylation (83.3%), which was significantly higher than in sporadic cases (9.4%; P<0.001). In addition, PTEN promoter methylation appeared more frequently in multiple CCMs, including familial cases (46.7%), than that in single-lesioned CCMs (11.8%; P<0.05). Immunostaining and Western blot revealed a more significant PTEN downregulation in PTEN-methylated CCMs in comparison to PTEN-unmethylated CCMs. Reduced PTEN expression was inversely correlated to the expression of proliferating cell nuclear antigen and to the activation of Erk1,2, but not of Akt. CONCLUSIONS: We reported here for the first time the involvement of PTEN promoter methylation in CCMs, particularly in familial CCMs, suggesting this epigenetic alteration as a potential pathomechanism of CCMs. The identification of Erk1,2 as triggered signaling in the lesions may be valuable for the development of effective therapy for this disease. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Pathological_formation, DNA_domain_or_region, Gene_or_gene_product, Cell
[ "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Pathological_formation", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Involvement of PTEN promoter methylation in cerebral cavernous malformations. BACKGROUND AND PURPOSE: Cerebral cavernous malformations (CCMs) are prevalent cerebral vascular lesions involving aberrant angiogenesis. However, the underlying mechanism is poorly understood. Phosphatase and tension homolog deleted on chromosome 10 (PTEN), a tumor suppressor, is frequently deficient in various pathologies due to mutation or epigenetic alterations. PTEN promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors. The present study aimed to investigate whether PTEN promoter methylation was involved in CCMs. METHODS: PTEN promoter methylation was detected in surgical specimens of CCMs (n=69) by methylation-specific polymerase chain reaction. The methylation status was correlated to the clinical manifestations and to PTEN expression, which was analyzed by both Western blot and immunohistochemistry. To investigate the endothelial proliferation and the potential signaling pathways affected by PTEN methylation, proliferating cell nuclear antigen as well as phosphor-Akt and phosphor-Erk1,2 were detected by immunofluorescence and Western blot, respectively, in CCM specimens. RESULTS: Methylation-specific polymerase chain reaction revealed PTEN promoter methylation in 15.9% CCMs. Strikingly, 5 of 6 familial CCMs showed PTEN promoter methylation (83.3%), which was significantly higher than in sporadic cases (9.4%; P<0.001). In addition, PTEN promoter methylation appeared more frequently in multiple CCMs, including familial cases (46.7%), than that in single-lesioned CCMs (11.8%; P<0.05). Immunostaining and Western blot revealed a more significant PTEN downregulation in PTEN-methylated CCMs in comparison to PTEN-unmethylated CCMs. Reduced PTEN expression was inversely correlated to the expression of proliferating cell nuclear antigen and to the activation of Erk1,2, but not of Akt. CONCLUSIONS: We reported here for the first time the involvement of PTEN promoter methylation in CCMs, particularly in familial CCMs, suggesting this epigenetic alteration as a potential pathomechanism of CCMs. The identification of Erk1,2 as triggered signaling in the lesions may be valuable for the development of effective therapy for this disease.
[ "Involvement", "of", "PTEN", "promoter", "methylation", "in", "cerebral", "cavernous", "malformations", ".", "\n\n", "BACKGROUND", "AND", "PURPOSE", ":", "Cerebral", "cavernous", "malformations", "(", "CCMs", ")", "are", "prevalent", "cerebral", "vascular", "lesions", "involving", "aberrant", "angiogenesis", ".", "However", ",", "the", "underlying", "mechanism", "is", "poorly", "understood", ".", "Phosphatase", "and", "tension", "homolog", "deleted", "on", "chromosome", "10", "(", "PTEN", ")", ",", "a", "tumor", "suppressor", ",", "is", "frequently", "deficient", "in", "various", "pathologies", "due", "to", "mutation", "or", "epigenetic", "alterations", ".", "PTEN", "promoter", "hypermethylation", "is", "a", "major", "epigenetic", "silencing", "mechanism", "leading", "to", "activation", "of", "angiogenesis", "in", "tumors", ".", "The", "present", "study", "aimed", "to", "investigate", "whether", "PTEN", "promoter", "methylation", "was", "involved", "in", "CCMs", ".", "METHODS", ":", "PTEN", "promoter", "methylation", "was", "detected", "in", "surgical", "specimens", "of", "CCMs", "(", "n=69", ")", "by", "methylation", "-", "specific", "polymerase", "chain", "reaction", ".", "The", "methylation", "status", "was", "correlated", "to", "the", "clinical", "manifestations", "and", "to", "PTEN", "expression", ",", "which", "was", "analyzed", "by", "both", "Western", "blot", "and", "immunohistochemistry", ".", "To", "investigate", "the", "endothelial", "proliferation", "and", "the", "potential", "signaling", "pathways", "affected", "by", "PTEN", "methylation", ",", "proliferating", "cell", "nuclear", "antigen", "as", "well", "as", "phosphor", "-", "Akt", "and", "phosphor", "-", "Erk1,2", "were", "detected", "by", "immunofluorescence", "and", "Western", "blot", ",", "respectively", ",", "in", "CCM", "specimens", ".", "RESULTS", ":", "Methylation", "-", "specific", "polymerase", "chain", "reaction", "revealed", "PTEN", "promoter", "methylation", "in", "15.9", "%", "CCMs", ".", "Strikingly", ",", "5", "of", "6", "familial", "CCMs", "showed", "PTEN", "promoter", "methylation", "(", "83.3", "%", ")", ",", "which", "was", "significantly", "higher", "than", "in", "sporadic", "cases", "(", "9.4", "%", ";", "P<0.001", ")", ".", "In", "addition", ",", "PTEN", "promoter", "methylation", "appeared", "more", "frequently", "in", "multiple", "CCMs", ",", "including", "familial", "cases", "(", "46.7", "%", ")", ",", "than", "that", "in", "single", "-", "lesioned", "CCMs", "(", "11.8", "%", ";", "P<0.05", ")", ".", "Immunostaining", "and", "Western", "blot", "revealed", "a", "more", "significant", "PTEN", "downregulation", "in", "PTEN", "-", "methylated", "CCMs", "in", "comparison", "to", "PTEN", "-", "unmethylated", "CCMs", ".", "Reduced", "PTEN", "expression", "was", "inversely", "correlated", "to", "the", "expression", "of", "proliferating", "cell", "nuclear", "antigen", "and", "to", "the", "activation", "of", "Erk1,2", ",", "but", "not", "of", "Akt", ".", "CONCLUSIONS", ":", "We", "reported", "here", "for", "the", "first", "time", "the", "involvement", "of", "PTEN", "promoter", "methylation", "in", "CCMs", ",", "particularly", "in", "familial", "CCMs", ",", "suggesting", "this", "epigenetic", "alteration", "as", "a", "potential", "pathomechanism", "of", "CCMs", ".", "The", "identification", "of", "Erk1,2", "as", "triggered", "signaling", "in", "the", "lesions", "may", "be", "valuable", "for", "the", "development", "of", "effective", "therapy", "for", "this", "disease", ".", "\n" ]
[ "Gene_or_gene_product", "Pathological_formation", "Cell", "DNA_domain_or_region" ]
PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, cerebral cavernous malformations is a Pathological_formation, Cerebral cavernous malformations is a Pathological_formation, CCMs is a Pathological_formation, cerebral vascular lesions is a Pathological_formation, Phosphatase and tension homolog deleted on chromosome 10 is a Gene_or_gene_product, PTEN is a Gene_or_gene_product, tumor is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, tumors is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, endothelial is a Cell, PTEN is a Gene_or_gene_product, proliferating cell nuclear antigen is a Gene_or_gene_product, phosphor - Akt is a Gene_or_gene_product, phosphor - Erk1,2 is a Gene_or_gene_product, CCM is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, PTEN is a Gene_or_gene_product, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, CCMs is a Pathological_formation, PTEN is a Gene_or_gene_product, proliferating cell nuclear antigen is a Gene_or_gene_product, Akt is a Gene_or_gene_product, PTEN is a Gene_or_gene_product, promoter is a DNA_domain_or_region, CCMs is a Pathological_formation, CCMs is a Pathological_formation, CCMs is a Pathological_formation, lesions is a Pathological_formation
53_task1
Sentence: Involvement of PTEN promoter methylation in cerebral cavernous malformations. BACKGROUND AND PURPOSE: Cerebral cavernous malformations (CCMs) are prevalent cerebral vascular lesions involving aberrant angiogenesis. However, the underlying mechanism is poorly understood. Phosphatase and tension homolog deleted on chromosome 10 (PTEN), a tumor suppressor, is frequently deficient in various pathologies due to mutation or epigenetic alterations. PTEN promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors. The present study aimed to investigate whether PTEN promoter methylation was involved in CCMs. METHODS: PTEN promoter methylation was detected in surgical specimens of CCMs (n=69) by methylation-specific polymerase chain reaction. The methylation status was correlated to the clinical manifestations and to PTEN expression, which was analyzed by both Western blot and immunohistochemistry. To investigate the endothelial proliferation and the potential signaling pathways affected by PTEN methylation, proliferating cell nuclear antigen as well as phosphor-Akt and phosphor-Erk1,2 were detected by immunofluorescence and Western blot, respectively, in CCM specimens. RESULTS: Methylation-specific polymerase chain reaction revealed PTEN promoter methylation in 15.9% CCMs. Strikingly, 5 of 6 familial CCMs showed PTEN promoter methylation (83.3%), which was significantly higher than in sporadic cases (9.4%; P<0.001). In addition, PTEN promoter methylation appeared more frequently in multiple CCMs, including familial cases (46.7%), than that in single-lesioned CCMs (11.8%; P<0.05). Immunostaining and Western blot revealed a more significant PTEN downregulation in PTEN-methylated CCMs in comparison to PTEN-unmethylated CCMs. Reduced PTEN expression was inversely correlated to the expression of proliferating cell nuclear antigen and to the activation of Erk1,2, but not of Akt. CONCLUSIONS: We reported here for the first time the involvement of PTEN promoter methylation in CCMs, particularly in familial CCMs, suggesting this epigenetic alteration as a potential pathomechanism of CCMs. The identification of Erk1,2 as triggered signaling in the lesions may be valuable for the development of effective therapy for this disease. Instructions: please typing these entity words according to sentence: PTEN, promoter, cerebral cavernous malformations, Cerebral cavernous malformations, CCMs, cerebral vascular lesions, Phosphatase and tension homolog deleted on chromosome 10, PTEN, tumor, PTEN, promoter, tumors, PTEN, promoter, CCMs, PTEN, promoter, CCMs, PTEN, endothelial, PTEN, proliferating cell nuclear antigen, phosphor - Akt, phosphor - Erk1,2, CCM, PTEN, promoter, CCMs, CCMs, PTEN, promoter, PTEN, promoter, CCMs, CCMs, PTEN, PTEN, CCMs, PTEN, CCMs, PTEN, proliferating cell nuclear antigen, Akt, PTEN, promoter, CCMs, CCMs, CCMs, lesions Options: Pathological_formation, DNA_domain_or_region, Gene_or_gene_product, Cell
[ "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Pathological_formation", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Involvement of PTEN promoter methylation in cerebral cavernous malformations. BACKGROUND AND PURPOSE: Cerebral cavernous malformations (CCMs) are prevalent cerebral vascular lesions involving aberrant angiogenesis. However, the underlying mechanism is poorly understood. Phosphatase and tension homolog deleted on chromosome 10 (PTEN), a tumor suppressor, is frequently deficient in various pathologies due to mutation or epigenetic alterations. PTEN promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors. The present study aimed to investigate whether PTEN promoter methylation was involved in CCMs. METHODS: PTEN promoter methylation was detected in surgical specimens of CCMs (n=69) by methylation-specific polymerase chain reaction. The methylation status was correlated to the clinical manifestations and to PTEN expression, which was analyzed by both Western blot and immunohistochemistry. To investigate the endothelial proliferation and the potential signaling pathways affected by PTEN methylation, proliferating cell nuclear antigen as well as phosphor-Akt and phosphor-Erk1,2 were detected by immunofluorescence and Western blot, respectively, in CCM specimens. RESULTS: Methylation-specific polymerase chain reaction revealed PTEN promoter methylation in 15.9% CCMs. Strikingly, 5 of 6 familial CCMs showed PTEN promoter methylation (83.3%), which was significantly higher than in sporadic cases (9.4%; P<0.001). In addition, PTEN promoter methylation appeared more frequently in multiple CCMs, including familial cases (46.7%), than that in single-lesioned CCMs (11.8%; P<0.05). Immunostaining and Western blot revealed a more significant PTEN downregulation in PTEN-methylated CCMs in comparison to PTEN-unmethylated CCMs. Reduced PTEN expression was inversely correlated to the expression of proliferating cell nuclear antigen and to the activation of Erk1,2, but not of Akt. CONCLUSIONS: We reported here for the first time the involvement of PTEN promoter methylation in CCMs, particularly in familial CCMs, suggesting this epigenetic alteration as a potential pathomechanism of CCMs. The identification of Erk1,2 as triggered signaling in the lesions may be valuable for the development of effective therapy for this disease.
[ "Involvement", "of", "PTEN", "promoter", "methylation", "in", "cerebral", "cavernous", "malformations", ".", "\n\n", "BACKGROUND", "AND", "PURPOSE", ":", "Cerebral", "cavernous", "malformations", "(", "CCMs", ")", "are", "prevalent", "cerebral", "vascular", "lesions", "involving", "aberrant", "angiogenesis", ".", "However", ",", "the", "underlying", "mechanism", "is", "poorly", "understood", ".", "Phosphatase", "and", "tension", "homolog", "deleted", "on", "chromosome", "10", "(", "PTEN", ")", ",", "a", "tumor", "suppressor", ",", "is", "frequently", "deficient", "in", "various", "pathologies", "due", "to", "mutation", "or", "epigenetic", "alterations", ".", "PTEN", "promoter", "hypermethylation", "is", "a", "major", "epigenetic", "silencing", "mechanism", "leading", "to", "activation", "of", "angiogenesis", "in", "tumors", ".", "The", "present", "study", "aimed", "to", "investigate", "whether", "PTEN", "promoter", "methylation", "was", "involved", "in", "CCMs", ".", "METHODS", ":", "PTEN", "promoter", "methylation", "was", "detected", "in", "surgical", "specimens", "of", "CCMs", "(", "n=69", ")", "by", "methylation", "-", "specific", "polymerase", "chain", "reaction", ".", "The", "methylation", "status", "was", "correlated", "to", "the", "clinical", "manifestations", "and", "to", "PTEN", "expression", ",", "which", "was", "analyzed", "by", "both", "Western", "blot", "and", "immunohistochemistry", ".", "To", "investigate", "the", "endothelial", "proliferation", "and", "the", "potential", "signaling", "pathways", "affected", "by", "PTEN", "methylation", ",", "proliferating", "cell", "nuclear", "antigen", "as", "well", "as", "phosphor", "-", "Akt", "and", "phosphor", "-", "Erk1,2", "were", "detected", "by", "immunofluorescence", "and", "Western", "blot", ",", "respectively", ",", "in", "CCM", "specimens", ".", "RESULTS", ":", "Methylation", "-", "specific", "polymerase", "chain", "reaction", "revealed", "PTEN", "promoter", "methylation", "in", "15.9", "%", "CCMs", ".", "Strikingly", ",", "5", "of", "6", "familial", "CCMs", "showed", "PTEN", "promoter", "methylation", "(", "83.3", "%", ")", ",", "which", "was", "significantly", "higher", "than", "in", "sporadic", "cases", "(", "9.4", "%", ";", "P<0.001", ")", ".", "In", "addition", ",", "PTEN", "promoter", "methylation", "appeared", "more", "frequently", "in", "multiple", "CCMs", ",", "including", "familial", "cases", "(", "46.7", "%", ")", ",", "than", "that", "in", "single", "-", "lesioned", "CCMs", "(", "11.8", "%", ";", "P<0.05", ")", ".", "Immunostaining", "and", "Western", "blot", "revealed", "a", "more", "significant", "PTEN", "downregulation", "in", "PTEN", "-", "methylated", "CCMs", "in", "comparison", "to", "PTEN", "-", "unmethylated", "CCMs", ".", "Reduced", "PTEN", "expression", "was", "inversely", "correlated", "to", "the", "expression", "of", "proliferating", "cell", "nuclear", "antigen", "and", "to", "the", "activation", "of", "Erk1,2", ",", "but", "not", "of", "Akt", ".", "CONCLUSIONS", ":", "We", "reported", "here", "for", "the", "first", "time", "the", "involvement", "of", "PTEN", "promoter", "methylation", "in", "CCMs", ",", "particularly", "in", "familial", "CCMs", ",", "suggesting", "this", "epigenetic", "alteration", "as", "a", "potential", "pathomechanism", "of", "CCMs", ".", "The", "identification", "of", "Erk1,2", "as", "triggered", "signaling", "in", "the", "lesions", "may", "be", "valuable", "for", "the", "development", "of", "effective", "therapy", "for", "this", "disease", ".", "\n" ]
[ "Gene_or_gene_product", "Pathological_formation", "Cell", "DNA_domain_or_region" ]
PTEN, promoter, cerebral cavernous malformations, Cerebral cavernous malformations, CCMs, cerebral vascular lesions, Phosphatase and tension homolog deleted on chromosome 10, PTEN, tumor, PTEN, promoter, tumors, PTEN, promoter, CCMs, PTEN, promoter, CCMs, PTEN, endothelial, PTEN, proliferating cell nuclear antigen, phosphor - Akt, phosphor - Erk1,2, CCM, PTEN, promoter, CCMs, CCMs, PTEN, promoter, PTEN, promoter, CCMs, CCMs, PTEN, PTEN, CCMs, PTEN, CCMs, PTEN, proliferating cell nuclear antigen, Akt, PTEN, promoter, CCMs, CCMs, CCMs, lesions
53_task2
Sentence: Involvement of PTEN promoter methylation in cerebral cavernous malformations. BACKGROUND AND PURPOSE: Cerebral cavernous malformations (CCMs) are prevalent cerebral vascular lesions involving aberrant angiogenesis. However, the underlying mechanism is poorly understood. Phosphatase and tension homolog deleted on chromosome 10 (PTEN), a tumor suppressor, is frequently deficient in various pathologies due to mutation or epigenetic alterations. PTEN promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors. The present study aimed to investigate whether PTEN promoter methylation was involved in CCMs. METHODS: PTEN promoter methylation was detected in surgical specimens of CCMs (n=69) by methylation-specific polymerase chain reaction. The methylation status was correlated to the clinical manifestations and to PTEN expression, which was analyzed by both Western blot and immunohistochemistry. To investigate the endothelial proliferation and the potential signaling pathways affected by PTEN methylation, proliferating cell nuclear antigen as well as phosphor-Akt and phosphor-Erk1,2 were detected by immunofluorescence and Western blot, respectively, in CCM specimens. RESULTS: Methylation-specific polymerase chain reaction revealed PTEN promoter methylation in 15.9% CCMs. Strikingly, 5 of 6 familial CCMs showed PTEN promoter methylation (83.3%), which was significantly higher than in sporadic cases (9.4%; P<0.001). In addition, PTEN promoter methylation appeared more frequently in multiple CCMs, including familial cases (46.7%), than that in single-lesioned CCMs (11.8%; P<0.05). Immunostaining and Western blot revealed a more significant PTEN downregulation in PTEN-methylated CCMs in comparison to PTEN-unmethylated CCMs. Reduced PTEN expression was inversely correlated to the expression of proliferating cell nuclear antigen and to the activation of Erk1,2, but not of Akt. CONCLUSIONS: We reported here for the first time the involvement of PTEN promoter methylation in CCMs, particularly in familial CCMs, suggesting this epigenetic alteration as a potential pathomechanism of CCMs. The identification of Erk1,2 as triggered signaling in the lesions may be valuable for the development of effective therapy for this disease. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "B-Pathological_formation", "O", "O", "O", "B-Pathological_formation", "I-Pathological_formation", "I-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Pathological_formation", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Pathological_formation", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "B-DNA_domain_or_region", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Pathological_formation", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Involvement of PTEN promoter methylation in cerebral cavernous malformations. BACKGROUND AND PURPOSE: Cerebral cavernous malformations (CCMs) are prevalent cerebral vascular lesions involving aberrant angiogenesis. However, the underlying mechanism is poorly understood. Phosphatase and tension homolog deleted on chromosome 10 (PTEN), a tumor suppressor, is frequently deficient in various pathologies due to mutation or epigenetic alterations. PTEN promoter hypermethylation is a major epigenetic silencing mechanism leading to activation of angiogenesis in tumors. The present study aimed to investigate whether PTEN promoter methylation was involved in CCMs. METHODS: PTEN promoter methylation was detected in surgical specimens of CCMs (n=69) by methylation-specific polymerase chain reaction. The methylation status was correlated to the clinical manifestations and to PTEN expression, which was analyzed by both Western blot and immunohistochemistry. To investigate the endothelial proliferation and the potential signaling pathways affected by PTEN methylation, proliferating cell nuclear antigen as well as phosphor-Akt and phosphor-Erk1,2 were detected by immunofluorescence and Western blot, respectively, in CCM specimens. RESULTS: Methylation-specific polymerase chain reaction revealed PTEN promoter methylation in 15.9% CCMs. Strikingly, 5 of 6 familial CCMs showed PTEN promoter methylation (83.3%), which was significantly higher than in sporadic cases (9.4%; P<0.001). In addition, PTEN promoter methylation appeared more frequently in multiple CCMs, including familial cases (46.7%), than that in single-lesioned CCMs (11.8%; P<0.05). Immunostaining and Western blot revealed a more significant PTEN downregulation in PTEN-methylated CCMs in comparison to PTEN-unmethylated CCMs. Reduced PTEN expression was inversely correlated to the expression of proliferating cell nuclear antigen and to the activation of Erk1,2, but not of Akt. CONCLUSIONS: We reported here for the first time the involvement of PTEN promoter methylation in CCMs, particularly in familial CCMs, suggesting this epigenetic alteration as a potential pathomechanism of CCMs. The identification of Erk1,2 as triggered signaling in the lesions may be valuable for the development of effective therapy for this disease.
[ "Involvement", "of", "PTEN", "promoter", "methylation", "in", "cerebral", "cavernous", "malformations", ".", "\n\n", "BACKGROUND", "AND", "PURPOSE", ":", "Cerebral", "cavernous", "malformations", "(", "CCMs", ")", "are", "prevalent", "cerebral", "vascular", "lesions", "involving", "aberrant", "angiogenesis", ".", "However", ",", "the", "underlying", "mechanism", "is", "poorly", "understood", ".", "Phosphatase", "and", "tension", "homolog", "deleted", "on", "chromosome", "10", "(", "PTEN", ")", ",", "a", "tumor", "suppressor", ",", "is", "frequently", "deficient", "in", "various", "pathologies", "due", "to", "mutation", "or", "epigenetic", "alterations", ".", "PTEN", "promoter", "hypermethylation", "is", "a", "major", "epigenetic", "silencing", "mechanism", "leading", "to", "activation", "of", "angiogenesis", "in", "tumors", ".", "The", "present", "study", "aimed", "to", "investigate", "whether", "PTEN", "promoter", "methylation", "was", "involved", "in", "CCMs", ".", "METHODS", ":", "PTEN", "promoter", "methylation", "was", "detected", "in", "surgical", "specimens", "of", "CCMs", "(", "n=69", ")", "by", "methylation", "-", "specific", "polymerase", "chain", "reaction", ".", "The", "methylation", "status", "was", "correlated", "to", "the", "clinical", "manifestations", "and", "to", "PTEN", "expression", ",", "which", "was", "analyzed", "by", "both", "Western", "blot", "and", "immunohistochemistry", ".", "To", "investigate", "the", "endothelial", "proliferation", "and", "the", "potential", "signaling", "pathways", "affected", "by", "PTEN", "methylation", ",", "proliferating", "cell", "nuclear", "antigen", "as", "well", "as", "phosphor", "-", "Akt", "and", "phosphor", "-", "Erk1,2", "were", "detected", "by", "immunofluorescence", "and", "Western", "blot", ",", "respectively", ",", "in", "CCM", "specimens", ".", "RESULTS", ":", "Methylation", "-", "specific", "polymerase", "chain", "reaction", "revealed", "PTEN", "promoter", "methylation", "in", "15.9", "%", "CCMs", ".", "Strikingly", ",", "5", "of", "6", "familial", "CCMs", "showed", "PTEN", "promoter", "methylation", "(", "83.3", "%", ")", ",", "which", "was", "significantly", "higher", "than", "in", "sporadic", "cases", "(", "9.4", "%", ";", "P<0.001", ")", ".", "In", "addition", ",", "PTEN", "promoter", "methylation", "appeared", "more", "frequently", "in", "multiple", "CCMs", ",", "including", "familial", "cases", "(", "46.7", "%", ")", ",", "than", "that", "in", "single", "-", "lesioned", "CCMs", "(", "11.8", "%", ";", "P<0.05", ")", ".", "Immunostaining", "and", "Western", "blot", "revealed", "a", "more", "significant", "PTEN", "downregulation", "in", "PTEN", "-", "methylated", "CCMs", "in", "comparison", "to", "PTEN", "-", "unmethylated", "CCMs", ".", "Reduced", "PTEN", "expression", "was", "inversely", "correlated", "to", "the", "expression", "of", "proliferating", "cell", "nuclear", "antigen", "and", "to", "the", "activation", "of", "Erk1,2", ",", "but", "not", "of", "Akt", ".", "CONCLUSIONS", ":", "We", "reported", "here", "for", "the", "first", "time", "the", "involvement", "of", "PTEN", "promoter", "methylation", "in", "CCMs", ",", "particularly", "in", "familial", "CCMs", ",", "suggesting", "this", "epigenetic", "alteration", "as", "a", "potential", "pathomechanism", "of", "CCMs", ".", "The", "identification", "of", "Erk1,2", "as", "triggered", "signaling", "in", "the", "lesions", "may", "be", "valuable", "for", "the", "development", "of", "effective", "therapy", "for", "this", "disease", ".", "\n" ]
[ "Gene_or_gene_product", "Pathological_formation", "Cell", "DNA_domain_or_region" ]
Pseudomonas aeruginosa is an organism, Pseudomonas cepacia is an organism, gangliotetraosylceramide is a chemical, Asialo GM1 is a chemical, gangliotriaosylceramide is a chemical, Asialo GM2 is a chemical
1.0alpha7.train.807_task0
Sentence: Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide ( Asialo GM1) and gangliotriaosylceramide ( Asialo GM2). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: organism, chemical
[ "B-organism", "I-organism", "O", "O", "B-organism", "I-organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "B-chemical", "I-chemical", "O", "O", "B-chemical", "O", "B-chemical", "I-chemical", "O", "O" ]
Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide ( Asialo GM1) and gangliotriaosylceramide ( Asialo GM2).
[ "Pseudomonas", "aeruginosa", "and", " ", "Pseudomonas", "cepacia", "isolated", "from", " ", "cystic", "fibrosis", "patients", "bind", "specifically", "to", "gangliotetraosylceramide", "(", "Asialo", "GM1", ")", "and", "gangliotriaosylceramide", "(", "Asialo", "GM2", ")", "." ]
[ "chemical", "organism" ]
Pseudomonas aeruginosa is an organism, Pseudomonas cepacia is an organism, gangliotetraosylceramide is a chemical, Asialo GM1 is a chemical, gangliotriaosylceramide is a chemical, Asialo GM2 is a chemical
1.0alpha7.train.807_task1
Sentence: Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide ( Asialo GM1) and gangliotriaosylceramide ( Asialo GM2). Instructions: please typing these entity words according to sentence: Pseudomonas aeruginosa, Pseudomonas cepacia, gangliotetraosylceramide, Asialo GM1, gangliotriaosylceramide, Asialo GM2 Options: organism, chemical
[ "B-organism", "I-organism", "O", "O", "B-organism", "I-organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "B-chemical", "I-chemical", "O", "O", "B-chemical", "O", "B-chemical", "I-chemical", "O", "O" ]
Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide ( Asialo GM1) and gangliotriaosylceramide ( Asialo GM2).
[ "Pseudomonas", "aeruginosa", "and", " ", "Pseudomonas", "cepacia", "isolated", "from", " ", "cystic", "fibrosis", "patients", "bind", "specifically", "to", "gangliotetraosylceramide", "(", "Asialo", "GM1", ")", "and", "gangliotriaosylceramide", "(", "Asialo", "GM2", ")", "." ]
[ "chemical", "organism" ]
Pseudomonas aeruginosa, Pseudomonas cepacia, gangliotetraosylceramide, Asialo GM1, gangliotriaosylceramide, Asialo GM2
1.0alpha7.train.807_task2
Sentence: Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide ( Asialo GM1) and gangliotriaosylceramide ( Asialo GM2). Instructions: please extract entity words from the input sentence
[ "B-organism", "I-organism", "O", "O", "B-organism", "I-organism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "B-chemical", "I-chemical", "O", "O", "B-chemical", "O", "B-chemical", "I-chemical", "O", "O" ]
Pseudomonas aeruginosa and Pseudomonas cepacia isolated from cystic fibrosis patients bind specifically to gangliotetraosylceramide ( Asialo GM1) and gangliotriaosylceramide ( Asialo GM2).
[ "Pseudomonas", "aeruginosa", "and", " ", "Pseudomonas", "cepacia", "isolated", "from", " ", "cystic", "fibrosis", "patients", "bind", "specifically", "to", "gangliotetraosylceramide", "(", "Asialo", "GM1", ")", "and", "gangliotriaosylceramide", "(", "Asialo", "GM2", ")", "." ]
[ "chemical", "organism" ]
naloxone is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, opioids is a GROUP, naloxone is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, naloxone is a DRUG, beta - endorphin is a DRUG_N, naloxone is a DRUG, beta - endorphin is a DRUG_N, naloxone is a DRUG, morphine is a DRUG, naloxone is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, naloxone is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG
3155550_task0
Sentence: Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats. In the present study, it is proposed that the opioids applied to supraspinal brain sites produced their analgesic effects by the activation of different descending pain inhibitory systems. The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, DRUG_N, DRUG
[ "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O" ]
Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats. In the present study, it is proposed that the opioids applied to supraspinal brain sites produced their analgesic effects by the activation of different descending pain inhibitory systems. The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.
[ "Differential", "actions", "of", "intrathecal", "naloxone", "on", "blocking", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "and", "morphine", "in", "rats", ".", "In", "the", "present", "study", ",", "it", "is", "proposed", "that", "the", "opioids", "applied", "to", "supraspinal", "brain", "sites", "produced", "their", "analgesic", "effects", "by", "the", "activation", "of", "different", "descending", "pain", "inhibitory", "systems", ".", "The", "blockade", "of", "the", "spinal", "endorphinergic", "system", "by", "intrathecal", "naloxone", "on", "the", "production", "of", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "and", "morphine", "was", "then", "studied", ".", "Intraventricular", "injection", "of", "beta", "-", "endorphin", "and", "morphine", "produced", "an", "inhibition", "of", "the", "tail", "-", "flick", "response", "to", "the", "heat", "stimulus", "in", "rats", ".", "Intrathecal", "injection", "of", "naloxone", "at", "doses", "of", "0.4", "to", "40", "micrograms", "caused", "a", "dose", "-", "related", "blockade", "of", "the", "inhibition", "of", "the", "tail", "-", "flick", "response", "induced", "by", "intraventricular", "injection", "of", "beta", "-", "endorphin", ",", "and", "a", "high", "dose", "of", "naloxone", "(", "40", "micrograms", ")", "completely", "blocked", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "(", "16", "micrograms", ")", ".", "On", "the", "other", "hand", ",", "intrathecal", "naloxone", "(", "12", "-", "120", "micrograms", ")", "had", "only", "a", "very", "weak", "effect", "on", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "morphine", "(", "40", "micrograms", ")", ".", "Intraventricular", "injection", "of", "naloxone", "at", "doses", "of", "1.2", "to", "12", "micrograms", "equally", "antagonized", "in", "a", "dose", "-", "dependent", "manner", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "and", "morphine", ".", "The", "results", "indicate", "that", "a", "spinal", "naloxone", "-", "sensitive", "endorphinergic", "system", "is", "involved", "in", "the", "production", "of", "beta", "-", "endorphin", "but", "not", "morphine", "-", "induced", "tail", "-", "flick", "inhibition", ",", "and", "suggest", "that", "intraventricular", "beta", "-", "endorphin", "and", "morphine", "elicit", "their", "pharmacological", "actions", "via", "the", "activation", "of", "different", "descending", "pain", "inhibitory", "systems", ";", "descending", "epsilon", "and", "mu", "systems", "for", "beta", "-", "endorphin", "and", "morphine", ",", "respectively", ",", "are", "proposed", "." ]
[ "DRUG_N", "DRUG", "GROUP" ]
naloxone is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, opioids is a GROUP, naloxone is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, naloxone is a DRUG, beta - endorphin is a DRUG_N, naloxone is a DRUG, beta - endorphin is a DRUG_N, naloxone is a DRUG, morphine is a DRUG, naloxone is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, naloxone is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG, beta - endorphin is a DRUG_N, morphine is a DRUG
3155550_task1
Sentence: Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats. In the present study, it is proposed that the opioids applied to supraspinal brain sites produced their analgesic effects by the activation of different descending pain inhibitory systems. The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed. Instructions: please typing these entity words according to sentence: naloxone, beta - endorphin, morphine, opioids, naloxone, beta - endorphin, morphine, beta - endorphin, morphine, naloxone, beta - endorphin, naloxone, beta - endorphin, naloxone, morphine, naloxone, beta - endorphin, morphine, naloxone, beta - endorphin, morphine, beta - endorphin, morphine, beta - endorphin, morphine Options: GROUP, DRUG_N, DRUG
[ "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O" ]
Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats. In the present study, it is proposed that the opioids applied to supraspinal brain sites produced their analgesic effects by the activation of different descending pain inhibitory systems. The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.
[ "Differential", "actions", "of", "intrathecal", "naloxone", "on", "blocking", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "and", "morphine", "in", "rats", ".", "In", "the", "present", "study", ",", "it", "is", "proposed", "that", "the", "opioids", "applied", "to", "supraspinal", "brain", "sites", "produced", "their", "analgesic", "effects", "by", "the", "activation", "of", "different", "descending", "pain", "inhibitory", "systems", ".", "The", "blockade", "of", "the", "spinal", "endorphinergic", "system", "by", "intrathecal", "naloxone", "on", "the", "production", "of", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "and", "morphine", "was", "then", "studied", ".", "Intraventricular", "injection", "of", "beta", "-", "endorphin", "and", "morphine", "produced", "an", "inhibition", "of", "the", "tail", "-", "flick", "response", "to", "the", "heat", "stimulus", "in", "rats", ".", "Intrathecal", "injection", "of", "naloxone", "at", "doses", "of", "0.4", "to", "40", "micrograms", "caused", "a", "dose", "-", "related", "blockade", "of", "the", "inhibition", "of", "the", "tail", "-", "flick", "response", "induced", "by", "intraventricular", "injection", "of", "beta", "-", "endorphin", ",", "and", "a", "high", "dose", "of", "naloxone", "(", "40", "micrograms", ")", "completely", "blocked", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "(", "16", "micrograms", ")", ".", "On", "the", "other", "hand", ",", "intrathecal", "naloxone", "(", "12", "-", "120", "micrograms", ")", "had", "only", "a", "very", "weak", "effect", "on", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "morphine", "(", "40", "micrograms", ")", ".", "Intraventricular", "injection", "of", "naloxone", "at", "doses", "of", "1.2", "to", "12", "micrograms", "equally", "antagonized", "in", "a", "dose", "-", "dependent", "manner", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "and", "morphine", ".", "The", "results", "indicate", "that", "a", "spinal", "naloxone", "-", "sensitive", "endorphinergic", "system", "is", "involved", "in", "the", "production", "of", "beta", "-", "endorphin", "but", "not", "morphine", "-", "induced", "tail", "-", "flick", "inhibition", ",", "and", "suggest", "that", "intraventricular", "beta", "-", "endorphin", "and", "morphine", "elicit", "their", "pharmacological", "actions", "via", "the", "activation", "of", "different", "descending", "pain", "inhibitory", "systems", ";", "descending", "epsilon", "and", "mu", "systems", "for", "beta", "-", "endorphin", "and", "morphine", ",", "respectively", ",", "are", "proposed", "." ]
[ "DRUG_N", "DRUG", "GROUP" ]
naloxone, beta - endorphin, morphine, opioids, naloxone, beta - endorphin, morphine, beta - endorphin, morphine, naloxone, beta - endorphin, naloxone, beta - endorphin, naloxone, morphine, naloxone, beta - endorphin, morphine, naloxone, beta - endorphin, morphine, beta - endorphin, morphine, beta - endorphin, morphine
3155550_task2
Sentence: Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats. In the present study, it is proposed that the opioids applied to supraspinal brain sites produced their analgesic effects by the activation of different descending pain inhibitory systems. The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GROUP", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG_N", "I-DRUG_N", "I-DRUG_N", "O", "B-DRUG", "O", "O", "O", "O", "O", "O" ]
Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and morphine in rats. In the present study, it is proposed that the opioids applied to supraspinal brain sites produced their analgesic effects by the activation of different descending pain inhibitory systems. The blockade of the spinal endorphinergic system by intrathecal naloxone on the production of tail-flick inhibition induced by intraventricular beta-endorphin and morphine was then studied. Intraventricular injection of beta-endorphin and morphine produced an inhibition of the tail-flick response to the heat stimulus in rats. Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). On the other hand, intrathecal naloxone (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular morphine (40 micrograms). Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular beta-endorphin and morphine. The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; descending epsilon and mu systems for beta-endorphin and morphine, respectively, are proposed.
[ "Differential", "actions", "of", "intrathecal", "naloxone", "on", "blocking", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "and", "morphine", "in", "rats", ".", "In", "the", "present", "study", ",", "it", "is", "proposed", "that", "the", "opioids", "applied", "to", "supraspinal", "brain", "sites", "produced", "their", "analgesic", "effects", "by", "the", "activation", "of", "different", "descending", "pain", "inhibitory", "systems", ".", "The", "blockade", "of", "the", "spinal", "endorphinergic", "system", "by", "intrathecal", "naloxone", "on", "the", "production", "of", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "and", "morphine", "was", "then", "studied", ".", "Intraventricular", "injection", "of", "beta", "-", "endorphin", "and", "morphine", "produced", "an", "inhibition", "of", "the", "tail", "-", "flick", "response", "to", "the", "heat", "stimulus", "in", "rats", ".", "Intrathecal", "injection", "of", "naloxone", "at", "doses", "of", "0.4", "to", "40", "micrograms", "caused", "a", "dose", "-", "related", "blockade", "of", "the", "inhibition", "of", "the", "tail", "-", "flick", "response", "induced", "by", "intraventricular", "injection", "of", "beta", "-", "endorphin", ",", "and", "a", "high", "dose", "of", "naloxone", "(", "40", "micrograms", ")", "completely", "blocked", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "(", "16", "micrograms", ")", ".", "On", "the", "other", "hand", ",", "intrathecal", "naloxone", "(", "12", "-", "120", "micrograms", ")", "had", "only", "a", "very", "weak", "effect", "on", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "morphine", "(", "40", "micrograms", ")", ".", "Intraventricular", "injection", "of", "naloxone", "at", "doses", "of", "1.2", "to", "12", "micrograms", "equally", "antagonized", "in", "a", "dose", "-", "dependent", "manner", "the", "tail", "-", "flick", "inhibition", "induced", "by", "intraventricular", "beta", "-", "endorphin", "and", "morphine", ".", "The", "results", "indicate", "that", "a", "spinal", "naloxone", "-", "sensitive", "endorphinergic", "system", "is", "involved", "in", "the", "production", "of", "beta", "-", "endorphin", "but", "not", "morphine", "-", "induced", "tail", "-", "flick", "inhibition", ",", "and", "suggest", "that", "intraventricular", "beta", "-", "endorphin", "and", "morphine", "elicit", "their", "pharmacological", "actions", "via", "the", "activation", "of", "different", "descending", "pain", "inhibitory", "systems", ";", "descending", "epsilon", "and", "mu", "systems", "for", "beta", "-", "endorphin", "and", "morphine", ",", "respectively", ",", "are", "proposed", "." ]
[ "DRUG_N", "DRUG", "GROUP" ]
Immunitaet is an umlsterm, Hitzeschockprotein is an umlsterm, Endothelzellen is an umlsterm, Endothelzellen is an umlsterm, Stress is an umlsterm, Zigarettenrauch is an umlsterm, Zytokine is an umlsterm, Atherosklerose is an umlsterm
Herz.00250087.ger.abstr_task0
Sentence: In dieser kurzen Zusammenfassung wird unser autoimmunes Konzept " " der Atherogenese beschrieben . Dieses Konzept besagt , dass wir fuer unsere schuetzende Immunitaet gegen mikrobielles Hitzeschockprotein 60 ( hsp60) mit der Gefahr einer Kreuzreaktion mit autologem hsp60 " bezahlen " muessen , falls arterielle Endothelzellen durch klassische Atherosklerose-Risikofaktoren gestresst werden . Die Expression von hsp60 wird in Endothelzellen durch mechanischen Stress ( arterieller Bluthochdruck ) , hohe Serumcholesterinspiegel , Inhaltsstoffe von Zigarettenrauch , proinflammatorische Zytokine etc. produziert . Es wird auch die Moeglichkeit diskutiert , dass es sich beim ersten entzuendlichen Stadium der Atherosklerose um eine echte Autoimmunreaktion gegen biochemisch veraendertes autologes hsp60 handeln koennte . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In dieser kurzen Zusammenfassung wird unser autoimmunes Konzept " " der Atherogenese beschrieben . Dieses Konzept besagt , dass wir fuer unsere schuetzende Immunitaet gegen mikrobielles Hitzeschockprotein 60 ( hsp60) mit der Gefahr einer Kreuzreaktion mit autologem hsp60 " bezahlen " muessen , falls arterielle Endothelzellen durch klassische Atherosklerose-Risikofaktoren gestresst werden . Die Expression von hsp60 wird in Endothelzellen durch mechanischen Stress ( arterieller Bluthochdruck ) , hohe Serumcholesterinspiegel , Inhaltsstoffe von Zigarettenrauch , proinflammatorische Zytokine etc. produziert . Es wird auch die Moeglichkeit diskutiert , dass es sich beim ersten entzuendlichen Stadium der Atherosklerose um eine echte Autoimmunreaktion gegen biochemisch veraendertes autologes hsp60 handeln koennte .
[ "In", "dieser", "kurzen", "Zusammenfassung", "wird", "unser", "autoimmunes", "Konzept", "\"", "\"", "der", "Atherogenese", "beschrieben", ".", "Dieses", "Konzept", "besagt", ",", "dass", "wir", "fuer", "unsere", "schuetzende", "Immunitaet", "gegen", "mikrobielles", "Hitzeschockprotein", "60", "(", "hsp60", ")", "mit", "der", "Gefahr", "einer", "Kreuzreaktion", "mit", "autologem", "hsp60", "\"", "bezahlen", "\"", "muessen", ",", "falls", "arterielle", "Endothelzellen", "durch", "klassische", "Atherosklerose", "-", "Risikofaktoren", "gestresst", "werden", ".", "Die", "Expression", "von", "hsp60", "wird", "in", "Endothelzellen", "durch", "mechanischen", "Stress", "(", "arterieller", "Bluthochdruck", ")", ",", "hohe", "Serumcholesterinspiegel", ",", "Inhaltsstoffe", "von", "Zigarettenrauch", ",", "proinflammatorische", "Zytokine", "etc", ".", "produziert", ".", "Es", "wird", "auch", "die", "Moeglichkeit", "diskutiert", ",", "dass", "es", "sich", "beim", "ersten", "entzuendlichen", "Stadium", "der", "Atherosklerose", "um", "eine", "echte", "Autoimmunreaktion", "gegen", "biochemisch", "veraendertes", "autologes", "hsp60", "handeln", "koennte", "." ]
[ "umlsterm" ]
Immunitaet is an umlsterm, Hitzeschockprotein is an umlsterm, Endothelzellen is an umlsterm, Endothelzellen is an umlsterm, Stress is an umlsterm, Zigarettenrauch is an umlsterm, Zytokine is an umlsterm, Atherosklerose is an umlsterm
Herz.00250087.ger.abstr_task1
Sentence: In dieser kurzen Zusammenfassung wird unser autoimmunes Konzept " " der Atherogenese beschrieben . Dieses Konzept besagt , dass wir fuer unsere schuetzende Immunitaet gegen mikrobielles Hitzeschockprotein 60 ( hsp60) mit der Gefahr einer Kreuzreaktion mit autologem hsp60 " bezahlen " muessen , falls arterielle Endothelzellen durch klassische Atherosklerose-Risikofaktoren gestresst werden . Die Expression von hsp60 wird in Endothelzellen durch mechanischen Stress ( arterieller Bluthochdruck ) , hohe Serumcholesterinspiegel , Inhaltsstoffe von Zigarettenrauch , proinflammatorische Zytokine etc. produziert . Es wird auch die Moeglichkeit diskutiert , dass es sich beim ersten entzuendlichen Stadium der Atherosklerose um eine echte Autoimmunreaktion gegen biochemisch veraendertes autologes hsp60 handeln koennte . Instructions: please typing these entity words according to sentence: Immunitaet, Hitzeschockprotein, Endothelzellen, Endothelzellen, Stress, Zigarettenrauch, Zytokine, Atherosklerose Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In dieser kurzen Zusammenfassung wird unser autoimmunes Konzept " " der Atherogenese beschrieben . Dieses Konzept besagt , dass wir fuer unsere schuetzende Immunitaet gegen mikrobielles Hitzeschockprotein 60 ( hsp60) mit der Gefahr einer Kreuzreaktion mit autologem hsp60 " bezahlen " muessen , falls arterielle Endothelzellen durch klassische Atherosklerose-Risikofaktoren gestresst werden . Die Expression von hsp60 wird in Endothelzellen durch mechanischen Stress ( arterieller Bluthochdruck ) , hohe Serumcholesterinspiegel , Inhaltsstoffe von Zigarettenrauch , proinflammatorische Zytokine etc. produziert . Es wird auch die Moeglichkeit diskutiert , dass es sich beim ersten entzuendlichen Stadium der Atherosklerose um eine echte Autoimmunreaktion gegen biochemisch veraendertes autologes hsp60 handeln koennte .
[ "In", "dieser", "kurzen", "Zusammenfassung", "wird", "unser", "autoimmunes", "Konzept", "\"", "\"", "der", "Atherogenese", "beschrieben", ".", "Dieses", "Konzept", "besagt", ",", "dass", "wir", "fuer", "unsere", "schuetzende", "Immunitaet", "gegen", "mikrobielles", "Hitzeschockprotein", "60", "(", "hsp60", ")", "mit", "der", "Gefahr", "einer", "Kreuzreaktion", "mit", "autologem", "hsp60", "\"", "bezahlen", "\"", "muessen", ",", "falls", "arterielle", "Endothelzellen", "durch", "klassische", "Atherosklerose", "-", "Risikofaktoren", "gestresst", "werden", ".", "Die", "Expression", "von", "hsp60", "wird", "in", "Endothelzellen", "durch", "mechanischen", "Stress", "(", "arterieller", "Bluthochdruck", ")", ",", "hohe", "Serumcholesterinspiegel", ",", "Inhaltsstoffe", "von", "Zigarettenrauch", ",", "proinflammatorische", "Zytokine", "etc", ".", "produziert", ".", "Es", "wird", "auch", "die", "Moeglichkeit", "diskutiert", ",", "dass", "es", "sich", "beim", "ersten", "entzuendlichen", "Stadium", "der", "Atherosklerose", "um", "eine", "echte", "Autoimmunreaktion", "gegen", "biochemisch", "veraendertes", "autologes", "hsp60", "handeln", "koennte", "." ]
[ "umlsterm" ]
Immunitaet, Hitzeschockprotein, Endothelzellen, Endothelzellen, Stress, Zigarettenrauch, Zytokine, Atherosklerose
Herz.00250087.ger.abstr_task2
Sentence: In dieser kurzen Zusammenfassung wird unser autoimmunes Konzept " " der Atherogenese beschrieben . Dieses Konzept besagt , dass wir fuer unsere schuetzende Immunitaet gegen mikrobielles Hitzeschockprotein 60 ( hsp60) mit der Gefahr einer Kreuzreaktion mit autologem hsp60 " bezahlen " muessen , falls arterielle Endothelzellen durch klassische Atherosklerose-Risikofaktoren gestresst werden . Die Expression von hsp60 wird in Endothelzellen durch mechanischen Stress ( arterieller Bluthochdruck ) , hohe Serumcholesterinspiegel , Inhaltsstoffe von Zigarettenrauch , proinflammatorische Zytokine etc. produziert . Es wird auch die Moeglichkeit diskutiert , dass es sich beim ersten entzuendlichen Stadium der Atherosklerose um eine echte Autoimmunreaktion gegen biochemisch veraendertes autologes hsp60 handeln koennte . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In dieser kurzen Zusammenfassung wird unser autoimmunes Konzept " " der Atherogenese beschrieben . Dieses Konzept besagt , dass wir fuer unsere schuetzende Immunitaet gegen mikrobielles Hitzeschockprotein 60 ( hsp60) mit der Gefahr einer Kreuzreaktion mit autologem hsp60 " bezahlen " muessen , falls arterielle Endothelzellen durch klassische Atherosklerose-Risikofaktoren gestresst werden . Die Expression von hsp60 wird in Endothelzellen durch mechanischen Stress ( arterieller Bluthochdruck ) , hohe Serumcholesterinspiegel , Inhaltsstoffe von Zigarettenrauch , proinflammatorische Zytokine etc. produziert . Es wird auch die Moeglichkeit diskutiert , dass es sich beim ersten entzuendlichen Stadium der Atherosklerose um eine echte Autoimmunreaktion gegen biochemisch veraendertes autologes hsp60 handeln koennte .
[ "In", "dieser", "kurzen", "Zusammenfassung", "wird", "unser", "autoimmunes", "Konzept", "\"", "\"", "der", "Atherogenese", "beschrieben", ".", "Dieses", "Konzept", "besagt", ",", "dass", "wir", "fuer", "unsere", "schuetzende", "Immunitaet", "gegen", "mikrobielles", "Hitzeschockprotein", "60", "(", "hsp60", ")", "mit", "der", "Gefahr", "einer", "Kreuzreaktion", "mit", "autologem", "hsp60", "\"", "bezahlen", "\"", "muessen", ",", "falls", "arterielle", "Endothelzellen", "durch", "klassische", "Atherosklerose", "-", "Risikofaktoren", "gestresst", "werden", ".", "Die", "Expression", "von", "hsp60", "wird", "in", "Endothelzellen", "durch", "mechanischen", "Stress", "(", "arterieller", "Bluthochdruck", ")", ",", "hohe", "Serumcholesterinspiegel", ",", "Inhaltsstoffe", "von", "Zigarettenrauch", ",", "proinflammatorische", "Zytokine", "etc", ".", "produziert", ".", "Es", "wird", "auch", "die", "Moeglichkeit", "diskutiert", ",", "dass", "es", "sich", "beim", "ersten", "entzuendlichen", "Stadium", "der", "Atherosklerose", "um", "eine", "echte", "Autoimmunreaktion", "gegen", "biochemisch", "veraendertes", "autologes", "hsp60", "handeln", "koennte", "." ]
[ "umlsterm" ]
MTSS1 is a Gene_or_gene_product, cancer is a Cancer, MTSS1 is a Gene_or_gene_product, metastasis suppressor-1 is a Gene_or_gene_product, bladder carcinoma cell lines is a Cell, MTSS1 is a Gene_or_gene_product, DNA is a Cellular_component, cancer is a Cancer, MTSS1 is a Gene_or_gene_product, actin is a Gene_or_gene_product, MTSS1 is a Gene_or_gene_product, Shh is a Gene_or_gene_product, hair follicle is a Multi-tissue_structure, basal cell carcinomas is a Cancer, skin is a Organ, MTSS1 is a Gene_or_gene_product, MTSS1 is a Gene_or_gene_product, cells is a Cell, MTSS1 is a Gene_or_gene_product, cancer is a Cancer, MTSS1 is a Gene_or_gene_product
275_task0
Sentence: MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. MTSS1 (metastasis suppressor-1) was first identified as a metastasis suppressor missing in metastatic bladder carcinoma cell lines. The down-regulation of MTSS1 that may be caused by DNA methylation was also observed in many other types of cancer. While accumlating evidence for the function of MTSS1 support the concept that it is unlikely to be a metastasis suppressor, but actually acts as a scaffold protein that interacts with multiple partners to regulate actin dynamics. It has also been demonstrated that MTSS1 is involved in the Shh signaling pathway in the developing hair follicle and in basal cell carcinomas of the skin. Such evidence indicates that MTSS1 as a multiple functional molecular player and has an important role in development, carcinogenesis and metastasis. However, the biochemical mechanisms by which MTSS1 functions in cells and the physiological role of this protein in animals remain largely unknown. In this review, we will discuss the current knowledge of MTSS1's role in cancer metastasis, carcinogenesis, and development. The clinical significance of MTSS1 will also be discussed. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Gene_or_gene_product, Organ, Cellular_component, Cancer, Multi-tissue_structure, Cell
[ "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O" ]
MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. MTSS1 (metastasis suppressor-1) was first identified as a metastasis suppressor missing in metastatic bladder carcinoma cell lines. The down-regulation of MTSS1 that may be caused by DNA methylation was also observed in many other types of cancer. While accumlating evidence for the function of MTSS1 support the concept that it is unlikely to be a metastasis suppressor, but actually acts as a scaffold protein that interacts with multiple partners to regulate actin dynamics. It has also been demonstrated that MTSS1 is involved in the Shh signaling pathway in the developing hair follicle and in basal cell carcinomas of the skin. Such evidence indicates that MTSS1 as a multiple functional molecular player and has an important role in development, carcinogenesis and metastasis. However, the biochemical mechanisms by which MTSS1 functions in cells and the physiological role of this protein in animals remain largely unknown. In this review, we will discuss the current knowledge of MTSS1's role in cancer metastasis, carcinogenesis, and development. The clinical significance of MTSS1 will also be discussed.
[ "MTSS1", ":", "a", "multifunctional", "protein", "and", "its", "role", "in", "cancer", "invasion", "and", "metastasis", ".", "\n", "MTSS1", "(", "metastasis", "suppressor-1", ")", "was", "first", "identified", "as", "a", "metastasis", "suppressor", "missing", "in", "metastatic", "bladder", "carcinoma", "cell", "lines", ".", "The", "down", "-", "regulation", "of", "MTSS1", "that", "may", "be", "caused", "by", "DNA", "methylation", "was", "also", "observed", "in", "many", "other", "types", "of", "cancer", ".", "While", "accumlating", "evidence", "for", "the", "function", "of", "MTSS1", "support", "the", "concept", "that", "it", "is", "unlikely", "to", "be", "a", "metastasis", "suppressor", ",", "but", "actually", "acts", "as", "a", "scaffold", "protein", "that", "interacts", "with", "multiple", "partners", "to", "regulate", "actin", "dynamics", ".", "It", "has", "also", "been", "demonstrated", "that", "MTSS1", "is", "involved", "in", "the", "Shh", "signaling", "pathway", "in", "the", "developing", "hair", "follicle", "and", "in", "basal", "cell", "carcinomas", "of", "the", "skin", ".", "Such", "evidence", "indicates", "that", "MTSS1", "as", "a", "multiple", "functional", "molecular", "player", "and", "has", "an", "important", "role", "in", "development", ",", "carcinogenesis", "and", "metastasis", ".", "However", ",", "the", "biochemical", "mechanisms", "by", "which", "MTSS1", "functions", "in", "cells", "and", "the", "physiological", "role", "of", "this", "protein", "in", "animals", "remain", "largely", "unknown", ".", "In", "this", "review", ",", "we", "will", "discuss", "the", "current", "knowledge", "of", "MTSS1", "'s", "role", "in", "cancer", "metastasis", ",", "carcinogenesis", ",", "and", "development", ".", "The", "clinical", "significance", "of", "MTSS1", "will", "also", "be", "discussed", ".", "\n" ]
[ "Cell", "Gene_or_gene_product", "Cancer", "Multi-tissue_structure", "Organ", "Cellular_component" ]
MTSS1 is a Gene_or_gene_product, cancer is a Cancer, MTSS1 is a Gene_or_gene_product, metastasis suppressor-1 is a Gene_or_gene_product, bladder carcinoma cell lines is a Cell, MTSS1 is a Gene_or_gene_product, DNA is a Cellular_component, cancer is a Cancer, MTSS1 is a Gene_or_gene_product, actin is a Gene_or_gene_product, MTSS1 is a Gene_or_gene_product, Shh is a Gene_or_gene_product, hair follicle is a Multi-tissue_structure, basal cell carcinomas is a Cancer, skin is a Organ, MTSS1 is a Gene_or_gene_product, MTSS1 is a Gene_or_gene_product, cells is a Cell, MTSS1 is a Gene_or_gene_product, cancer is a Cancer, MTSS1 is a Gene_or_gene_product
275_task1
Sentence: MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. MTSS1 (metastasis suppressor-1) was first identified as a metastasis suppressor missing in metastatic bladder carcinoma cell lines. The down-regulation of MTSS1 that may be caused by DNA methylation was also observed in many other types of cancer. While accumlating evidence for the function of MTSS1 support the concept that it is unlikely to be a metastasis suppressor, but actually acts as a scaffold protein that interacts with multiple partners to regulate actin dynamics. It has also been demonstrated that MTSS1 is involved in the Shh signaling pathway in the developing hair follicle and in basal cell carcinomas of the skin. Such evidence indicates that MTSS1 as a multiple functional molecular player and has an important role in development, carcinogenesis and metastasis. However, the biochemical mechanisms by which MTSS1 functions in cells and the physiological role of this protein in animals remain largely unknown. In this review, we will discuss the current knowledge of MTSS1's role in cancer metastasis, carcinogenesis, and development. The clinical significance of MTSS1 will also be discussed. Instructions: please typing these entity words according to sentence: MTSS1, cancer, MTSS1, metastasis suppressor-1, bladder carcinoma cell lines, MTSS1, DNA, cancer, MTSS1, actin, MTSS1, Shh, hair follicle, basal cell carcinomas, skin, MTSS1, MTSS1, cells, MTSS1, cancer, MTSS1 Options: Gene_or_gene_product, Organ, Cellular_component, Cancer, Multi-tissue_structure, Cell
[ "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O" ]
MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. MTSS1 (metastasis suppressor-1) was first identified as a metastasis suppressor missing in metastatic bladder carcinoma cell lines. The down-regulation of MTSS1 that may be caused by DNA methylation was also observed in many other types of cancer. While accumlating evidence for the function of MTSS1 support the concept that it is unlikely to be a metastasis suppressor, but actually acts as a scaffold protein that interacts with multiple partners to regulate actin dynamics. It has also been demonstrated that MTSS1 is involved in the Shh signaling pathway in the developing hair follicle and in basal cell carcinomas of the skin. Such evidence indicates that MTSS1 as a multiple functional molecular player and has an important role in development, carcinogenesis and metastasis. However, the biochemical mechanisms by which MTSS1 functions in cells and the physiological role of this protein in animals remain largely unknown. In this review, we will discuss the current knowledge of MTSS1's role in cancer metastasis, carcinogenesis, and development. The clinical significance of MTSS1 will also be discussed.
[ "MTSS1", ":", "a", "multifunctional", "protein", "and", "its", "role", "in", "cancer", "invasion", "and", "metastasis", ".", "\n", "MTSS1", "(", "metastasis", "suppressor-1", ")", "was", "first", "identified", "as", "a", "metastasis", "suppressor", "missing", "in", "metastatic", "bladder", "carcinoma", "cell", "lines", ".", "The", "down", "-", "regulation", "of", "MTSS1", "that", "may", "be", "caused", "by", "DNA", "methylation", "was", "also", "observed", "in", "many", "other", "types", "of", "cancer", ".", "While", "accumlating", "evidence", "for", "the", "function", "of", "MTSS1", "support", "the", "concept", "that", "it", "is", "unlikely", "to", "be", "a", "metastasis", "suppressor", ",", "but", "actually", "acts", "as", "a", "scaffold", "protein", "that", "interacts", "with", "multiple", "partners", "to", "regulate", "actin", "dynamics", ".", "It", "has", "also", "been", "demonstrated", "that", "MTSS1", "is", "involved", "in", "the", "Shh", "signaling", "pathway", "in", "the", "developing", "hair", "follicle", "and", "in", "basal", "cell", "carcinomas", "of", "the", "skin", ".", "Such", "evidence", "indicates", "that", "MTSS1", "as", "a", "multiple", "functional", "molecular", "player", "and", "has", "an", "important", "role", "in", "development", ",", "carcinogenesis", "and", "metastasis", ".", "However", ",", "the", "biochemical", "mechanisms", "by", "which", "MTSS1", "functions", "in", "cells", "and", "the", "physiological", "role", "of", "this", "protein", "in", "animals", "remain", "largely", "unknown", ".", "In", "this", "review", ",", "we", "will", "discuss", "the", "current", "knowledge", "of", "MTSS1", "'s", "role", "in", "cancer", "metastasis", ",", "carcinogenesis", ",", "and", "development", ".", "The", "clinical", "significance", "of", "MTSS1", "will", "also", "be", "discussed", ".", "\n" ]
[ "Cell", "Gene_or_gene_product", "Cancer", "Multi-tissue_structure", "Organ", "Cellular_component" ]
MTSS1, cancer, MTSS1, metastasis suppressor-1, bladder carcinoma cell lines, MTSS1, DNA, cancer, MTSS1, actin, MTSS1, Shh, hair follicle, basal cell carcinomas, skin, MTSS1, MTSS1, cells, MTSS1, cancer, MTSS1
275_task2
Sentence: MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. MTSS1 (metastasis suppressor-1) was first identified as a metastasis suppressor missing in metastatic bladder carcinoma cell lines. The down-regulation of MTSS1 that may be caused by DNA methylation was also observed in many other types of cancer. While accumlating evidence for the function of MTSS1 support the concept that it is unlikely to be a metastasis suppressor, but actually acts as a scaffold protein that interacts with multiple partners to regulate actin dynamics. It has also been demonstrated that MTSS1 is involved in the Shh signaling pathway in the developing hair follicle and in basal cell carcinomas of the skin. Such evidence indicates that MTSS1 as a multiple functional molecular player and has an important role in development, carcinogenesis and metastasis. However, the biochemical mechanisms by which MTSS1 functions in cells and the physiological role of this protein in animals remain largely unknown. In this review, we will discuss the current knowledge of MTSS1's role in cancer metastasis, carcinogenesis, and development. The clinical significance of MTSS1 will also be discussed. Instructions: please extract entity words from the input sentence
[ "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "I-Cell", "I-Cell", "I-Cell", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cellular_component", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Multi-tissue_structure", "I-Multi-tissue_structure", "O", "O", "B-Cancer", "I-Cancer", "I-Cancer", "O", "O", "B-Organ", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cancer", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O" ]
MTSS1: a multifunctional protein and its role in cancer invasion and metastasis. MTSS1 (metastasis suppressor-1) was first identified as a metastasis suppressor missing in metastatic bladder carcinoma cell lines. The down-regulation of MTSS1 that may be caused by DNA methylation was also observed in many other types of cancer. While accumlating evidence for the function of MTSS1 support the concept that it is unlikely to be a metastasis suppressor, but actually acts as a scaffold protein that interacts with multiple partners to regulate actin dynamics. It has also been demonstrated that MTSS1 is involved in the Shh signaling pathway in the developing hair follicle and in basal cell carcinomas of the skin. Such evidence indicates that MTSS1 as a multiple functional molecular player and has an important role in development, carcinogenesis and metastasis. However, the biochemical mechanisms by which MTSS1 functions in cells and the physiological role of this protein in animals remain largely unknown. In this review, we will discuss the current knowledge of MTSS1's role in cancer metastasis, carcinogenesis, and development. The clinical significance of MTSS1 will also be discussed.
[ "MTSS1", ":", "a", "multifunctional", "protein", "and", "its", "role", "in", "cancer", "invasion", "and", "metastasis", ".", "\n", "MTSS1", "(", "metastasis", "suppressor-1", ")", "was", "first", "identified", "as", "a", "metastasis", "suppressor", "missing", "in", "metastatic", "bladder", "carcinoma", "cell", "lines", ".", "The", "down", "-", "regulation", "of", "MTSS1", "that", "may", "be", "caused", "by", "DNA", "methylation", "was", "also", "observed", "in", "many", "other", "types", "of", "cancer", ".", "While", "accumlating", "evidence", "for", "the", "function", "of", "MTSS1", "support", "the", "concept", "that", "it", "is", "unlikely", "to", "be", "a", "metastasis", "suppressor", ",", "but", "actually", "acts", "as", "a", "scaffold", "protein", "that", "interacts", "with", "multiple", "partners", "to", "regulate", "actin", "dynamics", ".", "It", "has", "also", "been", "demonstrated", "that", "MTSS1", "is", "involved", "in", "the", "Shh", "signaling", "pathway", "in", "the", "developing", "hair", "follicle", "and", "in", "basal", "cell", "carcinomas", "of", "the", "skin", ".", "Such", "evidence", "indicates", "that", "MTSS1", "as", "a", "multiple", "functional", "molecular", "player", "and", "has", "an", "important", "role", "in", "development", ",", "carcinogenesis", "and", "metastasis", ".", "However", ",", "the", "biochemical", "mechanisms", "by", "which", "MTSS1", "functions", "in", "cells", "and", "the", "physiological", "role", "of", "this", "protein", "in", "animals", "remain", "largely", "unknown", ".", "In", "this", "review", ",", "we", "will", "discuss", "the", "current", "knowledge", "of", "MTSS1", "'s", "role", "in", "cancer", "metastasis", ",", "carcinogenesis", ",", "and", "development", ".", "The", "clinical", "significance", "of", "MTSS1", "will", "also", "be", "discussed", ".", "\n" ]
[ "Cell", "Gene_or_gene_product", "Cancer", "Multi-tissue_structure", "Organ", "Cellular_component" ]
recommendations is an umlsterm, prophylaxis is an umlsterm, HIV is an umlsterm, recommendations is an umlsterm, risks of is an umlsterm, prophylaxis is an umlsterm, injection is an umlsterm, drug use is an umlsterm, HIV is an umlsterm, use is an umlsterm, reverse transcriptase inhibitors is an umlsterm, AZT is an umlsterm, 3TC is an umlsterm, protease inhibitor is an umlsterm, indinavir is an umlsterm, nelfinavir is an umlsterm, drugs is an umlsterm, drugs is an umlsterm, drugs is an umlsterm, pregnancy is an umlsterm, protease inhibitors is an umlsterm, recommendations is an umlsterm
Bundesgesundheitsblatt.0043s018.eng.abstr_task0
Sentence: In 1998 recommendations for postexposure prophylaxis after occupational and nonoccupational HIV exposure of the Deutsch-Oesterreichische AIDS-Gesellschaften were developed and published . The recommendations describe the risks of HIV-transmission and the indications of postexposure prophylaxis after occupational , sexual and injection drug use HIV exposure . In general , the use of two reverse transcriptase inhibitors ( normally AZT and 3TC ) and one protease inhibitor ( indinavir or nelfinavir ) are recommended . In consideration of individual circumstances other drugs also could be given . The antiretroviral drugs should be taken as soon as possible following exposure . Good efficacy can be expected when drugs are taken within 2 hours after HIV-exposure . During pregnancy , protease inhibitors should not be given . The official recommendations of the Deutsch-Oesterreichische AIDS-Gesellschaften are illustrated and discussed . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In 1998 recommendations for postexposure prophylaxis after occupational and nonoccupational HIV exposure of the Deutsch-Oesterreichische AIDS-Gesellschaften were developed and published . The recommendations describe the risks of HIV-transmission and the indications of postexposure prophylaxis after occupational , sexual and injection drug use HIV exposure . In general , the use of two reverse transcriptase inhibitors ( normally AZT and 3TC ) and one protease inhibitor ( indinavir or nelfinavir ) are recommended . In consideration of individual circumstances other drugs also could be given . The antiretroviral drugs should be taken as soon as possible following exposure . Good efficacy can be expected when drugs are taken within 2 hours after HIV-exposure . During pregnancy , protease inhibitors should not be given . The official recommendations of the Deutsch-Oesterreichische AIDS-Gesellschaften are illustrated and discussed .
[ "In", "1998", "recommendations", "for", "postexposure", "prophylaxis", "after", "occupational", "and", "nonoccupational", "HIV", "exposure", "of", "the", "Deutsch", "-", "Oesterreichische", "AIDS", "-", "Gesellschaften", "were", "developed", "and", "published", ".", "The", "recommendations", "describe", "the", "risks", "of", "HIV", "-", "transmission", "and", "the", "indications", "of", "postexposure", "prophylaxis", "after", "occupational", ",", "sexual", "and", "injection", "drug", "use", "HIV", "exposure", ".", "In", "general", ",", "the", "use", "of", "two", "reverse", "transcriptase", "inhibitors", "(", "normally", "AZT", "and", "3TC", ")", "and", "one", "protease", "inhibitor", "(", "indinavir", "or", "nelfinavir", ")", "are", "recommended", ".", "In", "consideration", "of", "individual", "circumstances", "other", "drugs", "also", "could", "be", "given", ".", "The", "antiretroviral", "drugs", "should", "be", "taken", "as", "soon", "as", "possible", "following", "exposure", ".", "Good", "efficacy", "can", "be", "expected", "when", "drugs", "are", "taken", "within", "2", "hours", "after", "HIV", "-", "exposure", ".", "During", "pregnancy", ",", "protease", "inhibitors", "should", "not", "be", "given", ".", "The", "official", "recommendations", "of", "the", "Deutsch", "-", "Oesterreichische", "AIDS", "-", "Gesellschaften", "are", "illustrated", "and", "discussed", "." ]
[ "umlsterm" ]
recommendations is an umlsterm, prophylaxis is an umlsterm, HIV is an umlsterm, recommendations is an umlsterm, risks of is an umlsterm, prophylaxis is an umlsterm, injection is an umlsterm, drug use is an umlsterm, HIV is an umlsterm, use is an umlsterm, reverse transcriptase inhibitors is an umlsterm, AZT is an umlsterm, 3TC is an umlsterm, protease inhibitor is an umlsterm, indinavir is an umlsterm, nelfinavir is an umlsterm, drugs is an umlsterm, drugs is an umlsterm, drugs is an umlsterm, pregnancy is an umlsterm, protease inhibitors is an umlsterm, recommendations is an umlsterm
Bundesgesundheitsblatt.0043s018.eng.abstr_task1
Sentence: In 1998 recommendations for postexposure prophylaxis after occupational and nonoccupational HIV exposure of the Deutsch-Oesterreichische AIDS-Gesellschaften were developed and published . The recommendations describe the risks of HIV-transmission and the indications of postexposure prophylaxis after occupational , sexual and injection drug use HIV exposure . In general , the use of two reverse transcriptase inhibitors ( normally AZT and 3TC ) and one protease inhibitor ( indinavir or nelfinavir ) are recommended . In consideration of individual circumstances other drugs also could be given . The antiretroviral drugs should be taken as soon as possible following exposure . Good efficacy can be expected when drugs are taken within 2 hours after HIV-exposure . During pregnancy , protease inhibitors should not be given . The official recommendations of the Deutsch-Oesterreichische AIDS-Gesellschaften are illustrated and discussed . Instructions: please typing these entity words according to sentence: recommendations, prophylaxis, HIV, recommendations, risks of, prophylaxis, injection, drug use, HIV, use, reverse transcriptase inhibitors, AZT, 3TC, protease inhibitor, indinavir, nelfinavir, drugs, drugs, drugs, pregnancy, protease inhibitors, recommendations Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In 1998 recommendations for postexposure prophylaxis after occupational and nonoccupational HIV exposure of the Deutsch-Oesterreichische AIDS-Gesellschaften were developed and published . The recommendations describe the risks of HIV-transmission and the indications of postexposure prophylaxis after occupational , sexual and injection drug use HIV exposure . In general , the use of two reverse transcriptase inhibitors ( normally AZT and 3TC ) and one protease inhibitor ( indinavir or nelfinavir ) are recommended . In consideration of individual circumstances other drugs also could be given . The antiretroviral drugs should be taken as soon as possible following exposure . Good efficacy can be expected when drugs are taken within 2 hours after HIV-exposure . During pregnancy , protease inhibitors should not be given . The official recommendations of the Deutsch-Oesterreichische AIDS-Gesellschaften are illustrated and discussed .
[ "In", "1998", "recommendations", "for", "postexposure", "prophylaxis", "after", "occupational", "and", "nonoccupational", "HIV", "exposure", "of", "the", "Deutsch", "-", "Oesterreichische", "AIDS", "-", "Gesellschaften", "were", "developed", "and", "published", ".", "The", "recommendations", "describe", "the", "risks", "of", "HIV", "-", "transmission", "and", "the", "indications", "of", "postexposure", "prophylaxis", "after", "occupational", ",", "sexual", "and", "injection", "drug", "use", "HIV", "exposure", ".", "In", "general", ",", "the", "use", "of", "two", "reverse", "transcriptase", "inhibitors", "(", "normally", "AZT", "and", "3TC", ")", "and", "one", "protease", "inhibitor", "(", "indinavir", "or", "nelfinavir", ")", "are", "recommended", ".", "In", "consideration", "of", "individual", "circumstances", "other", "drugs", "also", "could", "be", "given", ".", "The", "antiretroviral", "drugs", "should", "be", "taken", "as", "soon", "as", "possible", "following", "exposure", ".", "Good", "efficacy", "can", "be", "expected", "when", "drugs", "are", "taken", "within", "2", "hours", "after", "HIV", "-", "exposure", ".", "During", "pregnancy", ",", "protease", "inhibitors", "should", "not", "be", "given", ".", "The", "official", "recommendations", "of", "the", "Deutsch", "-", "Oesterreichische", "AIDS", "-", "Gesellschaften", "are", "illustrated", "and", "discussed", "." ]
[ "umlsterm" ]
recommendations, prophylaxis, HIV, recommendations, risks of, prophylaxis, injection, drug use, HIV, use, reverse transcriptase inhibitors, AZT, 3TC, protease inhibitor, indinavir, nelfinavir, drugs, drugs, drugs, pregnancy, protease inhibitors, recommendations
Bundesgesundheitsblatt.0043s018.eng.abstr_task2
Sentence: In 1998 recommendations for postexposure prophylaxis after occupational and nonoccupational HIV exposure of the Deutsch-Oesterreichische AIDS-Gesellschaften were developed and published . The recommendations describe the risks of HIV-transmission and the indications of postexposure prophylaxis after occupational , sexual and injection drug use HIV exposure . In general , the use of two reverse transcriptase inhibitors ( normally AZT and 3TC ) and one protease inhibitor ( indinavir or nelfinavir ) are recommended . In consideration of individual circumstances other drugs also could be given . The antiretroviral drugs should be taken as soon as possible following exposure . Good efficacy can be expected when drugs are taken within 2 hours after HIV-exposure . During pregnancy , protease inhibitors should not be given . The official recommendations of the Deutsch-Oesterreichische AIDS-Gesellschaften are illustrated and discussed . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In 1998 recommendations for postexposure prophylaxis after occupational and nonoccupational HIV exposure of the Deutsch-Oesterreichische AIDS-Gesellschaften were developed and published . The recommendations describe the risks of HIV-transmission and the indications of postexposure prophylaxis after occupational , sexual and injection drug use HIV exposure . In general , the use of two reverse transcriptase inhibitors ( normally AZT and 3TC ) and one protease inhibitor ( indinavir or nelfinavir ) are recommended . In consideration of individual circumstances other drugs also could be given . The antiretroviral drugs should be taken as soon as possible following exposure . Good efficacy can be expected when drugs are taken within 2 hours after HIV-exposure . During pregnancy , protease inhibitors should not be given . The official recommendations of the Deutsch-Oesterreichische AIDS-Gesellschaften are illustrated and discussed .
[ "In", "1998", "recommendations", "for", "postexposure", "prophylaxis", "after", "occupational", "and", "nonoccupational", "HIV", "exposure", "of", "the", "Deutsch", "-", "Oesterreichische", "AIDS", "-", "Gesellschaften", "were", "developed", "and", "published", ".", "The", "recommendations", "describe", "the", "risks", "of", "HIV", "-", "transmission", "and", "the", "indications", "of", "postexposure", "prophylaxis", "after", "occupational", ",", "sexual", "and", "injection", "drug", "use", "HIV", "exposure", ".", "In", "general", ",", "the", "use", "of", "two", "reverse", "transcriptase", "inhibitors", "(", "normally", "AZT", "and", "3TC", ")", "and", "one", "protease", "inhibitor", "(", "indinavir", "or", "nelfinavir", ")", "are", "recommended", ".", "In", "consideration", "of", "individual", "circumstances", "other", "drugs", "also", "could", "be", "given", ".", "The", "antiretroviral", "drugs", "should", "be", "taken", "as", "soon", "as", "possible", "following", "exposure", ".", "Good", "efficacy", "can", "be", "expected", "when", "drugs", "are", "taken", "within", "2", "hours", "after", "HIV", "-", "exposure", ".", "During", "pregnancy", ",", "protease", "inhibitors", "should", "not", "be", "given", ".", "The", "official", "recommendations", "of", "the", "Deutsch", "-", "Oesterreichische", "AIDS", "-", "Gesellschaften", "are", "illustrated", "and", "discussed", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, neurologischen Defizit is an umlsterm, Schlaganfall is an umlsterm, neurologischen Defizits is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Schlaganfalls is an umlsterm, Diagnostik is an umlsterm, Computertomographie is an umlsterm, Behandlung is an umlsterm, Medizin is an umlsterm
Gefaesschirurgie.80030158.ger.abstr_task0
Sentence: Fuer die akute Symptomatik der cerebrovasculaeren Insuffizienz besteht Unsicherheit bezueglich des diagnostischen und therapeutischen Vorgehens . In den Jahren 1995 und 1996 wurden in unserem Hause 876 Operationen an der A. carotis durchgefuehrt . Hierbei wurde im neurologisch instabilen Stadium in 27 Faellen ( 3,1% ) die Indikation zum operativen Vorgehen gestellt ; 3 Patienten verstarben an einem neurologischen Defizit ; 2 weitere entwickelten trotz sofortiger Operation einen kompletten Schlaganfall . In 10 Faellen kam es jedoch zu einer deutlichen Besserung des praeoperativ bestehenden neurologischen Defizits und 12 Patienten waren nach der Operation neurologisch unauffaellig . Dies stellt eine Komplikationsrate von 18,5% dar . Die Ergebnisse der operativen Behandlung des akuten Schlaganfalls rechtfertigen eine ausgiebige Diagnostik mit unverzueglicher Duplexsonographie und kranieller Computertomographie sowie grosszuegiger Indikationsstellung zur Operation . Jedoch ist die alleinige chirurgische Behandlung der Gefaessveraenderungen nicht ausreichend . Vielmehr ist die enge Kooperation zwischen diagnostischer , konservativer und operativer Medizin von entscheidender Bedeutung . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Fuer die akute Symptomatik der cerebrovasculaeren Insuffizienz besteht Unsicherheit bezueglich des diagnostischen und therapeutischen Vorgehens . In den Jahren 1995 und 1996 wurden in unserem Hause 876 Operationen an der A. carotis durchgefuehrt . Hierbei wurde im neurologisch instabilen Stadium in 27 Faellen ( 3,1% ) die Indikation zum operativen Vorgehen gestellt ; 3 Patienten verstarben an einem neurologischen Defizit ; 2 weitere entwickelten trotz sofortiger Operation einen kompletten Schlaganfall . In 10 Faellen kam es jedoch zu einer deutlichen Besserung des praeoperativ bestehenden neurologischen Defizits und 12 Patienten waren nach der Operation neurologisch unauffaellig . Dies stellt eine Komplikationsrate von 18,5% dar . Die Ergebnisse der operativen Behandlung des akuten Schlaganfalls rechtfertigen eine ausgiebige Diagnostik mit unverzueglicher Duplexsonographie und kranieller Computertomographie sowie grosszuegiger Indikationsstellung zur Operation . Jedoch ist die alleinige chirurgische Behandlung der Gefaessveraenderungen nicht ausreichend . Vielmehr ist die enge Kooperation zwischen diagnostischer , konservativer und operativer Medizin von entscheidender Bedeutung .
[ "Fuer", "die", "akute", "Symptomatik", "der", "cerebrovasculaeren", "Insuffizienz", "besteht", "Unsicherheit", "bezueglich", "des", "diagnostischen", "und", "therapeutischen", "Vorgehens", ".", "In", "den", "Jahren", "1995", "und", "1996", "wurden", "in", "unserem", "Hause", "876", "Operationen", "an", "der", "A.", "carotis", "durchgefuehrt", ".", "Hierbei", "wurde", "im", "neurologisch", "instabilen", "Stadium", "in", "27", "Faellen", "(", "3,1", "%", ")", "die", "Indikation", "zum", "operativen", "Vorgehen", "gestellt", ";", "3", "Patienten", "verstarben", "an", "einem", "neurologischen", "Defizit", ";", "2", "weitere", "entwickelten", "trotz", "sofortiger", "Operation", "einen", "kompletten", "Schlaganfall", ".", "In", "10", "Faellen", "kam", "es", "jedoch", "zu", "einer", "deutlichen", "Besserung", "des", "praeoperativ", "bestehenden", "neurologischen", "Defizits", "und", "12", "Patienten", "waren", "nach", "der", "Operation", "neurologisch", "unauffaellig", ".", "Dies", "stellt", "eine", "Komplikationsrate", "von", "18,5", "%", "dar", ".", "Die", "Ergebnisse", "der", "operativen", "Behandlung", "des", "akuten", "Schlaganfalls", "rechtfertigen", "eine", "ausgiebige", "Diagnostik", "mit", "unverzueglicher", "Duplexsonographie", "und", "kranieller", "Computertomographie", "sowie", "grosszuegiger", "Indikationsstellung", "zur", "Operation", ".", "Jedoch", "ist", "die", "alleinige", "chirurgische", "Behandlung", "der", "Gefaessveraenderungen", "nicht", "ausreichend", ".", "Vielmehr", "ist", "die", "enge", "Kooperation", "zwischen", "diagnostischer", ",", "konservativer", "und", "operativer", "Medizin", "von", "entscheidender", "Bedeutung", "." ]
[ "umlsterm" ]
Patienten is an umlsterm, neurologischen Defizit is an umlsterm, Schlaganfall is an umlsterm, neurologischen Defizits is an umlsterm, Patienten is an umlsterm, Behandlung is an umlsterm, Schlaganfalls is an umlsterm, Diagnostik is an umlsterm, Computertomographie is an umlsterm, Behandlung is an umlsterm, Medizin is an umlsterm
Gefaesschirurgie.80030158.ger.abstr_task1
Sentence: Fuer die akute Symptomatik der cerebrovasculaeren Insuffizienz besteht Unsicherheit bezueglich des diagnostischen und therapeutischen Vorgehens . In den Jahren 1995 und 1996 wurden in unserem Hause 876 Operationen an der A. carotis durchgefuehrt . Hierbei wurde im neurologisch instabilen Stadium in 27 Faellen ( 3,1% ) die Indikation zum operativen Vorgehen gestellt ; 3 Patienten verstarben an einem neurologischen Defizit ; 2 weitere entwickelten trotz sofortiger Operation einen kompletten Schlaganfall . In 10 Faellen kam es jedoch zu einer deutlichen Besserung des praeoperativ bestehenden neurologischen Defizits und 12 Patienten waren nach der Operation neurologisch unauffaellig . Dies stellt eine Komplikationsrate von 18,5% dar . Die Ergebnisse der operativen Behandlung des akuten Schlaganfalls rechtfertigen eine ausgiebige Diagnostik mit unverzueglicher Duplexsonographie und kranieller Computertomographie sowie grosszuegiger Indikationsstellung zur Operation . Jedoch ist die alleinige chirurgische Behandlung der Gefaessveraenderungen nicht ausreichend . Vielmehr ist die enge Kooperation zwischen diagnostischer , konservativer und operativer Medizin von entscheidender Bedeutung . Instructions: please typing these entity words according to sentence: Patienten, neurologischen Defizit, Schlaganfall, neurologischen Defizits, Patienten, Behandlung, Schlaganfalls, Diagnostik, Computertomographie, Behandlung, Medizin Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Fuer die akute Symptomatik der cerebrovasculaeren Insuffizienz besteht Unsicherheit bezueglich des diagnostischen und therapeutischen Vorgehens . In den Jahren 1995 und 1996 wurden in unserem Hause 876 Operationen an der A. carotis durchgefuehrt . Hierbei wurde im neurologisch instabilen Stadium in 27 Faellen ( 3,1% ) die Indikation zum operativen Vorgehen gestellt ; 3 Patienten verstarben an einem neurologischen Defizit ; 2 weitere entwickelten trotz sofortiger Operation einen kompletten Schlaganfall . In 10 Faellen kam es jedoch zu einer deutlichen Besserung des praeoperativ bestehenden neurologischen Defizits und 12 Patienten waren nach der Operation neurologisch unauffaellig . Dies stellt eine Komplikationsrate von 18,5% dar . Die Ergebnisse der operativen Behandlung des akuten Schlaganfalls rechtfertigen eine ausgiebige Diagnostik mit unverzueglicher Duplexsonographie und kranieller Computertomographie sowie grosszuegiger Indikationsstellung zur Operation . Jedoch ist die alleinige chirurgische Behandlung der Gefaessveraenderungen nicht ausreichend . Vielmehr ist die enge Kooperation zwischen diagnostischer , konservativer und operativer Medizin von entscheidender Bedeutung .
[ "Fuer", "die", "akute", "Symptomatik", "der", "cerebrovasculaeren", "Insuffizienz", "besteht", "Unsicherheit", "bezueglich", "des", "diagnostischen", "und", "therapeutischen", "Vorgehens", ".", "In", "den", "Jahren", "1995", "und", "1996", "wurden", "in", "unserem", "Hause", "876", "Operationen", "an", "der", "A.", "carotis", "durchgefuehrt", ".", "Hierbei", "wurde", "im", "neurologisch", "instabilen", "Stadium", "in", "27", "Faellen", "(", "3,1", "%", ")", "die", "Indikation", "zum", "operativen", "Vorgehen", "gestellt", ";", "3", "Patienten", "verstarben", "an", "einem", "neurologischen", "Defizit", ";", "2", "weitere", "entwickelten", "trotz", "sofortiger", "Operation", "einen", "kompletten", "Schlaganfall", ".", "In", "10", "Faellen", "kam", "es", "jedoch", "zu", "einer", "deutlichen", "Besserung", "des", "praeoperativ", "bestehenden", "neurologischen", "Defizits", "und", "12", "Patienten", "waren", "nach", "der", "Operation", "neurologisch", "unauffaellig", ".", "Dies", "stellt", "eine", "Komplikationsrate", "von", "18,5", "%", "dar", ".", "Die", "Ergebnisse", "der", "operativen", "Behandlung", "des", "akuten", "Schlaganfalls", "rechtfertigen", "eine", "ausgiebige", "Diagnostik", "mit", "unverzueglicher", "Duplexsonographie", "und", "kranieller", "Computertomographie", "sowie", "grosszuegiger", "Indikationsstellung", "zur", "Operation", ".", "Jedoch", "ist", "die", "alleinige", "chirurgische", "Behandlung", "der", "Gefaessveraenderungen", "nicht", "ausreichend", ".", "Vielmehr", "ist", "die", "enge", "Kooperation", "zwischen", "diagnostischer", ",", "konservativer", "und", "operativer", "Medizin", "von", "entscheidender", "Bedeutung", "." ]
[ "umlsterm" ]
Patienten, neurologischen Defizit, Schlaganfall, neurologischen Defizits, Patienten, Behandlung, Schlaganfalls, Diagnostik, Computertomographie, Behandlung, Medizin
Gefaesschirurgie.80030158.ger.abstr_task2
Sentence: Fuer die akute Symptomatik der cerebrovasculaeren Insuffizienz besteht Unsicherheit bezueglich des diagnostischen und therapeutischen Vorgehens . In den Jahren 1995 und 1996 wurden in unserem Hause 876 Operationen an der A. carotis durchgefuehrt . Hierbei wurde im neurologisch instabilen Stadium in 27 Faellen ( 3,1% ) die Indikation zum operativen Vorgehen gestellt ; 3 Patienten verstarben an einem neurologischen Defizit ; 2 weitere entwickelten trotz sofortiger Operation einen kompletten Schlaganfall . In 10 Faellen kam es jedoch zu einer deutlichen Besserung des praeoperativ bestehenden neurologischen Defizits und 12 Patienten waren nach der Operation neurologisch unauffaellig . Dies stellt eine Komplikationsrate von 18,5% dar . Die Ergebnisse der operativen Behandlung des akuten Schlaganfalls rechtfertigen eine ausgiebige Diagnostik mit unverzueglicher Duplexsonographie und kranieller Computertomographie sowie grosszuegiger Indikationsstellung zur Operation . Jedoch ist die alleinige chirurgische Behandlung der Gefaessveraenderungen nicht ausreichend . Vielmehr ist die enge Kooperation zwischen diagnostischer , konservativer und operativer Medizin von entscheidender Bedeutung . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Fuer die akute Symptomatik der cerebrovasculaeren Insuffizienz besteht Unsicherheit bezueglich des diagnostischen und therapeutischen Vorgehens . In den Jahren 1995 und 1996 wurden in unserem Hause 876 Operationen an der A. carotis durchgefuehrt . Hierbei wurde im neurologisch instabilen Stadium in 27 Faellen ( 3,1% ) die Indikation zum operativen Vorgehen gestellt ; 3 Patienten verstarben an einem neurologischen Defizit ; 2 weitere entwickelten trotz sofortiger Operation einen kompletten Schlaganfall . In 10 Faellen kam es jedoch zu einer deutlichen Besserung des praeoperativ bestehenden neurologischen Defizits und 12 Patienten waren nach der Operation neurologisch unauffaellig . Dies stellt eine Komplikationsrate von 18,5% dar . Die Ergebnisse der operativen Behandlung des akuten Schlaganfalls rechtfertigen eine ausgiebige Diagnostik mit unverzueglicher Duplexsonographie und kranieller Computertomographie sowie grosszuegiger Indikationsstellung zur Operation . Jedoch ist die alleinige chirurgische Behandlung der Gefaessveraenderungen nicht ausreichend . Vielmehr ist die enge Kooperation zwischen diagnostischer , konservativer und operativer Medizin von entscheidender Bedeutung .
[ "Fuer", "die", "akute", "Symptomatik", "der", "cerebrovasculaeren", "Insuffizienz", "besteht", "Unsicherheit", "bezueglich", "des", "diagnostischen", "und", "therapeutischen", "Vorgehens", ".", "In", "den", "Jahren", "1995", "und", "1996", "wurden", "in", "unserem", "Hause", "876", "Operationen", "an", "der", "A.", "carotis", "durchgefuehrt", ".", "Hierbei", "wurde", "im", "neurologisch", "instabilen", "Stadium", "in", "27", "Faellen", "(", "3,1", "%", ")", "die", "Indikation", "zum", "operativen", "Vorgehen", "gestellt", ";", "3", "Patienten", "verstarben", "an", "einem", "neurologischen", "Defizit", ";", "2", "weitere", "entwickelten", "trotz", "sofortiger", "Operation", "einen", "kompletten", "Schlaganfall", ".", "In", "10", "Faellen", "kam", "es", "jedoch", "zu", "einer", "deutlichen", "Besserung", "des", "praeoperativ", "bestehenden", "neurologischen", "Defizits", "und", "12", "Patienten", "waren", "nach", "der", "Operation", "neurologisch", "unauffaellig", ".", "Dies", "stellt", "eine", "Komplikationsrate", "von", "18,5", "%", "dar", ".", "Die", "Ergebnisse", "der", "operativen", "Behandlung", "des", "akuten", "Schlaganfalls", "rechtfertigen", "eine", "ausgiebige", "Diagnostik", "mit", "unverzueglicher", "Duplexsonographie", "und", "kranieller", "Computertomographie", "sowie", "grosszuegiger", "Indikationsstellung", "zur", "Operation", ".", "Jedoch", "ist", "die", "alleinige", "chirurgische", "Behandlung", "der", "Gefaessveraenderungen", "nicht", "ausreichend", ".", "Vielmehr", "ist", "die", "enge", "Kooperation", "zwischen", "diagnostischer", ",", "konservativer", "und", "operativer", "Medizin", "von", "entscheidender", "Bedeutung", "." ]
[ "umlsterm" ]
neu differentiation factors is a Protein, neu differentiation factor is a Protein, NDF is a Protein, NDF is a Protein, NDFs is a Protein, NDF is a Protein, epidermal growth factor is a Protein, NDF - alpha is a Protein, -beta is a Protein, NDF - alpha is a Protein, -beta is a Protein, NDF is a Protein, NDF is a Protein, NDF - beta is a Protein, NDF - alpha is a Protein, NDF - beta is a Protein, HER-3 is a Protein, HER-4 is a Protein, NDF - alpha is a Protein, NDF - alpha is a Protein, -beta is a Protein
537_task0
Sentence: Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. Comparative analyses of both glycosylated and nonglycosylated neu differentiation factor (NDF) isoforms revealed significant similarities and differences of their overall structures and functions. Biophysical analyses confirmed that all NDF isoforms are monomeric, but have an extended ellipsoidal shape in solution. All full-length NDFs are similar in secondary and tertiary structures and they contain no alpha-helix but are abundant in beta-strand structures. A small NDF fragment containing only the epidermal growth factor domain is also rich in beta-strand structures, but exhibits tertiary structure different from the long NDF forms. Monoclonal antibodies that selectively recognize epidermal growth factor domains of human NDF-alpha and -beta can specifically bind the respective NDF-alpha and -beta isoforms independent of NDF origins. Western blot analysis and quantitative binding assays further identify that an NDF preparation produced naturally from Rat1-EJ cells contains both alpha and beta isoforms in a 3 to 2 ratio. In receptor-binding competition experiments, human and rat NDF-beta isoforms have higher affinity than NDF-alpha isoforms. NDF-beta isoforms can dramatically enhance the stimulation of DNA synthesis for transfected NIH3T3 cells that overexpress HER-3 and HER-4 receptors, while NDF-alpha isoforms can only stimulate proliferation of HER-4-transfected cells with lower activity. Taken together, NDF-alpha and -beta isoforms share similar gross protein conformations but are biologically distinct. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. Comparative analyses of both glycosylated and nonglycosylated neu differentiation factor (NDF) isoforms revealed significant similarities and differences of their overall structures and functions. Biophysical analyses confirmed that all NDF isoforms are monomeric, but have an extended ellipsoidal shape in solution. All full-length NDFs are similar in secondary and tertiary structures and they contain no alpha-helix but are abundant in beta-strand structures. A small NDF fragment containing only the epidermal growth factor domain is also rich in beta-strand structures, but exhibits tertiary structure different from the long NDF forms. Monoclonal antibodies that selectively recognize epidermal growth factor domains of human NDF-alpha and -beta can specifically bind the respective NDF-alpha and -beta isoforms independent of NDF origins. Western blot analysis and quantitative binding assays further identify that an NDF preparation produced naturally from Rat1-EJ cells contains both alpha and beta isoforms in a 3 to 2 ratio. In receptor-binding competition experiments, human and rat NDF-beta isoforms have higher affinity than NDF-alpha isoforms. NDF-beta isoforms can dramatically enhance the stimulation of DNA synthesis for transfected NIH3T3 cells that overexpress HER-3 and HER-4 receptors, while NDF-alpha isoforms can only stimulate proliferation of HER-4-transfected cells with lower activity. Taken together, NDF-alpha and -beta isoforms share similar gross protein conformations but are biologically distinct.
[ "Studies", "on", "the", "structure", "and", "function", "of", "glycosylated", "and", "nonglycosylated", "neu", "differentiation", "factors", ".", " ", "Similarities", "and", "differences", "of", "the", "alpha", "and", "beta", "isoforms", ".", "\n", "Comparative", "analyses", "of", "both", "glycosylated", "and", "nonglycosylated", "neu", "differentiation", "factor", "(", "NDF", ")", "isoforms", "revealed", "significant", "similarities", "and", "differences", "of", "their", "overall", "structures", "and", "functions", ".", "Biophysical", "analyses", "confirmed", "that", "all", "NDF", "isoforms", "are", "monomeric", ",", "but", "have", "an", "extended", "ellipsoidal", "shape", "in", "solution", ".", "All", "full", "-", "length", "NDFs", "are", "similar", "in", "secondary", "and", "tertiary", "structures", "and", "they", "contain", "no", "alpha", "-", "helix", "but", "are", "abundant", "in", "beta", "-", "strand", "structures", ".", "A", "small", "NDF", "fragment", "containing", "only", "the", "epidermal", "growth", "factor", "domain", "is", "also", "rich", "in", "beta", "-", "strand", "structures", ",", "but", "exhibits", "tertiary", "structure", "different", "from", "the", "long", "NDF", "forms", ".", "Monoclonal", "antibodies", "that", "selectively", "recognize", "epidermal", "growth", "factor", "domains", "of", "human", "NDF", "-", "alpha", "and", "-beta", "can", "specifically", "bind", "the", "respective", "NDF", "-", "alpha", "and", "-beta", "isoforms", "independent", "of", "NDF", "origins", ".", "Western", "blot", "analysis", "and", "quantitative", "binding", "assays", "further", "identify", "that", "an", "NDF", "preparation", "produced", "naturally", "from", "Rat1-EJ", "cells", "contains", "both", "alpha", "and", "beta", "isoforms", "in", "a", "3", "to", "2", "ratio", ".", "In", "receptor", "-", "binding", "competition", "experiments", ",", "human", "and", "rat", "NDF", "-", "beta", "isoforms", "have", "higher", "affinity", "than", "NDF", "-", "alpha", "isoforms", ".", "NDF", "-", "beta", "isoforms", "can", "dramatically", "enhance", "the", "stimulation", "of", "DNA", "synthesis", "for", "transfected", "NIH3T3", "cells", "that", "overexpress", "HER-3", "and", "HER-4", "receptors", ",", "while", "NDF", "-", "alpha", "isoforms", "can", "only", "stimulate", "proliferation", "of", "HER-4-transfected", "cells", "with", "lower", "activity", ".", "Taken", "together", ",", "NDF", "-", "alpha", "and", "-beta", "isoforms", "share", "similar", "gross", "protein", "conformations", "but", "are", "biologically", "distinct", ".", "\n" ]
[ "Protein" ]
neu differentiation factors is a Protein, neu differentiation factor is a Protein, NDF is a Protein, NDF is a Protein, NDFs is a Protein, NDF is a Protein, epidermal growth factor is a Protein, NDF - alpha is a Protein, -beta is a Protein, NDF - alpha is a Protein, -beta is a Protein, NDF is a Protein, NDF is a Protein, NDF - beta is a Protein, NDF - alpha is a Protein, NDF - beta is a Protein, HER-3 is a Protein, HER-4 is a Protein, NDF - alpha is a Protein, NDF - alpha is a Protein, -beta is a Protein
537_task1
Sentence: Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. Comparative analyses of both glycosylated and nonglycosylated neu differentiation factor (NDF) isoforms revealed significant similarities and differences of their overall structures and functions. Biophysical analyses confirmed that all NDF isoforms are monomeric, but have an extended ellipsoidal shape in solution. All full-length NDFs are similar in secondary and tertiary structures and they contain no alpha-helix but are abundant in beta-strand structures. A small NDF fragment containing only the epidermal growth factor domain is also rich in beta-strand structures, but exhibits tertiary structure different from the long NDF forms. Monoclonal antibodies that selectively recognize epidermal growth factor domains of human NDF-alpha and -beta can specifically bind the respective NDF-alpha and -beta isoforms independent of NDF origins. Western blot analysis and quantitative binding assays further identify that an NDF preparation produced naturally from Rat1-EJ cells contains both alpha and beta isoforms in a 3 to 2 ratio. In receptor-binding competition experiments, human and rat NDF-beta isoforms have higher affinity than NDF-alpha isoforms. NDF-beta isoforms can dramatically enhance the stimulation of DNA synthesis for transfected NIH3T3 cells that overexpress HER-3 and HER-4 receptors, while NDF-alpha isoforms can only stimulate proliferation of HER-4-transfected cells with lower activity. Taken together, NDF-alpha and -beta isoforms share similar gross protein conformations but are biologically distinct. Instructions: please typing these entity words according to sentence: neu differentiation factors, neu differentiation factor, NDF, NDF, NDFs, NDF, epidermal growth factor, NDF - alpha, -beta, NDF - alpha, -beta, NDF, NDF, NDF - beta, NDF - alpha, NDF - beta, HER-3, HER-4, NDF - alpha, NDF - alpha, -beta Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. Comparative analyses of both glycosylated and nonglycosylated neu differentiation factor (NDF) isoforms revealed significant similarities and differences of their overall structures and functions. Biophysical analyses confirmed that all NDF isoforms are monomeric, but have an extended ellipsoidal shape in solution. All full-length NDFs are similar in secondary and tertiary structures and they contain no alpha-helix but are abundant in beta-strand structures. A small NDF fragment containing only the epidermal growth factor domain is also rich in beta-strand structures, but exhibits tertiary structure different from the long NDF forms. Monoclonal antibodies that selectively recognize epidermal growth factor domains of human NDF-alpha and -beta can specifically bind the respective NDF-alpha and -beta isoforms independent of NDF origins. Western blot analysis and quantitative binding assays further identify that an NDF preparation produced naturally from Rat1-EJ cells contains both alpha and beta isoforms in a 3 to 2 ratio. In receptor-binding competition experiments, human and rat NDF-beta isoforms have higher affinity than NDF-alpha isoforms. NDF-beta isoforms can dramatically enhance the stimulation of DNA synthesis for transfected NIH3T3 cells that overexpress HER-3 and HER-4 receptors, while NDF-alpha isoforms can only stimulate proliferation of HER-4-transfected cells with lower activity. Taken together, NDF-alpha and -beta isoforms share similar gross protein conformations but are biologically distinct.
[ "Studies", "on", "the", "structure", "and", "function", "of", "glycosylated", "and", "nonglycosylated", "neu", "differentiation", "factors", ".", " ", "Similarities", "and", "differences", "of", "the", "alpha", "and", "beta", "isoforms", ".", "\n", "Comparative", "analyses", "of", "both", "glycosylated", "and", "nonglycosylated", "neu", "differentiation", "factor", "(", "NDF", ")", "isoforms", "revealed", "significant", "similarities", "and", "differences", "of", "their", "overall", "structures", "and", "functions", ".", "Biophysical", "analyses", "confirmed", "that", "all", "NDF", "isoforms", "are", "monomeric", ",", "but", "have", "an", "extended", "ellipsoidal", "shape", "in", "solution", ".", "All", "full", "-", "length", "NDFs", "are", "similar", "in", "secondary", "and", "tertiary", "structures", "and", "they", "contain", "no", "alpha", "-", "helix", "but", "are", "abundant", "in", "beta", "-", "strand", "structures", ".", "A", "small", "NDF", "fragment", "containing", "only", "the", "epidermal", "growth", "factor", "domain", "is", "also", "rich", "in", "beta", "-", "strand", "structures", ",", "but", "exhibits", "tertiary", "structure", "different", "from", "the", "long", "NDF", "forms", ".", "Monoclonal", "antibodies", "that", "selectively", "recognize", "epidermal", "growth", "factor", "domains", "of", "human", "NDF", "-", "alpha", "and", "-beta", "can", "specifically", "bind", "the", "respective", "NDF", "-", "alpha", "and", "-beta", "isoforms", "independent", "of", "NDF", "origins", ".", "Western", "blot", "analysis", "and", "quantitative", "binding", "assays", "further", "identify", "that", "an", "NDF", "preparation", "produced", "naturally", "from", "Rat1-EJ", "cells", "contains", "both", "alpha", "and", "beta", "isoforms", "in", "a", "3", "to", "2", "ratio", ".", "In", "receptor", "-", "binding", "competition", "experiments", ",", "human", "and", "rat", "NDF", "-", "beta", "isoforms", "have", "higher", "affinity", "than", "NDF", "-", "alpha", "isoforms", ".", "NDF", "-", "beta", "isoforms", "can", "dramatically", "enhance", "the", "stimulation", "of", "DNA", "synthesis", "for", "transfected", "NIH3T3", "cells", "that", "overexpress", "HER-3", "and", "HER-4", "receptors", ",", "while", "NDF", "-", "alpha", "isoforms", "can", "only", "stimulate", "proliferation", "of", "HER-4-transfected", "cells", "with", "lower", "activity", ".", "Taken", "together", ",", "NDF", "-", "alpha", "and", "-beta", "isoforms", "share", "similar", "gross", "protein", "conformations", "but", "are", "biologically", "distinct", ".", "\n" ]
[ "Protein" ]
neu differentiation factors, neu differentiation factor, NDF, NDF, NDFs, NDF, epidermal growth factor, NDF - alpha, -beta, NDF - alpha, -beta, NDF, NDF, NDF - beta, NDF - alpha, NDF - beta, HER-3, HER-4, NDF - alpha, NDF - alpha, -beta
537_task2
Sentence: Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. Comparative analyses of both glycosylated and nonglycosylated neu differentiation factor (NDF) isoforms revealed significant similarities and differences of their overall structures and functions. Biophysical analyses confirmed that all NDF isoforms are monomeric, but have an extended ellipsoidal shape in solution. All full-length NDFs are similar in secondary and tertiary structures and they contain no alpha-helix but are abundant in beta-strand structures. A small NDF fragment containing only the epidermal growth factor domain is also rich in beta-strand structures, but exhibits tertiary structure different from the long NDF forms. Monoclonal antibodies that selectively recognize epidermal growth factor domains of human NDF-alpha and -beta can specifically bind the respective NDF-alpha and -beta isoforms independent of NDF origins. Western blot analysis and quantitative binding assays further identify that an NDF preparation produced naturally from Rat1-EJ cells contains both alpha and beta isoforms in a 3 to 2 ratio. In receptor-binding competition experiments, human and rat NDF-beta isoforms have higher affinity than NDF-alpha isoforms. NDF-beta isoforms can dramatically enhance the stimulation of DNA synthesis for transfected NIH3T3 cells that overexpress HER-3 and HER-4 receptors, while NDF-alpha isoforms can only stimulate proliferation of HER-4-transfected cells with lower activity. Taken together, NDF-alpha and -beta isoforms share similar gross protein conformations but are biologically distinct. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Studies on the structure and function of glycosylated and nonglycosylated neu differentiation factors. Similarities and differences of the alpha and beta isoforms. Comparative analyses of both glycosylated and nonglycosylated neu differentiation factor (NDF) isoforms revealed significant similarities and differences of their overall structures and functions. Biophysical analyses confirmed that all NDF isoforms are monomeric, but have an extended ellipsoidal shape in solution. All full-length NDFs are similar in secondary and tertiary structures and they contain no alpha-helix but are abundant in beta-strand structures. A small NDF fragment containing only the epidermal growth factor domain is also rich in beta-strand structures, but exhibits tertiary structure different from the long NDF forms. Monoclonal antibodies that selectively recognize epidermal growth factor domains of human NDF-alpha and -beta can specifically bind the respective NDF-alpha and -beta isoforms independent of NDF origins. Western blot analysis and quantitative binding assays further identify that an NDF preparation produced naturally from Rat1-EJ cells contains both alpha and beta isoforms in a 3 to 2 ratio. In receptor-binding competition experiments, human and rat NDF-beta isoforms have higher affinity than NDF-alpha isoforms. NDF-beta isoforms can dramatically enhance the stimulation of DNA synthesis for transfected NIH3T3 cells that overexpress HER-3 and HER-4 receptors, while NDF-alpha isoforms can only stimulate proliferation of HER-4-transfected cells with lower activity. Taken together, NDF-alpha and -beta isoforms share similar gross protein conformations but are biologically distinct.
[ "Studies", "on", "the", "structure", "and", "function", "of", "glycosylated", "and", "nonglycosylated", "neu", "differentiation", "factors", ".", " ", "Similarities", "and", "differences", "of", "the", "alpha", "and", "beta", "isoforms", ".", "\n", "Comparative", "analyses", "of", "both", "glycosylated", "and", "nonglycosylated", "neu", "differentiation", "factor", "(", "NDF", ")", "isoforms", "revealed", "significant", "similarities", "and", "differences", "of", "their", "overall", "structures", "and", "functions", ".", "Biophysical", "analyses", "confirmed", "that", "all", "NDF", "isoforms", "are", "monomeric", ",", "but", "have", "an", "extended", "ellipsoidal", "shape", "in", "solution", ".", "All", "full", "-", "length", "NDFs", "are", "similar", "in", "secondary", "and", "tertiary", "structures", "and", "they", "contain", "no", "alpha", "-", "helix", "but", "are", "abundant", "in", "beta", "-", "strand", "structures", ".", "A", "small", "NDF", "fragment", "containing", "only", "the", "epidermal", "growth", "factor", "domain", "is", "also", "rich", "in", "beta", "-", "strand", "structures", ",", "but", "exhibits", "tertiary", "structure", "different", "from", "the", "long", "NDF", "forms", ".", "Monoclonal", "antibodies", "that", "selectively", "recognize", "epidermal", "growth", "factor", "domains", "of", "human", "NDF", "-", "alpha", "and", "-beta", "can", "specifically", "bind", "the", "respective", "NDF", "-", "alpha", "and", "-beta", "isoforms", "independent", "of", "NDF", "origins", ".", "Western", "blot", "analysis", "and", "quantitative", "binding", "assays", "further", "identify", "that", "an", "NDF", "preparation", "produced", "naturally", "from", "Rat1-EJ", "cells", "contains", "both", "alpha", "and", "beta", "isoforms", "in", "a", "3", "to", "2", "ratio", ".", "In", "receptor", "-", "binding", "competition", "experiments", ",", "human", "and", "rat", "NDF", "-", "beta", "isoforms", "have", "higher", "affinity", "than", "NDF", "-", "alpha", "isoforms", ".", "NDF", "-", "beta", "isoforms", "can", "dramatically", "enhance", "the", "stimulation", "of", "DNA", "synthesis", "for", "transfected", "NIH3T3", "cells", "that", "overexpress", "HER-3", "and", "HER-4", "receptors", ",", "while", "NDF", "-", "alpha", "isoforms", "can", "only", "stimulate", "proliferation", "of", "HER-4-transfected", "cells", "with", "lower", "activity", ".", "Taken", "together", ",", "NDF", "-", "alpha", "and", "-beta", "isoforms", "share", "similar", "gross", "protein", "conformations", "but", "are", "biologically", "distinct", ".", "\n" ]
[ "Protein" ]
flosequinan is an intervention, resting heart rate is an outcome, left ventricular systolic function is an outcome
789_task0
Sentence: While long-term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome
[ "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]
While long-term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function .
[ "While", "long", "-", "term", "flosequinan", "administration", "also", "effected", "a", "progressive", "increase", "in", "resting", "heart", "rate", ",", "it", "did", "not", "consistently", "improve", "indices", "of", "left", "ventricular", "systolic", "function", "." ]
[ "outcome", "intervention" ]
flosequinan is an intervention, resting heart rate is an outcome, left ventricular systolic function is an outcome
789_task1
Sentence: While long-term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function . Instructions: please typing these entity words according to sentence: flosequinan, resting heart rate, left ventricular systolic function Options: intervention, outcome
[ "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]
While long-term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function .
[ "While", "long", "-", "term", "flosequinan", "administration", "also", "effected", "a", "progressive", "increase", "in", "resting", "heart", "rate", ",", "it", "did", "not", "consistently", "improve", "indices", "of", "left", "ventricular", "systolic", "function", "." ]
[ "outcome", "intervention" ]
flosequinan, resting heart rate, left ventricular systolic function
789_task2
Sentence: While long-term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "I-outcome", "I-outcome", "O" ]
While long-term flosequinan administration also effected a progressive increase in resting heart rate , it did not consistently improve indices of left ventricular systolic function .
[ "While", "long", "-", "term", "flosequinan", "administration", "also", "effected", "a", "progressive", "increase", "in", "resting", "heart", "rate", ",", "it", "did", "not", "consistently", "improve", "indices", "of", "left", "ventricular", "systolic", "function", "." ]
[ "outcome", "intervention" ]
Diagnostic is an umlsterm, therapeutic is an umlsterm, lymphomas is an umlsterm, mucosa - associated is an umlsterm, lymphoid tissue is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, evaluation is an umlsterm, biopsy is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, biopsies is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, biopsies is an umlsterm, patient is an umlsterm, surgical is an umlsterm, patients is an umlsterm, Institute is an umlsterm, Pathology is an umlsterm, Tumor is an umlsterm, diagnosis is an umlsterm, tumor is an umlsterm, biopsy is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, secondary is an umlsterm, high - grade lymphomas is an umlsterm, immunohistochemistry is an umlsterm, techniques is an umlsterm, histology is an umlsterm, diagnosis is an umlsterm, MALT - type is an umlsterm, lymphoma is an umlsterm, biopsies is an umlsterm, Institute is an umlsterm, Pathology is an umlsterm, secondary is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, biopsies is an umlsterm, Diagnostic is an umlsterm, lymphomas is an umlsterm, biopsies is an umlsterm, biopsy is an umlsterm, artefacts is an umlsterm, immunohistochemistry is an umlsterm, techniques is an umlsterm, secondary is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, diagnosis is an umlsterm, biopsies is an umlsterm, biopsy is an umlsterm
DerPathologe.80190209.eng.abstr_task0
Sentence: Diagnostic und therapeutic management of gastric lymphomas of the mucosa-associated lymphoid tissue type ( MALT-type lymphomas ) is often based exclusively on the evaluation of biopsy material . To evaluate the diagnostic value of gastric biopsies in gastric MALT-type lymphomas , biopsies - on average six per patient - and subsequent surgical specimens of 64 patients were compared at the Institute of Pathology , Unversity of Wuerzburg . Tumor diagnosis and tumor gradind were assessed . Using biopsy specimens , primary gastric MALT-type lymphomas were correctly diagnosed by local pathologists in 69% of cases , but correctly graded as low-grade , high-grade or secondary high-grade lymphomas in only 41% . When immunohistochemistry and molecular biological techniques were applied in addition to conventional histology , diagnosis of gastric MALT-type lymphoma was achieved in biopsies in 95% of cases at the Institute of Pathology Wuerzburg , but correct grading in only 73% . In secondary high-grade MALT-type lymphomas , both components - the high-grade and the low-grade component - were identified in gastric biopsies in only 33% of cases . Diagnostic accuracy in gastric lymphomas based on biopsies is limited by biopsy artefacts , but improved by using immunohistochemistry and molecular biological techniques . Particularly in secondary high-grade MALT-type lymphomas the correct diagnosis is often missed when using biopsies , due to a low number of biopsy specimens . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Diagnostic und therapeutic management of gastric lymphomas of the mucosa-associated lymphoid tissue type ( MALT-type lymphomas ) is often based exclusively on the evaluation of biopsy material . To evaluate the diagnostic value of gastric biopsies in gastric MALT-type lymphomas , biopsies - on average six per patient - and subsequent surgical specimens of 64 patients were compared at the Institute of Pathology , Unversity of Wuerzburg . Tumor diagnosis and tumor gradind were assessed . Using biopsy specimens , primary gastric MALT-type lymphomas were correctly diagnosed by local pathologists in 69% of cases , but correctly graded as low-grade , high-grade or secondary high-grade lymphomas in only 41% . When immunohistochemistry and molecular biological techniques were applied in addition to conventional histology , diagnosis of gastric MALT-type lymphoma was achieved in biopsies in 95% of cases at the Institute of Pathology Wuerzburg , but correct grading in only 73% . In secondary high-grade MALT-type lymphomas , both components - the high-grade and the low-grade component - were identified in gastric biopsies in only 33% of cases . Diagnostic accuracy in gastric lymphomas based on biopsies is limited by biopsy artefacts , but improved by using immunohistochemistry and molecular biological techniques . Particularly in secondary high-grade MALT-type lymphomas the correct diagnosis is often missed when using biopsies , due to a low number of biopsy specimens .
[ "Diagnostic", "und", "therapeutic", "management", "of", "gastric", "lymphomas", "of", "the", "mucosa", "-", "associated", "lymphoid", "tissue", "type", "(", "MALT", "-", "type", "lymphomas", ")", "is", "often", "based", "exclusively", "on", "the", "evaluation", "of", "biopsy", "material", ".", "To", "evaluate", "the", "diagnostic", "value", "of", "gastric", "biopsies", "in", "gastric", "MALT", "-", "type", "lymphomas", ",", "biopsies", "-", "on", "average", "six", "per", "patient", "-", "and", "subsequent", "surgical", "specimens", "of", "64", "patients", "were", "compared", "at", "the", "Institute", "of", "Pathology", ",", "Unversity", "of", "Wuerzburg", ".", "Tumor", "diagnosis", "and", "tumor", "gradind", "were", "assessed", ".", "Using", "biopsy", "specimens", ",", "primary", "gastric", "MALT", "-", "type", "lymphomas", "were", "correctly", "diagnosed", "by", "local", "pathologists", "in", "69", "%", "of", "cases", ",", "but", "correctly", "graded", "as", "low", "-", "grade", ",", "high", "-", "grade", "or", "secondary", "high", "-", "grade", "lymphomas", "in", "only", "41", "%", ".", "When", "immunohistochemistry", "and", "molecular", "biological", "techniques", "were", "applied", "in", "addition", "to", "conventional", "histology", ",", "diagnosis", "of", "gastric", "MALT", "-", "type", "lymphoma", "was", "achieved", "in", "biopsies", "in", "95", "%", "of", "cases", "at", "the", "Institute", "of", "Pathology", "Wuerzburg", ",", "but", "correct", "grading", "in", "only", "73", "%", ".", "In", "secondary", "high", "-", "grade", "MALT", "-", "type", "lymphomas", ",", "both", "components", "-", "the", "high", "-", "grade", "and", "the", "low", "-", "grade", "component", "-", "were", "identified", "in", "gastric", "biopsies", "in", "only", "33", "%", "of", "cases", ".", "Diagnostic", "accuracy", "in", "gastric", "lymphomas", "based", "on", "biopsies", "is", "limited", "by", "biopsy", "artefacts", ",", "but", "improved", "by", "using", "immunohistochemistry", "and", "molecular", "biological", "techniques", ".", "Particularly", "in", "secondary", "high", "-", "grade", "MALT", "-", "type", "lymphomas", "the", "correct", "diagnosis", "is", "often", "missed", "when", "using", "biopsies", ",", "due", "to", "a", "low", "number", "of", "biopsy", "specimens", "." ]
[ "umlsterm" ]
Diagnostic is an umlsterm, therapeutic is an umlsterm, lymphomas is an umlsterm, mucosa - associated is an umlsterm, lymphoid tissue is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, evaluation is an umlsterm, biopsy is an umlsterm, diagnostic is an umlsterm, value is an umlsterm, biopsies is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, biopsies is an umlsterm, patient is an umlsterm, surgical is an umlsterm, patients is an umlsterm, Institute is an umlsterm, Pathology is an umlsterm, Tumor is an umlsterm, diagnosis is an umlsterm, tumor is an umlsterm, biopsy is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, secondary is an umlsterm, high - grade lymphomas is an umlsterm, immunohistochemistry is an umlsterm, techniques is an umlsterm, histology is an umlsterm, diagnosis is an umlsterm, MALT - type is an umlsterm, lymphoma is an umlsterm, biopsies is an umlsterm, Institute is an umlsterm, Pathology is an umlsterm, secondary is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, biopsies is an umlsterm, Diagnostic is an umlsterm, lymphomas is an umlsterm, biopsies is an umlsterm, biopsy is an umlsterm, artefacts is an umlsterm, immunohistochemistry is an umlsterm, techniques is an umlsterm, secondary is an umlsterm, MALT - type is an umlsterm, lymphomas is an umlsterm, diagnosis is an umlsterm, biopsies is an umlsterm, biopsy is an umlsterm
DerPathologe.80190209.eng.abstr_task1
Sentence: Diagnostic und therapeutic management of gastric lymphomas of the mucosa-associated lymphoid tissue type ( MALT-type lymphomas ) is often based exclusively on the evaluation of biopsy material . To evaluate the diagnostic value of gastric biopsies in gastric MALT-type lymphomas , biopsies - on average six per patient - and subsequent surgical specimens of 64 patients were compared at the Institute of Pathology , Unversity of Wuerzburg . Tumor diagnosis and tumor gradind were assessed . Using biopsy specimens , primary gastric MALT-type lymphomas were correctly diagnosed by local pathologists in 69% of cases , but correctly graded as low-grade , high-grade or secondary high-grade lymphomas in only 41% . When immunohistochemistry and molecular biological techniques were applied in addition to conventional histology , diagnosis of gastric MALT-type lymphoma was achieved in biopsies in 95% of cases at the Institute of Pathology Wuerzburg , but correct grading in only 73% . In secondary high-grade MALT-type lymphomas , both components - the high-grade and the low-grade component - were identified in gastric biopsies in only 33% of cases . Diagnostic accuracy in gastric lymphomas based on biopsies is limited by biopsy artefacts , but improved by using immunohistochemistry and molecular biological techniques . Particularly in secondary high-grade MALT-type lymphomas the correct diagnosis is often missed when using biopsies , due to a low number of biopsy specimens . Instructions: please typing these entity words according to sentence: Diagnostic, therapeutic, lymphomas, mucosa - associated, lymphoid tissue, MALT - type, lymphomas, evaluation, biopsy, diagnostic, value, biopsies, MALT - type, lymphomas, biopsies, patient, surgical, patients, Institute, Pathology, Tumor, diagnosis, tumor, biopsy, MALT - type, lymphomas, secondary, high - grade lymphomas, immunohistochemistry, techniques, histology, diagnosis, MALT - type, lymphoma, biopsies, Institute, Pathology, secondary, MALT - type, lymphomas, biopsies, Diagnostic, lymphomas, biopsies, biopsy, artefacts, immunohistochemistry, techniques, secondary, MALT - type, lymphomas, diagnosis, biopsies, biopsy Options: umlsterm
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Diagnostic und therapeutic management of gastric lymphomas of the mucosa-associated lymphoid tissue type ( MALT-type lymphomas ) is often based exclusively on the evaluation of biopsy material . To evaluate the diagnostic value of gastric biopsies in gastric MALT-type lymphomas , biopsies - on average six per patient - and subsequent surgical specimens of 64 patients were compared at the Institute of Pathology , Unversity of Wuerzburg . Tumor diagnosis and tumor gradind were assessed . Using biopsy specimens , primary gastric MALT-type lymphomas were correctly diagnosed by local pathologists in 69% of cases , but correctly graded as low-grade , high-grade or secondary high-grade lymphomas in only 41% . When immunohistochemistry and molecular biological techniques were applied in addition to conventional histology , diagnosis of gastric MALT-type lymphoma was achieved in biopsies in 95% of cases at the Institute of Pathology Wuerzburg , but correct grading in only 73% . In secondary high-grade MALT-type lymphomas , both components - the high-grade and the low-grade component - were identified in gastric biopsies in only 33% of cases . Diagnostic accuracy in gastric lymphomas based on biopsies is limited by biopsy artefacts , but improved by using immunohistochemistry and molecular biological techniques . Particularly in secondary high-grade MALT-type lymphomas the correct diagnosis is often missed when using biopsies , due to a low number of biopsy specimens .
[ "Diagnostic", "und", "therapeutic", "management", "of", "gastric", "lymphomas", "of", "the", "mucosa", "-", "associated", "lymphoid", "tissue", "type", "(", "MALT", "-", "type", "lymphomas", ")", "is", "often", "based", "exclusively", "on", "the", "evaluation", "of", "biopsy", "material", ".", "To", "evaluate", "the", "diagnostic", "value", "of", "gastric", "biopsies", "in", "gastric", "MALT", "-", "type", "lymphomas", ",", "biopsies", "-", "on", "average", "six", "per", "patient", "-", "and", "subsequent", "surgical", "specimens", "of", "64", "patients", "were", "compared", "at", "the", "Institute", "of", "Pathology", ",", "Unversity", "of", "Wuerzburg", ".", "Tumor", "diagnosis", "and", "tumor", "gradind", "were", "assessed", ".", "Using", "biopsy", "specimens", ",", "primary", "gastric", "MALT", "-", "type", "lymphomas", "were", "correctly", "diagnosed", "by", "local", "pathologists", "in", "69", "%", "of", "cases", ",", "but", "correctly", "graded", "as", "low", "-", "grade", ",", "high", "-", "grade", "or", "secondary", "high", "-", "grade", "lymphomas", "in", "only", "41", "%", ".", "When", "immunohistochemistry", "and", "molecular", "biological", "techniques", "were", "applied", "in", "addition", "to", "conventional", "histology", ",", "diagnosis", "of", "gastric", "MALT", "-", "type", "lymphoma", "was", "achieved", "in", "biopsies", "in", "95", "%", "of", "cases", "at", "the", "Institute", "of", "Pathology", "Wuerzburg", ",", "but", "correct", "grading", "in", "only", "73", "%", ".", "In", "secondary", "high", "-", "grade", "MALT", "-", "type", "lymphomas", ",", "both", "components", "-", "the", "high", "-", "grade", "and", "the", "low", "-", "grade", "component", "-", "were", "identified", "in", "gastric", "biopsies", "in", "only", "33", "%", "of", "cases", ".", "Diagnostic", "accuracy", "in", "gastric", "lymphomas", "based", "on", "biopsies", "is", "limited", "by", "biopsy", "artefacts", ",", "but", "improved", "by", "using", "immunohistochemistry", "and", "molecular", "biological", "techniques", ".", "Particularly", "in", "secondary", "high", "-", "grade", "MALT", "-", "type", "lymphomas", "the", "correct", "diagnosis", "is", "often", "missed", "when", "using", "biopsies", ",", "due", "to", "a", "low", "number", "of", "biopsy", "specimens", "." ]
[ "umlsterm" ]
Diagnostic, therapeutic, lymphomas, mucosa - associated, lymphoid tissue, MALT - type, lymphomas, evaluation, biopsy, diagnostic, value, biopsies, MALT - type, lymphomas, biopsies, patient, surgical, patients, Institute, Pathology, Tumor, diagnosis, tumor, biopsy, MALT - type, lymphomas, secondary, high - grade lymphomas, immunohistochemistry, techniques, histology, diagnosis, MALT - type, lymphoma, biopsies, Institute, Pathology, secondary, MALT - type, lymphomas, biopsies, Diagnostic, lymphomas, biopsies, biopsy, artefacts, immunohistochemistry, techniques, secondary, MALT - type, lymphomas, diagnosis, biopsies, biopsy
DerPathologe.80190209.eng.abstr_task2
Sentence: Diagnostic und therapeutic management of gastric lymphomas of the mucosa-associated lymphoid tissue type ( MALT-type lymphomas ) is often based exclusively on the evaluation of biopsy material . To evaluate the diagnostic value of gastric biopsies in gastric MALT-type lymphomas , biopsies - on average six per patient - and subsequent surgical specimens of 64 patients were compared at the Institute of Pathology , Unversity of Wuerzburg . Tumor diagnosis and tumor gradind were assessed . Using biopsy specimens , primary gastric MALT-type lymphomas were correctly diagnosed by local pathologists in 69% of cases , but correctly graded as low-grade , high-grade or secondary high-grade lymphomas in only 41% . When immunohistochemistry and molecular biological techniques were applied in addition to conventional histology , diagnosis of gastric MALT-type lymphoma was achieved in biopsies in 95% of cases at the Institute of Pathology Wuerzburg , but correct grading in only 73% . In secondary high-grade MALT-type lymphomas , both components - the high-grade and the low-grade component - were identified in gastric biopsies in only 33% of cases . Diagnostic accuracy in gastric lymphomas based on biopsies is limited by biopsy artefacts , but improved by using immunohistochemistry and molecular biological techniques . Particularly in secondary high-grade MALT-type lymphomas the correct diagnosis is often missed when using biopsies , due to a low number of biopsy specimens . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O" ]
Diagnostic und therapeutic management of gastric lymphomas of the mucosa-associated lymphoid tissue type ( MALT-type lymphomas ) is often based exclusively on the evaluation of biopsy material . To evaluate the diagnostic value of gastric biopsies in gastric MALT-type lymphomas , biopsies - on average six per patient - and subsequent surgical specimens of 64 patients were compared at the Institute of Pathology , Unversity of Wuerzburg . Tumor diagnosis and tumor gradind were assessed . Using biopsy specimens , primary gastric MALT-type lymphomas were correctly diagnosed by local pathologists in 69% of cases , but correctly graded as low-grade , high-grade or secondary high-grade lymphomas in only 41% . When immunohistochemistry and molecular biological techniques were applied in addition to conventional histology , diagnosis of gastric MALT-type lymphoma was achieved in biopsies in 95% of cases at the Institute of Pathology Wuerzburg , but correct grading in only 73% . In secondary high-grade MALT-type lymphomas , both components - the high-grade and the low-grade component - were identified in gastric biopsies in only 33% of cases . Diagnostic accuracy in gastric lymphomas based on biopsies is limited by biopsy artefacts , but improved by using immunohistochemistry and molecular biological techniques . Particularly in secondary high-grade MALT-type lymphomas the correct diagnosis is often missed when using biopsies , due to a low number of biopsy specimens .
[ "Diagnostic", "und", "therapeutic", "management", "of", "gastric", "lymphomas", "of", "the", "mucosa", "-", "associated", "lymphoid", "tissue", "type", "(", "MALT", "-", "type", "lymphomas", ")", "is", "often", "based", "exclusively", "on", "the", "evaluation", "of", "biopsy", "material", ".", "To", "evaluate", "the", "diagnostic", "value", "of", "gastric", "biopsies", "in", "gastric", "MALT", "-", "type", "lymphomas", ",", "biopsies", "-", "on", "average", "six", "per", "patient", "-", "and", "subsequent", "surgical", "specimens", "of", "64", "patients", "were", "compared", "at", "the", "Institute", "of", "Pathology", ",", "Unversity", "of", "Wuerzburg", ".", "Tumor", "diagnosis", "and", "tumor", "gradind", "were", "assessed", ".", "Using", "biopsy", "specimens", ",", "primary", "gastric", "MALT", "-", "type", "lymphomas", "were", "correctly", "diagnosed", "by", "local", "pathologists", "in", "69", "%", "of", "cases", ",", "but", "correctly", "graded", "as", "low", "-", "grade", ",", "high", "-", "grade", "or", "secondary", "high", "-", "grade", "lymphomas", "in", "only", "41", "%", ".", "When", "immunohistochemistry", "and", "molecular", "biological", "techniques", "were", "applied", "in", "addition", "to", "conventional", "histology", ",", "diagnosis", "of", "gastric", "MALT", "-", "type", "lymphoma", "was", "achieved", "in", "biopsies", "in", "95", "%", "of", "cases", "at", "the", "Institute", "of", "Pathology", "Wuerzburg", ",", "but", "correct", "grading", "in", "only", "73", "%", ".", "In", "secondary", "high", "-", "grade", "MALT", "-", "type", "lymphomas", ",", "both", "components", "-", "the", "high", "-", "grade", "and", "the", "low", "-", "grade", "component", "-", "were", "identified", "in", "gastric", "biopsies", "in", "only", "33", "%", "of", "cases", ".", "Diagnostic", "accuracy", "in", "gastric", "lymphomas", "based", "on", "biopsies", "is", "limited", "by", "biopsy", "artefacts", ",", "but", "improved", "by", "using", "immunohistochemistry", "and", "molecular", "biological", "techniques", ".", "Particularly", "in", "secondary", "high", "-", "grade", "MALT", "-", "type", "lymphomas", "the", "correct", "diagnosis", "is", "often", "missed", "when", "using", "biopsies", ",", "due", "to", "a", "low", "number", "of", "biopsy", "specimens", "." ]
[ "umlsterm" ]
Beckens is an umlsterm, Techniken is an umlsterm, Chirurgie is an umlsterm, Weichteilendoskopie is an umlsterm, Technik is an umlsterm, Leiche is an umlsterm, Technik is an umlsterm, Methodik is an umlsterm, Leiche is an umlsterm, Beckens is an umlsterm, Vagina is an umlsterm, Prostata is an umlsterm, Harnblase is an umlsterm, Dilatation is an umlsterm, Komplikationen is an umlsterm, Methode is an umlsterm, Patienten is an umlsterm
DerChirurg.90700294.ger.abstr_task0
Sentence: Zusammenfassung . Grundlagen : Der dorsoposteriore bzw. perineale Zugang zu den bindegewebigen Raeumen des kleinen Beckens hat aufgrund verbesserter transabdomineller Techniken an Bedeutung verloren . Aufgrund der Entwicklung der minimal-invasiven Chirurgie auch in Richtung " Weichteilendoskopie " interessierte es uns , ob die videoassistierte Technik dem perinealen Zugangsweg wieder neue Impulse fuer operative Massnahmen geben kann . Nach der experimentellen Entwicklung an der Leiche konnte die Technik erstmals erfolgreich klinische Anwendung finden . Methodik : Unsere Praeparationen wurden zunaechst an der Leiche erprobt und schliesslich bei einer 59 jaehrigen Patientin mit einer iatrogenen Rectumperforation erstmals klinisch vorgenommen . Von perineal wurde das Spatium retrorectale mit einem Dilatationsballonsystem aufgedehnt und anschliessend ein Pneumoextraperitoneum angelegt . Danach konnten die extraperitoneal gelegenen Strukturen des kleinen Beckens praepariert werden . Ergebnisse : Im Experiment wie bei der klinischen Durchfuehrung konnte eine hervorragende Uebersicht erreicht werden . Experimentell gelang die vollstaendige , zirkulaere Praeparation des Rectums . Ventral kamen Teile der Vagina , Prostata und Harnblase zur Darstellung . Lateral konnten die Paraproctien , Ureteren und Iliacalgefaesse praepariert werden . In der klinischen Anwendung gelang die Dilatation des Spatium retrorectale problemlos und es konnte unter Sicht gespuelt und drainiert werden . Postoperativ kam es zu keinen Komplikationen . Die Entlassung erfolgte am 17. postoperativen Tag . Schlussfolgerung : Die beschriebene Methode ist fuer den Einsatz am Patienten geeignet . Ausser der geschilderten Indikation ergeben sich noch weitere chirurgische Anwendungsmoeglichkeiten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Grundlagen : Der dorsoposteriore bzw. perineale Zugang zu den bindegewebigen Raeumen des kleinen Beckens hat aufgrund verbesserter transabdomineller Techniken an Bedeutung verloren . Aufgrund der Entwicklung der minimal-invasiven Chirurgie auch in Richtung " Weichteilendoskopie " interessierte es uns , ob die videoassistierte Technik dem perinealen Zugangsweg wieder neue Impulse fuer operative Massnahmen geben kann . Nach der experimentellen Entwicklung an der Leiche konnte die Technik erstmals erfolgreich klinische Anwendung finden . Methodik : Unsere Praeparationen wurden zunaechst an der Leiche erprobt und schliesslich bei einer 59 jaehrigen Patientin mit einer iatrogenen Rectumperforation erstmals klinisch vorgenommen . Von perineal wurde das Spatium retrorectale mit einem Dilatationsballonsystem aufgedehnt und anschliessend ein Pneumoextraperitoneum angelegt . Danach konnten die extraperitoneal gelegenen Strukturen des kleinen Beckens praepariert werden . Ergebnisse : Im Experiment wie bei der klinischen Durchfuehrung konnte eine hervorragende Uebersicht erreicht werden . Experimentell gelang die vollstaendige , zirkulaere Praeparation des Rectums . Ventral kamen Teile der Vagina , Prostata und Harnblase zur Darstellung . Lateral konnten die Paraproctien , Ureteren und Iliacalgefaesse praepariert werden . In der klinischen Anwendung gelang die Dilatation des Spatium retrorectale problemlos und es konnte unter Sicht gespuelt und drainiert werden . Postoperativ kam es zu keinen Komplikationen . Die Entlassung erfolgte am 17. postoperativen Tag . Schlussfolgerung : Die beschriebene Methode ist fuer den Einsatz am Patienten geeignet . Ausser der geschilderten Indikation ergeben sich noch weitere chirurgische Anwendungsmoeglichkeiten .
[ "Zusammenfassung", ".", "Grundlagen", ":", "Der", "dorsoposteriore", "bzw", ".", "perineale", "Zugang", "zu", "den", "bindegewebigen", "Raeumen", "des", "kleinen", "Beckens", "hat", "aufgrund", "verbesserter", "transabdomineller", "Techniken", "an", "Bedeutung", "verloren", ".", "Aufgrund", "der", "Entwicklung", "der", "minimal", "-", "invasiven", "Chirurgie", "auch", "in", "Richtung", "\"", "Weichteilendoskopie", "\"", "interessierte", "es", "uns", ",", "ob", "die", "videoassistierte", "Technik", "dem", "perinealen", "Zugangsweg", "wieder", "neue", "Impulse", "fuer", "operative", "Massnahmen", "geben", "kann", ".", "Nach", "der", "experimentellen", "Entwicklung", "an", "der", "Leiche", "konnte", "die", "Technik", "erstmals", "erfolgreich", "klinische", "Anwendung", "finden", ".", "Methodik", ":", "Unsere", "Praeparationen", "wurden", "zunaechst", "an", "der", "Leiche", "erprobt", "und", "schliesslich", "bei", "einer", "59", "jaehrigen", "Patientin", "mit", "einer", "iatrogenen", "Rectumperforation", "erstmals", "klinisch", "vorgenommen", ".", "Von", "perineal", "wurde", "das", "Spatium", "retrorectale", "mit", "einem", "Dilatationsballonsystem", "aufgedehnt", "und", "anschliessend", "ein", "Pneumoextraperitoneum", "angelegt", ".", "Danach", "konnten", "die", "extraperitoneal", "gelegenen", "Strukturen", "des", "kleinen", "Beckens", "praepariert", "werden", ".", "Ergebnisse", ":", "Im", "Experiment", "wie", "bei", "der", "klinischen", "Durchfuehrung", "konnte", "eine", "hervorragende", "Uebersicht", "erreicht", "werden", ".", "Experimentell", "gelang", "die", "vollstaendige", ",", "zirkulaere", "Praeparation", "des", "Rectums", ".", "Ventral", "kamen", "Teile", "der", "Vagina", ",", "Prostata", "und", "Harnblase", "zur", "Darstellung", ".", "Lateral", "konnten", "die", "Paraproctien", ",", "Ureteren", "und", "Iliacalgefaesse", "praepariert", "werden", ".", "In", "der", "klinischen", "Anwendung", "gelang", "die", "Dilatation", "des", "Spatium", "retrorectale", "problemlos", "und", "es", "konnte", "unter", "Sicht", "gespuelt", "und", "drainiert", "werden", ".", "Postoperativ", "kam", "es", "zu", "keinen", "Komplikationen", ".", "Die", "Entlassung", "erfolgte", "am", "17", ".", "postoperativen", "Tag", ".", "Schlussfolgerung", ":", "Die", "beschriebene", "Methode", "ist", "fuer", "den", "Einsatz", "am", "Patienten", "geeignet", ".", "Ausser", "der", "geschilderten", "Indikation", "ergeben", "sich", "noch", "weitere", "chirurgische", "Anwendungsmoeglichkeiten", "." ]
[ "umlsterm" ]
Beckens is an umlsterm, Techniken is an umlsterm, Chirurgie is an umlsterm, Weichteilendoskopie is an umlsterm, Technik is an umlsterm, Leiche is an umlsterm, Technik is an umlsterm, Methodik is an umlsterm, Leiche is an umlsterm, Beckens is an umlsterm, Vagina is an umlsterm, Prostata is an umlsterm, Harnblase is an umlsterm, Dilatation is an umlsterm, Komplikationen is an umlsterm, Methode is an umlsterm, Patienten is an umlsterm
DerChirurg.90700294.ger.abstr_task1
Sentence: Zusammenfassung . Grundlagen : Der dorsoposteriore bzw. perineale Zugang zu den bindegewebigen Raeumen des kleinen Beckens hat aufgrund verbesserter transabdomineller Techniken an Bedeutung verloren . Aufgrund der Entwicklung der minimal-invasiven Chirurgie auch in Richtung " Weichteilendoskopie " interessierte es uns , ob die videoassistierte Technik dem perinealen Zugangsweg wieder neue Impulse fuer operative Massnahmen geben kann . Nach der experimentellen Entwicklung an der Leiche konnte die Technik erstmals erfolgreich klinische Anwendung finden . Methodik : Unsere Praeparationen wurden zunaechst an der Leiche erprobt und schliesslich bei einer 59 jaehrigen Patientin mit einer iatrogenen Rectumperforation erstmals klinisch vorgenommen . Von perineal wurde das Spatium retrorectale mit einem Dilatationsballonsystem aufgedehnt und anschliessend ein Pneumoextraperitoneum angelegt . Danach konnten die extraperitoneal gelegenen Strukturen des kleinen Beckens praepariert werden . Ergebnisse : Im Experiment wie bei der klinischen Durchfuehrung konnte eine hervorragende Uebersicht erreicht werden . Experimentell gelang die vollstaendige , zirkulaere Praeparation des Rectums . Ventral kamen Teile der Vagina , Prostata und Harnblase zur Darstellung . Lateral konnten die Paraproctien , Ureteren und Iliacalgefaesse praepariert werden . In der klinischen Anwendung gelang die Dilatation des Spatium retrorectale problemlos und es konnte unter Sicht gespuelt und drainiert werden . Postoperativ kam es zu keinen Komplikationen . Die Entlassung erfolgte am 17. postoperativen Tag . Schlussfolgerung : Die beschriebene Methode ist fuer den Einsatz am Patienten geeignet . Ausser der geschilderten Indikation ergeben sich noch weitere chirurgische Anwendungsmoeglichkeiten . Instructions: please typing these entity words according to sentence: Beckens, Techniken, Chirurgie, Weichteilendoskopie, Technik, Leiche, Technik, Methodik, Leiche, Beckens, Vagina, Prostata, Harnblase, Dilatation, Komplikationen, Methode, Patienten Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Grundlagen : Der dorsoposteriore bzw. perineale Zugang zu den bindegewebigen Raeumen des kleinen Beckens hat aufgrund verbesserter transabdomineller Techniken an Bedeutung verloren . Aufgrund der Entwicklung der minimal-invasiven Chirurgie auch in Richtung " Weichteilendoskopie " interessierte es uns , ob die videoassistierte Technik dem perinealen Zugangsweg wieder neue Impulse fuer operative Massnahmen geben kann . Nach der experimentellen Entwicklung an der Leiche konnte die Technik erstmals erfolgreich klinische Anwendung finden . Methodik : Unsere Praeparationen wurden zunaechst an der Leiche erprobt und schliesslich bei einer 59 jaehrigen Patientin mit einer iatrogenen Rectumperforation erstmals klinisch vorgenommen . Von perineal wurde das Spatium retrorectale mit einem Dilatationsballonsystem aufgedehnt und anschliessend ein Pneumoextraperitoneum angelegt . Danach konnten die extraperitoneal gelegenen Strukturen des kleinen Beckens praepariert werden . Ergebnisse : Im Experiment wie bei der klinischen Durchfuehrung konnte eine hervorragende Uebersicht erreicht werden . Experimentell gelang die vollstaendige , zirkulaere Praeparation des Rectums . Ventral kamen Teile der Vagina , Prostata und Harnblase zur Darstellung . Lateral konnten die Paraproctien , Ureteren und Iliacalgefaesse praepariert werden . In der klinischen Anwendung gelang die Dilatation des Spatium retrorectale problemlos und es konnte unter Sicht gespuelt und drainiert werden . Postoperativ kam es zu keinen Komplikationen . Die Entlassung erfolgte am 17. postoperativen Tag . Schlussfolgerung : Die beschriebene Methode ist fuer den Einsatz am Patienten geeignet . Ausser der geschilderten Indikation ergeben sich noch weitere chirurgische Anwendungsmoeglichkeiten .
[ "Zusammenfassung", ".", "Grundlagen", ":", "Der", "dorsoposteriore", "bzw", ".", "perineale", "Zugang", "zu", "den", "bindegewebigen", "Raeumen", "des", "kleinen", "Beckens", "hat", "aufgrund", "verbesserter", "transabdomineller", "Techniken", "an", "Bedeutung", "verloren", ".", "Aufgrund", "der", "Entwicklung", "der", "minimal", "-", "invasiven", "Chirurgie", "auch", "in", "Richtung", "\"", "Weichteilendoskopie", "\"", "interessierte", "es", "uns", ",", "ob", "die", "videoassistierte", "Technik", "dem", "perinealen", "Zugangsweg", "wieder", "neue", "Impulse", "fuer", "operative", "Massnahmen", "geben", "kann", ".", "Nach", "der", "experimentellen", "Entwicklung", "an", "der", "Leiche", "konnte", "die", "Technik", "erstmals", "erfolgreich", "klinische", "Anwendung", "finden", ".", "Methodik", ":", "Unsere", "Praeparationen", "wurden", "zunaechst", "an", "der", "Leiche", "erprobt", "und", "schliesslich", "bei", "einer", "59", "jaehrigen", "Patientin", "mit", "einer", "iatrogenen", "Rectumperforation", "erstmals", "klinisch", "vorgenommen", ".", "Von", "perineal", "wurde", "das", "Spatium", "retrorectale", "mit", "einem", "Dilatationsballonsystem", "aufgedehnt", "und", "anschliessend", "ein", "Pneumoextraperitoneum", "angelegt", ".", "Danach", "konnten", "die", "extraperitoneal", "gelegenen", "Strukturen", "des", "kleinen", "Beckens", "praepariert", "werden", ".", "Ergebnisse", ":", "Im", "Experiment", "wie", "bei", "der", "klinischen", "Durchfuehrung", "konnte", "eine", "hervorragende", "Uebersicht", "erreicht", "werden", ".", "Experimentell", "gelang", "die", "vollstaendige", ",", "zirkulaere", "Praeparation", "des", "Rectums", ".", "Ventral", "kamen", "Teile", "der", "Vagina", ",", "Prostata", "und", "Harnblase", "zur", "Darstellung", ".", "Lateral", "konnten", "die", "Paraproctien", ",", "Ureteren", "und", "Iliacalgefaesse", "praepariert", "werden", ".", "In", "der", "klinischen", "Anwendung", "gelang", "die", "Dilatation", "des", "Spatium", "retrorectale", "problemlos", "und", "es", "konnte", "unter", "Sicht", "gespuelt", "und", "drainiert", "werden", ".", "Postoperativ", "kam", "es", "zu", "keinen", "Komplikationen", ".", "Die", "Entlassung", "erfolgte", "am", "17", ".", "postoperativen", "Tag", ".", "Schlussfolgerung", ":", "Die", "beschriebene", "Methode", "ist", "fuer", "den", "Einsatz", "am", "Patienten", "geeignet", ".", "Ausser", "der", "geschilderten", "Indikation", "ergeben", "sich", "noch", "weitere", "chirurgische", "Anwendungsmoeglichkeiten", "." ]
[ "umlsterm" ]
Beckens, Techniken, Chirurgie, Weichteilendoskopie, Technik, Leiche, Technik, Methodik, Leiche, Beckens, Vagina, Prostata, Harnblase, Dilatation, Komplikationen, Methode, Patienten
DerChirurg.90700294.ger.abstr_task2
Sentence: Zusammenfassung . Grundlagen : Der dorsoposteriore bzw. perineale Zugang zu den bindegewebigen Raeumen des kleinen Beckens hat aufgrund verbesserter transabdomineller Techniken an Bedeutung verloren . Aufgrund der Entwicklung der minimal-invasiven Chirurgie auch in Richtung " Weichteilendoskopie " interessierte es uns , ob die videoassistierte Technik dem perinealen Zugangsweg wieder neue Impulse fuer operative Massnahmen geben kann . Nach der experimentellen Entwicklung an der Leiche konnte die Technik erstmals erfolgreich klinische Anwendung finden . Methodik : Unsere Praeparationen wurden zunaechst an der Leiche erprobt und schliesslich bei einer 59 jaehrigen Patientin mit einer iatrogenen Rectumperforation erstmals klinisch vorgenommen . Von perineal wurde das Spatium retrorectale mit einem Dilatationsballonsystem aufgedehnt und anschliessend ein Pneumoextraperitoneum angelegt . Danach konnten die extraperitoneal gelegenen Strukturen des kleinen Beckens praepariert werden . Ergebnisse : Im Experiment wie bei der klinischen Durchfuehrung konnte eine hervorragende Uebersicht erreicht werden . Experimentell gelang die vollstaendige , zirkulaere Praeparation des Rectums . Ventral kamen Teile der Vagina , Prostata und Harnblase zur Darstellung . Lateral konnten die Paraproctien , Ureteren und Iliacalgefaesse praepariert werden . In der klinischen Anwendung gelang die Dilatation des Spatium retrorectale problemlos und es konnte unter Sicht gespuelt und drainiert werden . Postoperativ kam es zu keinen Komplikationen . Die Entlassung erfolgte am 17. postoperativen Tag . Schlussfolgerung : Die beschriebene Methode ist fuer den Einsatz am Patienten geeignet . Ausser der geschilderten Indikation ergeben sich noch weitere chirurgische Anwendungsmoeglichkeiten . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Zusammenfassung . Grundlagen : Der dorsoposteriore bzw. perineale Zugang zu den bindegewebigen Raeumen des kleinen Beckens hat aufgrund verbesserter transabdomineller Techniken an Bedeutung verloren . Aufgrund der Entwicklung der minimal-invasiven Chirurgie auch in Richtung " Weichteilendoskopie " interessierte es uns , ob die videoassistierte Technik dem perinealen Zugangsweg wieder neue Impulse fuer operative Massnahmen geben kann . Nach der experimentellen Entwicklung an der Leiche konnte die Technik erstmals erfolgreich klinische Anwendung finden . Methodik : Unsere Praeparationen wurden zunaechst an der Leiche erprobt und schliesslich bei einer 59 jaehrigen Patientin mit einer iatrogenen Rectumperforation erstmals klinisch vorgenommen . Von perineal wurde das Spatium retrorectale mit einem Dilatationsballonsystem aufgedehnt und anschliessend ein Pneumoextraperitoneum angelegt . Danach konnten die extraperitoneal gelegenen Strukturen des kleinen Beckens praepariert werden . Ergebnisse : Im Experiment wie bei der klinischen Durchfuehrung konnte eine hervorragende Uebersicht erreicht werden . Experimentell gelang die vollstaendige , zirkulaere Praeparation des Rectums . Ventral kamen Teile der Vagina , Prostata und Harnblase zur Darstellung . Lateral konnten die Paraproctien , Ureteren und Iliacalgefaesse praepariert werden . In der klinischen Anwendung gelang die Dilatation des Spatium retrorectale problemlos und es konnte unter Sicht gespuelt und drainiert werden . Postoperativ kam es zu keinen Komplikationen . Die Entlassung erfolgte am 17. postoperativen Tag . Schlussfolgerung : Die beschriebene Methode ist fuer den Einsatz am Patienten geeignet . Ausser der geschilderten Indikation ergeben sich noch weitere chirurgische Anwendungsmoeglichkeiten .
[ "Zusammenfassung", ".", "Grundlagen", ":", "Der", "dorsoposteriore", "bzw", ".", "perineale", "Zugang", "zu", "den", "bindegewebigen", "Raeumen", "des", "kleinen", "Beckens", "hat", "aufgrund", "verbesserter", "transabdomineller", "Techniken", "an", "Bedeutung", "verloren", ".", "Aufgrund", "der", "Entwicklung", "der", "minimal", "-", "invasiven", "Chirurgie", "auch", "in", "Richtung", "\"", "Weichteilendoskopie", "\"", "interessierte", "es", "uns", ",", "ob", "die", "videoassistierte", "Technik", "dem", "perinealen", "Zugangsweg", "wieder", "neue", "Impulse", "fuer", "operative", "Massnahmen", "geben", "kann", ".", "Nach", "der", "experimentellen", "Entwicklung", "an", "der", "Leiche", "konnte", "die", "Technik", "erstmals", "erfolgreich", "klinische", "Anwendung", "finden", ".", "Methodik", ":", "Unsere", "Praeparationen", "wurden", "zunaechst", "an", "der", "Leiche", "erprobt", "und", "schliesslich", "bei", "einer", "59", "jaehrigen", "Patientin", "mit", "einer", "iatrogenen", "Rectumperforation", "erstmals", "klinisch", "vorgenommen", ".", "Von", "perineal", "wurde", "das", "Spatium", "retrorectale", "mit", "einem", "Dilatationsballonsystem", "aufgedehnt", "und", "anschliessend", "ein", "Pneumoextraperitoneum", "angelegt", ".", "Danach", "konnten", "die", "extraperitoneal", "gelegenen", "Strukturen", "des", "kleinen", "Beckens", "praepariert", "werden", ".", "Ergebnisse", ":", "Im", "Experiment", "wie", "bei", "der", "klinischen", "Durchfuehrung", "konnte", "eine", "hervorragende", "Uebersicht", "erreicht", "werden", ".", "Experimentell", "gelang", "die", "vollstaendige", ",", "zirkulaere", "Praeparation", "des", "Rectums", ".", "Ventral", "kamen", "Teile", "der", "Vagina", ",", "Prostata", "und", "Harnblase", "zur", "Darstellung", ".", "Lateral", "konnten", "die", "Paraproctien", ",", "Ureteren", "und", "Iliacalgefaesse", "praepariert", "werden", ".", "In", "der", "klinischen", "Anwendung", "gelang", "die", "Dilatation", "des", "Spatium", "retrorectale", "problemlos", "und", "es", "konnte", "unter", "Sicht", "gespuelt", "und", "drainiert", "werden", ".", "Postoperativ", "kam", "es", "zu", "keinen", "Komplikationen", ".", "Die", "Entlassung", "erfolgte", "am", "17", ".", "postoperativen", "Tag", ".", "Schlussfolgerung", ":", "Die", "beschriebene", "Methode", "ist", "fuer", "den", "Einsatz", "am", "Patienten", "geeignet", ".", "Ausser", "der", "geschilderten", "Indikation", "ergeben", "sich", "noch", "weitere", "chirurgische", "Anwendungsmoeglichkeiten", "." ]
[ "umlsterm" ]
Beschaeftigung is an umlsterm, Patienten is an umlsterm, Androgeneinsatz is an umlsterm, Virilisierung is an umlsterm, Stimme is an umlsterm, geschlechtsangleichenden is an umlsterm, maennlich is an umlsterm, Stimme is an umlsterm, Geschlechts is an umlsterm, Standards is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Stimme is an umlsterm, Zielgeschlecht is an umlsterm, maennliche is an umlsterm, Geschlecht is an umlsterm, weiblichen is an umlsterm, Zielgeschlecht is an umlsterm, Behandlung is an umlsterm, Transsexualismus is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Standards is an umlsterm, Fachgesellschaften is an umlsterm, Stimme is an umlsterm, Transsexualitaet is an umlsterm, Krankheit is an umlsterm, erwachsenden is an umlsterm, Krankenbehandlung is an umlsterm, Stimme is an umlsterm, Fachgesellschaften is an umlsterm, Behandlung is an umlsterm, Transsexualismus is an umlsterm, Leidensdruck is an umlsterm
HNO.90470556.ger.abstr_task0
Sentence: Die phoniatrische Beschaeftigung mit transsexuellen Patienten zielt auf deren Stimmprobleme . Beim Frau-zu-Mann-Transsexualismus kommt es durch den therapeutischen Androgeneinsatz zu einer Massenzunahme der Stimmlippen und damit zu einer in der Regel von den Betroffenen als ausreichend empfundenen Virilisierung der Stimme . Beim Mann-zu-Frau-Transsexualismus bleibt - zumeist bis zum Ende des geschlechtsangleichenden Behandlungsprozesses - eine subjektiv als maennlich empfundene Stimme als stigmatisierendes Merkmal des urspruenglichen koerperlichen Geschlechts bestehen . In diesen Faellen kann durch unterschiedliche operative Massnahmen ( Krikothyreoidopexie nach Isshiki oder Glottoplastik nach Wendler ) eine Erhoehung der mittleren Sprechstimmlage angestrebt werden . Derartige Massnahmen werden von den aktuellen Standards sexualmedizinischer Behandlungsempfehlungen noch nicht erfasst . Im Einzelfall kann z.B. zur Frage der Kostenuebernahme fuer eine stimmangleichende Behandlung eine phoniatrische Begutachtung erforderlich werden . Eine 51jaehrige Mann-zu-Frau-transsexuelle Patienten erhob vor einem Sozialgericht gegen ihre Krankenkasse Klage , da diese die Kostenuebernahme fuer eine stimmangleichende Operation verweigert hatte . Die Beweisfragen zielten auf die Stimmigkeit der aktuellen Stimme mit dem Zielgeschlecht , auf die therapeutischen Moeglichkeiten und wo diese angeboten werden , sowie auf die Nutzen-Risiko- und die Nutzen-Kosten-Relation im Falle der Klaegerin . Bei der phoniatrischen Untersuchung wurde ein fuer das urspruenglich maennliche Geschlecht " normaler " Befund erhoben . Dieser Befunde wurde als nicht stimmig mit dem weiblichen Zielgeschlecht bewertet . Die aktuellen Moeglichkeiten und Grenzen konservativer und operativer stimmangleichender Behandlungsformen wurden dargestellt und die Nutzen-Risiko- und die Nutzen-Kosten-Relation wurden auf der Basis der individuellen Abwaegung als guenstig eingeschaetzt . Das Gericht verurteilte die Krankenkasse zur Kostenuebernahme fuer die stimmangleichende Behandlung , das Urteil ist rechtskraeftig ( Sozialgericht Bayreuth S 6 KR 72/96 ) . Der Transsexualismus wird durch die gaengigen Krankheitsklassifikationssysteme erfasst , er ist eine Erkrankung im Sinne der Reichsversicherungsordnung ( RVO ) . Die Diagnostik und Therapie erfolgen nach den Standards wissenschaftlicher Fachgesellschaften , die jedoch den Komplex " Stimme " als wesentliches Geschlechtsspezifikum bisher noch nicht beruecksichtigen . Phoniatrische Leitlinien zur Stimmbehandlung bei Transsexuellen bestehen noch nicht . Die dadurch im Einzelfall offen verbleibenden Fragen muessen u.U. gutachterlich beantwortet werden . Im beschriebenen Begutachtungsfall betonte das Gericht die Anerkennung der Transsexualitaet als Krankheit und den daraus erwachsenden Anspruch auf Krankenbehandlung einschliesslich operativer Massnahmen , wovon die Stimme nicht ausgenommen werden duerfe , ohne dass jedoch aus der Entscheidung Rueckschluesse fuer weitere Verfahren gezogen werden koennten . Grundsaetzlich ist fuer die adaequate individuelle Indikationsstellung und Behandlungsdurchfuehrung sowie fuer die sachgerechte Begutachtung eine intensive Kooperation des Phoniaters mit dem Sexualmediziner unerlaesslich . Die wissenschaftlichen Fachgesellschaften sind aufgefordert , stimmangleichende Behandlungsmassnahmen als optionale Behandlung - auf der Basis einer individuellen phoniatrischen Stellungnahme - in den Behandlungskatalog beim Transsexualismus aufzunehmen . Dem ja nur bei entsprechendem Leidensdruck vorgebrachten Behandlungsansinnen ( Operationsbegehren ) wuerde damit besser genuegt als gegenwaertig , und unnoetige Gerichtsverfahren und Begutachtungen koennten vermieden werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die phoniatrische Beschaeftigung mit transsexuellen Patienten zielt auf deren Stimmprobleme . Beim Frau-zu-Mann-Transsexualismus kommt es durch den therapeutischen Androgeneinsatz zu einer Massenzunahme der Stimmlippen und damit zu einer in der Regel von den Betroffenen als ausreichend empfundenen Virilisierung der Stimme . Beim Mann-zu-Frau-Transsexualismus bleibt - zumeist bis zum Ende des geschlechtsangleichenden Behandlungsprozesses - eine subjektiv als maennlich empfundene Stimme als stigmatisierendes Merkmal des urspruenglichen koerperlichen Geschlechts bestehen . In diesen Faellen kann durch unterschiedliche operative Massnahmen ( Krikothyreoidopexie nach Isshiki oder Glottoplastik nach Wendler ) eine Erhoehung der mittleren Sprechstimmlage angestrebt werden . Derartige Massnahmen werden von den aktuellen Standards sexualmedizinischer Behandlungsempfehlungen noch nicht erfasst . Im Einzelfall kann z.B. zur Frage der Kostenuebernahme fuer eine stimmangleichende Behandlung eine phoniatrische Begutachtung erforderlich werden . Eine 51jaehrige Mann-zu-Frau-transsexuelle Patienten erhob vor einem Sozialgericht gegen ihre Krankenkasse Klage , da diese die Kostenuebernahme fuer eine stimmangleichende Operation verweigert hatte . Die Beweisfragen zielten auf die Stimmigkeit der aktuellen Stimme mit dem Zielgeschlecht , auf die therapeutischen Moeglichkeiten und wo diese angeboten werden , sowie auf die Nutzen-Risiko- und die Nutzen-Kosten-Relation im Falle der Klaegerin . Bei der phoniatrischen Untersuchung wurde ein fuer das urspruenglich maennliche Geschlecht " normaler " Befund erhoben . Dieser Befunde wurde als nicht stimmig mit dem weiblichen Zielgeschlecht bewertet . Die aktuellen Moeglichkeiten und Grenzen konservativer und operativer stimmangleichender Behandlungsformen wurden dargestellt und die Nutzen-Risiko- und die Nutzen-Kosten-Relation wurden auf der Basis der individuellen Abwaegung als guenstig eingeschaetzt . Das Gericht verurteilte die Krankenkasse zur Kostenuebernahme fuer die stimmangleichende Behandlung , das Urteil ist rechtskraeftig ( Sozialgericht Bayreuth S 6 KR 72/96 ) . Der Transsexualismus wird durch die gaengigen Krankheitsklassifikationssysteme erfasst , er ist eine Erkrankung im Sinne der Reichsversicherungsordnung ( RVO ) . Die Diagnostik und Therapie erfolgen nach den Standards wissenschaftlicher Fachgesellschaften , die jedoch den Komplex " Stimme " als wesentliches Geschlechtsspezifikum bisher noch nicht beruecksichtigen . Phoniatrische Leitlinien zur Stimmbehandlung bei Transsexuellen bestehen noch nicht . Die dadurch im Einzelfall offen verbleibenden Fragen muessen u.U. gutachterlich beantwortet werden . Im beschriebenen Begutachtungsfall betonte das Gericht die Anerkennung der Transsexualitaet als Krankheit und den daraus erwachsenden Anspruch auf Krankenbehandlung einschliesslich operativer Massnahmen , wovon die Stimme nicht ausgenommen werden duerfe , ohne dass jedoch aus der Entscheidung Rueckschluesse fuer weitere Verfahren gezogen werden koennten . Grundsaetzlich ist fuer die adaequate individuelle Indikationsstellung und Behandlungsdurchfuehrung sowie fuer die sachgerechte Begutachtung eine intensive Kooperation des Phoniaters mit dem Sexualmediziner unerlaesslich . Die wissenschaftlichen Fachgesellschaften sind aufgefordert , stimmangleichende Behandlungsmassnahmen als optionale Behandlung - auf der Basis einer individuellen phoniatrischen Stellungnahme - in den Behandlungskatalog beim Transsexualismus aufzunehmen . Dem ja nur bei entsprechendem Leidensdruck vorgebrachten Behandlungsansinnen ( Operationsbegehren ) wuerde damit besser genuegt als gegenwaertig , und unnoetige Gerichtsverfahren und Begutachtungen koennten vermieden werden .
[ "Die", "phoniatrische", "Beschaeftigung", "mit", "transsexuellen", "Patienten", "zielt", "auf", "deren", "Stimmprobleme", ".", "Beim", "Frau", "-", "zu", "-", "Mann", "-", "Transsexualismus", "kommt", "es", "durch", "den", "therapeutischen", "Androgeneinsatz", "zu", "einer", "Massenzunahme", "der", "Stimmlippen", "und", "damit", "zu", "einer", "in", "der", "Regel", "von", "den", "Betroffenen", "als", "ausreichend", "empfundenen", "Virilisierung", "der", "Stimme", ".", "Beim", "Mann", "-", "zu", "-", "Frau", "-", "Transsexualismus", "bleibt", "-", "zumeist", "bis", "zum", "Ende", "des", "geschlechtsangleichenden", "Behandlungsprozesses", "-", "eine", "subjektiv", "als", "maennlich", "empfundene", "Stimme", "als", "stigmatisierendes", "Merkmal", "des", "urspruenglichen", "koerperlichen", "Geschlechts", "bestehen", ".", "In", "diesen", "Faellen", "kann", "durch", "unterschiedliche", "operative", "Massnahmen", "(", "Krikothyreoidopexie", "nach", "Isshiki", "oder", "Glottoplastik", "nach", "Wendler", ")", "eine", "Erhoehung", "der", "mittleren", "Sprechstimmlage", "angestrebt", "werden", ".", "Derartige", "Massnahmen", "werden", "von", "den", "aktuellen", "Standards", "sexualmedizinischer", "Behandlungsempfehlungen", "noch", "nicht", "erfasst", ".", "Im", "Einzelfall", "kann", "z.", "B.", "zur", "Frage", "der", "Kostenuebernahme", "fuer", "eine", "stimmangleichende", "Behandlung", "eine", "phoniatrische", "Begutachtung", "erforderlich", "werden", ".", "Eine", "51jaehrige", "Mann", "-", "zu", "-", "Frau", "-", "transsexuelle", "Patienten", "erhob", "vor", "einem", "Sozialgericht", "gegen", "ihre", "Krankenkasse", "Klage", ",", "da", "diese", "die", "Kostenuebernahme", "fuer", "eine", "stimmangleichende", "Operation", "verweigert", "hatte", ".", "Die", "Beweisfragen", "zielten", "auf", "die", "Stimmigkeit", "der", "aktuellen", "Stimme", "mit", "dem", "Zielgeschlecht", ",", "auf", "die", "therapeutischen", "Moeglichkeiten", "und", "wo", "diese", "angeboten", "werden", ",", "sowie", "auf", "die", "Nutzen", "-", "Risiko-", "und", "die", "Nutzen", "-", "Kosten", "-", "Relation", "im", "Falle", "der", "Klaegerin", ".", "Bei", "der", "phoniatrischen", "Untersuchung", "wurde", "ein", "fuer", "das", "urspruenglich", "maennliche", "Geschlecht", "\"", "normaler", "\"", "Befund", "erhoben", ".", "Dieser", "Befunde", "wurde", "als", "nicht", "stimmig", "mit", "dem", "weiblichen", "Zielgeschlecht", "bewertet", ".", "Die", "aktuellen", "Moeglichkeiten", "und", "Grenzen", "konservativer", "und", "operativer", "stimmangleichender", "Behandlungsformen", "wurden", "dargestellt", "und", "die", "Nutzen", "-", "Risiko-", "und", "die", "Nutzen", "-", "Kosten", "-", "Relation", "wurden", "auf", "der", "Basis", "der", "individuellen", "Abwaegung", "als", "guenstig", "eingeschaetzt", ".", "Das", "Gericht", "verurteilte", "die", "Krankenkasse", "zur", "Kostenuebernahme", "fuer", "die", "stimmangleichende", "Behandlung", ",", "das", "Urteil", "ist", "rechtskraeftig", "(", "Sozialgericht", "Bayreuth", "S", "6", "KR", "72/96", ")", ".", "Der", "Transsexualismus", "wird", "durch", "die", "gaengigen", "Krankheitsklassifikationssysteme", "erfasst", ",", "er", "ist", "eine", "Erkrankung", "im", "Sinne", "der", "Reichsversicherungsordnung", "(", "RVO", ")", ".", "Die", "Diagnostik", "und", "Therapie", "erfolgen", "nach", "den", "Standards", "wissenschaftlicher", "Fachgesellschaften", ",", "die", "jedoch", "den", "Komplex", "\"", "Stimme", "\"", "als", "wesentliches", "Geschlechtsspezifikum", "bisher", "noch", "nicht", "beruecksichtigen", ".", "Phoniatrische", "Leitlinien", "zur", "Stimmbehandlung", "bei", "Transsexuellen", "bestehen", "noch", "nicht", ".", "Die", "dadurch", "im", "Einzelfall", "offen", "verbleibenden", "Fragen", "muessen", "u.", "U.", "gutachterlich", "beantwortet", "werden", ".", "Im", "beschriebenen", "Begutachtungsfall", "betonte", "das", "Gericht", "die", "Anerkennung", "der", "Transsexualitaet", "als", "Krankheit", "und", "den", "daraus", "erwachsenden", "Anspruch", "auf", "Krankenbehandlung", "einschliesslich", "operativer", "Massnahmen", ",", "wovon", "die", "Stimme", "nicht", "ausgenommen", "werden", "duerfe", ",", "ohne", "dass", "jedoch", "aus", "der", "Entscheidung", "Rueckschluesse", "fuer", "weitere", "Verfahren", "gezogen", "werden", "koennten", ".", "Grundsaetzlich", "ist", "fuer", "die", "adaequate", "individuelle", "Indikationsstellung", "und", "Behandlungsdurchfuehrung", "sowie", "fuer", "die", "sachgerechte", "Begutachtung", "eine", "intensive", "Kooperation", "des", "Phoniaters", "mit", "dem", "Sexualmediziner", "unerlaesslich", ".", "Die", "wissenschaftlichen", "Fachgesellschaften", "sind", "aufgefordert", ",", "stimmangleichende", "Behandlungsmassnahmen", "als", "optionale", "Behandlung", "-", "auf", "der", "Basis", "einer", "individuellen", "phoniatrischen", "Stellungnahme", "-", "in", "den", "Behandlungskatalog", "beim", "Transsexualismus", "aufzunehmen", ".", "Dem", "ja", "nur", "bei", "entsprechendem", "Leidensdruck", "vorgebrachten", "Behandlungsansinnen", "(", "Operationsbegehren", ")", "wuerde", "damit", "besser", "genuegt", "als", "gegenwaertig", ",", "und", "unnoetige", "Gerichtsverfahren", "und", "Begutachtungen", "koennten", "vermieden", "werden", "." ]
[ "umlsterm" ]
Beschaeftigung is an umlsterm, Patienten is an umlsterm, Androgeneinsatz is an umlsterm, Virilisierung is an umlsterm, Stimme is an umlsterm, geschlechtsangleichenden is an umlsterm, maennlich is an umlsterm, Stimme is an umlsterm, Geschlechts is an umlsterm, Standards is an umlsterm, Behandlung is an umlsterm, Patienten is an umlsterm, Stimme is an umlsterm, Zielgeschlecht is an umlsterm, maennliche is an umlsterm, Geschlecht is an umlsterm, weiblichen is an umlsterm, Zielgeschlecht is an umlsterm, Behandlung is an umlsterm, Transsexualismus is an umlsterm, Diagnostik is an umlsterm, Therapie is an umlsterm, Standards is an umlsterm, Fachgesellschaften is an umlsterm, Stimme is an umlsterm, Transsexualitaet is an umlsterm, Krankheit is an umlsterm, erwachsenden is an umlsterm, Krankenbehandlung is an umlsterm, Stimme is an umlsterm, Fachgesellschaften is an umlsterm, Behandlung is an umlsterm, Transsexualismus is an umlsterm, Leidensdruck is an umlsterm
HNO.90470556.ger.abstr_task1
Sentence: Die phoniatrische Beschaeftigung mit transsexuellen Patienten zielt auf deren Stimmprobleme . Beim Frau-zu-Mann-Transsexualismus kommt es durch den therapeutischen Androgeneinsatz zu einer Massenzunahme der Stimmlippen und damit zu einer in der Regel von den Betroffenen als ausreichend empfundenen Virilisierung der Stimme . Beim Mann-zu-Frau-Transsexualismus bleibt - zumeist bis zum Ende des geschlechtsangleichenden Behandlungsprozesses - eine subjektiv als maennlich empfundene Stimme als stigmatisierendes Merkmal des urspruenglichen koerperlichen Geschlechts bestehen . In diesen Faellen kann durch unterschiedliche operative Massnahmen ( Krikothyreoidopexie nach Isshiki oder Glottoplastik nach Wendler ) eine Erhoehung der mittleren Sprechstimmlage angestrebt werden . Derartige Massnahmen werden von den aktuellen Standards sexualmedizinischer Behandlungsempfehlungen noch nicht erfasst . Im Einzelfall kann z.B. zur Frage der Kostenuebernahme fuer eine stimmangleichende Behandlung eine phoniatrische Begutachtung erforderlich werden . Eine 51jaehrige Mann-zu-Frau-transsexuelle Patienten erhob vor einem Sozialgericht gegen ihre Krankenkasse Klage , da diese die Kostenuebernahme fuer eine stimmangleichende Operation verweigert hatte . Die Beweisfragen zielten auf die Stimmigkeit der aktuellen Stimme mit dem Zielgeschlecht , auf die therapeutischen Moeglichkeiten und wo diese angeboten werden , sowie auf die Nutzen-Risiko- und die Nutzen-Kosten-Relation im Falle der Klaegerin . Bei der phoniatrischen Untersuchung wurde ein fuer das urspruenglich maennliche Geschlecht " normaler " Befund erhoben . Dieser Befunde wurde als nicht stimmig mit dem weiblichen Zielgeschlecht bewertet . Die aktuellen Moeglichkeiten und Grenzen konservativer und operativer stimmangleichender Behandlungsformen wurden dargestellt und die Nutzen-Risiko- und die Nutzen-Kosten-Relation wurden auf der Basis der individuellen Abwaegung als guenstig eingeschaetzt . Das Gericht verurteilte die Krankenkasse zur Kostenuebernahme fuer die stimmangleichende Behandlung , das Urteil ist rechtskraeftig ( Sozialgericht Bayreuth S 6 KR 72/96 ) . Der Transsexualismus wird durch die gaengigen Krankheitsklassifikationssysteme erfasst , er ist eine Erkrankung im Sinne der Reichsversicherungsordnung ( RVO ) . Die Diagnostik und Therapie erfolgen nach den Standards wissenschaftlicher Fachgesellschaften , die jedoch den Komplex " Stimme " als wesentliches Geschlechtsspezifikum bisher noch nicht beruecksichtigen . Phoniatrische Leitlinien zur Stimmbehandlung bei Transsexuellen bestehen noch nicht . Die dadurch im Einzelfall offen verbleibenden Fragen muessen u.U. gutachterlich beantwortet werden . Im beschriebenen Begutachtungsfall betonte das Gericht die Anerkennung der Transsexualitaet als Krankheit und den daraus erwachsenden Anspruch auf Krankenbehandlung einschliesslich operativer Massnahmen , wovon die Stimme nicht ausgenommen werden duerfe , ohne dass jedoch aus der Entscheidung Rueckschluesse fuer weitere Verfahren gezogen werden koennten . Grundsaetzlich ist fuer die adaequate individuelle Indikationsstellung und Behandlungsdurchfuehrung sowie fuer die sachgerechte Begutachtung eine intensive Kooperation des Phoniaters mit dem Sexualmediziner unerlaesslich . Die wissenschaftlichen Fachgesellschaften sind aufgefordert , stimmangleichende Behandlungsmassnahmen als optionale Behandlung - auf der Basis einer individuellen phoniatrischen Stellungnahme - in den Behandlungskatalog beim Transsexualismus aufzunehmen . Dem ja nur bei entsprechendem Leidensdruck vorgebrachten Behandlungsansinnen ( Operationsbegehren ) wuerde damit besser genuegt als gegenwaertig , und unnoetige Gerichtsverfahren und Begutachtungen koennten vermieden werden . Instructions: please typing these entity words according to sentence: Beschaeftigung, Patienten, Androgeneinsatz, Virilisierung, Stimme, geschlechtsangleichenden, maennlich, Stimme, Geschlechts, Standards, Behandlung, Patienten, Stimme, Zielgeschlecht, maennliche, Geschlecht, weiblichen, Zielgeschlecht, Behandlung, Transsexualismus, Diagnostik, Therapie, Standards, Fachgesellschaften, Stimme, Transsexualitaet, Krankheit, erwachsenden, Krankenbehandlung, Stimme, Fachgesellschaften, Behandlung, Transsexualismus, Leidensdruck Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die phoniatrische Beschaeftigung mit transsexuellen Patienten zielt auf deren Stimmprobleme . Beim Frau-zu-Mann-Transsexualismus kommt es durch den therapeutischen Androgeneinsatz zu einer Massenzunahme der Stimmlippen und damit zu einer in der Regel von den Betroffenen als ausreichend empfundenen Virilisierung der Stimme . Beim Mann-zu-Frau-Transsexualismus bleibt - zumeist bis zum Ende des geschlechtsangleichenden Behandlungsprozesses - eine subjektiv als maennlich empfundene Stimme als stigmatisierendes Merkmal des urspruenglichen koerperlichen Geschlechts bestehen . In diesen Faellen kann durch unterschiedliche operative Massnahmen ( Krikothyreoidopexie nach Isshiki oder Glottoplastik nach Wendler ) eine Erhoehung der mittleren Sprechstimmlage angestrebt werden . Derartige Massnahmen werden von den aktuellen Standards sexualmedizinischer Behandlungsempfehlungen noch nicht erfasst . Im Einzelfall kann z.B. zur Frage der Kostenuebernahme fuer eine stimmangleichende Behandlung eine phoniatrische Begutachtung erforderlich werden . Eine 51jaehrige Mann-zu-Frau-transsexuelle Patienten erhob vor einem Sozialgericht gegen ihre Krankenkasse Klage , da diese die Kostenuebernahme fuer eine stimmangleichende Operation verweigert hatte . Die Beweisfragen zielten auf die Stimmigkeit der aktuellen Stimme mit dem Zielgeschlecht , auf die therapeutischen Moeglichkeiten und wo diese angeboten werden , sowie auf die Nutzen-Risiko- und die Nutzen-Kosten-Relation im Falle der Klaegerin . Bei der phoniatrischen Untersuchung wurde ein fuer das urspruenglich maennliche Geschlecht " normaler " Befund erhoben . Dieser Befunde wurde als nicht stimmig mit dem weiblichen Zielgeschlecht bewertet . Die aktuellen Moeglichkeiten und Grenzen konservativer und operativer stimmangleichender Behandlungsformen wurden dargestellt und die Nutzen-Risiko- und die Nutzen-Kosten-Relation wurden auf der Basis der individuellen Abwaegung als guenstig eingeschaetzt . Das Gericht verurteilte die Krankenkasse zur Kostenuebernahme fuer die stimmangleichende Behandlung , das Urteil ist rechtskraeftig ( Sozialgericht Bayreuth S 6 KR 72/96 ) . Der Transsexualismus wird durch die gaengigen Krankheitsklassifikationssysteme erfasst , er ist eine Erkrankung im Sinne der Reichsversicherungsordnung ( RVO ) . Die Diagnostik und Therapie erfolgen nach den Standards wissenschaftlicher Fachgesellschaften , die jedoch den Komplex " Stimme " als wesentliches Geschlechtsspezifikum bisher noch nicht beruecksichtigen . Phoniatrische Leitlinien zur Stimmbehandlung bei Transsexuellen bestehen noch nicht . Die dadurch im Einzelfall offen verbleibenden Fragen muessen u.U. gutachterlich beantwortet werden . Im beschriebenen Begutachtungsfall betonte das Gericht die Anerkennung der Transsexualitaet als Krankheit und den daraus erwachsenden Anspruch auf Krankenbehandlung einschliesslich operativer Massnahmen , wovon die Stimme nicht ausgenommen werden duerfe , ohne dass jedoch aus der Entscheidung Rueckschluesse fuer weitere Verfahren gezogen werden koennten . Grundsaetzlich ist fuer die adaequate individuelle Indikationsstellung und Behandlungsdurchfuehrung sowie fuer die sachgerechte Begutachtung eine intensive Kooperation des Phoniaters mit dem Sexualmediziner unerlaesslich . Die wissenschaftlichen Fachgesellschaften sind aufgefordert , stimmangleichende Behandlungsmassnahmen als optionale Behandlung - auf der Basis einer individuellen phoniatrischen Stellungnahme - in den Behandlungskatalog beim Transsexualismus aufzunehmen . Dem ja nur bei entsprechendem Leidensdruck vorgebrachten Behandlungsansinnen ( Operationsbegehren ) wuerde damit besser genuegt als gegenwaertig , und unnoetige Gerichtsverfahren und Begutachtungen koennten vermieden werden .
[ "Die", "phoniatrische", "Beschaeftigung", "mit", "transsexuellen", "Patienten", "zielt", "auf", "deren", "Stimmprobleme", ".", "Beim", "Frau", "-", "zu", "-", "Mann", "-", "Transsexualismus", "kommt", "es", "durch", "den", "therapeutischen", "Androgeneinsatz", "zu", "einer", "Massenzunahme", "der", "Stimmlippen", "und", "damit", "zu", "einer", "in", "der", "Regel", "von", "den", "Betroffenen", "als", "ausreichend", "empfundenen", "Virilisierung", "der", "Stimme", ".", "Beim", "Mann", "-", "zu", "-", "Frau", "-", "Transsexualismus", "bleibt", "-", "zumeist", "bis", "zum", "Ende", "des", "geschlechtsangleichenden", "Behandlungsprozesses", "-", "eine", "subjektiv", "als", "maennlich", "empfundene", "Stimme", "als", "stigmatisierendes", "Merkmal", "des", "urspruenglichen", "koerperlichen", "Geschlechts", "bestehen", ".", "In", "diesen", "Faellen", "kann", "durch", "unterschiedliche", "operative", "Massnahmen", "(", "Krikothyreoidopexie", "nach", "Isshiki", "oder", "Glottoplastik", "nach", "Wendler", ")", "eine", "Erhoehung", "der", "mittleren", "Sprechstimmlage", "angestrebt", "werden", ".", "Derartige", "Massnahmen", "werden", "von", "den", "aktuellen", "Standards", "sexualmedizinischer", "Behandlungsempfehlungen", "noch", "nicht", "erfasst", ".", "Im", "Einzelfall", "kann", "z.", "B.", "zur", "Frage", "der", "Kostenuebernahme", "fuer", "eine", "stimmangleichende", "Behandlung", "eine", "phoniatrische", "Begutachtung", "erforderlich", "werden", ".", "Eine", "51jaehrige", "Mann", "-", "zu", "-", "Frau", "-", "transsexuelle", "Patienten", "erhob", "vor", "einem", "Sozialgericht", "gegen", "ihre", "Krankenkasse", "Klage", ",", "da", "diese", "die", "Kostenuebernahme", "fuer", "eine", "stimmangleichende", "Operation", "verweigert", "hatte", ".", "Die", "Beweisfragen", "zielten", "auf", "die", "Stimmigkeit", "der", "aktuellen", "Stimme", "mit", "dem", "Zielgeschlecht", ",", "auf", "die", "therapeutischen", "Moeglichkeiten", "und", "wo", "diese", "angeboten", "werden", ",", "sowie", "auf", "die", "Nutzen", "-", "Risiko-", "und", "die", "Nutzen", "-", "Kosten", "-", "Relation", "im", "Falle", "der", "Klaegerin", ".", "Bei", "der", "phoniatrischen", "Untersuchung", "wurde", "ein", "fuer", "das", "urspruenglich", "maennliche", "Geschlecht", "\"", "normaler", "\"", "Befund", "erhoben", ".", "Dieser", "Befunde", "wurde", "als", "nicht", "stimmig", "mit", "dem", "weiblichen", "Zielgeschlecht", "bewertet", ".", "Die", "aktuellen", "Moeglichkeiten", "und", "Grenzen", "konservativer", "und", "operativer", "stimmangleichender", "Behandlungsformen", "wurden", "dargestellt", "und", "die", "Nutzen", "-", "Risiko-", "und", "die", "Nutzen", "-", "Kosten", "-", "Relation", "wurden", "auf", "der", "Basis", "der", "individuellen", "Abwaegung", "als", "guenstig", "eingeschaetzt", ".", "Das", "Gericht", "verurteilte", "die", "Krankenkasse", "zur", "Kostenuebernahme", "fuer", "die", "stimmangleichende", "Behandlung", ",", "das", "Urteil", "ist", "rechtskraeftig", "(", "Sozialgericht", "Bayreuth", "S", "6", "KR", "72/96", ")", ".", "Der", "Transsexualismus", "wird", "durch", "die", "gaengigen", "Krankheitsklassifikationssysteme", "erfasst", ",", "er", "ist", "eine", "Erkrankung", "im", "Sinne", "der", "Reichsversicherungsordnung", "(", "RVO", ")", ".", "Die", "Diagnostik", "und", "Therapie", "erfolgen", "nach", "den", "Standards", "wissenschaftlicher", "Fachgesellschaften", ",", "die", "jedoch", "den", "Komplex", "\"", "Stimme", "\"", "als", "wesentliches", "Geschlechtsspezifikum", "bisher", "noch", "nicht", "beruecksichtigen", ".", "Phoniatrische", "Leitlinien", "zur", "Stimmbehandlung", "bei", "Transsexuellen", "bestehen", "noch", "nicht", ".", "Die", "dadurch", "im", "Einzelfall", "offen", "verbleibenden", "Fragen", "muessen", "u.", "U.", "gutachterlich", "beantwortet", "werden", ".", "Im", "beschriebenen", "Begutachtungsfall", "betonte", "das", "Gericht", "die", "Anerkennung", "der", "Transsexualitaet", "als", "Krankheit", "und", "den", "daraus", "erwachsenden", "Anspruch", "auf", "Krankenbehandlung", "einschliesslich", "operativer", "Massnahmen", ",", "wovon", "die", "Stimme", "nicht", "ausgenommen", "werden", "duerfe", ",", "ohne", "dass", "jedoch", "aus", "der", "Entscheidung", "Rueckschluesse", "fuer", "weitere", "Verfahren", "gezogen", "werden", "koennten", ".", "Grundsaetzlich", "ist", "fuer", "die", "adaequate", "individuelle", "Indikationsstellung", "und", "Behandlungsdurchfuehrung", "sowie", "fuer", "die", "sachgerechte", "Begutachtung", "eine", "intensive", "Kooperation", "des", "Phoniaters", "mit", "dem", "Sexualmediziner", "unerlaesslich", ".", "Die", "wissenschaftlichen", "Fachgesellschaften", "sind", "aufgefordert", ",", "stimmangleichende", "Behandlungsmassnahmen", "als", "optionale", "Behandlung", "-", "auf", "der", "Basis", "einer", "individuellen", "phoniatrischen", "Stellungnahme", "-", "in", "den", "Behandlungskatalog", "beim", "Transsexualismus", "aufzunehmen", ".", "Dem", "ja", "nur", "bei", "entsprechendem", "Leidensdruck", "vorgebrachten", "Behandlungsansinnen", "(", "Operationsbegehren", ")", "wuerde", "damit", "besser", "genuegt", "als", "gegenwaertig", ",", "und", "unnoetige", "Gerichtsverfahren", "und", "Begutachtungen", "koennten", "vermieden", "werden", "." ]
[ "umlsterm" ]
Beschaeftigung, Patienten, Androgeneinsatz, Virilisierung, Stimme, geschlechtsangleichenden, maennlich, Stimme, Geschlechts, Standards, Behandlung, Patienten, Stimme, Zielgeschlecht, maennliche, Geschlecht, weiblichen, Zielgeschlecht, Behandlung, Transsexualismus, Diagnostik, Therapie, Standards, Fachgesellschaften, Stimme, Transsexualitaet, Krankheit, erwachsenden, Krankenbehandlung, Stimme, Fachgesellschaften, Behandlung, Transsexualismus, Leidensdruck
HNO.90470556.ger.abstr_task2
Sentence: Die phoniatrische Beschaeftigung mit transsexuellen Patienten zielt auf deren Stimmprobleme . Beim Frau-zu-Mann-Transsexualismus kommt es durch den therapeutischen Androgeneinsatz zu einer Massenzunahme der Stimmlippen und damit zu einer in der Regel von den Betroffenen als ausreichend empfundenen Virilisierung der Stimme . Beim Mann-zu-Frau-Transsexualismus bleibt - zumeist bis zum Ende des geschlechtsangleichenden Behandlungsprozesses - eine subjektiv als maennlich empfundene Stimme als stigmatisierendes Merkmal des urspruenglichen koerperlichen Geschlechts bestehen . In diesen Faellen kann durch unterschiedliche operative Massnahmen ( Krikothyreoidopexie nach Isshiki oder Glottoplastik nach Wendler ) eine Erhoehung der mittleren Sprechstimmlage angestrebt werden . Derartige Massnahmen werden von den aktuellen Standards sexualmedizinischer Behandlungsempfehlungen noch nicht erfasst . Im Einzelfall kann z.B. zur Frage der Kostenuebernahme fuer eine stimmangleichende Behandlung eine phoniatrische Begutachtung erforderlich werden . Eine 51jaehrige Mann-zu-Frau-transsexuelle Patienten erhob vor einem Sozialgericht gegen ihre Krankenkasse Klage , da diese die Kostenuebernahme fuer eine stimmangleichende Operation verweigert hatte . Die Beweisfragen zielten auf die Stimmigkeit der aktuellen Stimme mit dem Zielgeschlecht , auf die therapeutischen Moeglichkeiten und wo diese angeboten werden , sowie auf die Nutzen-Risiko- und die Nutzen-Kosten-Relation im Falle der Klaegerin . Bei der phoniatrischen Untersuchung wurde ein fuer das urspruenglich maennliche Geschlecht " normaler " Befund erhoben . Dieser Befunde wurde als nicht stimmig mit dem weiblichen Zielgeschlecht bewertet . Die aktuellen Moeglichkeiten und Grenzen konservativer und operativer stimmangleichender Behandlungsformen wurden dargestellt und die Nutzen-Risiko- und die Nutzen-Kosten-Relation wurden auf der Basis der individuellen Abwaegung als guenstig eingeschaetzt . Das Gericht verurteilte die Krankenkasse zur Kostenuebernahme fuer die stimmangleichende Behandlung , das Urteil ist rechtskraeftig ( Sozialgericht Bayreuth S 6 KR 72/96 ) . Der Transsexualismus wird durch die gaengigen Krankheitsklassifikationssysteme erfasst , er ist eine Erkrankung im Sinne der Reichsversicherungsordnung ( RVO ) . Die Diagnostik und Therapie erfolgen nach den Standards wissenschaftlicher Fachgesellschaften , die jedoch den Komplex " Stimme " als wesentliches Geschlechtsspezifikum bisher noch nicht beruecksichtigen . Phoniatrische Leitlinien zur Stimmbehandlung bei Transsexuellen bestehen noch nicht . Die dadurch im Einzelfall offen verbleibenden Fragen muessen u.U. gutachterlich beantwortet werden . Im beschriebenen Begutachtungsfall betonte das Gericht die Anerkennung der Transsexualitaet als Krankheit und den daraus erwachsenden Anspruch auf Krankenbehandlung einschliesslich operativer Massnahmen , wovon die Stimme nicht ausgenommen werden duerfe , ohne dass jedoch aus der Entscheidung Rueckschluesse fuer weitere Verfahren gezogen werden koennten . Grundsaetzlich ist fuer die adaequate individuelle Indikationsstellung und Behandlungsdurchfuehrung sowie fuer die sachgerechte Begutachtung eine intensive Kooperation des Phoniaters mit dem Sexualmediziner unerlaesslich . Die wissenschaftlichen Fachgesellschaften sind aufgefordert , stimmangleichende Behandlungsmassnahmen als optionale Behandlung - auf der Basis einer individuellen phoniatrischen Stellungnahme - in den Behandlungskatalog beim Transsexualismus aufzunehmen . Dem ja nur bei entsprechendem Leidensdruck vorgebrachten Behandlungsansinnen ( Operationsbegehren ) wuerde damit besser genuegt als gegenwaertig , und unnoetige Gerichtsverfahren und Begutachtungen koennten vermieden werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die phoniatrische Beschaeftigung mit transsexuellen Patienten zielt auf deren Stimmprobleme . Beim Frau-zu-Mann-Transsexualismus kommt es durch den therapeutischen Androgeneinsatz zu einer Massenzunahme der Stimmlippen und damit zu einer in der Regel von den Betroffenen als ausreichend empfundenen Virilisierung der Stimme . Beim Mann-zu-Frau-Transsexualismus bleibt - zumeist bis zum Ende des geschlechtsangleichenden Behandlungsprozesses - eine subjektiv als maennlich empfundene Stimme als stigmatisierendes Merkmal des urspruenglichen koerperlichen Geschlechts bestehen . In diesen Faellen kann durch unterschiedliche operative Massnahmen ( Krikothyreoidopexie nach Isshiki oder Glottoplastik nach Wendler ) eine Erhoehung der mittleren Sprechstimmlage angestrebt werden . Derartige Massnahmen werden von den aktuellen Standards sexualmedizinischer Behandlungsempfehlungen noch nicht erfasst . Im Einzelfall kann z.B. zur Frage der Kostenuebernahme fuer eine stimmangleichende Behandlung eine phoniatrische Begutachtung erforderlich werden . Eine 51jaehrige Mann-zu-Frau-transsexuelle Patienten erhob vor einem Sozialgericht gegen ihre Krankenkasse Klage , da diese die Kostenuebernahme fuer eine stimmangleichende Operation verweigert hatte . Die Beweisfragen zielten auf die Stimmigkeit der aktuellen Stimme mit dem Zielgeschlecht , auf die therapeutischen Moeglichkeiten und wo diese angeboten werden , sowie auf die Nutzen-Risiko- und die Nutzen-Kosten-Relation im Falle der Klaegerin . Bei der phoniatrischen Untersuchung wurde ein fuer das urspruenglich maennliche Geschlecht " normaler " Befund erhoben . Dieser Befunde wurde als nicht stimmig mit dem weiblichen Zielgeschlecht bewertet . Die aktuellen Moeglichkeiten und Grenzen konservativer und operativer stimmangleichender Behandlungsformen wurden dargestellt und die Nutzen-Risiko- und die Nutzen-Kosten-Relation wurden auf der Basis der individuellen Abwaegung als guenstig eingeschaetzt . Das Gericht verurteilte die Krankenkasse zur Kostenuebernahme fuer die stimmangleichende Behandlung , das Urteil ist rechtskraeftig ( Sozialgericht Bayreuth S 6 KR 72/96 ) . Der Transsexualismus wird durch die gaengigen Krankheitsklassifikationssysteme erfasst , er ist eine Erkrankung im Sinne der Reichsversicherungsordnung ( RVO ) . Die Diagnostik und Therapie erfolgen nach den Standards wissenschaftlicher Fachgesellschaften , die jedoch den Komplex " Stimme " als wesentliches Geschlechtsspezifikum bisher noch nicht beruecksichtigen . Phoniatrische Leitlinien zur Stimmbehandlung bei Transsexuellen bestehen noch nicht . Die dadurch im Einzelfall offen verbleibenden Fragen muessen u.U. gutachterlich beantwortet werden . Im beschriebenen Begutachtungsfall betonte das Gericht die Anerkennung der Transsexualitaet als Krankheit und den daraus erwachsenden Anspruch auf Krankenbehandlung einschliesslich operativer Massnahmen , wovon die Stimme nicht ausgenommen werden duerfe , ohne dass jedoch aus der Entscheidung Rueckschluesse fuer weitere Verfahren gezogen werden koennten . Grundsaetzlich ist fuer die adaequate individuelle Indikationsstellung und Behandlungsdurchfuehrung sowie fuer die sachgerechte Begutachtung eine intensive Kooperation des Phoniaters mit dem Sexualmediziner unerlaesslich . Die wissenschaftlichen Fachgesellschaften sind aufgefordert , stimmangleichende Behandlungsmassnahmen als optionale Behandlung - auf der Basis einer individuellen phoniatrischen Stellungnahme - in den Behandlungskatalog beim Transsexualismus aufzunehmen . Dem ja nur bei entsprechendem Leidensdruck vorgebrachten Behandlungsansinnen ( Operationsbegehren ) wuerde damit besser genuegt als gegenwaertig , und unnoetige Gerichtsverfahren und Begutachtungen koennten vermieden werden .
[ "Die", "phoniatrische", "Beschaeftigung", "mit", "transsexuellen", "Patienten", "zielt", "auf", "deren", "Stimmprobleme", ".", "Beim", "Frau", "-", "zu", "-", "Mann", "-", "Transsexualismus", "kommt", "es", "durch", "den", "therapeutischen", "Androgeneinsatz", "zu", "einer", "Massenzunahme", "der", "Stimmlippen", "und", "damit", "zu", "einer", "in", "der", "Regel", "von", "den", "Betroffenen", "als", "ausreichend", "empfundenen", "Virilisierung", "der", "Stimme", ".", "Beim", "Mann", "-", "zu", "-", "Frau", "-", "Transsexualismus", "bleibt", "-", "zumeist", "bis", "zum", "Ende", "des", "geschlechtsangleichenden", "Behandlungsprozesses", "-", "eine", "subjektiv", "als", "maennlich", "empfundene", "Stimme", "als", "stigmatisierendes", "Merkmal", "des", "urspruenglichen", "koerperlichen", "Geschlechts", "bestehen", ".", "In", "diesen", "Faellen", "kann", "durch", "unterschiedliche", "operative", "Massnahmen", "(", "Krikothyreoidopexie", "nach", "Isshiki", "oder", "Glottoplastik", "nach", "Wendler", ")", "eine", "Erhoehung", "der", "mittleren", "Sprechstimmlage", "angestrebt", "werden", ".", "Derartige", "Massnahmen", "werden", "von", "den", "aktuellen", "Standards", "sexualmedizinischer", "Behandlungsempfehlungen", "noch", "nicht", "erfasst", ".", "Im", "Einzelfall", "kann", "z.", "B.", "zur", "Frage", "der", "Kostenuebernahme", "fuer", "eine", "stimmangleichende", "Behandlung", "eine", "phoniatrische", "Begutachtung", "erforderlich", "werden", ".", "Eine", "51jaehrige", "Mann", "-", "zu", "-", "Frau", "-", "transsexuelle", "Patienten", "erhob", "vor", "einem", "Sozialgericht", "gegen", "ihre", "Krankenkasse", "Klage", ",", "da", "diese", "die", "Kostenuebernahme", "fuer", "eine", "stimmangleichende", "Operation", "verweigert", "hatte", ".", "Die", "Beweisfragen", "zielten", "auf", "die", "Stimmigkeit", "der", "aktuellen", "Stimme", "mit", "dem", "Zielgeschlecht", ",", "auf", "die", "therapeutischen", "Moeglichkeiten", "und", "wo", "diese", "angeboten", "werden", ",", "sowie", "auf", "die", "Nutzen", "-", "Risiko-", "und", "die", "Nutzen", "-", "Kosten", "-", "Relation", "im", "Falle", "der", "Klaegerin", ".", "Bei", "der", "phoniatrischen", "Untersuchung", "wurde", "ein", "fuer", "das", "urspruenglich", "maennliche", "Geschlecht", "\"", "normaler", "\"", "Befund", "erhoben", ".", "Dieser", "Befunde", "wurde", "als", "nicht", "stimmig", "mit", "dem", "weiblichen", "Zielgeschlecht", "bewertet", ".", "Die", "aktuellen", "Moeglichkeiten", "und", "Grenzen", "konservativer", "und", "operativer", "stimmangleichender", "Behandlungsformen", "wurden", "dargestellt", "und", "die", "Nutzen", "-", "Risiko-", "und", "die", "Nutzen", "-", "Kosten", "-", "Relation", "wurden", "auf", "der", "Basis", "der", "individuellen", "Abwaegung", "als", "guenstig", "eingeschaetzt", ".", "Das", "Gericht", "verurteilte", "die", "Krankenkasse", "zur", "Kostenuebernahme", "fuer", "die", "stimmangleichende", "Behandlung", ",", "das", "Urteil", "ist", "rechtskraeftig", "(", "Sozialgericht", "Bayreuth", "S", "6", "KR", "72/96", ")", ".", "Der", "Transsexualismus", "wird", "durch", "die", "gaengigen", "Krankheitsklassifikationssysteme", "erfasst", ",", "er", "ist", "eine", "Erkrankung", "im", "Sinne", "der", "Reichsversicherungsordnung", "(", "RVO", ")", ".", "Die", "Diagnostik", "und", "Therapie", "erfolgen", "nach", "den", "Standards", "wissenschaftlicher", "Fachgesellschaften", ",", "die", "jedoch", "den", "Komplex", "\"", "Stimme", "\"", "als", "wesentliches", "Geschlechtsspezifikum", "bisher", "noch", "nicht", "beruecksichtigen", ".", "Phoniatrische", "Leitlinien", "zur", "Stimmbehandlung", "bei", "Transsexuellen", "bestehen", "noch", "nicht", ".", "Die", "dadurch", "im", "Einzelfall", "offen", "verbleibenden", "Fragen", "muessen", "u.", "U.", "gutachterlich", "beantwortet", "werden", ".", "Im", "beschriebenen", "Begutachtungsfall", "betonte", "das", "Gericht", "die", "Anerkennung", "der", "Transsexualitaet", "als", "Krankheit", "und", "den", "daraus", "erwachsenden", "Anspruch", "auf", "Krankenbehandlung", "einschliesslich", "operativer", "Massnahmen", ",", "wovon", "die", "Stimme", "nicht", "ausgenommen", "werden", "duerfe", ",", "ohne", "dass", "jedoch", "aus", "der", "Entscheidung", "Rueckschluesse", "fuer", "weitere", "Verfahren", "gezogen", "werden", "koennten", ".", "Grundsaetzlich", "ist", "fuer", "die", "adaequate", "individuelle", "Indikationsstellung", "und", "Behandlungsdurchfuehrung", "sowie", "fuer", "die", "sachgerechte", "Begutachtung", "eine", "intensive", "Kooperation", "des", "Phoniaters", "mit", "dem", "Sexualmediziner", "unerlaesslich", ".", "Die", "wissenschaftlichen", "Fachgesellschaften", "sind", "aufgefordert", ",", "stimmangleichende", "Behandlungsmassnahmen", "als", "optionale", "Behandlung", "-", "auf", "der", "Basis", "einer", "individuellen", "phoniatrischen", "Stellungnahme", "-", "in", "den", "Behandlungskatalog", "beim", "Transsexualismus", "aufzunehmen", ".", "Dem", "ja", "nur", "bei", "entsprechendem", "Leidensdruck", "vorgebrachten", "Behandlungsansinnen", "(", "Operationsbegehren", ")", "wuerde", "damit", "besser", "genuegt", "als", "gegenwaertig", ",", "und", "unnoetige", "Gerichtsverfahren", "und", "Begutachtungen", "koennten", "vermieden", "werden", "." ]
[ "umlsterm" ]
Nuclear is a Entity, beta - catenin is a Protein, lymphoid enhancer factor 1 is a Protein, beta - catenin is a Protein, nucleus is a Entity, beta - catenin is a Protein, beta - catenin is a Protein, nucleus is a Entity, beta - catenin is a Protein, LEF-1 is a Protein, E - cadherin is a Protein, APC is a Protein, axin is a Protein, beta - catenin is a Protein, beta - catenin is a Protein, nucleus is a Entity, beta - Catenin is a Protein, LEF-1 is a Protein, nuclear is a Entity, nucleus is a Entity, beta - catenin is a Protein, VP16 is a Protein
10330189_task0
Sentence: Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "B-Entity", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Protein", "O", "O", "B-Protein", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Nuclear localization and formation of beta-catenin-lymphoid enhancer factor 1 complexes are not sufficient for activation of gene expression. In response to activation of the Wnt signaling pathway, beta-catenin accumulates in the nucleus, where it cooperates with LEF/TCF (for lymphoid enhancer factor and T-cell factor) transcription factors to activate gene expression. The mechanisms by which beta-catenin undergoes this shift in location and participates in activation of gene transcription are unknown. We demonstrate here that beta-catenin can be imported into the nucleus independently of LEF/TCF binding, and it may also be exported from nuclei. We have introduced a small deletion within beta-catenin (Delta19) that disrupts binding to LEF-1, E-cadherin, and APC but not axin. This Delta19 beta-catenin mutant localizes to the nucleus because it may not be efficiently sequestered in the cytoplasm. The nuclear localization of Delta19 definitively demonstrates that the mechanisms by which beta-catenin localizes in the nucleus are completely independent of LEF/TCF factors. beta-Catenin and LEF-1 complexes can activate reporter gene expression in a transformed T-lymphocyte cell line (Jurkat) but not in normal T lymphocytes, even though both factors are nuclear. Thus, localization of both factors to the nucleus is not sufficient for activation of gene expression. Excess beta-catenin can squelch reporter gene activation by LEF-1-beta-catenin complexes but not activation by the transcription factor VP16. Taken together, these data suggest that a third component is necessary for gene activation and that this third component may vary with cell type.
[ "Nuclear", "localization", "and", "formation", "of", "beta", "-", "catenin", "-", "lymphoid", "enhancer", "factor", "1", "complexes", "are", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "\n", "In", "response", "to", "activation", "of", "the", "Wnt", "signaling", "pathway", ",", "beta", "-", "catenin", "accumulates", "in", "the", "nucleus", ",", "where", "it", "cooperates", "with", "LEF", "/", "TCF", "(", "for", "lymphoid", "enhancer", "factor", "and", "T", "-", "cell", "factor", ")", "transcription", "factors", "to", "activate", "gene", "expression", ".", "The", "mechanisms", "by", "which", "beta", "-", "catenin", "undergoes", "this", "shift", "in", "location", "and", "participates", "in", "activation", "of", "gene", "transcription", "are", "unknown", ".", "We", "demonstrate", "here", "that", "beta", "-", "catenin", "can", "be", "imported", "into", "the", "nucleus", "independently", "of", "LEF", "/", "TCF", "binding", ",", "and", "it", "may", "also", "be", "exported", "from", "nuclei", ".", "We", "have", "introduced", "a", "small", "deletion", "within", "beta", "-", "catenin", "(", "Delta19", ")", "that", "disrupts", "binding", "to", "LEF-1", ",", "E", "-", "cadherin", ",", "and", "APC", "but", "not", "axin", ".", "This", "Delta19", "beta", "-", "catenin", "mutant", "localizes", "to", "the", "nucleus", "because", "it", "may", "not", "be", "efficiently", "sequestered", "in", "the", "cytoplasm", ".", "The", "nuclear", "localization", "of", "Delta19", "definitively", "demonstrates", "that", "the", "mechanisms", "by", "which", "beta", "-", "catenin", "localizes", "in", "the", "nucleus", "are", "completely", "independent", "of", "LEF", "/", "TCF", "factors", ".", "beta", "-", "Catenin", "and", "LEF-1", "complexes", "can", "activate", "reporter", "gene", "expression", "in", "a", "transformed", "T", "-", "lymphocyte", "cell", "line", "(", "Jurkat", ")", "but", "not", "in", "normal", "T", "lymphocytes", ",", "even", "though", "both", "factors", "are", "nuclear", ".", "Thus", ",", "localization", "of", "both", "factors", "to", "the", "nucleus", "is", "not", "sufficient", "for", "activation", "of", "gene", "expression", ".", "Excess", "beta", "-", "catenin", "can", "squelch", "reporter", "gene", "activation", "by", "LEF-1-beta", "-", "catenin", "complexes", "but", "not", "activation", "by", "the", "transcription", "factor", "VP16", ".", "Taken", "together", ",", "these", "data", "suggest", "that", "a", "third", "component", "is", "necessary", "for", "gene", "activation", "and", "that", "this", "third", "component", "may", "vary", "with", "cell", "type", "." ]
[ "Protein", "Entity" ]